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1 Introduction 
1. Introduction 
A wide spectrum of diseases primarly affecting the motor neurons has been described in 
humanes. Among these, the spinal muscular atrophies represent a large group. Common to 
all of them is the progressive loss of lower motor neurons in the spinal cord, leading to a 
preferential denervation of the voluntary muscles. Hence, main symptoms are muscle 
weakness and atrophy, which can be present either proximally or distally as well 
symmetrically or asymmetrically. Moreover, the individual mode of inheritance ranges from 
sporadic cases to X-linked as well as recessive or dominant forms. The most common spinal 
muscular atrophy is autosomal proximal spinal muscular atrophy, which will therefore simply 
be termed SMA in the following. Other well-described spinal muscular atrophies include X-
linked SMA (XL-SMA), spinal and bulbar muscular atrophy (Kennedy´s disease) and spinal 
muscular atrophy with respiratory distress (SMARD). 
1.1 Autosomal recessive proximal spinal muscular atrophy (SMA) 
In the Western European population, SMA is the second most frequent autosomal 
recessive disorder in humans after cystic fibrosis. Nowadays, it is the leading genetic cause of 
early infant death. The incidence of SMA is 1 in 10,000 to 1 in 6,000 live births in Western 
Europe (Emery 1991; Pearn 1978). In Germany. the carrier frequency has been estimated to 
be between 1:25 to 1:35 (Anhuf et al. 2003; Emery 1991; Feldkotter et al. 2002; Pearn 1978). 
SMA is caused by the progressive degeneration of -motor neurons in the anterior horns of 
the spinal cord. This leads to a steadily increasing hypotonia and weakness of the voluntary 
muscles, ultimately resulting in their atrophy. Typically, muscle weakness occurs first in the 
voluntary muscles of proximal limbs. While the atrophy is more pronounced in the lower 
extremities, hands and feet are usually spared in the early stages of SMA (Markowitz et al. 
2004). Further symptoms include a weak cough and cry, difficulties to suck and swallow, 
bladder weakness, tremor of the hands, areflexia and an increased susceptibility to 
respiratory tract infections (Rudnik-Schoneborn et al. 1994). In contrast, facial and 
oculomotor nerves are typically unaffected and also cognitive skills are not impaired. 
1.1.1 Clinical diagnosis 
The classical main diagnostic tool for SMA diagnosis is recording of electric pulses 
controlling voluntary muscle movement by electromyography (EMG). These pulses originate 
in the motor cortex and are transmitted by the motor neurons to the respective muscles. 
EMG technique allows determining of both transmission current and velocity. In SMA 
patients, EMG demonstrates spontaneous muscle activity with fibrillations and fasciculations 
of single muscle fibers as well as an increased mean duration and amplitude of action 
potentials. Nerve conduction velocity (NCV) is normal or mildly reduced, while the number 
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of motor units decreases during disease progression (Swoboda et al. 2005; Zerres and Davies 
1999).  
The progess made in molecular diagnostics dramatically improved SMA diagnosis. 
15 years ago the SMA determining gene, termed survival of motor neuron 1 (SMN1), was 
identified on chromosome 5q (Lefebvre et al. 1995). Its identification allowed confirmation 
of clinical SMA diagnosis by screening the SMN1 gene for specific mutations, deletions or 
gene conversions. This eventually led to the modification of the originally forwarded 
diagnostic criteria from the International SMA Consortium in 1992 (Munsat and Davies 1992) 
by Zerres and Davies (Zerres and Davies 1999).  
In order to distinguish SMA from other motor neuron diseases, exclusion criteria such as 
CNS dysfunction or arthrogryposis have been defined (Munsat and Davies 1992). 
Furthermore, serum levels of creatine kinase (CK) can be used to rule out SMA in unclear 
cases. CK levels are a common clinical marker for muscle membrane permeability. Typical 
serum levels are around 140 to 170 U/l, but can moderately be elevated by a variety of 
neuromuscular disorders, after external injury or even after excessive physical activity. 
However, highly increased CK levels (>10 fold) are a feature of conditions that cause severe 
muscle damage like myocardial infarction or Duchenne Muscular Dystrophy (DMD). In 
contrast to that, few mildly-affected SMA patients exhibit modestly increased serum levels 
(Rudnik-Schoneborn et al. 1998). In very rare cases, SMA was found to be accompanied by 
arthrogryposis, CNS dysfunction, increased CK levels or congenital heart defects. However, 
the question remains open whether these “SMA plus” cases are coincidental or indeed 
associated (Guillot et al. 2008; Rudnik-Schöneborn et al. 1996; Rudnik-Schoneborn et al. 
2008). 
In the past, clinical diagnosis has further been corroborated by histological inspection of 
a muscle biopsy. Muscles contain two types of fibers: Reddish type I fibers using triglycerides 
as storage fuel and white type II fibers, which generate energy from glycogen. While type I 
fibers are suited for endurance, type II fibers are effective for short bursts of muscle 
contraction. In contrast to healthy individuals, SMA patients exhibit groups of both atrophic 
type I and II fibers as well as hypertrophic type I fibers. Typically, muscle spindles are not 
affected (Lunn and Wang 2008) and myopathic features such as necrosis and lipid 
accumulation are absent with the exclusion of long-standing SMA patients (Munsat and 
Davies 1992). 
A summary of the most commonly used inclusion and exclusion critera for SMA is given 
in Table 1. Based on these guidelines, a diagnostic algorithm has been proposed which 
combines all the above described diagnostic criteria (Lunn and Wang 2008). 
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System Criteria 
Muscle 
Inclusion 
weakness of trunk and limbs 
symmetrical weakness 
Exclusion weakness of facial, oculomotor muscles or diapraghm 
Neurological 
Inclusion fasciculation of tongue and tremor of hands 
Exclusion 
sensory disturbances 
CNS dysfunction 
Molecular 
level 
Inclusion 
homozygous absence of SMN1 
intragenic SMN1 mutation 
Electro-
physiology 
Inclusion 
abnormal spontaneous activity by EMG 
increased mean duration and amplitude of action potentials 
Exclusion 
NCV lower 70% than in healthy subjects 
abnormal sensory nerve action potentials 
Histology Inclusion groups of atrophic fibers of both types 
Others Exclusion higher than 10-fold  increased CK levels 
Table 1 Inclusion and exclusion criteria for the diagnosis of SMA (Zerres and Davies 1999). 
1.1.2 Classification of proximal SMA 
The phenotype of proximal SMA is highly variable. It ranges from the prenatal 
appearance of symptoms to first manifestations occuring during adulthood in the mildest 
forms. The severest form of SMA was first described more than 100 years ago by the 
Austrian neurologist Guido Werdnig (Werdnig 1891), whereas milder forms were reported 
for the first time in the 1950´s (Kugelberg and Welander 1956). Nowadays, SMA is classified 
into four types (type I-IV) based on the age of onset and disease severity (Munsat and Davies 
1992; Zerres and Rudnik-Schoneborn 1995). 
1.1.2.1 SMA type I (Werdnig-Hoffmann disease), MIM #25330 
Werdnig-Hoffmann disease is the most common form of SMA and accounts for about 
50% of SMA cases (Markowitz et al. 2004). It is the most severe form and is often referred to 
as SMA type I or acute SMA. Onset of the disease is typically before the age of six  months - 
in very rare cases already in the third trimester of pregnancy - and death occurs within the 
first two years of life (Cobben et al. 2008; Fidzianska and Rafalowska 2002; Markowitz et al. 
2004). Mean survival has been estimated to be approx. seven months (Rudnik-Schoneborn 
et al. 2009). SMA type I children suffer from generalized muscle weakness, hypotonia and 
are never able to sit unassisted (“floppy infants”). Furthermore, patients exhibit symmetrical 
paralysis and cannot control head movement. Bulbar denervation results in characteristic 
fasciculation of the tongue thus leading to problems with sucking and swallowing. Due to a 
spared diaphragm and weakened intercostals muscles, the chest is typically deformed and  
bell-shaped. In severe cases, also arthrogryposis multiplex congenita may occur (Falsaperla 
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et al. 2001; Guillot et al. 2008). Furthermore, it has been reported that in some cases SMA 
type I patients also suffer from congenital heart defects (Finsterer and Stollberger 1999; 
Rudnik-Schoneborn et al. 2008) or necrosis of fingers and toes (Araujo Ade et al. 2009; 
Rudnik-Schoneborn et al. 2010). 
1.1.2.2 SMA type II, MIM #253550 
SMA type II is an intermediate SMA type and often called chronic SMA. Disease onset of 
SMA type II is between the 6th and 18th month of life. Affected children are able to sit 
indepently, but never learn to walk and require assistance to stand. Life expectancy is 
reduced, but more than 70% of patients reach an age of 20 years or older (Russman et al. 
1996; Zerres et al. 1997). Frequent symptoms are tremors of the hands, paraparesis and 
problems with tracheal secretions as well as coughing due to weak intercostal muscles 
(Iannaccone 1998). Often surgical intervention is needed to correct developing scoliosis 
(Bertini et al. 2005). The most frequent cause of death of SMA type II patients is respiratory 
insufficieny during adolescence. 
1.1.2.3 SMA type III (Kugelberg-Welander disease), MIM #253400 
SMA type III was described for the first time in 1956 (Kugelberg and Welander 1956). 
Characteristic for this juvenile form of SMA, which is often confused with limb girdle 
muscular dystrophy, is the appearance of disease manifestations after the 18th month of life. 
Depending on the actual age of onset, SMA type III is divided into two subtypes. If first 
symptoms occur before the age of three years the disease is classified as type IIIa, whereas 
in SMA type IIIb the diseases occurs after an age of three years (Zerres and Rudnik-
Schoneborn 1995). Symptoms of SMA type III include a waddling gait and overall thin 
appearance as well as scoliosis (Iannaccone 1998). However, the overall clinical picture of 
SMA type III is very heterogenous. Some individuals may need wheelchair assistance, while 
others may be able to walk throughout their life. 
1.1.2.4 SMA type IV (adult SMA), MIM #271150 
SMA type IV is the mildest form of SMA. Typically, first disease manifestations occur after 
the third decade of life (Wirth 2002). Symptoms are typically very mild and patients have a 
normal life expectancy. However, only a very low percentage of these patients are linked to 
mutations in the SMN1 gene, while for the majority an underlying molecular cause is still 
unknown.  
1.2 The molecular basis of SMA 
In order to identify the critical SMA locus, researches started linkage analysis. In 1990 
finally, three independent groups mapped SMA to a 10 cM region on the long arm of 
chromosome 5 (5q11.2-13.3) (Brzustowicz et al. 1990; Gilliam et al. 1990; Melki et al. 1990). 
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Progress in the development of highly polymorphic markers allowed narrowing down the 
SMA locus to an interval less than 750 kb between the markers A31 and 95/23-CA (DiDonato 
et al. 1994; Melki et al. 1993; Melki et al. 1994; Soares et al. 1993; Wirth et al. 1995; Wirth et 
al. 1994). Subsequent studies identified an inverted duplication of a 500 kb element within 
this region, of which each of the duplicates can be present in zero to four copies (Lefebvre et 
al. 1995; Wirth et al. 2006a). This complex genomic organization severely hampered the 
construction of a uniform physical map of the region surrounding the SMA determining gene 
(Melki et al. 1994; Roy et al. 1995a; Roy et al. 1995b; Thompson et al. 1993). However, in 
95% of healthy controls, a newly identified 20 kb gene was present in both the centromeric 
and telomeric 500 kb copy, whereas the telomeric one was either lacking or interrupted in 
the vast majority of patients. This suggested that the identified telomoric gene copy is 
indeed the SMA determing gene. Since SMA is characterized by the degeneration of motor 
neurons, the gene was termed survival motor neuron (SMN) (Lefebvre et al. 1995). Besides 
SMN, another four genes have been shown to be included in the duplicated 500 kb segment: 
BIRC1 (baculoviral IAP repeat-containing protein 1) which is also known as NAIP (neuronal 
apoptosis inhibitory protein), SERF1 (small EDRK-rich factor 1), also termed H4F5, GTF2H2 
(general transcription factor IIH) or p44, and OCLN (occludin) (Lefebvre et al. 1995; Schmutz 
et al. 2004). Proximally, this highly polymorphic region is flanked by RAD17, whereas the 
distally adjacent gene is BDP1 (Figure 1) (Deimling von et al. 1999; Kelter et al. 2000) 
 
Figure 1 Schematic overview of the “SMA region” on chromosome 5q13. Arrow heads indicated 
reading direction. (SMNc = centromeric SMN, SMNt = telomeric SMN) 
1.2.1 SMN1 and SMN2 
Within the SMA region, two copies of SMN have been identified each spanning 28 kb on 
genomic level (Chen et al. 1998). Both genes consist of nine exons (1, 2a, 2b, 3-8) with an 
open reading frame of 882 bp (294 codons) encoding for a 38 kDa protein (Lefebvre et al. 
1995). The 1.5 kb SMN transcript is expressed in all somatic tissues, in which the expression 
is ~50- to 100-fold higher in the spinal cord compared to other tissues (Coovert et al. 1997; 
Lefebvre et al. 1997). The telomeric SMN copy, termed SMN1, has been identified as the 
SMA determining gene (Lefebvre et al. 1995). Over 96% of SMA patients have homozygous 
deletions or gene conversion from SMN1 into SMN2 (Lefebvre et al. 1995; Wirth 2000). The 
latter case is predominantly found in type II or III patients who have multiple SMN2 copies 
(Wirth et al. 1997). Besides homozygous deletion of SMN1 in approx. 4% of SMA patients 
intragenic SMN1 mutations are observed, which interfere with normal gene function or lead 
 
6 Introduction 
to Nonsense-mediated-mRNA-decay (NMD). These patients are typically compound 
heterozygous, with a deletion of one SMN1 allele and a mutation in the other allele (Brichta 
et al. 2008; Lefebvre et al. 1995; Sun et al. 2005; Wirth 2000).  
All SMA patients retain at least one copy of SMN2. Although SMN2 produces 90% 
truncated protein due to alternative splicing (presented in detail in 1.2.2), the remaining 10% 
full-length protein substantially influence the SMA phenotype: The more SMN2 copies are 
present, the less severe is the phenotype. Most of SMA type I patients have two SMN2 
copies, whereas e.g the majority of SMA type II cases possess three copies (Lefebvre et al. 
1995; Wirth 2000).  
Recently, a positive modifier of the SMA phenotype has been identified within SMN2. At 
position +25 in exon 7, a single base substitution (c.859G>C) was identified, leading to a less 
severe SMA phenotype than expected from the SMN2 copy number (Prior et al. 2009; Vezain 
et al. 2010).  However, the SMA phenotype is also influenced by other genes. For example in 
very rare cases, high expression levels of PLS3 have been found to fully protect women from 
developing SMA (Oprea et al. 2008). 
The finding that deletion of SMN1 causes SMA, whereas SMN2 only modifies the actual 
phenotype, was of particular interest since both genes are almost identical except for 5 
nucleotide exchanges in the 3´-end of SMN2 (Burglen et al. 1996; Lefebvre et al. 1995): 
 Intron 6 nt position 27092  G>A 
 Exon 7 nt position 27141  c.840C>T, codon 280 (TTC>TTT, Phe>Phe) 
 Intron 7 nt position 27289  A>G 
   nt position 27404 A>G 
 Exon 8 nt position 27869 G>A (untranslated region) 
Nowadays, several other gene variants have been described, but these occur in both 
SMN1 and SMN2 (Brahe et al. 1996; Hahnen and Wirth 1996; Monani et al. 1999).  
Phylogenetic analysis showed that the SMN protein is highly conserved from yeast to 
man (Miguel-Aliaga et al. 1999; Paushkin et al. 2000; Schrank et al. 1997). The gene 
duplication event occurred for the first time in primates roughly five million years ago. 
However, also in man´s closest relative Pan troglodytes, only two to seven copies of SMN1 
are present whereas the SMN2 gene is unique to humans (Rochette et al. 2001) 
1.2.2 SMN splicing 
Although SMN1 and SMN2 differ by 5 nucleotides, both genes encode for the identical 
protein since these nucleotide exchanges are either intronic, in 3´-UTR or translationally 
silent (Burglen et al. 1996; Lefebvre et al. 1995). However, on mRNA level both SMN genes 
exhibit clear differences. SMN1 produces almost exclusively full-length transcripts, whereas 
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90% of SMN2 transcripts are alternatively spliced and lack exon 7 (SMN27). Merely 10% of 
SMN2 pre-mRNAs are correctly spliced and are processed to full-length transcripts (FL-
SMN2) (Gennarelli et al. 1995; Lefebvre et al. 1995; Lorson et al. 1999). The lack of SMN 
exon 7 dramatically influences SMN protein production, since it encodes the C-terminal 16 
aa and contains the first stop codon of full-length SMN transcripts (position +49 to +51). If 
exon 7 is included in the mature mRNA, it is translated into full-length SMN protein 
consisting of 294 aa. However, if exon 7 is skipped, an alternative stop codon at position 13 
of exon 8 is used, resulting in a truncated 282 aa protein (Figure 2) (Gennarelli et al. 1995; 
Lorson et al. 1998). Recently, it has been shown that this altered C-terminus creates a 
degron, which leads to a more rapid degradation of the 7-protein compared to the full-
length protein (Burnett et al. 2009; Cho and Dreyfuss 2010; Lorson and Androphy 2000). 
Furthermore, the truncated protein also exhibits a reduced oligomerization capacity (Lorson 
et al. 1998). From both SMN genes, also three other transcripts are produced, namely 
SMN5 lacking exon 5, SMN3 deficient of exon 3 as well as SMN57 in which both exons 
5 and 7 are skipped (Chang et al. 2001; Gennarelli et al. 1995; Singh 2007; Sossi et al. 2001). 
Self-evidently, research has focused on why SMN2 exon 7 is spliced in a different way 
than SMN1 exon 7. SMN exon 7 is a relatively short exon, spanning only 54 nucleotides. It is 
characterized by a weak 3` splice site due to a suboptimal polypyrimidine tract, making it 
prone to alternative splicing (Lim and Hertel 2001). Nowadays, two different hypotheses 
have been proposed to explain the differences in exon 7 splicing. Fundamental to both is the 
C to T transition in SMN2 at position +6 of exon 7. On the one hand, researchers argue that 
this particular nucleotide exchange destroys an exonic splicing enhancer (ESE) located at the 
beginning of exon 7 (Lorson and Androphy 2000; Lorson et al. 1999). This heptameric motif 
is typically recognized by the splice factor SF2/ASF, which favors exon inclusion. In the case 
of SMN2, SF2/ASF is not able to bind this ESE thus exon 7 is skipped (Figure 2) (Cartegni et al. 
2006; Cartegni and Krainer 2002). A concurring hypothesis suggests that the C to T transition 
leads to a formation of a novel exonic splicing silencer (ESS), which in turn recruits the splice 
factor hnRNP A1 leading to exon 7 skipping (Kashima and Manley 2003; Kashima et al. 
2007a; Singh et al. 2004). Furthermore, it has been shown that Sam68 also binds to the 
putative ESS and interacts with hnRNP A1 to cooperatively promote exon 7 skipping 
(Pedrotti et al. 2010). However, both hypotheses can also be combined in such a way that 
the C to T transition destroys an ESE and creates an ESS instead (Figure 2). 
In addition to SF2/ASF, hnRNP A1 and Sam68, a plethora of additional other factors is 
involved in the splicing of SMN2-pre-mRNA . Among these, the SR-like splice factor hTRA2-1 
(SFRS10, Serine/Arginine rich splice factor 10) has an exceptional role since its 
overexpression reverses the SMN2 splicing to 80% full-length FL-SMN2 (Hofmann et al. 
2000). hTRA2-1 binds to GA-rich second ESE in the central region of SMN exon 7 and acts as 
an platform for the binding of other splice factors, such as SRp30, hnRNP-G or TDP-43. All 
three of them have been demonstrated to favour SMN exon 7 inclusion by direct binding to 
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hTRA2-1 (Figure 2) (Bose et al. 2008; Helmken and Wirth 2000; Hofmann and Wirth 2002; 
Young et al. 2002).  
Adjacent to SMN exon 7, several regulatory elements have been identified (Figure 2). 
Among these, two positively acting intronic elements termed I7-1 and I7-2 have been 
identified in intron 7. It has clearly been demonstrated that I7-1 acts as an intronic splicing 
enhancer (ISE), which favors exon 7 inclusion (Gladman and Chandler 2009). In addition, 
several potent negatively acting elements have been detected, such as element 1 (E1) in 
intron 6 which is bound by PTB and FUSE (Baughan et al. 2009; Miyajima et al. 2002). 
Moreover, in intron 7 the stem-loop forming element 2 (E2)  (Miyaso et al. 2003) as well as 
ISS-N1, which is recognized by hnRNP-A1, have both been identified to promote exon 7 
skipping (Kashima et al. 2007b; Singh et al. 2006). 
 
 
Figure 2 Proposed molecular mechanism for SMN exon 7 inclusion and exclusion. In the case of 
SMN1 depicted in the upper part, SF2/ASF binds to the ESE at the beginning of exon 7. 
SF2/ASF interacts via U2AF with the U2 snRNP to facilitate the removal of intron 6. 
Additional splice factors such as hTRA2-1 or hnRNP-G act positively on exon 7 inclusion. In 
the case of SMN2 depicted in the lower part binding of hnRNP-A1 and Sam68 abolishs 
binding of SF2/ASF (potentially also of the U2 snRNP) thereby promoting exon 7 exclusion. 
Several cis-acting elements like E1, ISSN1 or I7-1 individually act on exon 7 inclusion or 
exclusion. (Modified from (Lorson et al. 2010)) 
Furthermore, a positive acting element within SMN2 in exon 7 has recently been 
identified in several SMA patients, showing a much milder phenotype than expected from 
the SMN2 copy number. Downstream of the putative ESE/ESS at position +25 a single base 
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substitution (c.859G>C) was located, which creates another putative SF2/ASF binding motif 
(Prior et al. 2009; Vezain et al. 2010). 
Although SMN2 splicing is quite complex, several therapeutic approaches have been 
undertaken which either directly or indirectly target SMN2 splicing. Though, these will be 
presented in 1.6. 
1.3 The SMN protein 
The human SMN protein is expressed in virtually all tissues, with highest levels present in 
the CNS and liver (Carvalho et al. 1999; Young et al. 2001; Young et al. 2000). Since SMN 
abundance markedly declines after birth, it is thought that elevated SMN levels may play an 
important role throughout prenatal development (Burlet et al. 1998). Similarly to that, also 
the rodent Smn is present at the highest levels before birth, but its abundance decreases 
soon thereafter by Smn promoter hypoacetylation (Battaglia et al. 1997; Jablonka et al. 
2000; Kernochan et al. 2005; Liu et al. 2010). 
 SMN has a molecular weight of 38 kDa and consists of 294 aa (Lefebvre et al. 1995). Like 
the majority of cytoplasmatic proteins, SMN is degraded via the ubiquitin-proteasome-
system (UPS) (Burnett et al. 2009; Chang et al. 2004). Very recently, the ubiquitin-ligase 
UCHL1 has been identified to transfer activated ubiquitin onto SMN, thus regulating its 
degradation (Hsu et al. 2010). Within the SMN protein, several functional domains have 
been identified during the last years. N-terminally, Exon 2b and the beginning of exon three 
encode for RNA-binding-domain (RBD) (Bertrandy et al. 1999), whereas the major part of 
exon 3 is spanned by a Tudor-domain facilitating Sm protein binding during U snRNP 
biogenesis (Selenko et al. 2001). In exons 4 and 5 a proline-rich stretch was identified, 
mediating interaction with Profilins (Bowerman et al. 2009; Bowerman et al. 2007; 
Giesemann et al. 1999). Furthermore, it has been shown that the YG-box, encoded by exon 6 
in conjunction with exon 2b, is required for SMN self-oligomerization (Lorson et al. 1998).  
Inside the cell, SMN is present in both the cytoplasm and the nucleus. While in the 
cytoplasm it is diffusely distributed, distinct SMN foci are observed inside the nucleus. These 
foci are most often found in close proximity or even overlapping with coiled bodies (also 
known as Cajal bodies). Based on these observations, the nuclear SMN foci were termed 
Gemini of coiled bodies or gems (Burlet et al. 1998; Coovert et al. 1997; Liu and Dreyfuss 
1996; Liu et al. 1997). In addition to the 38 kDa SMN protein, another shortened isoform has 
been identified which is selectively expressed in the axons of developing motor neurons 
(aSMN). This isoform includes exons 1 to 3 and a retained part of intron 3 (Setola et al. 
2007). 
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1.3.1 The SMN complex 
SMN is the major constituent of a large multi-subunit protein complex weighing approx. 
1 MDa, termed the SMN complex. The further core components Gemins2 to -8 are stably 
associated with the SMN complex and present in a stoichiometric manner (Carissimi et al. 
2006a; Carissimi et al. 2006b; Pellizzoni et al. 2001a; Pellizzoni et al. 2002). In addition, 
several transient interaction partners have been identified, which are mainly involved in 
snRNP-biogenesis. However, it is believed that SMN and Gemin2 represent the ancestral 
core of the SMN complex to which the other Gemins were added blockwise during evolution 
(Kroiss et al. 2008). From a structural point of view, SMN functions as modular backbone of 
the SMN complex since its ability to self-oligomerize allows binding of a multitude of 
partners (Figure 3) (Pellizzoni 2007). Furthermore, it has been shown that complexation 
markedly increases SMN protein half-life from approx. 4.3 hrs to around 15 hrs (Burnett et 
al. 2009). 
 
Figure 3 Schematic overview of the SMN complex. Stable binding partners are Gemin2, -3, -5, -7 
and -8 whereas Gemin4 and -6 are associated via other Gemins (taken from (Pellizzoni 
2007)).  
1.3.2 Functions of SMN 
Since SMN is involved in a vast number of cellular processes, these were subdivided into 
ubiquitous housekeeping ones and functions which are specific to either neurons or muscles.  
1.3.2.1 Housekeeping functions 
 Biogenesis of snRNPs 
Small nuclear ribonucleoproteins (snRNP) are of vital importance for the splice process in 
every cell since they identify and subsequently remove the introns from pre-mRNAs. snRNPs 
are constituented of a major proteinous part and a small nuclear RNA (snRNA) of 100 to 300 
bp transcribed by RNA-Polymerases II. It has been shown that the SMN complex facilitates 
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addition of the Sm proteins D1, D2, E, F, G and D3, B (Smith antigen) onto the respective 
snRNA and catalyzes Sm ring closing (Lorson et al. 1998; Meister and Fischer 2002; Pellizzoni 
et al. 1999). While the SMN complex directly recruits the respective snRNA, the Sm proteins 
are handed over by the assembly chaperone pICln (Chari et al. 2008). Following assembly, 
the SMN-snRNP-complex shuttles into the nucleus and is typically stored in gems until 
further usage. Once the snRNP is released, the SMN complex is translocated out of the 
nucleus and enters another round of snRNP assembly (Chari et al. 2009). 
However, several point mutations in SMN1 have been shown to impair binding of SMN 
to the Sm proteins, thus leading to generalized splicing defects (Gabanella et al. 2007; Lorson 
et al. 1998; Pellizzoni 2007; Sun et al. 2005; Zhang et al. 2008). 
 Stress response 
Exposure of a cell to stress factors such as heat or UV irradiation triggers wide-spread 
alterations in expression as well as distribution of cellular constituents. Studies showed that 
specific stress-induced genes e.g. the heat-shock-proteins (HSPs), which mostly fullfil 
chaperoning functions, are actively expressed upon stress stimulus while most other genes 
are silenced (Buchan and Parker 2009). The key factor in this process is the phosphorylation 
of eukaryotic initiation factor 2 (eIF2), leading to reduced global translation (Underhill et 
al. 2005). More than 50% of total mRNA transcripts are actively recruited into stress granules 
(SG) to protect them from degradation or denaturation (Buchan and Parker 2009). Stress 
granules are formed by shuttling of the RNA binding proteins TIA-1(T-cell internal antigen-1) 
and TIA-R (TIA1-related protein) from the nucleus into the cytoplasm where these proteins 
self-aggregate (Kedersha et al. 1999). However, it has been shown that SMN interacts with 
TIA-1/R as well as Rpp20, which accumulate in stress granules (Hua and Zhou 2004a, b). 
Nevertheless, since SMN accumulation precedes that of TIA-1/R, it has been suggested that 
SMN serves as a facilitator of SG formation (Hua and Zhou 2004b).  
 Regulation of transcription 
Transcription is opposingly regulated by the so-called co-activator and co-respressor 
complexes, which consist and recruit enzymes involved in chromatin remodelling or 
translational initiaton (Rosenfeld et al. 2006). Several years ago, it was shown that SMN 
interacts via its YG-box with mSin3A (Zou et al. 2004), which interacts with the corepressors 
SMRT and N-CoR (Nagy et al. 1997). Since both, SMN and mSin3A, are involved in formation 
of a >40 MDa complex, it has been suggested that SMN may also be involved in the 
regulation of transcriptional repression (Zou et al. 2004). Further evidence came from the 
observations that SMN associates with RNA polymerase II (Pellizzoni et al. 2001b) and 
dp103, a putative RNA helicase (Campbell et al. 2000). 
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 Regulation of translation 
Based on the finding that SMN is transporting mRNA along axons (1.3.2.2), it has been 
suggested that SMN may also be involved in translational regulation. Furter evidence 
pointing into this direction came from the observation that the C-terminal YG-box of SMN 
interacts with FMRP (Fragile X Mental Retardation Protein) (Piazzon et al. 2008). FMRP is 
involved in nuclear export and transport of yet unknown target mRNAs and is often detected 
near polysomes (Bardoni et al. 2001). However, debate is still ongoing whether the SMN 
complex is involved in the assembly of FRMP-containing mRNPs or whether SMN alone is 
transiently interacting with mRNPs during their transport. 
1.3.2.2 Neuron-specific functions 
 Axonal mRNA transport 
It has been observed that neurons of SMA-like mice exhibit reduced levels of -Actin mRNA 
at the axonal growth cones, which suggested that SMN is involved in mRNA transport along 
axons. This is in line with the finding that SMN interacts with hnRNP-R (heterogenus nuclear 
ribonucleoportein-R), which controls -actin localization (Rossoll et al. 2003). Furthermore, it 
has been demonstrated that SMN complexes traffic along neuronal processes to the growth 
cones of motor neurons (Zhang et al. 2006) and that SMN, Gemin2 and Gemin3 associate 
with -Actin mRNA in the cytoplasm of neuronal cells (Todd et al. 2010). Based on these 
findings, it was suggested that SMN or the SMN complex is actively involved in the transport 
of axonal mRNAs such as -Actin. However, it has been shown that also other cytoskeletal 
mRNAs like tubulin, peripherin and vimentin are transported along axons, but it has not yet 
been reported whether SMN is involved in their transport (Willis et al. 2007). 
 Neurite outgrowth 
Several in vitro as well as in vivo studies in zebrafish and mice showed that SMN depletion 
strongly reduces neurite outgrowth, a process depending on actin remodelling (Bowerman 
et al. 2009; Fan and Simard 2002; McWhorter et al. 2003; Oprea et al. 2008). Since 
knockdown of SMN alters the G-/F-actin ratio, it has been proposed that SMN may be 
involved in microfilament metabolism (van Bergeijk et al. 2007). In line with this, the 
protective SMA modifier PLS3 is an actin-bundling protein presumably restoring disturbed 
G-/F-actin ratios in SMA patients (Oprea et al. 2008). Furthermore, SMN depletion alters 
Profillin II expression, thus impairing the RhoA/ROCK actin remodelling pathway (Bowerman 
et al. 2007).   
 Neuromuscular junction formation 
Neuromuscular junctions (NMJ) are the connecting pieces between the axon terminal of a 
motor neuron and the respective muscle. Histological inspection of SMA-like mice revealed 
that the maturation of NMJs was severely reduced and AChR (Acetylcholine Receptor) 
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clusters did not form proper pretzel-like structures. Moreover, pre-terminal sprouting was 
also descreased (Kariya et al. 2008). Electrophysiologic examinations showed that reduced 
SMN levels in mice indeed lead to lower evoked endplate currents (EPC) due to reduced 
neurotransmitter release (Kong et al. 2009). Furthermore, even in Drosophila SMN depletion 
severely impaired NMJ structure and function (Chang et al. 2008). 
1.3.2.3 Muscle-specific functions 
Although in SMA the motor neurons are primarily affected, also muscle-specific functions 
of SMN have been identified. It has been shown that Smn knockdown in mouse C2C12 
myoblasts results in defective myoblast fusion and malformed myotubes, most likely due to 
Z-disc deficiency (Shafey et al. 2005; Walker et al. 2008). In addition, it has been proven that 
the Smn complex colocalizes with the Z-disc marker -Actinin in both skeletal and cardiac 
myofibrils and that SMN is a direct target of the muscle-specific protease Calpain-3 (Walker 
et al. 2008). 
Although the underlying cause is not known, recent findings suggest that Smn may also 
have a cardiac-specific role, since SMA-like mice exhibit bradycardia and develop dilated 
cardiomyopathy (Bevan et al. 2010; Shababi et al. 2010b). However, whether this is a 
primary effect of reduced Smn levels or a secondary one due to neuronal deficits remains to 
be determined. 
1.4 Animal models of SMA 
A number of animal models has been generated within the last ten years to model the 
SMA phenotype and to allow detailed examination of the pathophysiology and in vivo drug 
testing. However, humans are the only species known carrying the SMN2 gene. Complete 
loss of SMN/Smn leads to lethality in all organisms. 
1.4.1 Non-vertebrate SMA models 
 Schizosaccharomyces pombe 
Using a bioinformatic approach, an orthologue of SMN termed smn1+ was identified in the 
split yeast S.pombe. It has been demonstrated that smn1+ is essential for viability in S.pombe 
and that missense mutations mimicking SMA type I lead to Smn1p mislocalization and 
decreased cell viability. Furthermore, it has been shown that Smn1p interacts with human 
SMN and Sm proteins, thus implying a highly conserved function (Owen et al. 2000; Paushkin 
et al. 2000). 
 Caenorhabditis elegans 
More than 10 years ago, the nematode ortholgue of SMN termed smn-1/CeSMN was 
identified. While both disruption and overexpression result in reduced progeny as well as 
locomotive defects, transient knockdown causes sterility by embryonic lethality (Miguel-
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Aliaga et al. 1999). Smn-1 is expressed in various tissues, including the nervous system and 
body wall muscles. The hypomorphic smn-1 mutation (smn-1(ok355)) reduces lifespan and 
impairs locomotion and pharyngeal pumping. Interestingly, neuronal but not muscle-
directed expression of smn-1 rescues the smn-1(ok355) phenotype (Briese et al. 2009). 
Moreover, the nematode`s orthologue of Gemin2, termed SMI-1, interacts with smn-1, 
suggesting the presence of a simplified SMN complex in C.elegans (Burt et al. 2006). 
 Drosophila melanogaster 
Within the Drosophila genome only a single, but highly conserved orthologue of SMN is 
present. SMN loss of function (Smn73Ao) leads to recessive larval lethality and NMJ 
abnormalities such as an enlargement. However, the observed survival up to the larvae 
stage is depending on maternal wild-type smn stored in the nurse cells. Electrophysiologic 
examination revealed that these flies exhibit reduced exciaitory postsynaptic currents 
(EPSC), which is in line with the observed NMJ phenotype. Noteworthy, the expression of 
Smn`s C-terminus partially overcomes the phenotype (Chan et al. 2003). Unexpectedly, Smn-
null mutations did not exhibit any detectable snRNP reduction, suggesting that larvae 
lethality is due to a neuron-specific phenotype. In contrast to the Smn null allele, flies 
carrying hypomorphic Smn mutations survive but display atrophy and flightlessness 
(Rajendra et al. 2007). 
1.4.2 Vertebrate SMA models 
 Danio rerio 
Using Zebrafish is an elegant way to study motor neuron development in vivo, since the 
transparent embryos allow easy analysis of the phenotype (McWhorter et al. 2003; Oprea et 
al. 2008). Antisense morpholino knockdown of Smn led to motor axon specific effects like 
truncation and increased branching (McWhorter et al. 2003). Using ENU-induced mutants, it 
could be shown that, similar to flies, maternal RNAs and proteins deposited in egg allow 
survival of these mutants up to the larvae stage. However, analysis of these ENU-mutants 
revealed extremely reduced levels of the presynaptic protein SV2 in Smn mutants. This 
suggested a specific role for SMN in production and/or stability of SV2, which is important 
for effective vesicle release. Interestingly, motor neuron specific expression of human SMN 
corrected the NMJ defect, underlining the necessity of SMN for NMJ integrity (Boon et al. 
2009).  
Studies using Gemin2 and pICln morphants revealed a similar axonal phenotype (Winkler 
et al. 2005), but a reduced snRNP biogenesis could be excluded as the underlying cause 
(Carrel et al. 2006). However, refined experiments in which Gemin2 was knocked down 
exclusively in motor neurons, demonstrated that the axonal phenotype of ubiquitous 
Gemin2 morphants is rather a secondary than a primary effect (McWhorter et al. 2008). 
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 Mus musculus 
More than 10 years ago, the first classical knock-out of the murine Smn gene was 
described. Targeted insertion of a lacZ/Neomycin cassette-transgene into exon 2 resulted in 
early embryonic lethality between E2.5 and E3.5 due to a disorganized morula leading to 
apoptosis (Schrank et al. 1997). However, heterozygous Smn+/- mice exhibited no obvious 
muscle atrophy, but were found to have 46% reduced Smn levels and a SMA type III like 
degeneration of the -motor neurons without any visible clinical impairment (Jablonka et al. 
2000). In another approach, Smn exon 7 was replaced by a HPRT cassette, leading to 
embryonic lethality at around E6.5 in the homozygous embryos (Hsieh-Li et al. 2000). In 
conclusion, none of the generated Smn knock-out mice allowed analysis of the SMN 
phenotype due to the early lethality. To overcome this pitfall, it was tried to mimic the SMA 
phenotype by addition of the human SMN2 into a murine null Smn-/- background.  
 SMN2 transgenic mice 
Almost simultaneously, two groups reported the successfull generation of SMN2 
transgenic mice. Remarkedly, already one or two copies of the SMN2 transgene are 
sufficient to overcome the early embryonic lethality reported earlier. However, although 
present at a normal number at birth, motor neurons were dramatically reduced at 
postnatal day five and SMA animals died soon thereafter which ressembled a SMA type I. 
Similarly to humans, addition of more SMN2 copies ameliorated the phenotype and eigth 
SMN2 copies resulted in a rescue of the phenotype (Monani et al. 2000). In the same 
year, a Taiwanese group could demonstrate that integration of a BAC clone containing 
two human SMN2 copies gives rise to living pups. Several different founder lines were 
generated on a mixed background, exhibiting either a SMA type I, II or III phenotype. One 
of these strains is now commercially available on a pure FVB/N background. While 
homozygous  Smn-/-;SMN2tg/tg mice carrying four SMN2 copies are fertile and survive for 
about one year (Hsieh-Li et al. 2000) their Smn-/-;SMN2tg/wt littermates exhibit a SMA 
type I like phenotype, are lighter than their healthy littermates and survive for approx. 
10 days (Hsieh-Li et al. 2000; Riessland et al. 2010).  
Several years later, the SMN27 cDNA was introduced on a Smn-/-;SMN2tg/tg 
background to test whether SMN7 is beneficial or detrimental. It could be shown that 
survival increased from 5 to 14 days, suggesting that at least SMN7 in part retains some 
oliogomerization capacity and stabilizes the SMN complex (Le et al. 2005).  
Recently, a group of novel Smn-/-;SMN2tg/tg mice carrying one to four copies of SMN2 
was generated. Animals carrying three SMN2 copies exhibited an intermediate 
phenotype characterized by decreased respiratory rate and an increased apnea 
frequency. In line with this, NMJ defects at the diaphragm were observed thus 
culminating in a median survival of 15 days (Michaud et al. 2010) 
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As a result of the continuous identification of novel mutations in SMA patients, two 
additional transgenic mice strains were generated. The first one is based on three 
unrelated SMA patients carrying one intact SMN2 allele and one with an A2G missense 
mutation. These patients exhibited a much milder phenotype than expected from their 
SMN2 copy number (Parsons et al. 1998). Therefore, a SMN2A2G transgene was 
integrated into the previously described Monani et al. SMA-like mouse (Monani et al. 
2003). Similarly to SMA patients, these animals developed a SMA type III-like phenotype 
with a lifespan >15 months. Though, how SMNA2G ameliorates the phenotype remains 
elusive, since SMNA2G is markedly reduced in its oligomerization capacity. One possible 
explanation may be that full-length SMN serves as a scaffold which promotes formation 
of FL-SMN:SMNA2G oligomers enhancing binding to several other proteins (Monani et al. 
2003). Furthermore, it could be shown in a second mouse model that introduction of an 
allele carrying the previously described SMN1 mutation (SMNA111G) (Sun et al. 2005), 
which retains capability of snRNP assembly, is also able to ameliorate the phenotype of 
Smn-/-;SMN2tg/tg mice. Noteworthy, the SMNA111G allele was not able to rescue the SMA 
phenotype alone and also does not complement the A2G mutation, suggesting that both 
mutations affect the same function (Workman et al. 2009). 
Very recently, also a humanized knock-in SMA-like mouse has been reported. In this 
model, the C at Pos +6 of Smn exon 7 was replaced by a T resulting in a murine “Smn2”. 
This triggered exon 7 exclusion in 60 to 80% of Smn transcripts depending on the 
respective organ. However, although SMN protein was generally reduced by 60%, the 
animals developed an adult onset SMA phenotype (Gladman et al. 2010). 
 Conditional SMN knock-out mice 
Since neither the ubiquitous Smn deletion nor the addition of SMN2 transgenes allowed 
the investigation of tissue-specific functions of Smn, a few conditional knock-out strains 
were generated by emplyoing the Cre/LoxP system. 
 Deletion of Smn exon 7 in neurons by Cre-recombinase under the control of the 
neuron specific enolase (NSE) resulted in motor axon loss while the cell body remained 
unaffected. However, Smn exon 7Fl/Fl; NSE-Cre+ animals exhibited tremors, atrophic 
muscle fibers and had a mean survival of 25 days (Frugier et al. 2000). As a 
complementary experiment, Smn exon 7 was also deleted in the skeletal muscle using 
HSA-Cre (-skeletal actin promoter driven). Smn exon 7Fl/Fl; HAS-Cre+ animals are 
characterized by muscle paralysis after three weeks leading to death at a mean age of 
33 days. Furthermore, a progressive myopathy accompanied by muscular dystrophy was 
observed suggesting a destabilization of the sarcolemma (Cifuentes-Diaz et al. 2001). 
Using Aflp-Cre, Smn exon 7 was also deleted in the liver. Smn exon 7Fl/Fl; Aflp-Cre+ mice 
presented a dramatic liver atrophy associated with liver dysfunction and iron overload 
leading to embryonic lethality at E18 (Vitte et al. 2004). 
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In addition to tissue-specific deletion of Smn exon 7, full-length SMN was 
overexpressed by using either the neuronal-specific prion promoter (PrP) or the muscle-
specific HSA promoter. Smn-/-;SMN2tg/tg;PRP-SMNtg/tg survive for approx. 210 days 
whereas Smn-/-;SMN2tg/tg;HSA-SMNtg/tg animals exhibited no improvement in the SMA 
phenotype and survival. This suggested that atrophy in SMA is rather a secondary effect 
due to neuron degeneration than a primary one (Gavrilina et al. 2008). 
1.5 SMA: Why do specifically motor neurons die? 
The major characteristic of spinal muscular atrophy in humans is the specific 
degeneration of the -motor neurons in the anterior horns of the spinal cord while other cell 
types remain spared (Iannaccone 1998). Inspection of diverse SMA-like models led to the 
same conclusion that the predominant factor in disease progression is the continous 
degeneration of the -motor neurons (Chang et al. 2008; Frugier et al. 2000; Kariya et al. 
2008; McGovern et al. 2008; McWhorter et al. 2003). However, the fundamental question 
remains why specifically this type of cells is affected although SMN is ubiquitously 
expressed? Since SMN shows a more than 50-fold higher expression in the spinal cord 
compared to other tissues (Coovert et al. 1997; Lefebvre et al. 1995), it might be speculated 
whether -motor neurons are more vunerable to reduced SMN levels than other cells. But 
which specific role fulfilled (1.3.2) by SMN is the ultimate detrimental factor? 
Nowadays, based on the numerous SMA-like animal models researchers have proposed 
two popular hypotheses which try to explain the specific loss of -motor neurons in SMA 
patients (Burghes and Beattie 2009):  
 SMA is caused by the disruption of a neuron-specific function of SMN 
SMN has been found in growth cones and axons of neuronal cells in vitro (Fan and 
Simard 2002; Zhang et al. 2006). Furthermore, knockdown of Smn in zebrafish led to specific 
motor neuron axon defects like truncation and branching (McWhorter et al. 2003). A similar 
result was observed in cultured motor neurons from SMA-like mice, including shortened 
axons, smaller growth cones and, most importantly, reduced levels of -actin mRNA 
transport (Rossoll et al. 2003). In line with this, it could be demonstrated that overexpression 
of PLS3, an actin-bundling protein, is able to overcome the SMA phenotype in zebrafish 
(Oprea et al. 2008). The association between -Actin and SMN is further underlined by the 
observation that Smn knockdown in PC12 cells alters expression of profillin II. This leads to 
an inappropriate activation of the RhoA/ROCK pathway causing defective neuritogenesis 
(Bowerman et al. 2009; Bowerman et al. 2007). In line with this, it has been proven that 
ROCK-inhibition prolongs survival of SMA-like mice (Bowerman et al. 2010). 
Furthermore, there is evidence that SMN may also have a NMJ-specific role, since NMJ of 
SMA-like mice are typically immature due to an abnormal development (Kariya et al. 2008; 
Kong et al. 2009). Pointing into the same direction, it has been shown that intermediate SMA 
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mice exhibit less synaptic vesicle release, which may explained by the reduced Cav2.2 (a 
Ca2+ channel) expression observed in cultured motor neurons of SMA mice (Jablonka et al. 
2007; Kong et al. 2009). However, it might be speculated whether these observations can be 
attributed to the interaction between SMN and -Actin protein/mRNA transport (Bowerman 
et al. 2009; Oprea et al. 2008; Rossoll et al. 2003). Although not finally proven yet, it is also 
conceivable that lack of SMN disturbs transport of a certain additional mRNA to the growth 
cone, which leads to a reduced expression at the synapse thus resulting in an altered 
synaptic architecture. 
 SMA is caused by impaired snRNP biogenesis 
Since impaired snRNP biogenesis affects rather every cell than only motor neurons, it has 
been suggested that -motor neurons are more vulnerable to subtle defects in snRNP 
assembly because of their high mRNA demand (Yoo et al. 2010). Interestingly, it has been 
shown that there is a correlation between snRNP assembly and the severity of the SMA 
phenotype in mice (Gabanella et al. 2007). However, introduction of the SMNA111G construct, 
which is capable of undergoing snRNP-biogenesis, ameliorates the SMA phenotype of Smn-/-
;SMN2tg/tg mice, but does not rescue lethality in Smn-/- mice (Monani et al. 2003). In line with 
this, injection of assembled snRNPs into SMA zebrafish was, at least to some extent, able to 
restore the phenotype (Winkler et al. 2005), suggesting that reduced snRNP contributes to 
the SMA phenotype. Nevertheless, the question remains what are the consequences of 
reduced snRNP assembly? Although recent studies using exome arrays identified wide-
spread splicing differences in SMA-like mice, especially in intron-rich genes (Zhang et al. 
2008), it is difficult to decipher which of these changes are caused by low SMN levels and 
which of them are secondary due to the SMA phenotype. Although final proof is still missing, 
it is conceivable that reduced snRNP-biogenesis alters splicing of certain synaptic mRNA and 
thus leads to an altered synaptic architecture. 
In conclusion, both hypotheses provide good reasons why -motor neurons are 
preferentially affected in SMA.  Nevertheless, a number of questions still remain open. 
Especially which function of SMN is directly affecting motor axons? Is it indeed the decrease 
in -actin mRNA transport or does disruption of snRNP assembly alter splicing of a gene that 
is indispensable for proper axon and NMJ function? Consequently, further experiments are 
needed to answer these questions and finally explain the underlying molecular cause of 
SMA. 
1.6 Therapeutic approaches in SMA 
Although much research has been invested in the development of a therapy for SMA, no 
cure for SMA is available yet. Indeed, symptomatic treatments like physical exercise or 
respiratory drainage to remove tracheal mucus help to improve patient´s life quality, but 
they do not target the underlying genetic cause of SMA. Also several non-targeting strategies 
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have been followed over the past years, like neurotrophic agents which reduce -motor 
neuron degeneration. Although the use of these agents sounds attractive, they do not target 
the genetic cause of SMA. This is of particular importance, since in contrast to other genetic 
disorders, SMA offers the unique possibility of targeting a nearly identical copy of the 
disease-determining gene SMN1. Therefore, several therapies have been developed which 
will be briefly introduced in the following. However, much data comes from experiments 
using SMA-like mice and only a very few regimens have yet been tested in humans.  
1.6.1 Epigenetic therapy targeting SMN2 expression 
Although many different approaches have been undertaken to cure SMA, none of them 
has made it into routine clinical use yet. However, among the proposed therapies described 
in section 1.6 the epigenetic SMA therapy applying Histone Deactylase Inhibitors (HDACi) has 
proceeded farthest, since already three clinical trials with valproic acid and sodium butyrate 
have been performed. Furthermore, a number of second generation HDACis are currently in 
the pipeline undergoing extensive in vitro and in vivo testing. 
In general, epigenetics comprise two levels of gene expression regulation which are 
added as a superstructure onto the DNA. On the one hand, DNA methylation has been 
shown to effectively silence gene expression. For example, it has been demonstrated that 
methylation of four CpG-islands located within the SMN2 promoter dramatically alters the 
SMA phenotype by reducing SMN2 expression (Hauke et al. 2009). On the other hand, gene 
expression is controlled by covalent histone modifications. Individual modifications alter the 
chromatin structure in a way that either promotes or restricts gene expression (Strahl and 
Allis 2000).  
1.6.1.1 The concept of epigenetic therapy 
Conceptually, epigenetic therapy using HDACi relies on the loosening of DNA packaging 
leading to an enhanced transcriptional activity. DNA is associated in the nucleus with 
proteins to form chromatin. Since the human genome consists of approx. 3.2 x 109 bases, a 
completely unwound DNA would be almost 1.8 m in length. Therefore, DNA has to be 
packed very tightly to fit into a nucleus of around 15 µM in diameter. Consequently, approx 
150 bp of the 2 nm DNA double helix are wrapped around a histone octamere, resulting in 
the pearl necklace like 10 nm fiber (11 nm in diameter). The next level of packaging is added 
by the histone H1, which binds to the interspaced DNA between two histone octameres thus 
forming the 30 nm fiber. A further step of DNA tightening is then introduced by attaching 
the 30 nm fiber to the nucleic protein matrix to form an even more condensed chromatin 
structure (Maeshima and Eltsov 2008; McBryant et al. 2010). 
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Figure 4 Packaging of eukaryotic DNA in the nucleus. The 2 nm DNA fiber is wrapped around histone 
octameres to form the 10 nm fiber. It is then assumed that the 10 nm fiber is further 
condensed to a 30 nm chromatin fiber which is finally packaged to a 0.7 µm chromatid 
(Maeshima and Eltsov 2008). 
The basic elements of DNA packaging are the histone octameres which, together with 
approx. 150 bp of DNA, form the fundamental DNA packaging unit, the nucleosome. In total, 
five main types of histones are known for both animal and plant cells: H1, H2A, H2B, H3 and 
H4. Two histones of H2A, H2B, H3 and H4 each form together the histone octamere around 
which 1.65 superhelical turns of DNA are wrapped (Burlingame et al. 1985; McBryant et al. 
2010). The nucleosome itself is stabilized by extensive dipole interactions between the 
arginin residues of the core structure of the histone and the negatively charged phosphate 
backbone of the DNA. Common to all histones is a canonical -helical histone-fold motif of 
the globular core, which is responsible for the DNA interaction while the N-terminal “tail” 
domains (NTD) reach out of the nucleosomal structure. NTDS are 14 to 38 aa in length, 
enriched in lysine and arginine residues and typically without secondary structures (Luger 
and Richmond 1998). However, the pearl necklace like structure of nucleosomes on a DNA 
strand is further condensed by the linker histone H1 which binds to the interspaced DNA. 
Unlike the histones H2A to H4, the linker histone H1 possesses a threeparted structure with 
an unstructured N- (13 to 44 aa) and C-terminus (approx. 100 aa), which flank a well-folded 
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globular domain. Histone H1 binds asymmetrically the nucleosomal DNA entry and exit sites, 
thus inducing folding of the DNA to form the 30 nm fiber (McBryant et al. 2010). 
The NTDs of the nucleosomal histones have gained particular interest, since a number of 
post-translational modifications have been identified which lead to a highly dynamic 
chromatin structure and thereby control expression. Based on these observations, in 2000 
the “histone code” has been proposed, which tried to assign specific functions like 
expression or meiosis to certain NTD modifications (e.g. phosphorylation, methylation, 
acetylation and ubiquitinylation) (Strahl and Allis 2000). However, in the light of the 
identificaction and detailed characterization of numerous chromatin remodelling complexes, 
like SWI/SNF, ISWI, CHD and INO80, the original code has been rewritten and a final version 
is not yet available (Ho and Crabtree 2010). 
Among the observed NTD modifications, acetylation is the best characterized one.  
Addition of an acetyl residue to the positively charged -aminogroup of a histone´s lysine 
neutralizes its charge. Consequently, the DNA packaging is looser and the DNA is accessible 
for factors involved in transcription, replication and DNA repair (Figure 5). Furthermore, it 
has been suggested that acetylated histones may serve as binding platforms for activators or 
repressors (Khan and Khan 2010). Researchers have identified two groups of enzymes which 
oppositionally add or remove acetyl residues from NTD of histones. The Histone Acetyl 
Transferases (HAT) have been shown to pass an acetyl residue from acetyl-CoA onto the 
terminal amino group of lysine. The counteracting entities are the Histone Deacetylases 
(HDAC), which remove acetyl residues from the lysine side chains thus leading to denser 
heterochromatic structure (Figure 5). 
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Figure 5 Histone acetylation and deacetylation catalyzed by HAT and HDACs. The figure illustrates 
the molecular interaction between acetylated and deacetylated lysine residues and DNA 
and the resulting transition from Eu- to Heterchromatin (taken from (Khan and Khan 2010)) 
Within the human genome more than 20 HATs and 11 HDACs have been identified. 
Based on their sequence homology, these enzymes have been classified into several sub 
classes which will be briefly characterized in the following. 
1.6.1.2 Histone Acetyl Transferases (HAT) 
In contrast to HDACs, there is no regular structure among the HATs. Common to all of 
them is an acetyltransferase domain which is at least in some cases only suspected. 
However, based on the additional domains HATs were classified into several groups (Khan 
and Khan 2010). Perhaps the most prominent HAT families are CBP/P300 enzymes, the 
GNAT family, the MYST family and finally the group of Rtt109 enzymes. Several other HAT 
families have been identified, but they have yet only been studied in less detail. While the 
CBP/P300 family is involved in rather global histone acetylation (H2B K12/15, H3 K14/18 and 
H4 K5/8), the enzymes of the GNAT family primarily target H3 K14 and H4 K8 (Dekker and 
Haisma 2009). The MYST family of HATs is mainly involved in cell cycle and growth control 
and has also been linked to various types of cancer, especially Tip60 (Avvakumov and Cote 
2007). However, HATs have been shown to be implicated in learning (Dekker and Haisma 
2009) or diseases like asthma and chronic obstructive pulmonary disease (Barnes et al. 
2005). Noteworthy, the substrate specificity of HATs is not restricted to histones since also 
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other proteins like p53 or general transcription factors are substrates (Sterner and Berger 
2000). Within the past years, also several HAT inhibitors have been identified like 
isothiazolones or the naturally occurring substance curcumin but none of them has yet 
entered everyday clinics (Balasubramanyam et al. 2004). 
1.6.1.3 Histone Deacetylases (HDAC) 
The 11 classical histone deacetylases are classified into three classes. Class I, which is 
related to yeast HDAC Rpd3, contains HDAC1-3 and 8 while class II, which is structurally 
similar to the yeast Hda1 histone deacetylase, includes HDAC4-7, 9 and 10. In contrast to the 
other groups, class IV contains only HDAC11.  In addition to these classical HDACs, another 
group of deacetylases has been identified, the sirtuins, which are referred to as class III 
HDACs. However, in contrast to the classical HDACs, which are Zn2+-dependent, sirtuins rely 
on NAD+ as essential co-factor (Khan and Khan 2010). Notably, none of the HDACs possesses 
a DNA-binding domain thus target specificity must be conferred by individual binding 
partners (Glozak et al. 2005) 
1.6.1.3.1 Class I HDACs 
In contrast to class II and IV HDACs, all class I HDACs are ubiquitously expressed and are 
present in both cytoplasm and nucleus. The almost identical HDAC1 and 2 seem to be partly 
redundant, since depletion of one leads to an increase in the other (Brunmeir et al. 2009). 
The structure of HDAC3 is slightly different, since it lacks a second CK phosphorylation site 
whereas HDAC8 only possesses one PKA phosphorylation site (Yang and Seto 2008). With 
the exception of HDAC8 all class I HDACs are functioning as catalytic subunits of multiprotein 
complexes. For example, HDAC1 and 2 interact to form the catalytic subunit of the Sin3, 
NuRD (nucleosome remodeling deacetylase) and CoREST (corepressor of RE1-silencing 
transcription factor) complexes which repress transcription (Grozinger and Schreiber 2002; 
Yang and Seto 2008). 
1.6.1.3.2 Class II HDACs 
The class II HDACs are subdivided based on whether they contain one (class IIA; HDAC 4, 
5, 7 and 9) or two catalytic domains (class IIB; HDAC6 and 10). All class IIA members contain 
three conserved 14-3-3 binding sites, myocyte enhancer factor-2 (MEF2) binding sites as well 
as signals for the nuclear in- and export, since they are present in both, nucleus and 
cytoplasm (Yang and Seto 2008). Consequently, MEF2 and 14-3-3 oppositionally regulate 
localization of class IIA HDACs (Nishino et al. 2008) The class IIB member HDAC6 has 
emerged as the major cytoplasmatic deacetylase, since in vivo also tubulin, Hsp90 and 
cortactin are HDAC6 substrates (Haggarty et al. 2003). Interestingly, HDAC6 contains a 
C-terminal zinc finger which is involved in several pathways like clearance of aggresomes or 
dendritic outgrowth (Kawaguchi et al. 2003; Kim et al. 2009). The other class IIB member 
HDAC10 has been found to be decreased in lung cancer patients suggesting an important 
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role in the maintenance of normal cells. However, although HDAC10 has been shown to 
deacetylate Hsp70, a fundamental understanding of its function remains elusive (Lai et al. 
2010). 
1.6.1.3.3 Class III HDACs (sirtuins) 
Mammals contain seven sirtuins, which are characterized by their conserved 
NAD+-dependent catalyctic domain. However, the N- and C-termini are strikingly different 
which goes in line with their divergent roles as regulators of physiology, calorie restriction 
and aging (Haigis and Guarente 2006). Since sirtuins are not inhibited by classical HDACi, 
they will not be discussed any further at this point. 
1.6.1.3.4 Class IV HDACs 
HDAC11 is a highly conserved deacetylase and the only family member of class IV HDACs. 
Although little is known about its function, its high conservation from C.elegans to man 
suggests a fundamental role (Yang and Seto 2008). Some in vitro experiments showed that 
HDAC11 regulates interleukin-10 expression in antigen-presenting cells (Villagra et al. 2009) 
as well as myelin basic protein (MBP) and proteolipid protein (PLP) levels during 
oliogodendrocyte maturation (Liu et al. 2009). 
1.6.1.4 HDAC inhibitors 
In addition to classical transcription factors, gene expression is regulated in concert by 
HATs and HDACs. Consequently, interference with this tightly regulated balance by inhibition 
of either HAT or HDACs switches transcription either on or off. In 1990, this theoretical 
assumption was proven by the finding that Trichostatin A, a streptomyces metabolite, 
inhibits cell cycle and differentiation by blocking HDACs (Yoshida et al. 1990). In the 
following, several other compounds were identified which clearly inhibited the activity of 
HDACs (Strahl and Allis 2000). From a mechanistic point of view, HDAC inhibition leads to an 
overbalance of HAT activity resulting in a boosted transcriptional rate. Since this is an 
unbiased approach, which virtually should affect all genes, several studies tried to elucidate 
the impact of HDACi treatment on global gene expression. However, depending on the type 
of cells and HDACi employed, values ranged between 2% and 20% of differentially expressed 
genes (Mariadason et al. 2000; Peart et al. 2005; Stimson and La Thangue 2009; Van Lint et 
al. 1996).  
Initially, HDACi were intended to be used primarily in cancer therapy because excessive 
deacetylation was found in several cancer entities. The rationale of using HDACi was to re-
express heterochromatic regulatory genes by inducing a widespread transition into the 
euchromatic state (Bertrand 2010; Tan et al. 2010). However, the effect of HDACi treatment 
is not a simple up-regulation of gene expression since several secondary effects are 
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triggered. Induction of regulatory genes may in turn decrease expression of other genes 
resulting in a rather complex expression pattern under HDACi regimen. 
Depending on their chemical backbone, HDACi have been divided into several classes 
(Bertrand 2010): 
 Short chain fatty acids > Phenylbutyrate (PB) 
     > Sodium butyrate (SB) 
     > Valproic acid (VPA) 
 Hydroxamates  > Trichostatin A (TSA) 
     > Suberoylanilide hydroxamic acid (SAHA) 
     > Suberic bishydroxamic acid (SBHA) 
     > m-carboxycinnamic acid bishydroxamide (CBHA) 
     > LBH589 
     > NVP-LAQ824 
     > JnJ-248645815 
     > PCI-34051 
     > Oxamflamtin 
     > Scriptaid 
 Benzamides  > M344 
     > MS-275 
     > CI-994 
 Cyclic tetrapeptides > Trapoxin A 
     > Apicidin 
     > FK228 (Depsipeptide) 
Structural and mechanistic studies using TSA and SAHA suggested that HDACi block 
HDACs by chelating the central Zn2+ in the catalytic center (Bertrand 2010; Finnin et al. 
1999). Based on these observations, a well-accepted pharmacophore for HDAC has been 
proposed comprising the Zn2+ binding group (ZBG; chelating the Zn2+), a linker that passes 
through the tube-like access to the active centre and a cap group for interactions with the 
external surface (Figure 6).  
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Figure 6 Diagram depicting the typical structure of HDACi consisting of Zinc-binding domain, linker 
and cap using the example of SAHA. Similarly to most of the second generation HDACi, zinc 
is chelated by the hydroxamic acid residue (modified from (Bertrand 2010))  
However, depending on their chemical composition some HDACi generally inhibit HDACs 
(so-called panHDACi), whereas others preferentially block class I or II enzymes. Although 
suggested, there is no given rule yet which defines that certain residues either favor 
inhibition of class I or II. Nevertheless, some HDAC-specific HDACi have been developed in 
the past years, such as PCI-34051 which is an HDAC8-specific inhibitor (Balasubramanyam et 
al. 2004). 
 
 
Table 2 Inhibition profile of some HDACi and some downstream targets primarily affected by 
blocking of the respective HDAC. (taken from (Carew et al. 2008)) 
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1.6.1.5 Epigenetic SMA therapy with HDACi 
The rationale of using HDACi in SMA therapy is quite simple. Although SMN1 as the 
major source of FL-SMN is lacking, SMN2 still produces around 10% full-length transcript. 
Activation of SMN2 should consequently increase the amount of FL-SMN2. Almost 10 years 
ago, it could be shown that treatment of EBV-transformed lymphoblastoid cell lines derived 
from SMA patients with the HDACi Sodium butyrate markedly elevated FL-SMN2 levels 
(Chang et al. 2001). Within the same work, it could be demonstrated that treatment of 
pregnant mothers of Smn-/-;SMN2tg/tg mice improves survival of the pups thus implying that 
HDACi are indeed a prospective group of putative SMA drugs. In the following, several 
additional HDACi were tested in vitro and in vivo as putative SMA drugs such as Valproic acid 
(1.6.1.6) (Brichta et al. 2003; Brichta et al. 2006; Swoboda et al. 2010; Swoboda et al. 2009), 
Phenylbutyrate (Brahe et al. 2005; Mercuri et al. 2004; Mercuri et al. 2007), TSA (Avila et al. 
2007) or the second generation panHDACi SAHA (Hahnen et al. 2006; Riessland et al. 2010). 
In conclusion, the results were very promising although it has to be considered that highly 
potent panHDACi may exert several unfavorable side-effects.   
1.6.1.6 VPA in SMA therapy 
Valproic acid, abbreviated VPA, is a branched short-chain fatty acid. In 1963, VPA was 
accidently identified as a compound having anticonvulsant properties in a seizure model 
(Meunier et al. 1963). Since then, the therapeutic spectrum of VPA has been enlarged from 
epilepsy to bipolar disorder, migraine prophylaxis and even cancer. However, the 
mechanisms of action of VPA are poorly understood although it has been shown that VPA 
alters a wide variety of signalling pathways (Terbach and Williams 2009). For example, it has 
been shown that VPA has an inhibitory effect on a variety of ion channels, thus influencing 
sodium and calcium currents in hippocampal neurons (De Sarro et al. 1992; McLean and 
Macdonald 1986). However, it may be criticized that many of these studies used very high 
VPA concentrations like 400 mg/kg bodyweight (De Sarro et al. 1992). Data from studies 
further investigating the effect of VPA on neurons suggested that it increases levels of the 
inhibitory neurotransmitter GABA, but more recent studies did not verify this observation 
(Lindekens et al. 2000). Furthermore, it has been shown that, similarly to the the mood-
stabilizer Lithium, VPA decreases Inositol 1,4,5-triphosphate levels, thus increasing 
amphetamine levels (Shaltiel et al. 2007).  
VPA has been widely used in epilepsy therapy for more than 30 years, therefore side-
effects can be well estimated.  Among the observed ones carnitine depletion is frequent. The 
underlying cause is that VPA, like any other fatty acid, is transferred from Co-enzyme A (CoA) 
onto carnitine to form Carnityl-VPA. This metabolite inhibits the carnitine transporter 
supplying the cell with carnitine and furthermore reduces the intracellular carnitine content 
by diffusing out of the cell and getting lost by renal excretion (Luch 2010). 
 
28 Introduction 
The most important observation in terms of SMA therapy was the finding that VPA 
mimics the effects of TSA thus inhibits HDACs (Gottlicher et al. 2001; Phiel et al. 2001). This 
observation also provided a major breakthrough in the understanding of another major side 
effect of VPA, which is teratogenicity during pregnancy (Robert and Guibaud 1982). Since the 
HDACi Sodium butyrate already produced promising results, VPA was tested as a putative 
SMA drug in vitro (Brichta et al. 2003; Chang et al. 2001). It could be shown that 
concentrations between 0.5 and 500 µM VPA significantly elevated SMN2 mRNA and protein 
levels 2- to 4-fold. Based on these promising results, a first pilot clinical trial was enrolled 
with 20 SMA patients and 10 SMA carriers (Brichta et al. 2006). While in seven out of 
10 carriers SMN levels were elevated, the results in the VPA-treated patients were not that 
consistent: While in seven of the treated patients SMN blood levels were elevated, in six  of 
them no change was detected whereas another seven SMA patients exhibited declined SMN 
levels under VPA regimen (Brichta et al. 2006). More recently, VPA was tested in a phase II 
open-label clinical trial with 42 SMA patients (2 SMA type I, 29 SMA type II and 11 SMA type 
III) (Swoboda et al. 2009). In conclusion, VPA was well tolerated. In some cases motor 
function decreased due to weight gain, but in the majority of younger SMA type II cases the 
mean motor score increased significantly. Unexpectedly, no change in SMN2 expression 
could be detected on RNA level. However, against the background of previous findings 
(Brichta et al. 2006) the question may be raised whether a more differentiated analysis of 
individual patients would have led to a more convincing outcome. Furthermore, SMN2 
expression has not been stratified in the tested patients. Without determination of a proper 
basal level, it is hard to draw any final conclusion as to whether VPA affects SMN2 levels or 
not. These points have to be addressed since in a study VPA treatment of SMA-like mice 
clearly improved motor function and motor-evoked potentials as well as decreased motor 
neuron degeneration (Tsai et al. 2008). 
1.6.2 Further therapies targeting SMN2 
1.6.2.1 RNA-based therapy 
Since the detrimental difference between SMN1 and SMN2 is the splicing of exon 7, 
modulation of SMN2 pre-mRNA splicing has come into focus. Based on the tremendous work 
which has been spent on the understanding of SMN2 exon 7 skipping, several antisense 
oligonucleotides (ASO) strategies have been developed to correct SMN2 splicing. For 
example in vitro blocking of the 3´ splice site (ss) of exon 8 with an antisense probe altered 
the competition of exon 7 and 8 for the joining with the 5´ss of exon 6 in such way that exon 
7 was included in more than 53% (Geib and Hertel 2009; Lim and Hertel 2001). Furthermore, 
in vivo studies using SMN2 transgenic mice demonstrated that injection of ASOs targeting 
the ISS in intron 7 efficiently corrects SMN2 splicing (Hua et al. 2008). 
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The classical ASO approach was further extended by the creation of bifunctional RNAs 
binding SMN2 exon 7. In addition to the antisense sequence, these bifunctional RNAs also 
contain ESE sequences or covalently bound peptides functioning as binding platforms for 
SF2/ASF or hTRA2-1 to increase exon 7 inclusion (Baughan et al. 2006; Baughan et al. 2009; 
Marquis et al. 2007; Skordis et al. 2003). In such a way, it has been shown that addition of 
ESE sequences to an antisense U7 snRNAs incorporated into the U7 snRNP leads to nearly 
complete reinclusion of SMN2 exon 7 (Marquis et al. 2007). As a proof of principle, a 
bifunctional RNA covering the negative splice regulator E1 in intron 6 was injected in SMA-
like mice. Although SMN levels were more than 2-fold increased, the impact on survival was 
rather low (+10%) (Baughan et al. 2009). However, it could recently be demonstrated that 
direct infusion of an ASO targeting ISS-N1 in intron 7 via a micro-osmotic pump into the 
lateral cerebral ventricle in adult SMN2 transgenic mice resulted in a robust and long lasting 
increase in exon 7 inclusion. Moreover, a single neonatal or embryonic dose rescued the tail 
and ear necrosis in SMA-like mice (Hua et al. 2010). 
Furthermore, so-called trans-splicing (ts) RNAs have been developed. Conceptually, 
these ts-RNAs rely upon splicing between the target RNA and the therapeutic RNA providing 
the correct RNA sequence. Using this system to add exon 7 to the mature SMN2 mRNA, it 
could be demonstrated that ts-RNAs increase FL-SMN2 levels in vitro and in vivo (Coady and 
Lorson 2010; Coady et al. 2007). 
1.6.2.2 Gene therapy 
Another approach to treat SMA is the delivery of SMN into the CNS of SMA-like mice 
using adeno-associated vectors (AAV) to complement the lack of Smn. Injection of an AAV8 
vector encoding human SMN1 (AAV8-hSMN) into the CNS of newborn mice increased the 
survival from 15 to 50 days. Furthermore, myofiber size and NMJ architecture were 
substantially improved. Moreover, injection of self-complementary (sc) AAV8 vector 
improved efficacy of gene therapy to a median survival of more than 150 days (Passini et al. 
2010). More recent results conjecture that sc-AAV9 vectors encoding for SMN1 are the 
vectors of choice. Injection significantly improved motor function, NMJ architecture and the 
cardiac phenotype of SMA-like mice. In line with the previous results, median survival was 
extended from approx. 15 to more than 100 days (Bevan et al. 2010; Foust et al. 2010) or 
even 200 days  (Valori et al. 2010). 
1.6.2.3 Drug therapy 
Although data from ASO or gene therapy experiments sound quite promising, it is 
ambiguous whether one of these approaches will become state-of-the-art therapy for SMA 
due to the unknown side effects. Therefore, several small molecules have been developed 
and identified targeting SMN2 or the SMN7 protein, respectively.  
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 SMN2 promoter induction 
In addition to SMN2 splicing and stabilization of the SMN7 protein, also several 
compounds have been identified which elevated SMN2 expression in vitro. For example, it 
has been observed that treatment of SMA fibroblasts with 2-adrenoreceptor agonist 
Salbutamol rapidly increases FL-SMN2 levels and subsequently elevates SMN protein 
(Angelozzi et al. 2008). Moreover, based on the identification of an interferon-response-
element (IRE) in the SMN2 promoter it could be shown that treatment with either the 
interferon IFN- or IFN– elevates SMN levels merely 4-fold (Baron-Delage et al. 2000). 
Lastly, a compound screening campaign resulted in the identification of quinazolines which 
more than doubled SMN2 promoter activity (Jarecki et al. 2005).  
 SMN2 splicing 
Several compounds have been identified to alter SMN2 splicing and to increase the 
amount of full-length SMN protein derived from SMN2. By screening a compound library, 
Aclarubicin was identified to stimulate incorporation of exon 7 in SMA fibroblasts and 
NSC-34 cells (Andreassi et al. 2001). Presumably via STAT5 activation the phosphatase 
inhibitor Na-Vanadate has been demonstrated to increase exon 7 inclusion in vitro (Ting et 
al. 2007; Zhang et al. 2001).  Moreover, the cytostatic drug hydroxyurea (HU) has been 
tested in vitro and in vivo as a putative SMA drug. Although the exact mode of action is 
poorly understood, FL-SMN2 levels were increased in B-lymphoblastoid cells from SMA 
patients (Grzeschik et al. 2005).  However, in SMA patients treated with HU only slight 
improvements were observed but these may, as the authors argue, be “clinically 
meaningless” (Liang et al. 2008). 
 SMN protein 
Several aminoglycosides like Tobramycin or Geneticin have been identified to post-
transcriptionally elevate SMN levels by inducing read-through of the first stop codon in exon 
8 of SMN27 (Heier and DiDonato 2009; Mattis et al. 2006; Wolstencroft et al. 2005). Read-
through leads to an elongated C-terminus of the SMN7 protein, thus increasing its stability 
(Wolstencroft et al. 2005). In subsequent studies using the aminoglycosides TC007 in vivo, 
improved motor function was recorded and survival increased significantly by 30% (Mattis et 
al. 2009a; Mattis et al. 2009b). Furthermore, it has been suggested that inhibition of SMN 
turnover by MG-132 may be beneficial for SMA patients, but this has not yet been tested in 
vivo (Chang et al. 2004).  
1.6.3 SMN2-independent therapies 
1.6.3.1 Neurotrophic agents 
Riluzole, a small benzothiazol which antagonizes the effects of the neurotransmitter 
glutamate, was proven to be safe and effective in patients with ALS. Although Riluzole 
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improved median survival and NMJ architecture in SMA-like mice (Haddad et al. 2003), no 
such effect was detected in Riluzole-treated SMA patients. However, only 10 patients were 
enrolled during the clinical trial thus questioning the final conclusions (Russman et al. 2003). 
In another approach targeting synaptic transmission, SMA-like mice were treated with 
NMDA (N-Methyl-D-Aspartate) to activate the glutamatergic NMDA-receptors (NMDAR). 
NMDA improved NMJ maturation, induced SMN2 expression in the spinal cord via CREB 
activation and reduced motor neuron apoptosis (Biondi et al. 2010). Furthermore, the role of 
neurotrophic factor CNTF, which is typically secreted by Schwann cells, was investigated in 
SMA-like mice (Simon et al. 2010). However, since systemic treatment of ALS patients with 
CNTF elicits severe side effects such as fever and cachexia, treating SMA patients with CNTF 
is not feasible (ACTS 1996).  
1.6.3.2 Stem cell therapy 
The underlying idea of using stem cells in SMA therapy is to either replace the 
degenerated -motor neurons or to support the remaining cells by the addition of neural 
stem cells. Injection of spinal cord neural stem cells (NSC) in SMA-like mice improved 
neuromuscular function and increased life span by 40% from 13 to 18 days. Although NSC 
migrated into the parenchyma and generated a small proportion of motor neurons, the 
authors speculate that the transplanted cells rather serve as “chaperones” for host neurons 
and provide neuroprotective substances than replace degenerated -motor neurons (Corti 
et al. 2008). The latter hypothesis was underlined by the observation that using embryonic 
stem cell-derived NSC, which led to a similar amelioration of the phenotype, exhibited 
markedly increased levels of secreted neurotrophic factors (Corti et al. 2009). Recently, it 
was shown that it is possible to reprogram fibroblasts by the ectopic viral overexpression of 
the four factors Oct3/4, Sox2, Klf4 and c-Myc into induced pluripotent stem cells (iPS) 
(Takahashi et al. 2007). Subsequently, also SMA fibroblasts were successfully reprogrammed 
and in vitro differentiated into motor neurons expressing choline acetyltransferase (ChAT) 
(Dimos et al. 2008; Ebert et al. 2009). Although these data are promising, it remains elusive 
whether injection of (pre-differentiated) iPS-cells into a SMA patient is indeed a therapeutic 
option. Especially the ectoptic over-expression of several oncogenes is a risk factor which 
should not be underestimated.  
 
In summary, diverse therapeutic approaches are currently ongoing or under 
investigation. Among these, the HDACi discussed in section 1.6.1 have an exceptional role, 
since they are widely used in cancer therapy. The knowledge gained from these clinical trials 
helps to improve and increase safety in any putative SMA clinical trial. Furthermore, some of 
them, like VPA, are long known drugs which already have undergone intensive clinical 
testing. In addition, the in vivo testing of the HDACi in SMA-like mice did not reveal any 
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severe side effects. Nevertheless, the two clinical trials with VPA (Brichta et al. 2006; 
Swoboda et al. 2009) underline the need for a better understanding of how and why VPA 
elicits its action as an HDACi in SMA patients. The deeper understanding of the cause of non-
responsiveness would not only have great benefit for SMA therapy, but also improve the 
VPA therapy of other diseases like epilepsy or bipolar disorder. Furthermore, alternative and 
ideally more potent SMA drugs are still desperately needed to improve and advance future 
SMA therapy. 
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2. Study aims 
Nowadays, proximal spinal muscular atrophy is the leading genetic cause of infant death. 
Although much research has been spent on it, there is no cure available yet. The underlying 
genetic factor of SMA is the functional absence of the survival motor neuron 1 (SMN1) gene. 
While it generates nearly 100% full-length transcripts (FL-SMN) the majority of transcripts 
produced by the almost identical copy gene SMN2 lack exon 7 due to alternative splicing. 
Nevertheless, SMN2 still produces around 10% FL-SMN. While this is not enough to prevent 
disease-onset, it is sufficient to ameliorate the SMA phenotype. The more SMN2 copies are 
present in a SMA patient the milder is the SMA phenotype. Based on these observations 
SMN2 became naturally a major target of SMA drug therapy.  
Histone deacetylase inhibitors (HDACi) have been shown in numerous studies to activate 
SMN2 expression and in addition to modulate its splicing pattern which in combination 
boosts FL-SMN2 levels. Among the tested HDACi the short-chain fatty acid Valproic acid 
(VPA) has proven its efficacy as an SMA drug in vitro and also in vivo. In a first pilot clinical 
trial by our group around 1/3 of VPA treated SMA patients responded positively meaning that 
SMN levels were elevated in blood. In contrast to that in another 1/3 of patients SMN 
amounts dropped whereas in the latter 1/3 no change at all was detected.  
The primary aim of the present work was to identify the underlying cause why some SMA 
patients react positively to VPA treatment whereas others do not. To investigate this issue 
fibroblast lines from SMA patients included in the first pilot clinical trial were established and 
their response to VPA treatment should be characterized in detail by evaluation of SMN2 
DNA, RNA and protein level. Furthermore, transcriptomes of fibroblast lines responding 
positively or negatively to VPA were supposed to be compared by differential µ-array 
analysis. Potential differentially expressed genes should be selected and their role and 
impact in VPA treatment should be analyzed to uncover the underlying cause of VPA none-
responsiveness. The identifaction of the cause of the differential response to VPA may lead 
to the identification of biomarker which allows estimation of the therapeutic outcome 
before therapy has actually started. 
Since the question remains open whether a deeper understanding of VPA treatment will 
lead to the identification of a switch which controls the response to VPA also another 
putative SMA drug should be characterized. LBH589 is a novel second generation HDACi 
which exhibited a promising pharmacological profile in various malignancies. Its impact and 
mode of action were supposed to be characterized in detail to allow decision about potential 
evaluation of LBH589 in vivo in SMA-like mice.  
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3. Material and Methods 
3.1 Cell lines 
For all primary human fibroblast cell lines used throughout this study, a genetic analysis 
was carried out and informed written consent was given by the respective subjects or their 
legal guardians. All SMA patients, who donated human material, fulfilled the diagnostic 
criteria for SMA (Munsat and Davies 1992) and carry homozygous absense of SMN1 as 
determined by routine molecular testing. The number of SMN2 copies was measured using 
DNA isolated from EDTA blood samples collected from the respective donor. Exact 
determination of SMN2 copies, using either qRT-PCR or MLPA, was carried out in the 
diagnostic laboratory of the Institute of Human Genetics in Cologne (Feldkotter et al. 2002; 
Tomaszewicz et al. 2005). A list of all fibroblast lines used in this work is given in Table 3 on 
the next page. 
3.2 Mouse inbred strains 
Throughout this study two different SMA-like model mouse inbred strains were 
employed: 
 FVB.Cg-Tg(SMN2)2Hung Smn1tm1Hung/J (purchased from Jackson´s Laboratory; 
#005058) 
In this mouse model  the Smn locus is disrupted by a 1.6 kb deletion targeting 
Smn exon 7 using a 115 kb large BAC-clone integrate (clone 7) containing the 
SMN2 gene as well as NAIP and SERF1. Noteworthy, 2x SMN2 copies are present 
per BAC integrate (Hsieh-Li et al. 2000).  In the following, these mice were termed 
as SMAHung mice. These mice were originally on a mixed background, but were 
backcrossed by the Jackson´s Laboratory onto a pure FVB/N background. 
 FVB.Cg-Tg(SMN2)89Ahmb Smn1tm1Msd/J (kind gift from Michael Sendtner, 
Würzburg / Jackson´s Laboratory; # 001800). In this mouse model the Smn gene 
was disrupted by homologous recombination of the targeting vector into the Smn 
exon 2 (Schrank et al. 1997). The SMN2 transgene, which is only present as a 
single copy per integrate, is located on 35.5 kb large PAC-clone BamH1 fragment 
(clone 215P5). These mice were originally published on a C57Bl 6J background 
(Monani et al. 2000), but were later on backcrossed onto a pure FVB/NJ 
background. In the following these mice were termed as SMABurghes mice.  
Animals were housed in micro-isolation chambers in the mouse facility of the the Institute 
of Genetics in Cologne. All mice were humanely euthanized according to the guidelinces set 
forth by the Landesamt für Natur, Umwelt und Verbraucherschutz NRW. Mouse breedings 
and experiments were approved by the local animal protection committee and were 
performed under the reference number 9.93.2.10.31.07.292. 
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Fibroblast line Phenotype n(SMN1) n(SMN2) 
Identifier in 
Brichta et al. 
ML16 SMA type I  --- 3  --- 
ML17 SMA type I  --- 2  --- 
ML86 SMA type I  --- 2  --- 
ML95 SMA type I  --- 2  --- 
ML111 SMA type I  --- 2  --- 
ML108 SMA type I  --- 3  --- 
ML5 SMA type II  --- 3  --- 
ML62 SMA type II  --- 3 P10 
ML65 SMA type II  --- 3 P12 
ML60 SMA type II  --- 3 P5 
ML67 SMA type II  --- 3 P8 
ML71 SMA type II  --- 3 P6 
ML72 SMA type II  --- 3 P7 
ML59 SMA type II  --- 3 P13 
ML73 SMA type II  --- 3 P14 
ML79 SMA type II  --- 3  --- 
ML89 SMA type II  --- 3  --- 
ML94 SMA type II  --- 3  --- 
ML96 SMA type II  --- 3  --- 
ML104 SMA type II  --- n.d.  --- 
ML105 SMA type II  --- 3  --- 
ML110 SMA type II  --- n.d.  --- 
ML69 SMA type III  --- 4 P4 
ML82 SMA type IIIa  --- 3  --- 
ML103 SMA type IIIa  --- 3  --- 
ML100 SMA type IIIb  --- n.d.  --- 
ML106 SMA type IIIb  --- 4  --- 
ML49 Carrier 1 2 C5 
ML53 Carrier 1 1 C1 
ML63 Carrier 1 2 C7 
ML66 Carrier 1 3 C9 
ML68 Carrier 1 2 C4 
ML75 Carrier 1 3 C8 
ML6 healthy 2  ---  --- 
 
Table 3 Primary fibroblast lines derived from skin biopsies of SMA patients and carriers used 
throughout this thesis. Clinical diagnosis and number of SMN1 and SMN2 copies measured 
either by qRT-PCR or MPLA are given. In the case patients were included in the VPA pilot 
study by (Brichta et al. 2006) the respective identifier is given in the last column (n.d. = not 
determined).  
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3.3 Equipment and chemicals 
3.3.1 Equipment 
The following equipment was used throughout daily laboratory routine. 
 Centrifuges:   Allegra X22-R   Beckman Coulter 
      5415 D    Eppendorf 
      5415 R    Eppendorf 
      Avanti J-20XPI   Beckman Coulter 
 Spectrophotometer  BioPhotometer  Eppendorf 
      NanoDrop ND-1000  Peqlab 
 Cuvettes    UV-Vette   Eppendorf 
 Microplate reader  Safire²    Tecan 
 Luminometer   Glomax   Promega 
 Thermocycler   DNAengine Tetrad 2  MJ research 
 Realtime thermocycler  LightCycler 1.5  Roche 
      ABI 7500 Taqman  Applied Biosystems 
 Floating waterbath  FBC620   FisherBrand 
 Electrophoresis chambers 
o Agarose gels  SGE-020-02   CBS scientific 
o SDS-PAA gels  Mini-Protean 3 cell  Biorad 
     Protean II xi   Biorad 
 Western blot chambers  Mini-Protean 3 cell  Biorad 
      Trans blot transfer cell Biorad 
 Autoradiography cassette Developer cassette  Siemens 
 Developer machine  Curix 60   Agfa 
 Power supplies   PowerPac 1000  Biorad 
      PowerPac HC   Biorad 
 Imaging Systems   ChemiDoc XRS  Biorad 
 Bacterial incubator 
o Shaking incubator Innova 44   New Brunswick   
         scientific 
o Standard incubator Kelvitron T   Heraeus 
 Tissue culture hood  Hera Safe   Heraeus 
 Cell incubator   Hera Cell 150   Heraeus 
 Transfection apparatus  Nucleofector   Lonza 
 Cell counting chamber  Neubauer chamber  Optik Labor 
 Heating shaking block  HTMR-133   HLC 
 Shaker    3015    GFL 
      VS.R23    Grant BOEKEL 
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 pH meter    pH level 1   inoLab 
 Microscopes 
o Inverted microscope Leica DMIL   Leica 
o Fluorescene microscope Axioplan 2    Zeiss 
 Tissue homogenizer  Basic Ultra Turrax  IKA 
3.3.2 Chemicals 
Whenever possible, only chemicals with the purity grade “pro analysis” were used for the 
experiments described in this work. All standard chemicals and organic solvents were 
purchased from the following companies:  
 Sigma Aldrich,   Taufkirchen  Germany   
 Roche Molecular Biochemicals, Mannheim  Germany 
 Life sciene (formerly Invitrogen), Leek   Netherlands 
 Merck,    Darmstadt  Germany 
 Amersham,   Freiburg  Germany 
 Qiagen,    Hilden   Germany 
 AppliChem,   Darmstadt  Germany 
 Roth,    Karlsruhe  Germany 
For RNA isolation and analysis, only RNase-free chemicals were used. 
3.3.3 Frequently used kits 
The followings kits were used throughout routine lab work: 
 LowCell ChIP Kit      Diagenode 
 PowerSYBR green PCR Master Mix   Applied Biosystems 
 BigDye Terminator V1.1 Sequencing Kit   Applied Biosystems 
 LightCycler FastStar DNA Master SYBR green I  Roche 
 FastStart HighFidelity PCR-System   Roche 
 QIAshredder      Qiagen 
 RNase-free DNase I Set     Qiagen 
 RNeasy Mini Kit      Qiagen 
 QuantiTect Reverse Transcription Kit   Qiagen 
 QiaQuick PCR Purification Kit    Qiagen 
 Qiagen MiniPrep Kit     Qiagen 
 EndoFree Plasmid Maxi Kit    Qiagen 
 pcDNA3.1/V5-His TOPO TA Expression kit   Invitrogen 
 Quant-iT RiboGreen RNA assay Kit   Invitrogen 
 Superscript VILO      Invitrogen 
 SuperSignal West Pico ECL Substrate   Pierce 
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 BCA Protein Assay Reagent     Pierce 
 Nucleofector Kit for primary mammalian fibroblasts Lonza 
 CytoTox 96 non-radioactive cytotoxicity assay   Promega 
 Proteasome-Glo 3-Substrate Cell-Based Assay System  Promega 
 PepTag Assay for non-radioactive Detection of PKA Promega 
 QBT Fatty Acid Uptake Kit     Molecular Devices 
 CatchPoint Cyclic-AMP fluorescent assay kit  Molecular Devices 
 EpiQuik Global Histone H3 acetylation assay   EpiGentek 
3.3.4 Reagents used for molecular biology 
 Reagents for the work with nucleic acids 
o Oligo d(T) primers 0.5 µg/µl   Fermentas 
o 100 bp DNA Ladder    Invitrogen 
o 1 kb DNA Ladder     Invitrogen  
o Agarose      Sigma  
o GTG low-melting agarose   Nu Sieve 
o TBE-buffer (10x)     AppliChem  
o dNTPs      PeqLab 
o Ethidiumbromide     AppliChem 
 Reagents for the work with proteins 
o PageRuler Plus     Fermentas (SM1811) 
o Non-fat dried milk powder   AppliChem (2710453) 
o RIPA-buffer     Sigma 
o Complete Mini Protease Inhibitors  Roche 
o Leupeptin      Sigma 
o Aprotinin      Sigma 
o Aqua plus (29:1) Acrylamide   AppliChem (50984) 
o Ammoniumpersulfat    AppliChem 
o SuperSignal West Pico ECL Substrate  Pierce 
o Coomassie Brilliantblue R-250   AppliChem 
o Bovine serum albumin (BSA)   Sigma 
o Ponceau S      Sigma 
o Restore Western Blot Stripping Buffer  Pierce 
 Reagents for the work with bacteria 
o Ampicillin      Sigma 
o Kanamycin     Sigma 
o Bacto-Trypton     AppliChem 
o Bacto-Yeast-Extract    AppliChem 
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3.3.5 Reagents and supplies for cell culture 
 1xPBS Dulbecco w/o Ca2+, Mg2+,  low endotoxin Biochrom (L1825) 
 Trypsin-EDTA-Solution     Sigma (T3924) 
 DharmaFECT 1 Transfection Reagent   Dharmacon (T-2001) 
 Dimethylsulfoxide (DMSO)    Sigma 
 Disposable Filter Unit 0.2 μm FP30/0.2 CA-S  Whatman 
 4′,6-Diamidin-2-phenylindol (DAPI)   Vector Labs (H-1200) 
 Thiazolyl blue tetrazolium bromide (MTT)  Sigma 
 Amphotericin B      Gibco 
 Dimehtylformamide (DMF)    Sigma 
 Fetal Calf Serum,       Biochrom AG 
 PenStrep (Penicillin Streptomycin)   Invitrogen 
 Opti-MEM       Invitrogen (31985) 
For individual cell culture medium formulation, contents and suppliers please see 3.5.1. 
For reagents which were used in specific experiments such as HDACi treatment please see 
Table 13. 
3.3.6 Reagents for HPLC-MS/MS 
 Methylene chloride      Sigma (65463) 
 Triethylamine (TEA)      Sigma (17924) 
 2-chloro-1-methylpyridiniumiodide (CAS 14338-32-0)  Sigma (198005) 
 4-dimethylamino-benzylamindihydrochloride (CAS 34403-52-6) Sigma (285633) 
 Acetonitrile (ACN)      Sigma (34998) 
 Formic acid       AppliChem (3536) 
 HPLC-purified water      Sigma (34877) 
 Perdeuterized valproic acid (d15-VPA)(D5491)   CDN isotopes  
3.3.7 Enzymes 
The following enzymes were used throughout this study. 
 Taq DNA Polymerase Recombinant    Invitrogen  
          (10342020) 
 RNase-free DNase I      Qiagen (79254) 
 Exonuclease I       NEB (M0206) 
 Shrimp alkaline phosphatase I (SAP I)    NEB (R0569) 
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3.3.8 Purchased vectors 
 Myc-DDK-tagged ORF clone of Homo sapiens IGFBP5  Origene(RC203797) 
in pCMV 6 entry (Figure 66) 
3.4 Antibodies 
3.4.1 Primary antibodies 
Antibody Host species 
Blocking 
reagent 
Dilution 
Incubation 
time 
Supplier 
Product 
number 
-SMN mouse, monoclonal milk 1:2,000 2 h BD labs S55920 
-actin mouse, monoclonal milk 1:15,000 1 h Sigma A1978 
-tubulin rabbit, polyclonal milk 1:2,000 1 h Sigma T2200 
hTRA2 rabbit, polyclonal milk 1:2,000 2 h produced by Epigentech 
SRP20 mouse, monoclonal milk 1:200 o.n. Abnova 
H00006428-
M08 
SF2/ASF rabbit, polyclonal milk 1:1,000 o.n. Abcam ab-38017 
Gemin2 rabbit, polyclonal BSA 1:200 o.n. CIND MANSIP1a 
Gemin3 mouse, monoclonal BSA 1:250 o.n. Santa Cruz sc-57007 
PKAcat rabbit, polyclonal milk 1:200 o.n. Abcam ab-65067 
ODC mouse, monoclonal milk 1:1,000 2 h Abcam ab-66067 
Ubiquitin mouse, monoclonal milk 1:1,000 o.n. Santa Cruz sc-58448 
p53 mouse, monoclonal milk 1:250 o.n. Abcam ab-78316 
-SMN rabbit, polyclonal milk 1:250 o.n. Santa Cruz sc-15320 
-RAR rabbit, polyclonal BSA 1:1,000 o.n. Abcam ab-53161 
-CD36 rabbit, polyclonal BSA 1:1,000 o.n. Santa Cruz sc-7309 
-IGFBP5 * rabbit, polyclonal BSA 1:100 o.n. Santa Cruz sc-13093 
-SMN        
(FITC-labelled) 
mouse, monoclonal 
(used for fluorescene  
microscopy, see 3.8.2) 
BD labs 610646 
-H3K9ac rabbit, polyclonal (used for ChIP, see 3.10.2.1) Diagenode pAb-005-044 
Table 4 List of primary antibodies used throughout this study. * whenever the -RAR antibody was 
used, the NaCl concentration in the TBS-T buffer was increased from 137mM to 500mM 
during antibody incubation 
Antibody Host species 
Blocking 
reagent 
Dilution 
Incubation 
time 
Supplier Product number 
-mouse IgG goat milk/BSA 1:10,000 1 h Dianova 115-35-000 
-rabbit IgG donkey milk/BSA 1:5,000 1 h 
GE 
healthcare 
N934AV 
Table 5 List of secondary HRP-labeled antibodies, which were used for the detection of primary 
antibodies listed above (Table 4). 
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3.5 Solutions and media 
3.5.1 Media for eukaryotic cell culture 
Media for primary human fibroblasts (for 556,4ml): 
 1xD-MEM +4500 mg/l D-Glucose, +L-Glutamine,  500 ml (Invitrogen, #41966) 
+Pyruvate 
 Fetal calf serum (FCS)     50 ml (Biochrom) 
 Penicilin/Streptomycin     5 ml (Invitrogen) 
 Amphotericin B (250 µg/ml)    1.4 ml (Promocell) 
Media for murine embryonic fibroblasts (for 555,5ml): 
 1xD-MEM +GlutaMAX™, +4500 mg/l D-Glucose,  500 ml (Invitrogen, #31966) 
+Pyruvate 
 Fetal calf serum (FCS)     50 ml (Biochrom) 
 Penicilin/Streptomycin     5 ml (Invitrogen) 
 -Mercaptoethanol (10mM)    555 µl (Applichem) 
Media for stably transfected NSC-34 SMN bla cells (for 557 ml) (3.10.5): 
 1xD-MEM + 4500 mg/l D-Glucose, + L-Glutamine,  
+25 mM HEPES buffer      500 ml (Invitrogen, #42430) 
 Fetal calf serum (FCS)     50 ml (Biochrom) 
 Penicilin/Streptomycin     5 ml (Invitrogen) 
 Amphotericin B (250 µg/ml)    1.4 ml (Promocell) 
 G-418 (500 mg/ml)      557 µl (Gibco) 
Media for siRNA-transfection of primary human fibroblasts: 
 Opti-MEM       (Invitrogen, #31985) 
Freezing media for eukaryotic cells (for 1 ml): 
 DMSO       100 µl (Sigma) 
 Fetal calf serum (FCS)     900 µl (Biochrom) 
3.5.2 Frequently used buffers and solutions 
 10% Ammonium persulfate solution (10 ml)  
  → 1 g APS in 10 ml dH2O 
 6% Blocking solution (100 ml)  
  → 6 g fat-dry milk powder or BSA in 100 ml TBS-T 
 DEPC-H2O (1 l)  
  → 1 ml Diethylpyrocarbonate in 1 l ddH2O, mix o.n. then autoclave 
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 100 mM dNTP-Mix (1 ml)  
   → 12,5 µl of each dNTP, add ddH2O to 1 ml  
 LB-Media (2 l)  
  → 20 g Bacto Trypton, 10 g Bacto-Yeast Extract, 10 g NaCl, adjust pH to 7,5  
           then autoclave, store at 4°C 
 LB-Agar (500 ml)  
  → 500 ml LB-Media, 7.5 g Agar, autoclave and store at 4°C 
 1 M Tris pH=6.8 (400 ml)  
  → 60 g Tris, add 300 ml dH2O, adjust pH to 6,8 fill up to 400 ml 
 1.5 M Tris pH=8.8 (400 ml)  
  → 90.5 g Tris, add 300 ml dH2O, adjust pH to 8.8, fill up to 400 ml 
 TE-4 buffer (100 ml)  
  → 1 ml Tris pH=8.0, 20 µl 0.5 M EDTA pH=8.0, add ddH2O to 100 ml 
 Bradford solution (1 l) 
o 100 mg Coomassie Bril-
liant Blue G250 
o 100 ml H3PO4 (85%) 
o 50 ml EtOH (95%) 
 2x Laemmli buffer (100 ml) 
o 0.757 g Tris-Base 
o 20 ml Glycerin 
o 10 mg Bromphenol blue 
o 6 g SDS 
o (Prior to use) 10 ml Me 
 10x DNA loading buffer (50 ml)  
o 10 ml 100 mM EDTA 
(pH 7.2-8.5) 
o 2.5 ml 20% SDS 
o 28.7 ml Glycerol 
o 0.05 g Bromphenol Blue 
o Add ddH2O to 50 ml 
 TBS-Tween (1 l)  
o 2.42 g Tris 
o 8 g NaCl 
o 5 ml Tween 20 
o Adjust pH to 7.56 
3.5.2.1 Buffers used in combination with the Mini Protean 3 cell 
 10x Electrophoresis buffer (1 l) 
o 30.29 g Tris-Base 
o 144.13 g Glycine 
o 10 g SDS 
o Add dH2O to 1 l 
 Transfer buffer (5 l) 
o 12.1 g Tris-Base 
o 56.3 g Glycine 
o 1 l MeOH 
o Add dH2O to 5 l 
3.5.2.2 Buffers used with Protean II xi cell and Trans Blot electrophoresis cell 
 5x Electrophoresis buffer (3 l) 
o 45 g Tris-Base 
o 216 g Glycine 
o 15 g SDS 
o Add dH2O to 3 l 
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 Transfer buffer (1 l) 
o 3.03 g Tris 
o 14.4 g Glycine 
o 200 ml MeOH 
o Add dH2O to 1 l 
Separating & stacking gel for both SDS-PAGE chambers  
  12% separating gel 4% stacking gel 
  Mini  Cell Protean II xi Mini  Cell Protean II xi 
  5 ml 25 ml 2 ml 5 ml 
dH2O 1.7 ml 8.375 ml 1.4 ml 3.05 ml 
Acrylamide 
(29:1) 
2 ml 10 ml 330 µl 650 µl 
1.5 M Tris pH=8.8 1.3 ml 6.25 ml  ---  --- 
1 M Tris pH=6.8  ---  --- 250 µl 1.25 ml 
10% SDS 50 µl 250 µl 20 µl 50 µl 
10% APS 50 µl 250 µl 20 µl 50 µl 
TEMED 2 µl 10 µl 2 µl 5 µl 
Table 6 Recipes for the preparation of SDS-PAA gels. 5 ml gels were run at 50-100 V, whereas 25 ml  
gels were run at an amperage of 18 mA. Blots of 5 ml gels were performed at 30 V o.n. and 
those of 25 ml gels at 100 mA o.n. at 4°C. 
3.6 Primers and siRNAs 
3.6.1 Primers 
All primers used in this thesis were designed using the Primer Select software contained in 
the Lasergene package (DNA Star Inc.) or by hand. Primers were purchased from Metabion.  
Transcript Ensembl ID Sequence (5´ → 3´) ID# Name Tm 
SMN FL ENSDARG00000018494 
fwd CCA CCA CCC CAC TTA CTA TCA 1449 SMN ex5 for 
63°C 
rev GCT CTA TGC CAG CAT TTC TCC T 3054 
SMN_Ex7/8_re
1 
SMN FL ENSDARG00000018494 
fwd CCA CCA CCC CAC TTA CTA TCA 1449 SMN ex5 for 
61°C 
rev GCT CTA TGC CAG CAT TTC CAT A 1450 SMN Ex 6/8 rev 
hTRA2-1 ENSG00000136527 
fwd CCG AAG GCA TTA TAC CCG 2836 Htra_fw1a 
63°C 
rev CTC AGC CCA AAT ACT C 2841 Htra_rev1a 
SF2/ASF ENSG00000136450 
fwd CCG TGC GCT AGG CTT GGT G 3412 SF2/ASF fwd 
63°C 
rev CCC CCG CGG CGA TTC TTG A 3413 SF2/ASF 
SRp20 ENSG00000136450 
fwd GAA CGG GCT TTT GGC TAC TAT  3414 SRp20 fwd 
61°C 
rev TGG GCC ACG ATT TCT ACT TCT T 3415 SRp20 rev 
hnRNP A1 ENSG00000135486 
fwd GCC TGA GGA GCC ATT TTG AGC 3410 hnRNP A1 fwd 
61°C 
rev AGT GGG CAC CTG GTC TTT GAG 3411 hnRNP A1 rev 
c-Myc ENSG00000136997 
fwd CGA CGC GGG GAG GCT ATT CTG  3607 c-Myc fwd 
69°C 
rev GTC GCG GGA GGC TGC TGG TTT  3608 c-Myc rev 
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Col3A1 ENSG00000168542 
fwd CAG GGG CCC CAG GAC TTA GAG  3605 CollagenIIIafwd 
68°C 
rev GGG CCA GGA GGA CCA ATA GG 3606 CollagenIIIa rev 
RPS12 ENSG00000112306 
fwd CGC AAG CCG AAG AAG CCC AAC  3588 RPS12 fwd 
61°C 
rev GCC CCC AGC CGT CAC TTC TTC T 3589 RPS12 rev 
PKAcat ENSG00000072062 
fwd CCG GCG GGT GAT GCT GGT G 3774 PKA fwd 
69°C 
rev CCG ATC CGC CGT AGG TGT GA 3775 PKA rev 
Gemin2 ENSG00000092208 
fwd CCGGTAGAGCCTTGCGA TTGAC 3399 Gemin2 fwd 
64°C 
rev CCACTTGTTGCTGTTGCCATTGAA 3400 Gemin2 rev 
Gemin3 ENSG00000064703 
fwd GGAGGGACCCCATT TCACAAGA 3405 Gemin3 fwd2 
65°C 
rev CTGGCAGGCAAGGAAGAATAAAT 3406 Gemin3 rev2 
Table 7 Primers used for qRT-PCR on the LightCycler 1.5 machine (Roche). 
 
Transcript Ensembl ID Sequence (5´ → 3´) ID# Name 
TMTC2 ENSG00000179104 
fwd gtg ggg aag cga ggg aaa agt gaa 3798 TMTC2 fwd 
rev gag ggc agc agc ggc aac aa 3799 TMTC2 rev 
TGF ENSG00000163235 
fwd agt ggt gcc ggg ccc tca tct g 3800 TGFA fwd 
rev cca cct ggc caa act cct cct ctg 3801 TGFA rev 
RAR ENSG00000077092 
fwd cgc ccc ggc tgg att gg 3802 RARB fwd 
rev ttt ggc acg tag gct gtt ggt ctt 3803 RARB rev 
PITPNM3 ENSG00000091622 
fwd ggc cgg ccc acc aag aag ta 3804 PITPNM3 fwd 
rev ctc cag cgc ggc cag gtg tgc 3805 PITPNM3 rev 
MAB21L1 ENSG00000180660 
fwd tgg ccg gca agc aga gc 3806 MAB21L1 fwd 
rev tgg ccc ggc agt tca agg tg 3807 MAB21L1 rev 
LYPD6b ENSG00000150556 
fwd aaa tgg gca ccc acg ctg tat gtc 3808 LYPD6bnew fwd 
rev ggc caa tga ctc atg cag gtc tgt 3809 LYPD6bnew rev 
LYPD6 ENSG00000187123 
fwd ccg agc atg aag gcc aca agg tct 3810 LYPD6 fwd 
rev ttt cgg ggc agt ggc aag tta cag 3811 LYPD6 rev 
LOC404266 ENSG00000233101 
fwd ccc ggg cgt ggc gtg gtc 3812 LOC404266 fwd 
rev agg ggg tgg gga agg gaa tga gtc 3813 LOC404266 rev 
KIAA1772 ENSG00000141449 
fwd ccc tcg gac ata cca aga ttt aga 3814 KIAA1772 fwd 
rev tcc aag gcc gtg cga gtt a 3815 KIA1772 rev 
HOXD11 ENSG00000128713 
fwd gct gtc gtt ccc cct ccc cct ctc 3816 HOXD11 fwd 
rev ccc cca acc cgg ccc aac ttc cta 3817 HOXD11 rev 
HOXD10 ENSG00000128710 
fwd caa aac cgc cga atg aaa ctc 3818 HOXD10 fwd 
rev gaa cgc ggt gcc ccc tct c 3819 HOXD10 rev 
HOXB3 ENSG00000120093 
fwd tcc cgg cac caa ctc cac cct cac 3820 HOXB3 fwd 
rev acc gcc gcc gcc acc aca g 3821 HOXB3 rev 
GALNT12 ENSG00000119514 
fwd ccg gct gct ggg ggc gtc tg 3822 GALN12 fwd 
rev cat caa tca ccg ggc aca cca ctg 3823 GALN12 rev 
EPHA4 ENSG00000116106  
fwd gga agg cgt ggt cac taa atg taa 3824 EPHA4 fwd 
rev atg ccc acc agc tga atg act 3825 EPHA4 rev 
DIO2 ENSG00000211448 
fwd ggc tga ccg cat gga caa taa cg 3826 DIO2 fwd 
rev cca gcc aat gcc gga ctt ctt 3827 DIO2 rev 
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C11orf87 ENSG00000185742 
fwd gcg tgg gct ccg tcc tct tct tg 3828 C11orf87 fwd 
rev cgg cgc cct ggc act cat tg 3829 C11orf87 rev 
CD36 ENSG00000135218 
fwd cag cct cat ttc cac ctt ttg 3830 CD36 fwd 
rev cct ttc aga tta acg tcg gat tc 3831 CD36 rev 
IGFBP5 ENSG00000115461 
fwd cca ccc cca acg cca tct cca 3832 IGFPB5 fwd 
rev cac ccc caa gca acc acc gaa ata 3833 IGFBP5 rev 
ANKRD1 ENSG00000148677 
fwd gca gac ctc aac gcc aaa gac ag 3834 ANKRD1 fwd 
rev ccg cgc cat aca taa tca gga gt 3835 ANKRD1 rev 
PPAR ENSG00000132170 
fwd cca cag gcc gag aag gag aag c 4017 PPARg fwd 
rev cca ggg ccc gga ggt cag 4018 PPARg rev 
MCT1 
(SLC16A1) 
ENSG00000155380 
fwd ttc ttg ggg gct tgc tac taa act 4019 MCT1 fwd 
rev gct tgg gcc cga ttg gtc 4020 MCT1 rev 
MCT2 
(SLC16A7) 
ENSG00000118596 
fwd agc cgg ccg gtg gtg ata g 4021 MCT2 fwd 
rev taa ggc ggg ttg cag gtt gaa 4022 MCT2 rev 
MCT3 
(SLC16A8) 
ENSG00000100156 
fwd cgc ccc gct tcc cca gtg c 4023 MCT3 fwd 
rev cag agc cgg cca ggt aga aga tga 4024 MCT3 rev 
Table 8 Primers used for qRT-PCR on the ABI 7500 Taqman machine (Applied Biosystems) 
Promoter Ensembl ID Sequence (5´ → 3´) ID# Name 
CPT1C ENSG00000169169 
fwd gaa ggg gcg ggg ata gaa cg 4035 cCPT1C fwd 
rev gga gtc ctg ccc acc ccg aga t 4036 cCPT1C rev 
AZGP1 ENSG00000160862 
fwd ggc ccc agg acc cag gat aa 4039 cAZGP1 fwd 
rev gac agc agg aca ggc acc att ct 4055 cAZGP1 rev 
CD36 ENSG00000135218 
fwd taa gtt tcg caa gct cag tca aga 4056 cCD36 fwd 
rev aga ggc cag aaa aac aaa agg aac 4057 cCD36 rev 
TGF ENSG00000163235 
fwd gcc cgc ccg ccc gta aaa tgg tc 4058 cTGFa fwd 
rev ccg ggg gaa gca ggg tgt cg 4059 cTGFa rev 
RAR ENSG00000077092 
fwd cag aca gaa agg cgc aca gag gaa 4060 cRARb fwd 
rev ttg cgc cgg ctt agc ttg gaa aac 4061 cRARb rev 
IGFBP5 ENSG00000115461 
fwd ggt ggc aaa gtg gga gaa aag agg 4062 cIGFBP5 fwd 
rev cgg cgc cgc aga aca ggt aa 4063 cIGFBP5 rev 
SMN 
Region 1 
ENSDARG00000018494 
fwd cag agt ttc ttt gtt ggg tg   3361 Husp1_fw_M 
rev taa tcg ttt tag aga gta caa ttg   3362 Husp1_rev_M 
Region 2 
fwd ttg tac att ggc aac atc atc  3026  Husp2_fw 
rev cac gaa agg aac ttt gag ctc ttc  3027  Husp2_rev 
Region 3 
fwd ggt ttt aaa ttc cta gta gga gct tac a   3028 Husp3_fw 
rev ggg ttt cgg cat gtt gct t  3029  Husp3_rev 
Region 4 
fwd cac tcg tag aaa gcg tga gaa gtt a  3030  Husp4_fw 
rev gct tct tgg gag cgg aac ag   3031 Husp4_rev 
Table 9 Primers used for qPCR-anaylsis of ChIP experiments (3.10.2.1) 
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Gene/Plasmid Ensembl ID Sequence (5´ → 3´) ID# Name 
CD36 ENSG00000135218 
fwd ATG GGC TGT GAC CGG AAC TG 3921 CD36clone ex6ATG fwd 
rev TTT TAT TGT TTT CGA TCT GCA 3922 CD36clone ex17 rev 
RAR ENSG00000077092 
fwd ATG TTT GAC TGT ATG GAT GTT C 3925 RARßclone ex1ATG fwd 
rev TTG CAC GAG TGG TGA CTG ACT G 3926 RARßclone ex8 rev 
TGF ENSG00000163235 
fwd ATG GTC CCC TCG GCT GGA CAG C 3927 TGFa ex1ATG fwd 
rev GAC CAC TGT TTC TGA GTG GC 3928 TGFa ex5/6 rev 
pcDNA3.1-
V5/His-Topo 
 --- 
fwd TAA TAC GAC TCA CTA TAG GG 1840 T7 fwd 
rev AG AAG GCA CAG TCG AGG 1282 BGH 
rev GTT AGG GAT AGG CTT ACC TTC GAA 2951 TOPO_V5_rev 
Table 10 Primers used for TOPO TA cloning (3.9.6.1) and subsequent analysis including sequencing. 
 
Inbred 
strain 
Gene/ 
transcri
pt 
Sequence (5´ → 3´) ID# Name 
Amplicon 
length 
SMAHung 
Wt 
Smn 
fwd ATA ACA CCA CCA CTC TTA CTC 3370 Hung WT fw 
1050 bp 
rev GTA GCC GTG ATG CCA TTG TCA 3372 Hung WT_KO rev 
Hung 
KO 
fwd AGC CTG AAG AAC GAG ATC AGC 3371 Hung KO fw 
950 bp 
rev ATA ACA CCA CCA CTC TTA CTC 3372 Hung WT_KO rev 
transgenic 
5´UTR of 
SMN2 
fwd ACT GCA ACC TCC TGG GTT CAA GTG 3373 
HungSMA_mouse_tgS
MN2_fw_1F 
172 bp 
rev CAG TTC GAG ACC AGC CTG ACC AAT 3374 
HungSMA_mouse_tgS
MN2_rev_1B 
SMABurghes 
Wt 
Smna 
fwd CCG GGA TAT TGG GAT TGT AG 2649 m_smn forw 
782 bp 
rev TTC TTT TGG CTT TTA TTC TTC TTG 2650 m_smn rev 
Hung 
KOb 
fwd CCA GGC GAT TAA GTT GGG TAA CG 2647 GNA3 
600 bp 
rev GGC CTG GAA TTC AAT ATG CTA GAC TGG 2648 GMS11 
hSMN2 
fwd GTA AAC CAA AAA CCA CAC CTA AA 2713 hum SMN2 Ex2b forw 
1040 bp 
rev GGG AAA GTA GAT CGG ACA GAT 2714 hum SMN2 Ex3 rev 
Table 11 Primers used for genotyping of mice. All PCRs were performed using 0.5 µl of DNA-solution.  
a
 
1
/10 Vol 1 M Betain (Sigma) were added to the PCR mix to obtain signals. 
b
 
1
/10 Vol 
Q-Solution (Qiagen) were added. 
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3.6.2 siRNAs (small interfering RNAs) 
Target 
Transcript 
Ensembl ID Sense Sequence Supplier 
Product 
number 
hTRA2-1 ENSG00000136527 r(CGA UCU GAA UCU AGG UCU A)dTdT Qiagen SI02653504 
SRp20 ENSG00000112081 r(GGA AAU AGA AGA CAG UUU G) dTdT Qiagen * 
CD36 ENSG00000135218 r(GAA CCU AUU GAU GGA UUA ATT)dTdT Qiagen SI0001330 
IGFBP5 ENSG00000115461 r(GCC CAA UUG UGA CCG CAA ATT)dTdT Qiagen SI00012558 
TGF ENSG00000163235 r(CGG UAA GUA UGU UUA GAA ATT)dTdT Qiagen SI00049427 
RAR ENSG00000077092 r(GCC AGU UCA GUU AAU CAA AAT)dTdT  Qiagen  SI00019404 
siTOX control siRNA inducing apoptosis Dharmacon D-001500-01-05 
AllStars Negative 
Control siRNA Non-targeting siRNA Qiagen 1027280 
Table 12 siRNAs used throughout this thesis. * siRNA targeting SRp20 was a custom designed siRNA. 
Sequence was taken from (Bedard et al. 2007) 
3.7 Software, internet programs and databases 
The following software programs were used. 
 Quantity One 4.5.1  (densiometric analysis) Biorad 
 EndNote9/X2   (reference organization) Thomson Research 
 SigmaPlot 9/10   (creation of graphs)  Systat Software Inc. 
 Photoshop CS   (image editing)  Adobe 
 Office 2003/2007   (word processing etc.) Microsoft 
 LightCycler Software  (qRT-PCR analysis)  Roche 
 Sequence Detection Software (qRT-PCR analysis)  ABI 
 XFluor4Safire² software  (platereader)   Tecan 
 AxioVision Rel.4.7  (fluorescence imaging) Zeiss 
 Lasergene Package  (Sequence analysis)  DNAstar Inc. 
The following databases and internet programs were routinely employed. 
 NCBI    http://www.ncbi.nlm.nih.gov/ 
 Genecards   http://www.genecards.org/ 
 Ensembl    http://www.ensembl.org/ 
 UCSC    http://genome.ucsc.edu/ 
 Medline    https://www.ncbi.nlm.nih.gov/pubmed 
 OMIM    http://www.ncbi.nlm.nih.gov/omim 
 Gene Expression Atlas database http://www.ebi.ac.uk/gxa/ 
 Human promoter database http://zlab.bu.edu/~mfrith/HPD.html 
 Exon Primer   http://ihg2.helmholtz-muenchen.de/ihg/ExonPrimer.html 
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3.8 Cell culture procedures 
All cell culture work was performed under sterile conditions to avoid any contaminations 
with fungi or bacteria. Sterile conditions were guaranteed by laminar flow cell culture hoods 
as well as sterile solutions and materials. Growing cell lines were kept in an incubator at 37°C 
in a humid atmosphere containing 5% CO2. If not noted differently, cell culture media were 
supplemented with amphotericin B and penicillin/streptomycin.  
3.8.1 Cell culture of eukaryotic cells 
Fibroblast cell lines were grown as adherent monolayer cultures in D-MEM medium 
containing 10% FCS (3.5.1). Routinely, fibroblasts were cultured in either 25 cm2 or 75 cm2 
flaks, and, depending on the cell division rate, fibroblasts were splitted once or twice a week 
into new flasks. To split fibroblasts, cells were first washed once with 1xPBS w/o Mg2+, Ca2+ 
(Biochrom) and then trypsinised using Trypsin-EDTA (Sigma). After stopping the 
trypsinisation by addition of 1 Vol fibroblast medium, the cell suspension was evenly 
distributed into new flasks and media was added to a final volume of either 7 or 12 ml, 
respectively.  For long-term storage fibroblasts were frozen in liquid nitrogen. To this aim, 
following trypsinisation fibroblasts were pelleted for 10 min at 500 x g and afterwards 
resuspended in freezing medium (3.3.5).  Next, fibroblasts were frozen over night at -80°C 
and then transferred to -196°C. At any time these aliquots can be taken again into culture. 
Murine embryonic fibroblasts (MEF) and NSC-34 cells were basically cultured using the 
same procedures as described above, but a different medium was used. For detailed 
information see 3.5.1. 
3.8.1.1 Treatment of cells with different compounds 
To treat cells with any compound, cells were first grown to approx. 80% confluency, 
trypsinised and then counted using a haemocytometer.  After counting, an adequate 
number of cells were plated out (15 cm petri dish: 1x106 cells; 10 cm petri dish: 
2x105 fibroblasts; 6-well plate: 1x105 fibroblasts per well; 96-well plate: 1x104 fibroblasts per 
well) and cultured for 24 h to let the cells settle and start proliferating. For every 
experiment, at least one petri dish served as untreated control and was incubated with the 
respective solvent only (Table 13). All experiments were performed at least as triplicates or 
three different cell lines were used to calculated data. Final results are given as mean ± SEM 
if not indicated different. 
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Assay Compound Supplier Mode of action 
Time of 
treatment 
Concentration 
used 
Solvent 
SMN2 
activation 
Valproic acid 
(VPA) 
Sigma HDACi 16 h 5 µM - 5 mM ddH2O 
LBH589 
(Panobinostat) 
Novartis HDACi 16 h - 72 h 
100 nM - 1 
µM 
DMSO 
JnJ26481585 JnJ HDACi 16 h - 72 h 10 nM - 5 µM DMSO 
Sodium butyrate Sigma HDACi 24 h 500 µg/ml  ddH2O 
Phenylbutyrate  Sigma HDACi 4 h 2 mM DMSO  
mRNA 
stability 
Actinomycin D Sigma 
RNA synthesis 
inhibitor 
0 h - 25 h 5 µg/ml DMSO 
Protein 
stability 
NH4Cl AppliChem 
Lysosome 
inhibitor 
15 h 20 mM ddH2O 
MG-132                         
(Z-Leu-Leu-Leu-al) 
Sigma 
Proteasome 
inhibitor 
15 h 5 µM - 5 mM DMSO 
Bortezomib 
(Velcade) 
kind gift of    
Dr. Kashkar 
Proteasome 
inhibitor 
24 h 1 - 20 nM ddH2O 
Fatty acid 
uptake 
Oligomycin Sigma 
ATP synthase 
inhibitor 
16 h  10 µg/ml DMSO 
SSO                                           
(Sulfo-N-succini-    
midyl ester) 
Santa Cruz CD36 inhibitor 16 h  400 µM DMSO 
Oleic acid Sigma fatty acid  1 mM 16 h DMSO 
Retinoic acid Sigma   Bioactive acid 16 h  1 µM  DMSO 
cAMP ELISA 
Forskolin Sigma AC activator 2 h 100 µM DMSO 
IBMX                     
(3-isobutyl-1-
methylxanthine) 
Sigma PDE inhibitor 2 h 1 mM DMSO 
ddA 
(Dideoxyadenosin) 
Sigma AC inhibitor 16 h 0,5 mM DMSO 
Table 13 Compounds used for the treatment of primary fibroblasts (AC = Adenylyl cyclase, PDE = 
Phosposdiesterase). Given are concentrations and time periods typically used. Exceptions 
are separately mentioned in the text. 
3.8.1.2 Transient transfection of primary human fibroblasts 
To study the role of any protein inside the cellular machinery, it can either be knocked-
down or overexpressed. In both cases, nucleic acids have to be introduced into the cell 
either by lipofection, transduction or electroporation. To transfect primary human 
fibroblasts with either siRNAs or plasmids two different protocols were employed.  
For the transfection with siRNAs, 20 µM stocks of siRNAs in ddH2O were prepared, which 
were then diluted to a final concentration of 1 µM. 24 h prior to transfection, 
2x105 fibroblasts were plated out in a 6-well plate per transfection. At the day of 
transfection, 100 µl of the respective 1 µM siRNA solution were mixed with 100 µl Opti-MEM 
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(Gibco) and incubated for 5 min at RT.  At the same time, 2 µl of the transfection reagent 
Dharmafect1 (Dharmacon) were incubated with 198 µl Opti-MEM and also incubated for 5 
min at RT. Afterwards both solutions were combined and incubated for 20 min at RT to allow 
the formation of lipophilic complexes. Next, the culture medium was removed from the 
fibroblasts. Subsequently, 1.6 ml of fibroblast media w/o antibiotics were added 
(cfinal[siRNA]=50 nM) to the lipophilic complexes and the solution was added onto the cells. 
The non-targeting AllStars Negative Control siRNA (Qiagen) served always as mock control, 
whereas the siTOX siRNA (Dharmacon), which induces apoptosis allowed estimations of the 
transfection rate. All siRNA transfections were performed as triplicates. 
To transfect fibroblasts with expression plasmids, the Basic Nucleofector Kit for Primary 
Mammalian Fibroblasts (Lonza) was used according to the manufacturer´s instructions. In 
brief, for each transfection 3x105 fibroblasts from approx. 80% confluent flasks were 
trypsinised, pelleted and resuspended in 100 µl Nucleofector solution. 2 µg of the respective 
plasmid were added and transfection was carried out using the program U-20. Afterwards, 
1.5 ml of pre-warmed fibroblast media were added and the cell-suspension was dispensed 
into a single well of a 6-well plate. Transfection with the pmaxGFP expression vector (Lonza) 
served as transfection control. 
After the respective incubation time, fibroblasts were harvested for isolation of either RNA 
or protein (3.9.2.1.1 and 3.10.1.1.1). 
3.8.1.3 Cytotoxicity and cellviability assays 
To investigate the impact of HDACi treatment on the viability of fibroblasts as well as to 
allow estimations of toxic side effects, MTT and LDH assays were performed. Furthermore, 
the MTT-assay was used to assess siRNA-transfection rates (3.8.1.2). 
3.8.1.3.1 MTT assay 
Assessment of the number of viable fibroblasts was performed using a MTT assay. MTT 
(3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide), a yellow tetrazole salt, is 
reduced in active proliferating cells by the reduction equivalents NADH and NADPH to 
formazan (Berridge and Tan 1993). Formazan production leads to the formation of violet 
crystals having a distinct absorption maximum from MTT at 570 nm. Therefore, the amount 
of formed formazan is directly proportional to the glykolysis rate, which in turn gives a hint 
about the cell viability. To quantify formazan formation, some 1x104 fibroblasts in 200 µl 
were seeded in each well of a 96-well plate as described previously (Riessland et al. 2006), 
and 24 h later treated with the HDACi. After the respective incubation period, medium was 
replaced by 225 µl fresh-medium + 25 µl MTT stock solution (50mg MTT (Sigma) in 10 ml 
1xPBS (Biochrom)). Fibroblasts were again incubated for approx. 3 h at 37°C and 5% CO2 and 
then lysed by adding 1 Vol 20% SDS/DMF (1:1) and subsequent shaking for 30 min and 
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750 rpm on a shaking incubator. Next, photometric absorption was measured on a Safire² 
plate reader (Tecan).  For all measurements eight replicates were performed. 
To assess siRNA transfection rates fibroblasts, transfected with AllStars Negative- (Qiagen) 
were compared to fibroblasts transfected with siTOX siRNA (Dharmacon) via a MTT assay as 
described above. 
3.8.1.3.2 LDH assay 
Quantifaction of cytotoxicity was performed with the CytoTox 96 non-radioactive 
cytotoxicity assay (Promega). It is based on the finding that the lactate dehydrogenase (LDH), 
a typically cytoplasmatic enzyme, is rapidly released in the cell culture supernatant upon 
necrosis. Addition of the substrate mix (containing NAD+, lactate and INT, a tetrazole salt), 
leads to the reduction of lactate to pyruvate by the LDH, whereby NAD+ is reduced to 
NADH+H+. NADH+H+ in turn reduces INT to formazan. The amount of formed formazan can 
be quantified by measuring absorption at 490 nm. 
To assess any cytotoxic effects of HDACi-treatment, 8x103 fibroblasts in 200 µl were 
seeded into each well of a 96-well and then incubated for the respective time period with 
HDACi. Then, 50 µl of cell culture supernatant were transferred into a black 96-well plate 
and mixed with 50 µl of reconstitute substrate mix. Reactions were incubated for 30 min at 
RT in the absence of light and then stopped by adding 50 µl Stop-Solution. Subsequently, 
absorbance at 490 nm was measured on a Safire² plate reader (Tecan). To calculate the 
portion of overall released LDH, a maximal LDH release sample was prepared by lysing all 
cells of a well with lysis buffer. For all measurements eight replicates were performed. 
3.8.2 Immunofluorescent staining of primary human fibroblasts 
To stain nuclear SMN-accumulations, called gems, in primary human fibroblasts, some 
1x105 cells were plated out onto flame-sterilized cover-slip put into a 6-well plate. After 
HDACi treatment, cells were washed with 1xPBS and then fixed for 10 min using ice-cold 
MeOH/Aceton (1:1). Next, fibroblasts were permeabilized for 15 min with 2% TX-100 in 
1xPBS followed by 30 min blocking with 2% BSA in 1xPBS at gentle agitation. After addition 
of a mouse monoclonal FITC-labelled SMN-antibody (BD Transduction laboratories) for 1 h 
(dilution 1:1,000), fibroblasts were washed twice with 1xPBS and then mounted using the 
Vectashield containing DAPI (VectorLabs) to ensure nuclear localization of gems. For each 
condition, 300 nuclei were analysed on a fluorescence microscope (Carl Zeiss). 
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3.9 Molecular biology methods 
3.9.1 Working with DNA 
3.9.1.1 Genomic DNA isolation 
To isolate genomic DNA from mouse tail-tip biopsies, tail-tips were lysed by incubation 
with 500 µl Tail-tip lysis buffer at 55°C for at least 3 h and 700 rpm on a shaking heating 
block. Hairs and other insoluble debris were pelleted by centrifugation for 15 min at 
16,100 x g. The supernatant was transferred to a new 1.5 ml microcentrifuge tube and 1 Vol 
Isopropanol was added to precipitate nucleic acid. After centrifugation for 15 min at 
16,100 x g, the nucleic acid pellet was washed once with 200 µl 70% EtOH and afterwards 
dried in a 37°C incubator. Finally, the pellet was resupended in 50 µl TE-4 containing RNase to 
eliminate any RNA contaminations.   
Tail-tip lysis buffer 
 100 mM Tris pH=8.5 
 5 mM EDTA 
 0.2 % (w/v) SDS 
 200 mM NaCl 
 Added fresh → 200 µg/ml Proteinase K (AppliChem)  
3.9.1.2 Determination of DNA concentration 
Determination of DNA concentrations was performed on a NanoDrop ND-1000 
spectrophotometer (Peqlab) in triplicates.  From the absorption measured at 260 and 
280 nm, the software calculated DNA concentration as well as DNA purity. Only samples 
having a 260/280 of approx 1.8 were regarded as pure and used for subsequent PCRs. Higher 
ratios would indicate RNA-contaminations, whereas lower ratios point to protein or ethanol 
remains. 
3.9.2 Working with RNA 
3.9.2.1 RNA isolation 
3.9.2.1.1 RNA isolation from eukaryotic cells 
Depending on the amount of RNA needed, total RNA was either extracted from a 10 cm 
petri dish (2x105cells) or a 6-well plate (1x105cells). To extract RNA, cells were lysed first with 
RLT-buffer and QIAshredder (Qiagen). Subsequently the RNeasy Mini kit (Qiagen) was 
performed according to the manufacturer´s protocol. The optional 20 min DNaseI (Qiagen) 
digestion step was always included to eliminate any DNA-contamination. Finally, RNA was 
eluted with ddH2O. 
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3.9.2.1.2 RNA isolation from organ tissues 
Isolation of total RNA from snap-frozen murine organ biopsies was also performed with 
QIAshredder and the RNeasy Mini Kit (both Qiagen). To ensure proper tissue breakup, 
samples were after thawing on ice homegenised using a Basic Ultra Turrax Homogeniser 
(IKA) prior to RNA extraction. For the isolation out of fatty organs such as brain and spinal 
cord, extraction steps with Qiazol (Qiagen) were included as given in the manufacturer´s 
protocol. Again DNaseI digestion was included. 
3.9.2.2 Determination of RNA concentration 
To circumvent any misleading RNA-concentrations leading to artificial qRT-PCR-data, RNAs 
were generally measured using the Quant-It RiboGreen RNA assay (Invitrogen) as suggested 
by the manufacturer. The measurement was carried out on a Safire² plate reader (Tecan) in 
96-well format (Greiner bio one, #655076) and gives far more precise measurements than 
conventional photometric assays. The kit is based on the fluorescent dye RiboGreen, whose 
fluorescence is extremely enhanced when bound to nucleic acids. RiboGreen preferentially 
binds RNA; combination with the DNaseI digestion performed during RNA extraction 
(3.9.2.1) results in a RNA specific measurement. To verify that all samples are within the 
detection range of this assay, and to ensure RNA quality (260/280 ideally 2.0), all samples were 
beforehand measured using a classical spectrophotometer (Eppendorf).  
3.9.2.3 mRNA-stability assay using Actinomycin D 
Actinomycin D, a peptide antibiotic from Streptomycus parvulus, inhibits de novo RNA 
synthesis by intercalating with the DNA. This intercalation prevents the unwinding and 
opening of the DNA double helix during transcription as well as replication. Furthermore, 
Actinomycin D crosslinks the guanine nucleotides of the DNA, which, again, blocks DNA-
dependent RNA-synthesis. To assess mRNA-stability of different transcripts, fibroblasts were 
treated 24 h after seeding out in a 6-well plate with 5 µg/ml Actinomycin D (Sigma) (Table 13). 
After treatment for the respective time periods, RNA was isolated as describe above 
(3.9.2.1.1) and later on analyzed by qRT-PCR. Half-life periods (T0.5) of different transcripts 
were calculated by approximated e-functions and are represented as means of three 
different experiments. 
3.9.2.4 cDNA synthesis 
To allow expression analysis by measuring individual mRNA abundance, RNA has first to be 
reversely transcribed into cDNA since RNA cannot serve as template for qRT-PCR (3.9.3.3). 
To this aim, cDNA was produced using the QuantiTect Reverse Transcription Kit (Qiagen), 
which also includes a DNase digestion called gDNA wipeout. Exclusive transcription of 
mRNAs was warranted using an oligo-dT Primer (Fermentas) binding to the mRNA-specific 
poly-A-tail. 
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In the case total coding sequences of genes should be cloned, the SuperscriptVilo Kit 
(Invitrogen) was used, since the total yield of the QuantiTect Reverse Transcription Kit 
(Qiagen) is too low for cloning but sufficient for qRT-PCR. 
3.9.3 Polymerase chain reaction (PCR) 
Working with DNA has greatly been boosted in 1987, when Kary Mullis published the 
polymerase chain reaction (PCR), which allowed rapid amplification of single-stranded DNA 
(Mullis et al. 1992) . This work has been honored with the Nobel Prize in chemistry in 1993. 
The technique is based on the finding that DNA-dependent DNA Polymerases are able to 
synthesize complementary copies of a single-stranded DNA, when starting from a free 3´-
end. During PCR, these free 3´-ends are given by sequence specific oligo-nucleotides (primer) 
and are then elongated by a thermostable DNA-polymerase e.g. Taq-Polymerase from 
Thermophilus aquaticus. Numerous repetition of the 3 steps denaturing, primer binding 
(annealing) and elongation yields in enormous amplification of one and the same piece of 
DNA. 
3.9.3.1 Standard PCR 
Typical PCR conditions used to amplify either DNA or cDNA were as follows: 
 10 min  at  95°C  → initial denaturation 
 30 min at  95°C → denaturation 
 30 sec at  XX°C → annealing, XX°C (depending on individual primer)           35x 
 XX min at  72°C → elongation, 1 min per kb product length 
 10 min at 72°C → final extension 
Reactions were performed using Taq Polymerase (Invitrogen) and dNTPs (PeqLab) 
according to the manufacturer´s protocol. Enhancer of PCR efficiency, such as Q-Solution 
(Qiagen) or Betain (Sigma), were added when needed (Table 11). 
3.9.3.2 Agarose gel electrophoresis/Gel-Purification of PCR-Products 
Analysis of PCR products is normally done by agarose gel electrophoresis. Since the DNA 
backbone is negatively charged, placing DNA into an electric field leads to its migration 
towards the anode. To separate PCR products of different size, the electric field is put 
through a gel matrix out of polysaccharide agarose, which allows fast moving of small 
fragments but slows down big DNA molecules. 
Gels were either prepared with Agarose (Sigma) or, if PCR products should be cloned, with 
Agarose/Low-Melting agarose (1:2) (Biozym) in 1xTBE-buffer (AppliChem). Routinely, PCR 
products were resolved on 1-2% Agarose Gels containing 1 µg/ml Ethidiumbromide 
(AppliChem), which intercalates with DNA. Ethidiumbromide-DNA complexes were visualized 
at 254 nm using a ChemiDoc XRS imaging System (Biorad). Proper size of DNA fragment was 
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estimated by comparision with either 100bp or 1kb ladder (Fermentas). If PCR products 
should be cloned, the respective bands were cut out and purified using the Qiaquick PCR 
purification kit (Qiagen) according to the manufacturer´s instructions. 
3.9.3.3 Quantitative real-time PCR (qRT-PCR) 
Standard PCR, as described in 3.9.3.1, does not allow the inference of initial template 
amounts, since it is an endpoint determination during the plateau phase of the PCR. To draw 
conclusions on the template amounts, PCR product amounts have to be determined during 
the linear-logarithmic phase of the PCR. An easy way to do this is the addition of the 
fluorescent dye SYBR-green to the PCR master mix, which binds to double-stranded DNA. 
During each elongation step, SYBR green fluorescence is detected by an adequate detector 
and plotted against the cycle number. Calculations based on these data allow the deduction 
of the initial amount of a certain template. Typically, the quantification program is followed 
by a melting curve to ensure PCR product identity. 
3.9.3.3.1 qRT-PCR using the LightCycler 1.5 
To determine transcript levels in cells or organ tissues, total RNA was extracted and 
measured as described above 3.9.2. Prior to qRT-PCR, cDNA samples were diluted 1:5 with 
TE-4 and 3 µl from this dilution were used for analysis. PCR was carried out in 10 µl scale 
(Master Mix per sample: 4.2 µl dH2O, 1.2 µl MgCl2, 1 µl each primer, 0.166 µl FastStart-Mix, 
0.33 µl Polymerase) with the FastStart DNA Master SYBR green I Kit (Roche) on a LightCycler 
1.5 machine (Roche) in 20 µl capillaries (Roche). Analysis of resulting amplification curves 
was performed with the second derivative maximum method implemented in the 
LightCycler software. Primers for individual transcripts can be found in Table 7. All 
measurements were performed as duplicates. 
3.9.3.3.2 qRT-PCR using the ABI 7500 Realtime PCR machine 
Whenever more than 32 samples should be measured simultaneously (which is the 
maximum capacity of the LightCycler 1.5), the ABI 7500 Realtime PCR machine was used, 
since it allows qRT-PCR in 96-well format. To this aim, RNA extraction and cDNA-synthesis 
was performed analog to 3.9.3.3.1. Next, cDNAs were diluted 1:10 with TE-4 and 3 µl from 
this dilution were used per reaction. PCR was carried out in 96-well plates (Bioplastic) 
covered with an optical foil (Bioplastic) using the PowerSYBR green PCR Master Mix (Applied 
Biosystems) in 25 µl scale (Master Mix per sample: 12.5 µl PowerSYBR-green Mix, 8.5 µl 
dH2O, 1 µl each primer). Analysis of raw data was performed using the Sequence Detection 
Software (Applied Biosystems). Primers for individual transcripts can be found in Table 8. All 
samples were at least measured as triplicates.  
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3.9.4 Sanger-sequencing 
Sequencing of DNA was performed using the chain terminator method developed by 
Sanger (Sanger et al. 1977) employing the BigDye Terminator V1.1 Sequencing Kit (Applied 
Biosystems). This method is based on utilization of dNTPs combined with ddNTPs, which 
leads to chain termination during PCR. Each of the four didesoxynucleotides is labeled with a 
different fluorescent dye, which allows identification of the terminal nucleotide by capillary 
electrophoresis. To sequence genomic DNA, the region-of-interest was first amplified by 
standard PCR from 40 ng genomic DNA using the primers given in the appendix Table 18 to 
Table 21. 
Next, PCR products were cleaned up using the EXO/SAP-reaction. Typically, sequencing 
reactions were set up with 5 µl 3xsequencing buffer, 1 µl Terminator Mix (Applied 
Biosystems) and 0.5-2 µl purified PCR product or 150 ng plasmid-DNA, respectively. PCR 
conditions were as recommended by the manufacturer using an annealing temperature of 
55°C for 25 cycles. Capillary electrophoresis was carried out at the Cologne Center for 
Genomics in Cologne. Sequences were analyzed using Finch TV (Geospiza) and the Lasergene 
Package (Lasergene). 
EXO/SAP-reaction 
 ExoI (20 U/µl) 2 µl 
 SAP (1 U/µl) 0.3 µl 
 ddH2O  1.625 µl 
 PCR product 8 µl 
→ 20 min at 37°C then 15 min at 72°C 
3.9.5 Transcriptome-wide expression analysis using µ-arrays 
To identify transcripts differentially expressed between Non- and Pos-Responders, µ-
arrays (GeneChip Human Gene 1.0 ST Array, V1 April 2009, Affymetrix ) were employed. The 
basic principle of expression µ-arrays is the hybridization of fluorescent-labeled sample RNA 
derived to a glass-chip covered with thousands of different probes (>5,000 probes/cm²). 
Typically, each probe is approx. 50 bp in length and hybridizes to a different transcript. To 
validate data, sets of probes (5-30) are often detecting one and the same transcript. After 
hybridization, unspecific binding is washed away and fluorescence intensity is measured by a 
laser scanner. After fluorescence reading, intensities were normalized to exclude any 
degradation effects or bad quality of extracted RNAs. Comparison of diverse samples is done 
by labeling with different fluorescence dyes and simultaneous hybridization. 
To perform µ-arrays with fibroblast RNA, some 1x106 cells were plated out in 15 cm petri 
dishes and treated with 500 µM VPA or mock for 16h, respectively. Cells were washed with 
1xPBS, trypsinized and pelleted at 500 x g for 10 min. For each sample 2 petri dishes were 
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pooled to get enough material. An aliquot of the cell suspension was used for protein 
extraction and western blot analysis (3.10.1.2) to ensure a proper treatment effect. Next, 
RNA was extracted as described above (3.9.2.1.1). At least 3 µg of RNA were needed with a 
concentration >300 ng/µl. All subsequent steps including determination of RNA purity and 
bioinformatical analysis were performed at the Microarray facility in Tübingen. In brief, using 
the Bioconductor Software Package, it was first tested whether any artifacts or defective 
probe spots may interfere with the subsequent analysis. Therefore a linear model of the 
arrays was created and both the non-normalized standard error (NUSE) as well as the 
relative logarithmic expression (RLE) were analysed with boxplots. Comparable boxes 
indicate a similar signal distribution. Furthermore, defective spots were identified by false 
color pictures of the arrarys and control probes were used to determine receiver-operator-
characteristics (ROC). ROC is a method to analyse the dependence of the efficiency from the 
error rate of different parameters and varies between 0.5 and ideally 1. Since a ROC of 0.9 
was determined, and also the other tests indicated no possible faults, subsequent data 
analysis was carried as described in the following. First steps included background 
correction, intensity normalization, calculation of transcript intensities from the respective 
probes and elimination of control probes (approx. 4,100). 
After elimination of uninformative transcripts, differentially expressed transcripts were 
identified by three different models: 
(1) Paired model  > factor: group  (Pos-Responder vs. Non-Responder) 
(2) Paired model  > factor: treatment  (mock vs. VPA) 
(3) Unpaired model > combined factor: group + treatment 
Based on these models, the expression profile for gene was calculated and the standard 
error was modeled using a Bayesian model.  
3.9.6 Working with bacteria 
3.9.6.1 TOPO TA cloning 
One of the most common ways to study any protein-of-interest in a given context, is 
performing overexpression studies. Overexpression is typically done by cloning the gene into 
small circular double-stranded DNA-fragments of bacterial origin (plasmid), which were then 
transfected into the respective target cell. Most vectors contain strong expression 
promoters (e.g. CMV promoter) and allow the fusion with a tag (e.g. V5) to discriminate the 
overexpressed from the endogenous protein. 
To clone our candidate genes, PCR products encompassing the respective complete coding 
sequence (w/o stop codon) were generated (Table 10) using the FastStart HighFidelity PCR 
system (Roche). This kit makes use of a proof-reading polymerase, which minimizes the risk 
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of nucleotide exchanges. Next, PCR products were cloned into the pcDNA3.1/V5-His TOPO 
vector (Figure 67) using the pcDNA3.1/V5-His TOPO TA Expression kit (Invitrogen). Since this 
vector does not contain an ATG initiation codon, the native initiation codon was included to 
express the desired protein. Contrariwise, the stop codon was excluded to fuse the protein 
in-frame with the V5 epitope. Cloning reactions were performed as recommended in the 
manufacturer´s protocol. In brief, 4 µl of fresh PCR product were combined with 1 µl salt 
solution and 1 µl TOPO vector and incubated for 10 min at RT. Next, 1 µl thereof was mixed 
with 1 aliquot of chemical competent E.coli TOP10 (Invitrogen) and incubated for 30 min on 
ice. Heatshock at 42°C was performed for 45 sec and after addition of 250 µl SOC medium 
(Invitrogen) bacteria were plated out (50 µl and 150 µl) on prewarmed agar plates containing 
50 µg/ml Ampicillin for selection. 
Transfection of the purchased IGFBP5-coding vector in E.coli TOP10 was performed 
analogue using 30 µg/ml Kanamycin for selection (Figure 66). 
3.9.6.2 Identification of correct clones using colony PCR and sequencing 
To identify positive transformants carrying the insert in the right orientation, approx. 
10 clones were picked for each construct and lysed by osmotic shock in 20 µl dH2O. 10 µl of 
lysed bacteria were then used as template for colony PCR, which was performed with one 
vector-specific primer (Table 10 and Figure 8) and one insert specific primer, respectively. 
Only if the insert was integrated in the right orientation, PCR products were obtained and 
these clones were then regarded as positive clones.   
From each positive clone an 8 ml over-night culture was prepared and plasmids were 
isolated using a Qiagen MiniPrep Kit (Qiagen) according to the manufacturer´s protocol. The 
kit is based on the alkaline lysis of the bacteria followed by the binding of the plasmid DNA 
to a silica matrix. After several washing steps, plasmids are eluted in ddH2O. From each 
plasmid preparation 150 ng were used for sequencing (3.9.4) to identify any possible 
mutations. 
3.9.6.3 Maxi-Preparation of plasmids 
To prepare plasmids for the transfection of eukaryotic cells, the Endo Free Plasmid Maxi 
Kit (Qiagen) was used following the manufacturer´s instructions. This kit is specially designed 
to eliminate any bacterial component such as lipopolysaccharide (LPS), which may interefere 
with subsequent transfection experiments. Typically, 250 ml of bacterial culture were used 
for plasmid isolation. 
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3.10 Proteinbiochemical and immunological methods 
3.10.1 Working with proteins 
3.10.1.1 Protein extraction 
3.10.1.1.1 Extraction of proteins from eukaryotic cells 
To isolate proteins from eukaryotic cells either after transfection or treatment with 
various compounds, the culture medium was aspirated and the cells were washed once with 
1xPBS. All subsequent steps were performed on ice or at 4°C, since typically no protease 
inhibitors were used. An appropriate amount of RIPA buffer was added to the cell culture 
dish (10 cm petri dish:  50 µl; 6-well plate: 30 µl per well) and cells were lysed by incubation 
for 20 min on ice. Thereafter, cells were harvested using a cell scraper, transferred into a 
1.5 ml reaction tube and incubated on ice for another 20 min to complete lysis. Next, cell 
debris and DNA were pelleted by centrifugation at 4°C and 16,100 x g for 20 min and the 
supernatant containing the protein was stored at -80°C.  
3.10.1.1.2 Extraction of proteins from organ tissues 
After humanely sacrification of the respective mouse, organs of interest were quickly 
removed and snap frozen in liquid nitrogen. To extract protein from these organs approx. 
300 mg of tissue were transferred into 500 µl RIPA-buffer containing Protease Inhibitors  
(1 complete mini tablet per 7 ml) (Roche) and homogenized on ice using a Basic Ultra Turrax 
Homogeniser (IKA). Cellular debris and DNA were pelleted by centrifugation at 4°C and 
16,100 x g for 20 min and the supernatant containing the protein was carefully transferred 
into a new 1.5 ml reaction tube and stored at -80°C. 
3.10.1.1.3 Determination of protein concentration according to Bradford 
The Triphenylmethan-dye Coomassie Brilliant Blue G250 unspecifically interacts with basic 
sidechains of amino acids, whereby its absorbance is shifted from 465 nm to 595 nm. Based 
on this, Bradford (Bradford 1976) developed a method to quantify the protein amount in an 
unknown sample. Following her protocol, 2 µl of an unknown protein sample were mixed 
with 500 µl Bradford solution and incubated for 15 min at RT. Afterwards absorption was 
measured at 595 nm using a photometer (Eppendorf) and protein concentrations were 
calculated using a BSA standard curve. 
3.10.1.1.4 Determination of protein concentration using BCA 
Since determination of protein concentration according to Bradford is strongly influenced 
by protease inhibitors, proteins were also quantified using the more robust BCA 
(bicinchoninic acid) method. It is based on the fact that if both protein and Cu2+ are present 
the protein reduces Cu2+ to Cu+. In a next step Cu+ forms with BCA a Cu-BCA-complex having 
a distinct absorption maximum at 562 nm.  
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To determine protein with BCA, the BCA Protein Assay Reagent (Pierce) was used 
according to the manufacturer´s guidelines. In brief, 1 µl of protein sample was mixed with 
200 µl BCA solution, vigorously shaken for 30 sec and then incubated for 30 min at 37°C. 
Afterwards, absorbance was measured at 562 nm on a Safire² plate reader (Tecan) and 
protein concentrations were calculated using a BSA standard curve. 
3.10.1.2 Discontinuous denaturing PAA gel electrophoresis (SDS-PAGE) 
During native gel electrophoresis, the migration speed of proteins is strongly dependent 
on their net charge, structure and conformation, which makes identification of the correct 
protein sometimes quite laborious. To circumvent this stumbling block, SDS-PAGE has been 
developed. It is a widely used technique to separate proteins just depending on their size by 
employing the anionic detergent SDS.  SDS unfolds proteins and applies a negative charge to 
these, which is directly proportional to the mass of the respective protein (typically around 
1.4 g SDS per g peptide) (Laemmli 1970). Still, it has to be taken into account that some 
proteins, mostly glycoproteins, behave abnormal during SDS-PAGE. 
The underlying principle of SDS-PAGE is that inside the stacking gel the proteins are 
focused in one sharp starting zone from which proteins are then separate by size inside the 
separating gel. Protein focusing inside the stacking gel is achieved by a discontinuous buffer 
system. Typically, the stacking gel is prepared using a Tris-buffer with a pH of 6.8. When 
current is applied the glycine – dipolar ionized at this pH - migrates after the proteins to the 
anode, whereas the Cl- migrates in front of them. These 2 ions create an electric field in 
which all proteins are captured and are migrating depending just on their net charge. Since 
the net charge for all proteins is the same (1.4 g SDS per 1 g peptide) and size effects do not 
come into play inside the stacking gel, since its pores are too wide to hinder the proteins in 
their migration, proteins are concentrated in a thin starting zone. Once glycine enters the 
separating gel, it fully dissociates due to a pH of 8.8, the electric field collapses and glycine 
passes the proteins. Starting from this point onwards, proteins are separated by size since 
the small pores of the separating gel act as a sieve, which decreases the running speed of 
bigger proteins, whereas smaller protein more easily fit through it.  
To prepare a SDS-PAA gel, first the 12% seperating gel was prepared according to Table 6 
between 2 clean glass plates and 70% EtOH was added on top until the gel has fully 
polymerized. After solidification, EtOH was removed and the 4% stacking gel was poured on 
top of the separating gel.   
Protein samples indented to be analyzed by SDS-PAGE were supplemented with 5 µl 
2xLaemmli buffer and boiled for 5 min at 95°C to ensure full denaturation.  Typically 7.5 µg 
of protein were used for analysis. Once samples were loaded onto the gel, electrophoresis 
was performed using the respective 1x electrophoresis buffer (3.5.2). Protein size was 
estimated by using the Page Ruler Plus (Fermentas) loaded into a separate lane. 
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3.10.1.3 Coomassie staining of SDS Gels 
Coomassie Brilliant Blue R250 is a widely used dye to directly stain proteins inside a SDS-
PAA-gel. To visualize proteins directly in a SDS-PAA gel, SDS-Page was performed as 
described above (3.10.1.2). Afterwards, the gel was once shortly rinsed with dH2O, covered 
with staining solution and gently shaken for 3 h to o.n. at RT. The gel was destained with 
detaining solution until the desired staining intensity was reached. Pictures were taken using 
a ChemiDoc XRS imaging System (Biorad). 
Staining solution (400 ml) 
 0.4 g Coomassie blue R250 
 200 ml 40% (v/v) MeOH 
 Filter out insoluble remants 
 Add 200 ml 20% (v/v) acetic 
acid in dH2O 
Destaining solution (1 l) 
 500 ml ddH2O 
 300 ml MeOH 
 100 ml acetic acid 
 Add dH2O to 1 l 
3.10.1.4 Transfer of proteins onto nitrocellulose membranes 
After resolving proteins via SDS-PAGE, proteins were typically transferred onto 
nitrocellulose membranes by wet blotting to make them available for antibody detection. To 
this aim, membrane (Protran BA83, Whatman) and gel were equilibrated in the respective 
transfer buffer (3.5.2) and placed face-to-face between 2 filter and 2 sponge pads soaked 
with transfer buffer. Next, the gel sandwich was put into a transfer cell, a cooling module 
was added and transfer was performed over night by applying a current of 30 V. Since the 
current is orientated perpendicular to the gel, the charged proteins move onto the 
membrane where they adhere due to hydrophobic interactions, but keep the organization 
present in the SDS-PAA-gel. Once transferred onto the membrane, proteins are easily 
accessible for antibody detection.  
3.10.1.5 Ponceau staining of nitrocellulose membranes 
After wet blotting, protein transfer was checked by incubation of the membrane in a 
Ponceau S solution (Sigma) for 1 min. Ponceau is an azo-dye which reversibly binds to the 
positively charged amino-groups of proteins. Following staining the membrane was 
destained with TBS-T. 
3.10.1.6 Immunostaining of nitrocellulose-membranes using antibodies 
Immunostaining of proteins transferred onto membranes is the easiest way to specifically 
detect and analyze the amount of any protein-of-interest. Specificity is achieved by using 
primary antibodies binding an epitope exclusively present on the respective protein. Given 
that nitrocellulose membranes generally bind all proteins, unspecific binding of the 
antibodies has to be prevented by blocking the membrane either with 6% BSA (Sigma) or 6% 
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non-fat milk powder (Applichem) in TBS-T for at least 3 h before starting the antibody 
incubation. Next, membranes were incubated with a primary antibody targeting the protein-
of-interest diluted in TBS-T either containing 2% BSA or milk powder (detailed information 
about dilution, blocking reagent and incubation time are given in Table 4.) Subsequently 
unspecific binding of the primary antibody was eliminated by washing the membrane three 
times for 10 min with TBS-T following incubation with the secondary antibody for 1 h in the 
same solvent as the primary antibody. The secondary antibody is directed against the host 
IgG of the primary antibody and typically coupled to the horseradish peroxidase (HRP) which 
is used as a reporter enzyme (Table 5). Again unspecific antibody binding was eliminated by 
washing three times for 10 min with TBS-T. To visualize bound secondary antibody the 
membrane was then incubated for 5 min with 8 ml of SuperSignal West Pico 
Chemiluminescent Substrate (Pierce). This solution contains H2O2, which is cleaved by the 
HRP and the resulting OH-
.
 reacts with luminol by emitting light. The chemilumiscent signal 
was then detected by a radiographic film (Amersham) and later on densiometrically analyzed 
using a ChemiDoc XRS imaging System (Biorad). Typically, target-protein amounts were 
normalized by comparision with the housekeeping gene/protein ß-Actin. If not noted 
differently, all results are given as mean of three different experiment ± SEM. 
3.10.2 Precipitation/Purification of proteins and chromatin 
3.10.2.1 Chromatin Immunoprecipitation (ChIP) 
HDACi treatment induces widespread epigenetic changes and rearrangements in treated 
cells. One of the best known and characterized histone modifications is the acetylation of 
lysine 9 of histone H3 (H3K9ac), which is a clear mark of transcriptionally active chromatin. 
To check whether HDACi treatment leads to a hyperacetylation of different promoters and 
thereby to a higher expression of target genes, the LowCell ChIP Kit (Diagenode) was 
employed following the manufacturer´s guidelines. In brief, 3x105 cells were incubated with 
12.5 µl 37% formaldehyde in 500 µl 1xPBS by which DNA-Protein complexes are stably cross-
linked. Subsequently, cells were washed with 1xPBS, peletted at 500 x g and the pellet was 
resuspended in lysis buffer. Next, chromatin was sheared into 500-1,000 bp long fragments 
using the Bioruptor (10 min, full power, 30 sec cycles on/off) (Diagenode). Following steps 
included incubation of the sheared chromation with 2 µg of an anti-H3K9 antibody 
(Diagenode) over night, several washing steps and reverse crosslinking by boiling the sample 
twice for 10 min at 100°C. After cleanup of the DNA by a DNA-purification slurry contained in 
the kit, DNA concentrations were measured on a photometer (Eppendorf).  Next, equal DNA 
amounts were used for qRT-PCR using the ABI 7500 Realtime PCR machine to quantify the 
amount of precipitated individual DNA pieces (Table 9). Primers for the analysis of individual 
promoters can be found in Table 9. 
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3.10.2.2 Precipitation of ubiquitinylated proteins 
Ubiquitinylation is the most common post-transcriptional modification used to target 
proteins to proteasomal degradation. Typically, activated ubiquitin is transferred by a, 
presumably, target-specific E3-enzyme onto an -amine of a target´s protein lysine. In a next 
step, activated ubiquitin molecules can be added onto the bound ubiquitin e.g. onto K48, 
which ultimately results in poly-ubiquitin chains bound to the target protein. These chains 
are recognized by a certain subset of proteins, e.g. Rpn10/S5a, which are present at the 
regulatory subunit of the proteasome.  
To precipitate ubiquitinylated proteins, agarose beads were employed covalently coupled 
via glutathion (GSH) to the poly-ubiqutin-binding motif of Rpn10/S5a. Precipitation was 
carried out as described in the following: Per sample, 1x106 fibroblasts were plated out in 
15 cm petri dishes and incubated with HDACi for 64 h. Subsequently, cells were washed with 
1xPBS, trypsinized and pelleted for 5 min at 500 x g. The cell pellet was resuspended in 
500 µl 1xPBS and washed twice at 500 x g for 5 min. To lyse the cells, the pellet was 
resuspended in 500 µl TBS-TG and sonicated using the Bioruptor (10min, full power, 30 sec 
cycles on/off) (Diagenode). Since the Rpn10/S5a is bound via GSH to the agarose beads, the 
cell lysate was next pre-cleared using 50 µl GSH-Sepharose (Sigma) and incubated for 1 h at 
4°C on a rotating wheel. The beads were pelleted and the supernatant was transferred to a 
new 1.5 ml microcentrifuge tube. 20 µl of Rpn10/S5a agarose (Biomol) were added and the 
lysate was incubated over night at 4°C on a rotating wheel.  Afterwards, the beads were 
pelleted and washed twice with 500 µl TBS-TG for 5 min at 500 x g. To elute bound proteins, 
the bead-pellet was resuspended in 20 µl 2xLaemmli-buffer and boiled for 10 min at 95°C. 
Subsequently, SDS-PAGE and western blot were performed as described in 3.10.1.2 and 
1.1.1.1. Ubiquitinylated SMN was probed with a rabbit polyclonal anti-SMN antibody (Santa 
Cruz). 
TBS-TG 
 TBS pH=8.5 
 5% (v/v) Glycerol 
 1% (v/v) Triton-X 100 
 1 µg/ml Leupeptin and Aprotinin 
3.10.3 Determination of enzymatic activity 
3.10.3.1 Determintation of proteasomal activity 
To test whether HDACi such as LBH589 have an inhibitory effect on proteasomal 
degradation, the catabolic rate of the three catalytic activities (Caspase-like, Trypsin-like and 
Chymotrypsin-like) embedded in the proteasome were measured using Proteasome-Glo 3-
Substrate Cell-Based Assay System (Promega). The kit is based on synthetic substrates for 
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each of the three catalytic activities, which are conjugated to aminoluciferin. Once the 
proteasome substrate is degraded, aminoluciferin is liberated and available for luciferase 
reaction. 
The assay was performed according the manufacturer´s protocol. Some 1x105 fibroblasts 
were cultured in white-wall 96-well plates (Greiner bio one, #655088) and treated for the 
respective period of time (Table 13). Medium was aspirated and substituted by 100 µl fresh 
pre-warmed medium. Cells were incubated for 10 min at 37°C and 5% CO2. Next, 100 µl 
reconstituted Proteasome-Glo™ Cell-Based Reagent containing the individual proteasome 
substrate and Ultra-Glo rLuciferase (Promega) were added and mixed for 2 min at 700 rpm 
on a shaking block. This step lyses the cell while keeping the proteasome intact. 
Subsequently, the plate was incubated for 10 min at RT and afterwards luminescence was 
read on a Glomax luminometer (Promega). For all measurements eight replicates were 
performed. 
3.10.3.2 Inhibition of proteasomal protein degradation by MG-132 
General protein degradation under HDACi treatment was analyzed using the cell-
permeable proteasome inhibitor MG-132 (Sigma). To this aim, fibroblasts were pre-treated 
for 24 h with 400 nM LBH589, and MG-132 was added at a final concentration of 5 µM for 
15 h (Table 13). Within this time, proteins normally degraded by the proteasome enrich 
since they are not longer degraded by the proteasome. Subsequently, proteins were 
extracted (3.10.1.1.1) and analyzed by western blot (3.10.1.2) as described above. 
3.10.3.3 Determination of PKA-activity 
The cAMP-dependent protein kinase A (PKA) is an important mediator involved in the 
regulation of diverse cellular mechanisms. Most importantly, it has also been shown that 
VPA inhibits PKA activity by attenuating cellular cAMP-levels (Boeckeler et al. 2006; Chang et 
al. 2009). To assess PKA activity in HDACi-treated cells, the PepTag Assay for non-radioactive 
detection of cAMP-dependent Protein Kinase (Promega) was used. The underlying principle 
is that a synthetic PKA substrate is added to a whole cell extract, and depending on the 
respective PKA activity the amount of phophorylated substrate varies. Phosphorylated and 
unphosphorylated substrates are then separated by agarose-gel electrophoresis, since the 
unphosphorylated one has a positive net charge and is therefore migrating to the cathode. 
In contrast, the phosphorylated substrate is negatively charged and migrates to the anode. 
Once both substrates are separated, the respective bands are cut out, melted and quantified 
on a plate reader. 
The determination of PKA activity was carried out as recommended by the manufacturer. 
2x102 fibroblasts per sample were HDACi-treated for the respective time period, washed, 
trypsined and pelleted 5 min at 500 x g. The pellet was the resuspended in 20 µl ice-cold PKA 
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extraction buffer containing 0.5 mM PMSF, and  sonicated using the Bioruptor (10 min, full 
power, 30 sec cycles on/off) (Diagenode). Cellular debris and DNA were removed by 
centrifugation for 5 min at 14,000 x g. Next, samples and controls were prepared as given in 
Table 14 on ice. 
  
Sample 
Positive 
control 
Negative 
control 
PepTag PKA Reaction 5x Buffer 5 µl 5 µl 5 µl 
PepTag A1 Peptide (0,4 µg/µl)  5 µl 5 µl 5 µl 
PKA Activator 5x Solution 5 µl 5 µl 5 µl 
Protein Protection Mix 1 µl 1 µl 1 µl 
Recomb. PKA (2 µg/ml) * --- 5 µl --- 
Sample * 9 µl --- --- 
ddH2O --- 4 µl 9 µl 
Table 14  Composition of the sample, positive and negative control reactions for the determination of 
PKA activity. * sample and recombinant PKA were added after incubation for 1 min at 30°C. 
Reactions were warmed up for 1 min in 30°C waterbath. Afterwards, either sample or 
recombinant PKA was added and reactions were incubated for 30 min at RT. Subsequently 
reactions were stopped by incubating for 10 min at 95°C. After cooling down 1 µl 80% 
glycerol was added. To separate phosphorylated and unphosphorylated PKA substrate, a 
0.8% agarose gel in 50 mM Tris-HCl pH=8.0 was prepared with slots in the middle of the gel. 
Total reactions were loaded and both substrates were separated by applying 100 V for 
approx. 15 min. Respective bands were cut out and melted in 150 µl Gel Solubilization 
Solution (5 M Urea) at 95°C in a heating block. 120 µl of solublized gel were then mixed with 
50 µl acetic acid thereby hydroylysing all agarose chains and keeping the solution liquid.  
Next, samples were transferred into a black 96-well plates (Greiner bio one, #655076) and 
dye intensity was measured (excitation: 568 nm / emission: 592 nm) on a Safire² plate 
reader (Tecan). 
PKA extraction buffer 
 25 mM Tris-HCl (pH=7.4) 
 0.5 mM EDTA 
 0.5 mM EGTA 
 10 mM ß-Mercaptoethanol 
 1 µg/ml Leupeptin and Aprotinin 
 
 
 
PKA dilution buffer 
 350 mM K3PO4 (pH=6.8) 
 0.1 mM DTT 
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3.10.3.4 Determination of fatty acid uptake via BODIPY-FA 
CD36 is one of major fatty-acid transporters in the human body (Abumrad et al. 1993; 
Coburn et al. 2000; Endemann et al. 1993). To test whether higher CD36 amounts in the 
Non-Responders indeed lead to a higher fatty acid uptake, the QBT Fatty Acid Uptake Kit 
(Molecular Devices) was employed. It makes use of a BODIPY-labeled oleic acid analogue, 
which is actively transported into the cells. BODIPY (boron-dipyrromethene), a fluorescent 
dye, allows monitoring fatty acid uptake, since the more fluorescent is detected inside the 
cells, the higher was the fatty acid uptake. The protocol was as follows: Some 
1x105 fibroblasts were plated out in 96-well plates and 24 h later treated for 16 h either with 
500 µM VPA or mock.  Next, cells were deprived for 8 h with 100 µl/well serum free medium at 
37°C and 5% CO2. Subsequently, 10 µl test compound dissolved in 1x HBSS + 0.2 g BSA were 
added and cells were incubated for another 30 min (Table 13). Afterwards, 100 µl 1x loading 
buffer were added and cells were incubated o.n. at 37°C and 5% CO2. Medium was aspired 
and 200 µl 10% SDS in 1xPBS were added. Complete lysis was ensured by incubation for 
10 min on a shaking block. Next, fluorescence (excitation: 485 nm; emission: 515 nm) was 
measured on Safire² plate reader (Tecan). 
5x loading buffer (10 ml) 
 1 ml 10x HBSS (Gibco) 
 0.2 ml 1 M HEPES (Sigma) 
 20 mg fatty acid free BSA (Sigma) 
 8,8 ml ddH2O 
 1 Vial component A (containing BODIPY-labeled oleic acid) (Molecular Devices) 
3.10.4 Enzyme-linked immunosorbent assay (ELISA) 
3.10.4.1 Quantification of intracellular cAMP-content 
cAMP is an important second messenger involved in the regulation of a vast number of 
cellular processes (Pavan et al. 2009). To quantify basal as well as cAMP levels under VPA 
treatment, the CatchPoint Cyclic-AMP fluorescent assay kit was used (Molecular Devices). 
The basic principle of this kit is a competitive immunoassay using cell lysates. cAMP in the 
sample competes with a horseradish peroxidase-labeled cAMP conjugate for the binding 
sites of an anti-cAMP antibody bound to a microtiterplate. The more cAMP is present, the 
less cAMP-antibody conjugate is binding, thus less HRP-activity is detected. 
To quantify intracellular cAMP-levels some 1x104 fibroblasts were plated out in a 96-well 
plate. The following day, cells were treated with different compounds (Table 13) for the 
indicated time periods.  Following treatment, the media was aspirated and 50 µl 1xPBS was 
added to each well. Next, fibroblasts were lysed by adding 50 µl lysis reagent and gentle 
agitation on a shaking block for 10 min. 40 µl of cell lysate were then transferred into the 
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assay plate.  40 µl of reconstituted rabbit anti-cAMP antibody were added to each well the 
plate was gently shaken for 5 min. Subsequently, 40 µl reconstituted HRP-cAMP conjugate 
were added and following mixing, the assay plate was incubated for 2 h at RT. The plate 
contents were aspirated and the plate was washed four times with 300 µl wash buffer. 
100 µl Stoplight Red substrate were added to each well and the plate was incubated for 
10 min shielded from light. Finally fluorescence intensity (excitation: 530 nm; emission: 
590 nm) was measured on a Safire² plate reader (Tecan). 
To rule out any artifacts based on differential proliferation between cell lines, data was 
normalized to the protein amount determined by a BCA-assay (3.10.1.1.4) performed with 
the remaining 60 µl of protein lysate produced at the initial steps of this assay. 
3.10.4.2 Quantification of global histone H3 acetylation 
Change in histone acetylation is the major hallmark of HDACi-treatment. To test if HDACi 
are also able to induce histone hyperacetylation in vivo the EpiQuik Global Histone H3 
acetylation assay (EpiGentek) was used according to the manufacturer´s guidelines to detect 
changes in histone H3 acetylation. In brief, mice were injected with HDACi, sacrificed by 
gasification and brain and spinal cord were quickly prepared. 500 mg brain tissue or the 
whole spinal cord, respectively, were transferred into diluted buffer GF1 and homogenized 
using Basic Ultra Turrax Homogeniser (IKA). The lysate was centrifuged for 5 min at 9,300 x g 
and cellular debris pellet containing chromatin was resuspended in GF2/glycerol by 
vortexing. After incubation for 5 min on ice nucleic debris was pelleted at 13,400 x g for 
5 min at 4°C. The supernatant was transferred into a new 1.5 ml reaction tube and ¼ Vol 
100% TCA was added to precipitate histones. After incubation for 30 min on ice the pellet 
was collected (13,400 x g for 2 min at 4°C) and washed with 1 ml acetone (13,400 x g for 2 
min at 4°C). The supernatant was removed and the pellet was air dried before resuspended 
in 100 µl ddH2O. 
Protein concentration of all samples was adjusted to 400 ng/µl with GF4 and 5 µl of the 
protein solution were spread into a well of the assay plate. The plate was then dried for 
90 min at 37°C. 150 µl pf GF5 containing a HRP-coupled antibody directed against acetylated 
histone H3 were added to each well and incubated for 30 min at 37°C. After aspiration the 
wells were washed 4x with 150 µl with GF3. Subsequently 100 µl GF9 containing the HRP-
substrate were added to each well and the plate was incubated for 10 min in the absence of 
light. Reactions were stopped by adding 50 µl GF10 and absorbance was read at 450 nm on a 
Safire² plate reader (Tecan). Acetylated histone H3 amounts were calculated using a 
standard curve provided with the kit. 
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3.10.5 Determination of SMN2 promoter activity 
The basic idea behind using HDACi for the therapy of SMA is to activate the SMN2 
promoter and thereby activating the production of more functional protein from SMN2. 
Therefore it is of big interest to check whether HDACi treatment indeed increases SMN2 
promoter activity. To clarify this issue, a NSC-34 reporter cell line (Jarecki et al. 2005) was 
used, which is stably transfected with the -lactamase reporter gene under the control of 
the human SMN2 promoter (termed NSC-34 bla in the following). Addition of the fluorescent 
dye CCF2-AM (Invitrogen) allows monitoring SMN2 promoter, since the dye is cleaved by the 
-lactamase in a concentration-dependent manner. The protocol was as follows: Some 
8x105 NSC-34 bla cells were plated out in a 10 cm petri dish and treated for 64 h with 
different concentrations LBH589. Afterwards cells were washed twice with 1xPBS and 
resuspended in 2 ml culture medium w/o FCS by pipetting up and down several times. Six 
replicates of 100 µl cell suspension were transferred into a 96-well plate and let settle down 
for 3-5 h. Next 20 µl 6xCCF2-AM staining solution were added, and the plate was incubated 
for 1.5 h at RT in the absence of light. Next, fluorescence intensity (internalized dye: 
excitation: 395 nm; emission: 530 nm / dye cleaved by -lactamase: excitation: 395 nm; 
emission: 460 nm) was measured on a Safire² plate reader (Tecan). Promoter activity was 
calculated as ratio (460/530) of cleaved CCF2-AM to CCF2-AM internalized by the cells. 
6x CCF2-AM staining solution (Invitrogen) 
 60 µl Solution B  
 6 µl 1 mM CCF2-AM 
 12 µl 1 M Probencid (Sigma) in 1 M NaOH 
 1 ml Solution C 
3.10.6 Mass-spectroscopic determination of intracellular VPA content  
To precisely determine the intracellular VPA content HPLC-MS/MS is the method of 
choice, since it gives far more precise results the standard gas chromatography. After 
dissociation of the analyte via a HPLC-column, the separated reagents are identified by 
mass-spectroscopy. The underlying principle is the resolving of ionized and most often 
fragmented analysts in an electric field based on their charge to mass ratio (m/z). Ionization 
is typically achieved by electron-spray ionization or laser-ionization. Subsequently, ions are 
accelerated in vacuo using a static electric field, fragmented in a collision chamber and are 
afterwards separated based on m/z by a quadropol and individually detected. 
Furthermore, employing HPLC-MS/MS makes it possible to distinguish VPA from its blood 
metabolite, 4-ene VPA, allowinging to apply the assay also for the analysis of blood samples.  
HPLC-MS/MS procedures were carried out by Dr. Tim Bauer on a Triplequadrupole-tandem 
mass spectrometer Q Trap 4000 (Applied Biosystems) combined with SLC-20AD Prominance 
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HPLC machine (Shimadzu) at the Institute of Pharmacology in Cologne. Chromatographic 
runs were carried out for 10 min with a flow-rate between 200 and 400 µl. All chemicals 
used for HPLC-MS/MS experiments were of HPLC-purity. 
3.10.6.1 Derivatization of VPA/4-en VPA 
For the detection of VPA and 4-ene VPA, a published protocol for the detection of VPA in 
human blood (Cheng et al. 2007) was adopted and some modifications were added. The 
underlying principle is a pre-column activation of carboxylgroups with 
1-chloro-4-methylpyridinium iodide and TEA and subsequent formation of stable 
4-dimethylamino-benzylamide derivates. These derivates have a much higher atomic weight 
(VPA: 277.3 amu, 4-ene VPA 275.2 amu) than underivatized VPA (144.3 amu) and 4-ene VPA 
(142.2 amu) and thereby allow easier discrimination between both compounds based on 
their HPLC retention time (Figure 7). 
The intracellular VPA content was determined by treating 2x105 fibroblasts for 16 h with 
500 µM VPA in a 10 cm petri dish as described in 3.8.1.1.  Subsequently, cells were washed 
once with 1xPBS and collected by trypsinization and centrifugation at 500 x g for 5 min. 
Fibroblast were lysed by osmotic shock adding 200 µl ddH2O and after 5 min incubation on 
ice snap-frozen in liquid nitrogen. After thawing, 2 µl 3 N HCl were added to lower the pH to 
approx. 3. Next, proteins were precipitated by adding 300 µl methylenechloride and 
vigorous shaking for 30 min at 37°C in a shaking heating block. Afterwards, cell lysates were 
centrifuged for 1 min at 16,100 x g to separate organic and aqueous phase. 250 µl of the 
organic layer were transferred into the prepared 1.5 ml reaction tube containing 10 µl 
2-chloro-1-methylpyridiniumiodide (10 mg/ml), 10 µl 4-dimethylamino-benzylamindihydro-
chloride (10 mg/ml) and 20 µl TEA. Derivatization reactions (Figure 7) were carried out for 1 h 
at 900 rpm and 37°C on a shaking heating block. Subsequently, reactions were stopped by 
adding 200 µl acetate buffer, pH =4 and tubes were centrifuged for 1 min at 16,100 x g. 
200 µl of the organic layer were transferred into a new 1.5 ml reaction tube and evaporated 
to dryness for 2h at 50°C and 200 rpm in a shaking heating block under a sterile hood. The 
remaining precipitate was reconstituted in 120 µl ACN/ddH2O (1:1) containing 0.1% formic 
acid. Subsequent HPLC-MS/MS analysis was performed by electron-spray ionization (ESI; 
pos. 5500 V, neg. -4500 V) and fragmentation in multiple reaction monitoring (MRM) mode. 
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Figure 7 Reaction carried out for derivatisation of VPA, 4-ene VPA or any other organic acid.  
Catalyzed by 2-chloro-1-methylpyridiniumiodide and heating, 4-dimethylamino-benzyl-
amindihydro-chloride is added onto the carboxylic acid residue to form an amide (adapted 
from (Cheng et al. 2007) 
3.10.6.2 Determination of intracellular VPA content without derivatization 
To determine the intracellular VPA content without the detour of derivatisation, VPA and 
its metabolites were directly determined without fragmentation. To this aim, 1x105 treated 
fibroblasts from a well of 6-well plate were lysed by adding 200 µl of 4 mM HClO4. Proteins 
were pelleted by centrifugation for 1 min at 16,100 x g and 100 µl of the supernatant were 
used for injection into the LCMS using the single-ion-mode (SIM) without fragmentation. 
To identify any putative differences in the metabolism of VPA in Non- and Pos-Responders, 
a shading assay was performed (Grundemann et al. 2005). To this aim, mass spectra of three 
pooled Non- and three pooled Pos-Responders from 0 to 400 atomic units recorded in SIM 
were superimposed by MS-FullView (developed by D. Gründemann), allocated and 
differences were marked in orange. To distinguish between VPA-metabolites and molecules 
produced in response of VPA treatment, 250 µM VPA and 250 µM d15-VPA (CDN isotopes) 
were combined for treatment to give a final concentration of 500 µM VPA. 
3.11 Working with mice 
3.11.1 Animal breeding 
All animals used throughout this thesis were housed in micro-isolation chambers in the 
mouse facility of the Institute of Genetics, Cologne under a normal dark and light rhythm 
(12 h). Animalbedding, cages, water and feed was regularly changed and controlled by the 
animal keepers. Genotyping was performed using standard PCR (3.9.3.1) and primers 
described in Table 11. Breedings were always set up in a 1-to-1 manner. Mice showing a very 
mild SMA-phenotype were generated by crossbreeding a Smn-/-; SMN2tg/tg mouse (Hsieh-Li 
et al. 2000) with a Smn+/-;SMN2tg/tg mouse (Monani et al. 2000). Obtained SMA-animals and 
their healthy littermates were numbered soon after birth with a water-resistant marker on 
the abdomen. At an age of three weeks, from all mice tail-tips were taken and numbered 
ear-tags were set.  
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3.11.2 Determination of weight progression of mice 
To characterize mice showing a very mild SMA-phenotype, the weight progression was 
used as the main outcome measurement, since it is well-known that SMA-like mice have 
reduced weight compared to healthy littermates. Mice were weighed in plastic bowl placed 
on a standard laboratory balance. During the first 30 days of life, mice were weighed daily. 
Afterwards mice were weight once a week. Weighing was usually performed between 4 and 
6 pm. 
3.11.3 Subcutaneous injection of mice 
To test whether HDACi are able to cross the blood-brain-barrier and to induce 
hyperacetylation in the CNS, adult Smn-/-;SMN2tg/tg (Hsieh-Li et al. 2000) mice were sub-
cutaneously injected with either LBH589, JnJ26481585 or DMSO only into the neck pucker 
using a BD Micro-Fine + U-40 Insulin syringe (BD Medical). After treatment for the respective 
period of time, mice were killed by gasification and the organs-of-interest were removed. 
3.11.4 Preparation of mouse organs 
To prepare different mouse organs, the respective mouse was sacrificied by gasification on 
dry ice. Subsequently, the mouse was fixed on a preparation table and the body was opened 
by abdominal incision. Whole liver, gastrocnemius muscle, brain and spinal cord were 
removed and snap frozen in liquid nitrogen. 
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4. Results 
Proximal spinal muscular atrophy is a common autosomal recessive disorder and the 
leading genetic cause of infant death in the Western European population. Although 
nowadays the disease phenotype is quite well known, there is no cure for SMA available yet. 
On molecular level, SMA is caused by functional absence of the survival motor neuron gene 1 
(SMN1), leading to dramatically reduced SMN protein levels (Lefebvre et al. 1995). This 
causes degeneration of the -motor neurons in the anterior horns of the spinal cord 
resulting in progressive atrophy of the voluntary muscles and, ultimately, in lethal 
respiratory failure. Intensive analysis of the chromosomal regions surrounding SMN1 
revealed that SMN1 is located in an inverted and duplicated region spanning more than 
500 Kb (Lefebvre et al. 1995). Within this region, a nearly identical copy gene has been 
identified termed SMN2. Both genes encode for the same protein, but due to a silent 
nucleotide exchange SMN2 splicing is dramatically altered (Lorson et al. 1999). Only approx. 
10% of SMN2 transcripts give rise to the full-length SMN protein whereas 90% of SMN2 
transcripts lack the critical exon 7, thus coding for a truncated and unstable protein (Lorson 
et al. 1998). 
However, SMN2 is the only origin of functional SMN protein in SMA patients. Its vital 
importance is further underlined by the finding that the number of SMN2 copies inversely 
correlates with the SMA phenotype (Feldkotter et al. 2002; McAndrew et al. 1997; Wirth et 
al. 2006b). The more SMN2 copies are present in a SMA patient, the milder is the 
phenotype. Therefore, quite a few therapeutic strategies have been developed within the 
last years which directly target SMN2 either by gene activation, restoration the splicing 
pattern or gene replacement (Lorson et al. 2010).  
In our laboratory, we pursued the approach to increase SMN2 activity by means of HDAC 
inhibition. HDACis induce widespread chromatin hyperacetylation whereby general gene 
activity is increased. We identified the well-known HDACi valproic acid to markedly increase 
SMN protein amounts in fibroblasts derived from SMA patients (Brichta et al. 2003). Valproic 
acid, a short-chain fatty acid, is commonly used in the treatment of epilepsy but is also FDA-
approved for the treatment of diverse types of seizures or bipolar disorder. Using VPA, a first 
clinical trial in SMA patients and carriers was performed and showed that VPA indeed 
increases blood SMN-mRNA levels in 1/3 of treated patients (Positive Responder (Brichta et 
al. 2006)). However, 1/3 of treated SMA patients did not show any change at all (Non-
Responder) whereas the remaining 1/3 of patients even showed a down-regulation of SMN 
(Negative Responder). More recently, a phase II open-label clinical trial with VPA has been 
performed in SMA type II and III patients (Swoboda et al. 2009). Although this study 
suggested that VPA has no positive effect on SMA disease progression, at least two critical 
points have to be mentioned: First, no stratification of SMA patients depending on the SMN 
levels has been undertaken. This is of fundamental importance since throughout the study 
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huge fluctuations between individual samples have been observed. Second, the clinical trial 
was too short to allow any final statement. Since both SMA type II and III patients are rather 
slow in their disease progression, a read-out time of six months is too short to detect any 
significant impact. This argument is further underlined by the finding that SMA-like mice 
treated for up to 12 months with VPA clearly exhibit an amelioration of the SMA phenotype 
(Tsai et al. 2008). 
Based on these conflicting data, we tried to decipher the crucial factors which might help 
us to understand why somebody is positively responding to VPA or not. Understanding these 
factors would not only have great impact on SMA therapy but also on other diseases which 
are treated with VPA such as epilepsy. Furthermore we identified the new HDACi LBH589 as 
an auspicious candidate for SMA therapy and characterized its mode of action in detail. 
4.1 SMA therapy with VPA: Why do we have Non- and Pos-Responders? 
4.1.1 In vitro treatment of fibroblasts derived from SMA patients and carriers with 
valproic acid 
To answer the question why a given SMA patient either responds positively, not or 
negatively to VPA treatment enough material is needed to perform all necessary 
experiments. Since blood samples are quite precious and available only in limited amounts a 
more easily accessible experimental system was required. Therefore, primary dermal 
fibroblast cultures were established from all nine SMA patients and six carriers included in 
our first clinical trial with VPA (Brichta et al. 2006). Four fibroblast lines were derived from 
SMA patients in which VPA increases SMN levels, whereas two fibroblast lines were derived 
from SMA patients showing no change in SMN expression. Additionally, further three 
fibroblast lines were established from SMA patients having decreased SMN levels under VPA 
treatment. Within the group of carriers – six in total - no change in SMN expression levels 
was detected under VPA treatment in blood. With this tissue system in our hands, we were 
able to address the question why somebody reacts to VPA treatment or not. 
Since it was not known whether the response to VPA correlates among different tissues, it 
had first to be determined whether VPA treatment indeed triggers the same response 
regarding SMN levels in blood and fibroblasts. To this aim, all 15 fibroblast lines were treated 
for 16 h with VPA concentrations between 5 µM and 500 µM, resembling therapeutic doses 
routinely used in clinic (Brichta et al. 2003). Higher amounts were not used at this point since 
earlier publications had shown that these did not produce substantially stronger effects. All 
treatments were performed in triplicates from three different passages to exclude any 
passage-specfic effect. Protein extracts were then analyzed by semi-quantitative western 
blotting. -actin was used as loading control since it has previously been shown that VPA 
only has minimal effects on its expression. A summary of all treated fibroblast lines is given 
in Table 15.  
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4.1.1.1 Classification of fibroblasts into Non- and Pos-Responder 
To fascilitate comparison of the vast amount of western blot data derived from the VPA 
treatment of all 17 fibroblast lines tested, cell lines needed to be classified. Since the final 
goal of these experiments was to identify fibroblast lines which exhibit a similar response to 
VPA as the respective donor the results were sorted in two steps. The first parameter used 
to group VPA-treated fibroblast lines was the in vivo response to VPA of the individual SMA 
patients in the pilot clinical trial with VPA (Brichta et al. 2006): Pos-Responder were patients 
in whom VPA elevated SMN levels. Non-Responder included all SMA patients whi did not 
respond to VPA at all in vivo and, finally, the term Neg-Responder was used for patients in 
whom VPA declined SMN levels. Subsequently, VPA-treated fibroblast lines were 
discriminated by whether the response between blood and fibroblasts was concordant. Cell 
lines representing discrepant results were excluded from further analysis.   
To determine the SMN threshold at which a cell line should be regarded as a Pos-
Responder in vitro, the mean response of all fibroblast lines derived from SMA patients and 
carriers showing in vivo no change or reduced SMN levels under VPA treatment (ML49, 
ML53, ML63, ML66, ML68, ML75, ML62, ML65) was calculated. Based on this calculation 
(mean SMN level 114.7% +/- 5%), all cell lines exhibiting higher SMN levels than 120% under 
VPA treatment were defined as Pos-Responders. Furthermore, fibroblast lines showing 
reduced SMN levels upon VPA application were regarded as Neg-Responders whereas those 
exhibiting SMN amounts between 100 and 120% were classified as Non-Responders.  
  Carrier fibroblasts (marked grey in Table 14) 
In line with the in vivo situation, VPA only slightly affected SMN levels by either 
increasing or decreasing SMN levels by less than 20% in four out of six carrier cell lines 
(ML49, ML53, ML68 and ML75). In contrast to that, VPA elevated - inconsistently to 
the in vivo data - SMN protein levels in the carrier fibroblast lines ML63 and ML66 by 
more than 40% at concentrations of 50 or 500 µM VPA, respectively. 
  Non-Responder fibroblasts (marked orange in Table 14) 
Similarly to the carrier fibroblast lines ML63 and ML66, VPA dramatically altered SMN 
levels in both fibroblasts lines (ML62, ML65) derived from SMA patients showing no 
change in SMN expression under VPA treatment in vivo. In ML62, SMN was elevated 
for all three tested concentrations, whereas VPA reduced SMN in ML65 by more than 
20% at every dose thus not confirming the in vivo data.  
  Pos-Responder fibroblasts (marked green in Table 14) 
In total four cell lines were derived from SMA patients exhibiting augmented SMN 
levels under VPA treatment (ML60, ML67, ML71 and ML72). With the exception of 
ML71, in which a 5 to 10% decline in SMN was obtained for 5 and 50 µM, VPA 
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significantly increased SMN amounts in all cases. However, in ML60 the impact of VPA 
on SMN was rather low since its abundance was elevated only by 20% at 5 and 50 µM 
VPA. Noteworthy, ML67 showed the highest increase in SMN levels of all tested cell 
lines with > 200% at 500 µM VPA. 
  Neg-Responder fibroblasts (marked red in Table 14) 
In the case of the fibroblasts derived from SMA patients showing decreased SMN 
levels under VPA treatment (ML59, ML69, ML73 and ML82), reduced SMN levels were 
detected dose-dependently for ML69 and ML73. For ML82 a decline of 5 to 10% was 
observed for all tested concentrations. In contrast to that, ML59 showed slightly 
elevated SMN levels. Since these were below the Pos-Responder threshold, ML59 was 
regarded as a Non-Responder instead of a Neg-Responder. 
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In conclusion, the in vivo response to VPA could clearly be confirmed in nine out of 17 
cases. In three further fibroblast lines (ML75, ML65 and ML60) similar tendencies as in blood 
were obtained but these results were not as clear as in the other fibroblast lines. Therefore, 
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these cell lines were regarded as confirmed but under reservation. In another four cell lines 
a clearly opposite response to VPA was observed as expected from the in vivo data (ML63, 
ML66, ML62 and ML71). Therefore, these cell lines were excluded from further experiments. 
Furthermore, cell lines derived from carriers (ML49, ML53 and ML68) were also not used for 
further analysis, since it was not known to what extent the present SMN1 gene cloaks any 
SMN2 activation by VPA. Thus, the following six fibroblast lines were selected for further 
analysis (Figure 8). 
 Pos-Responder: ML67 and ML72 
 Non- & Neg-Responder:  ML59, ML82, ML69 and ML73 
Noteworthy, both Non- and Neg-Responders were grouped together for two reasons. 
Firstm the actual differences in SMN levels between both groups were sometimes blurred, 
e.g. in the case of ML59. Second, the project´s focus was to address the question why 
somebody does not respond positively to VPA. However, it has to be kept in mind that all 
Neg-Responders are indeed responding to VPA, but in an opposite way. For the sake of 
consistency, the group of Non- and Neg-Responder will thereafter be termed Non-
Responder in the following. 
In general, a VPA concentration of 500 µM had the highest impact on SMN protein levels 
(six out of nine treated SMA patient cell lines). Therefore, we chose this concentration as the 
“standard concentration” for further experiments. 
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4.1.1.2 Generation of an unrelated control group 
All cell lines characterized above had been established before the start of this work. During 
its accomplishment further fibroblast lines were collected from SMA patients undergoing 
VPA therapy. These cell lines were intended to be used as an unrelated control group, which 
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should serve to verify the data obtained from cell lines analyzed above (Table 15). All newly 
established fibroblast lines were treated in triplicate with VPA whenever they were 
available. To circumvent the possibility of missing some cell lines that do not react to VPA at 
lower concentrations but respond at higher doses, the treatment was changed in such a way 
that fibroblasts were treated for 16 h with 50 µM, 500 µM and 1 mM VPA. 
By treating 14 further fibroblast lines with VPA two additional concordant Pos-Responders 
(ML94, ML95) and three additional concordant Non-Responder were identified (ML79, 
ML86, ML105) (Table15). In the case of the Pos-Responders ML94 and ML95, the highest 
increase in SMN was detected at VPA concentration of 1 mM with SMN levels of around 160 
to 170%. A similar amount of SMN was also recorded at 50 µM VPA for ML94 whereas 500 
µM VPA only slightly increased SMN protein. For ML95 a dose-dependent increase in SMN 
was found. ML79 and ML86 were both identified as concordant Non-Responder either 
showing no change in SMN levels or a dose-dependent decrease down to approx. 70% at 
1 mM VPA for ML86. The fibroblast line ML89 was excluded from further analysis since SMN 
levels fluctuated between 140% at 50 µM and approx. 100% at 500 µM and 1 mM VPA, thus 
giving no consistent picture. ML96 showed a dose dependent increase to merely 150% SMN 
at 1 mM, but also had to be excluded since these data did not match in vivo data. Finally, the 
Non-Responder cell line ML105 SMN fluctuated by less than 10% at all three VPA- 
concentrations thereby confirming the in vivo data. 
In total, eight further fibroblast lines were treated with VPA, but it cannot be stated yet  
whether these cell lines are concordant or not, since the VPA therapy of the respective SMA 
patients is still ongoing (Table 14). Among these cell lines, ML103 most likely is a Non-
Responder since VPA treatment decreased SMN levels down to 86% at 1 mM. A similar 
pattern was found for ML104. In contrast to that, ML108 turned out to be a Pos-Responder 
since VPA significantly increased SMN levels to 144% at 1 mM VPA. In the remaining five 
fibroblast lines, VPA triggered neither a significant increase or decrease at all tested 
concentrations. 
Taken together, five additional concordant fibroblast lines were identified, two of which 
are Pos-Responders and three are Non-Responders. For another eight fibroblast lines VPA 
therapy is still ongoing and therefore the classification as either concordant or discordant 
needs to be awaited. Nevertheless, these fibroblast lines are currently being cultivated again 
to verify the data presented in the following.  
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4.1.2 Search for the molecular basis of VPA Non-Responders 
Based on the previously described fibroblast data the question arose why SMN is not 
increased in Non-Responders by VPA. Since the effect of VPA on SMN levels is mediated via 
HDAC inhibition, it was tested whether VPA has any effect on the acetylation status of the 
SMN2 promoter in Non-Responders. To this aim, fibroblasts from three Pos-Responders and 
three Non-Responders were treated with 500 µM VPA for 16 h and compared via Chromatin 
Immunoprecipitation (ChIP) using an antibody directed against acetylated histone H3 (Roh et 
al. 2005). Acetylation of lysine 9 of histone H3 is a clear sign of active transcription and was 
therefore chosen as the pivotal parameter of SMN2 promoter activity. Following ChIP, SMN2 
promoter acetylation was quantified by qRT-PCR at four regions known to be susceptible to 
HDACi-induced hyperacetylation (Kernochan et al. 2005). 
VPA increased acetylation in all three Pos-Responders throughout the whole SMN2 
promoter (Figure 9). Highest increases of around 50 to 75% were detected at HuSP2, approx. 
1.2kb upstream of the transcriptional start site (TSS), and HuSP4, which is located directly 
after the TSS. For both, HuSP1 and HuSP3, VPA increased acetylation by 25 to 50%. In 
contrast to that, for all three Non-Responders no general hyperacetylation was detected. In 
the case of HuSP1 and HuSP3 acetylation was even decreased by 25% in all three cases. 
Similar results were obtained for HuSP2 and HuSP4 with the exception of ML82 or ML59, 
respectively. Taken together, these data clearly show that VPA is not inducing histone 
hyperacetylation at the SMN2 promoter in Non-Responders and therefore does not act as an 
HDACi. 
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Figure 9 Change in H3K9 acetylation after 16 h 500 µM VPA treatment in three Pos- and three Non-
Responder cell lines. Location of all four analyzed regions is given in the lower part. (Pos- 
Responder → from left to right: ML17, ML67, ML72. Non-Responder → from left to right: 
ML59, ML73, ML82)  
Since ChIP analysis revealed that VPA did not induce hyperacetylation of the SMN2 
promoter in Non-Responder fibroblast lines, it was next tested whether Non-Responders are 
generally inert to HDACi treatment and could therefore be regarded as General HDACi-Non-
Responder. To clarify this issue, Non-Responder fibroblast lines were treated with various 
HDACi. Since VPA is a branched short-chain fatty acid, different fatty acid HDACi were tested 
such as Sodium Butyrate, a short-chain fatty acid HDACi shown to increase SMN amounts 
(Chang et al. 2001). Furthermore, the aromatic fatty acid Phenylbutyrate, a derivate of 
Sodium Butyrate, was included. As a control HDACi having no fatty acid characteristics 
LBH589 was employed. Treatment conditions of all HDACi were taken from the respective 
publication (VPA: 16 h 500 µM (Brichta et al. 2003); Sodium butyrate: 24 h 500 µg/ml 
(Andreassi et al. 2001); Phenylbutyrate: 4 h 2 mM (Andreassi et al. 2004); LBH589 64 h 
400 nM (Garbes et al. 2009)). Following treatment, SMN levels were analyzed by semi-
quantitative western blotting using a SMN and a -Actin antibody. As shown in Figure 10, all 
tested HDACi increased SMN levels in the Pos-Responder ML5, thereby confirming their 
capacity. As expected, LBH589 had the highest impact on SMN levels. VPA and 
Phenylbutyrate produced similar effects and increased SMN by 50%. Sodium butyrate 
merely doubled SMN amounts in ML5 whereas it did not affect SMN levels in neither ML73 
nor in ML59. VPA had, as expected, also no positive impact on SMN protein amounts, but 
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even decreased SMN in the case of ML59. There again, both Phenylbutyrate as well as 
LBH589 increased SMN levels comparable to ML5, thereby showing that ML73 and ML59 are 
not general HDACi Non-Responder. It rather gives the impression that the Non-Responders 
are inert to a small subset of HDACi, very probably those with a simple fatty acid backbone 
such as VPA and Sodium Butyrate. 
 
Figure 10 Western Blots with proteins extracted from a Pos-Responder and two Non-Responder 
fibroblasts lines treated with various HDACi. Membranes are stained simultaneously with 
an anti-SMN and an anti--Actin antibody, which served as loading control. Individual 
treatment conditions are given. Solvent for VPA and Sodium butyrate (NaBu) was H2O. 
Phenylbutyrate (PhenylBu) and LBH589 were dissolved in DMSO. 
It became clear that in Non-Responder cell lines VPA is not acting as an HDACi so that SMN 
protein is consequently not increased. VPA affects a variety of other cellular mechanisms of 
which its inhibitory effect on the cAMP-dependent Protein Kinase A (PKA) was chosen as 
second outcome measurement to characterize VPA treatment of Non-Responders 
(Boeckeler et al. 2006; Chang et al. 2009). To follow up this issue, PKA activity in VPA-treated 
fibroblasts was quantified by in vitro phosphorylation of a synthetic PKA substrate (PepTag 
Assay for non-radioactive Detection of cAMP-dependent Protein Kinase, Promega).  
Following 16 h VPA treatment, a dose-dependent decrease in PKA activity was found for 
all three tested Pos-Responder fibroblast lines (Figure 11, Figure 60). At 50 µM VPA PKA 
activity was reduced by approx. 10 to 20% whereas at 500 µM and 1 mM VPA PKA activity 
decreased by 30 or 40%, respectively. In contrast to the Pos-Responders, PKA activity did not 
decrease in the Non-Responders under VPA treatment. For both ML59 and ML73 only tiny 
fluctuations of around 10% were detected. In the case of ML103 VPA, unexpectedly, 
increased PKA activity at all three assayed concentrations. Taken together these data clearly 
show that besides not acting as an HDACi in Non-Responders, VPA also does not act as a PKA 
inhibitor in these cells. 
 
84 Results 
 
 
Figure 11 Change in PKA activity compared to untreated cells. Individual significances are given at 
each bar, brackets indicate comparison of Pos-Responders versus Non-Responders (n.s. = 
not significant; * P<0.05; ** P<0.005; *** P<0.001).  Pos-Responder → from left to right: 
ML16, ML17, ML67. Non-Responder → from left to right: ML59, ML73, ML103. All results are 
given as mean of three independent experiments. 
4.1.3 Transcriptome-wide comparison of Non- and Pos-Responders 
By comparing Non-Responders and Pos-Responders, it could be shown that VPA neither 
triggers SMN2 promoter hyperacetylation nor inhibits the PKA in Non-Responders. Since all 
fibroblasts are derived from different SMA patients, all Non-Responders should - most likely 
- have something in common which prevents VPA´s normal mode of action. On the other 
hand, this pivotal factor should not be present in Pos-Responders and therefore make up the 
difference why somebody reacts to VPA or not. To identify this factor, which may either be a 
specific gene or a group of genes, both groups should be compared by transcriptome-wide 
µ-array analysis.  
In the previous experiments six concordant fibroblast lines were identified: two of them 
Pos-Responder (ML67, ML72) and four Non-Responders (ML59, ML69, ML73 and ML82). To 
increase the statistical power of the µ-array analysis three additional fibroblast lines were 
included (ML5, SMA type II, 3x SMN2 / ML16, SMA type I, 3x SMN2 / ML17, SMA type I, 
2x SMN2) which previously have been shown to positively react to VPA (Brichta et al. 2003). 
These cell lines were not derived from SMA patients included in the pilot clinical trial with 
VPA (Brichta et al. 2006) but are routinely used in our laboratory for experiments with HDACi 
(Garbes et al. 2009; Riessland et al. 2006).  
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With a suefficient number of fibroblast lines available for µ-array analysis (five Pos-
Responder vs. four Non-Responder), cells were plated out and 24 h later treated for 16 h 
either with mock or 500 µM VPA, respectively. Since the amount of RNA needed for µ-arrays 
is >3 µg for each sample, 1x106 fibroblasts were seeded out in two separate 15 cm dishes 
each. In contrast to the normal procedure, cells were trypsinized, pooled, pelleted and then 
lysed with RLT-buffer (Qiagen) for RNA-extraction because a small aliquot of the cell 
suspension was used for protein extraction and subsequent western blot analysis. This was 
based on the observation that in very few cases the change in SMN levels triggered by VPA 
treatment was far lower than usual. To ensure that only strong samples are compared with 
each other, only those aliquots were used for µ-arrays in which a SMN response similar to 
previous data was verified by western blotting. 
The collected RNA samples were then sent to the Microarray facility in Tübingen where all 
subsequent steps including the bioinformatic analysis were performed (3.9.5). For the 
comparison of Non- and Pos-Responders, the GeneChip Human Gene 1.0 ST Array (V1 April 
2009) from Affymetrix was employed detecting 28,869 well-annotated genes via >760,000 
probes. The probe design is based on the human genome sequence assembly from spring 
2006 (UCSC Hg18, NCBI build 36) and covers more than 99% of mature mRNA (NM) 
sequences present in the RefSeq database (http://www.ncbi.nlm.nih.gov/refseq/). 
Background substraction is done by using around 17,000 background probes (GeneChip 
Human Gene 1.0 ST Array datasheet, Affymetrix).  
After µ-array read-out and background substraction, both Non- and Pos-Responders were 
compared groupwise. Taken together four different comparisons were performed (Table 17) 
and the following number of transcripts were detected to be differentially expressed. A 
complete list of all differentially expressed transcripts is given in the Appendix, Table 22 to 
Table 24. 
Comparison P≤0.05 P≤0.01 
P≤0.05  
(BH corrected) 
NR mock vs. NR treated 977 280 0 
PR mock vs. PR treated 1987 733 58 
NR mock vs. PR mock 1247 289 9 
NR treated vs. PR 
treated 
1418 293 21 
Table 17 Number of differentially expressed transcripts under different levels of significance.  
(NR =  Non-Responder; PR = Pos-Responder; BH corrected = after Benjamini-Hochberg 
correction) 
False positive transcripts due to multiple testing were eliminated by Benjamini-Hochberg 
(BH) correction. After BH correction it became obvious that no single transcript was 
significantly up- or downregulated. In contrast to that, more than 50 transcripts were 
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differentially expressed under VPA treatment in the Pos-Responders. Most interestingly, 
only nine transcripts were differentially expressed between untreated Pos- and Non-
Responders. These, and another 12 genes, were also found to be significantly expressed 
between treated Pos- and Non-Responders. 
In a next step, all transcripts were eliminated which showed a less than 2-fold expression 
(logFC<1) since these differences may also occur randomly without a significant impact. This 
reduced the list to a total of 22 transcripts which are given in Figure 12. 
 
Figure 12 Schematic overview of differentially expressed transcripts fulfilling the criteria of an 
adjusted P-Value (after BH correction) < 0.05 (5.00E-2) and logFC (log-fold change) > 1. Leading sign 
indicates in which group expression of the respective transcript was higher. Transcripts 
highlighted in yellow are differentially expressed between both treated and untreated Non- 
and Pos-Responder. 
Although data are corrected for multiple testing and RNAs of bad quality are excluded, µ-
array analysis may lead to false positive results. Therefore, the identified 22 differentially 
expressed transcripts had to be verified by a second method. Therefore, aliquots of the RNAs 
used for µ-array analysis were reversely transcribed into cDNA and the expression in all 18 
samples (five Pos-Responder + four Non-Responders, each mock and VPA-treated) were 
analyzed by qRT-PCR on an ABI 7500 Taqman machine. A detailed list of the qRT-PCR results 
and their comparison to the µ-array results is given in the appendix, Table 25 and Table 26. 
Taken together nine out of the 22 transcripts could be verified by qRT-PCR (DIO2, GALNT12, 
RAR, KIAA1772, LYPD6, MAB21L1, TGF, CD36 and IGFBP5) whereas for the remaining 13 
transcripts the µ-array data could not be reproduced by qRT-PCR. For example, µ-array 
detected a higher expression of EPHA4 in Non-Responders, but qRT-PCR indicated for both 
Non- and Pos-Responders a likewise expression. Of the verified transcripts three (DIO2, 
GALNT12, RARb) were generally differentially expressed between Non- and Pos-Responders, 
whereas the six transcripts were only found to be unequally expressed in VPA-treated cells.  
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Since nine different transcripts are too many to perform subsequent experiments, a 
practical number of the most likely candidates had to be selected. To identify the most 
promising candidates, literature was mined and the transcripts rather less likely to account 
for a differential response to VPA were excluded from further analysis (Table 27). The 
following four candidates were chosen based on their described function and their 
connections to different pathways (Figure 13). In the following, each candidate is briefly 
introduced and the individual expression pattern in the assayed fibroblasts is given. 
 
Figure 13 Schematic depiction of the detected expression pattern in Pos- and Non-Responder. CD36 = 
cluster of differentiation 36; RAR = Retinoic acid receptor ; IGFBP5 = Insulin-like growth 
factor binding protein 5; TGF = Transforming growth factor  
4.1.3.1 Cluster of differentiation 36 (CD36), MIM ID: 173510 
 alias:  thrombospondin receptor, fatty acid translocase, glycoprotein IV,  
   scavenger receptor class B member 3  
 outline:   7q11.2 / 17 exons / 471 aa > 53 kDA 
CD36 was identified more than 30 years ago as the 4th major glycoprotein in platelet 
membranes and therefore originally termed “glycoprotein IV” (Clemetson et al. 1977). Later 
studies showed that CD36 is not only expressed in blood but is also present in a large variety 
of different tissues such as endothelium, adipocytes, skeletal muscle as well as the intestine 
(Febbraio et al. 2001).  It is highly conserved among mammals, and orthologs have been 
identified down to drosophila (termed emp) (Hart and Wilcox 1993) and sponges (Muller et 
al. 2004). CD36 contains two transmembrane domains, a short intracellular domain but a 
very large extracellular domain forming a cloverleaf-like structure, which is heavily 
glycolysated (30-40 kDa) (Hoosdally et al. 2009; Rac et al. 2007). Within the group of 
vertebrates, CD36 is the defining member of class B scavenger receptor family comprising 
also CLA-1 and LIMP-II (Calvo et al. 1995; Calvo and Vega 1993). CD36 is virtually ubiquitously 
expressed and has various tissue specific-functions. One of the best characterized roles of 
CD36 is its function as a receptor of thrombospondin-1 (TSP1) as well as several other 
proteins containing thromobspondin repeats (TSR) (Silverstein et al. 1992). In this capacity, 
CD36 negatively controls angiogenesis, e.g. in the case of tumor growth or wound healing, 
by activating p59fyn, p38, caspase 3-like kinase and driving the cell into apoptosis (Jimenez et 
al. 2000). Furthermore, CD36 functions as a scavenger/pattern recognition sensor within the 
innate immune system and recognizes foreign agents such as bacteria or parasites (Means et 
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al. 2009). Recent studies have shown that CD36 acts as a co-receptor for toll-like receptor 2 
(TLR2) and is mainly responsible for the recognition of bacterial lipoproteins (Jimenez-
Dalmaroni et al. 2009). Studies with mice carrying a CD36 nonsense mutation revealed that  
these oblivious mice are hypersusceptible to Staphylococcus aureus infections due to an 
insensitity to MALP-2 (a bacterial lipopeptide) and lipoteichoic acid (Hoebe et al. 2005). 
Besides sensing foreign agents, CD36 is also involved in the recognition of endogenous 
specimens such as apoptotic cells (Ren et al. 1995) and oxidized lipoproteins (Endemann et 
al. 1993; Podrez et al. 2000; Ren et al. 2010). Especially CD36-mediated recognition of oxLDL 
has been intensively studied since oxLDL internalization promotes the formation of lipid-
loaden macrophages and smooth muscle cells (“foam-cells”) as well as atherosclerotic 
plaques. oxLDL binding by CD36 activates pro-inflammatory transcription factors such as NF-
B and triggers cytokine release (Febbraio et al. 2001; Kunjathoor et al. 2002). Moreover, 
CD36 mediates the microglial and macrophage response to -amyloid by triggering Src 
kinase dependent production of inflammatory mediators thereby suggesting that CD36 takes 
a major position in the proinflammatory events of Alzheimer´s disease (El Khoury et al. 2003; 
Moore et al. 2002). Taken together, CD36 signalling is diverse but some common patterns in 
response to scavenger ligands are present such as activation of Src and JNK kinase as well as 
kinases of the MAPK family (Jimenez et al. 2000; Moore et al. 2002; Rahaman et al. 2006). 
Because VPA is a short-chain fatty the most important finding in the context of this thesis 
is that CD36 has also been shown to be involed in the import of biologically active lipids and 
long-chain fatty acids (LCFA) into the cell (Abumrad et al. 1993; Coburn et al. 2000; 
Endemann et al. 1993). Studies using mice showed that CD36 expression is highest in tissue 
strongly dependent on high FA metabolism such as heart and oxidate muscles. Furthermore, 
it has been shown that CD36 is co-regulated with fatty acid binding proteins (FABP) (Poirier 
et al. 1996) and also increased in mice under high-fat diet (Heuckeroth et al. 1987). The 
exact mechanism of CD36-mediated LCFA-transport is yet unknown but its expression is 
regulated by the lipogenic transcription factors PPAR, LXR and RXR. Therefore, it also has 
been suggested that CD36 may contribute to the pathogenesis of obesity and steatosis (Zhou 
et al. 2008). Furthermore, two SNPs within the CD36 promoter region, most likely reducing 
CD36 expression, have been associated with insulin resistance (Corpeleijn et al. 2006; 
Miyaoka et al. 2001). Studies in CD36 null rats corroborate these findings by showing that 
indeed their liver became insulin resistant since the muscles only utilized glucose whereby 
the liver was flooded with an excess of LCFAs (Goudriaan et al. 2003). Underlining the role of 
CD36 in metabolic syndromes it has been observed that fatty acids and insulin 
opposotionally regulate lysosomal degradation of CD36 by controlling its ubiquinitylation 
(Smith et al. 2008).  
Taken together the vast number of cellular processes in which CD36 is involved, as well as 
function as a fatty acid transporter make it a very interesting candidate for the differential 
response to VPA. 
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The detected 5-fold higher expression of CD36 in Non-Responder compared to Pos-
Responders by µ-array was verified by qRT-PCR (Figure 14). In all five tested Pos-Responder 
fibroblast lines CD36 expression was between 0.3 and 1.0 au. In contrast to that, expression 
of CD36 was between 1.5 au in the Non-Responder ML69 and 4.8 au in ML59. Although 
more than 3 au differences in the transcript levels of CD36 were detected within the group 
of Non-Responders, analysis clearly showed a significant higher expression of CD36 
(P=0.0026) in this group compared to Pos-Responders. 
 
Figure 14 Expression of CD36 in Non- and Pos-Reponders under VPA treatment determined by qRT-
PCR and µ-array. On the right side mean values for both groups are given based on qRT-PCR 
data (PR = 0.53±0.27 au; NR = 2.73±0.89 au; P=0.0026). Dashed line represents mean 
expression of all nine tested fibroblast lines. (PR = Pos-Responder; NR = Non-Responder) 
4.1.3.2 Retinoic acid receptor  (RAR), MIM ID: 180220 
 alias:  Nuclear receptor subfamily 1 group B member 2, hepatitis B virus   
   activated protein 2 
 outline:   3q24 / 8 exons / 455 aa > 51 kDA 
Tissue homeostasis and development is regulated by a plethora of factors. Among these 
vitamin A and its bioactive derivates, termed retinoids, play a critical role. These non-steroid 
hormones are important regulators of differentiation, proliferation and apoptosis (Ross et al. 
2000). Typically, the retinoic acid (RA) signal is transduced by two families of nuclear 
receptors each consisting of three isotypes (,  and ) – the retinoic acid receptors (RAR) 
and the retinoid X receptors (RXR), which work as RXR/RAR heterodimers (Kastner et al. 
1997; Leid et al. 1992b; Mangelsdorf and Evans 1995). RARs are typically activated by all-
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trans retinoic acid (RA) and its 9-cis isomer, whereas RXRs are only activated by the latter 
isomer. From a structural point of view, all retinoid receptors are composed of six conserved 
regions, of which the third one – termed C-region – harbors the DNA-binding domain (DBD) 
(Zechel et al. 1994a; Zechel et al. 1994b) whereas the E-region is responsible for ligand-
binding (LBD) and heterodimerization (Wurtz et al. 1996). Interestingly, it has been shown 
that upon PKA activation a consensus site within in the LBD of RARs is phosphorylated 
whereby DNA binding is reduced (Rochette-Egly et al. 1995). RAR/RXR heterodimers bind to 
RA response elements (RARE) consisting of two direct repeats of a hexameric motif 
Pu(G/T)TCA (Leid et al. 1992b; Mangelsdorf and Evans 1995). Classical RAREs are found in a 
wide variety of promoters as in those of HOX genes (Dupe et al. 1997), but also in the 
promoters of RA-shuttle proteins CRBPI and CRAPII (Durand et al. 1992) and RAR itself (de 
The et al. 1990). Typically, unliganded RAR/RXR heterodimers are bound to their respective 
RARE and repress transcription via recruitment of co-repressors such as N-CoR, which in turn 
recruit HDAC-complexes (Glass and Rosenfeld 2000). Binding of RA to the heterodimer 
induces conformational changes (Rastinejad et al. 2000) leading to the dissociation of the co-
repressors. This triggers chromatin remodeling and allows the binding of co-activators 
(Depoix et al. 2001). As a last step of gene activation, retinoid receptors recruit the 
transcription machinery to the decondensed chromatin via the SMCC mediator complex 
(Dilworth and Chambon 2001). Besides activation by ligand binding, RARs are regulated by 
ubiquitinylation (Zhu et al. 1999) and phosphorylation, which allows cross-talk with other 
signalling pathways such as PKA, ERK and JNK mediated signalling (Rochette-Egly 2003). 
Although much research has focused on the role of RAR and RAR during development, 
there have also been some efforts to clarify the physiological role of RAR. Similar to other 
RAR isotypes, several isoforms of RAR are known (RAR1 to RAR4), which differ by their 
N-terminal A region. These different isoforms arise from alternative splicing as well as the 
facultative usage of two different promoters of which the second one – termed P2 - is RA-
inducible (Leid et al. 1992a). RAR-/- mice are viable but show symptoms like growth 
retardation, homeotic transformations of the cervical vertebrae and a retrolenticlar 
membrane due to hyperplasia of the primary vitreous body. Although the highest expression 
of RAR was detected in the striatum and the interdigital mesenchyme, brain and limbs of 
RAR-/- mice appeared normal (Ghyselinck et al. 1997). RAR/RAR double knockouts die 
prenatally or soon after birth due to respiratory problems. When analyzed at fetal stages, 
these mice display symptoms similar to the CATCH22 syndrome (microdeletion in 22q11), 
which can be mimiked in chicks by ablation of the neural crest cells (NCC) (Ghyselinck et al. 
1997; Mendelsohn et al. 1994). RAR/RAR knockout mice show major ocular defects similar 
to the fetal vitamin-A deficiency (VAD) syndrome (Ghyselinck et al. 1997; Lohnes et al. 1994; 
Mendelsohn et al. 1994). Further intensive studies using double mutants clearly reflected 
the roles of RAR signalling in axial rotation, brain segmentation and ontogenesis 
mesectodermal derived structures by controlling HOX gene expression (Dupe et al. 1997; 
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Mark et al. 1998; Mark et al. 1995). For example, it has been shown in mice that RAR 
controls expression of group four HOX genes but is also reciprocally regulated by Hoxb4 and 
Hoxd4, thereby controlling the segmentation of the hindbrain (Serpente et al. 2005). 
Noteworthy, two additional points have to be mentioned: Typically, RAR is not expressed 
or only present at very low levels in dermal fibroblasts in vitro but is quickly up-regulated 
upon RA stimulus (Redfern and Todd 1992). Furthermore, RA treatment of cells rapidly 
induces up-regulation of CD36 mRNA although it has not yet been worked out whether this 
is mediated via a RAR/RXR heterodimer (Wuttge et al. 2001). 
Similar to CD36, RAR was confirmed by qRT-PCR to be higher expressed in Non-
Responders (Figure 15). In contrast to CD36, expression of RAR was higher in mock (12.5 au 
vs. 0.2 au) and VPA-treated (4.5 au vs. 0.2 au) Non-Responders. Noteworthy, at least in qRT-
PCR-assay RAR was barely expressed in all in Pos-Responders leading to considerable 
differences between both groups. In line with this RAR signal intensities during µ-array 
analysis were only slightly over the threshold (oral communication with Dr. Walter, 
Tübingen). Within the group of Non-Responders, RARexpression varied in the mock-
treated cells between 7 (ML73) and 21 (ML59) au, but was still considerably highly 
expressed. Under VPA treatment, RARexpression dropped to around 4.5 au in the mean. In 
the case of ML73, which also showed the lowest RAR expression when mock-treated, RAR 
was not longer expressed under VPA treatment. 
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Figure 15 Expression of RAR in Non- and Pos-Reponders under VPA treatment and mock-treated  
determined by qRT-PCR and µ-array. On the right side mean values for both groups are 
given based on qRT-PCR data (PR mock = 0.31±0.14 au; PR VPA = 0.43±0.39 au; n.s. / NR 
mock = 12.56±4.33 au; NR VPA = 3.15±1.81 au; P=0.006 /PR mock vs. NR mock; P<0.001 / PR 
VPA vs. NR VPA; P=0.012). Dashed line represents mean expression of all nine tested 
fibroblast lines. (PR = Pos-Responder; NR = Non-Responder; n.s. = not significant) 
4.1.3.3 Insulin-like growth factor binding protein 5 (IGFBP5), MIM ID: 146734 
 alias:  IGF-binding protein 5 
 outline:   2q35 / 4 exons / 272 aa > 30 kDA 
During the 1970´s, the insulin-like growth factors were discovered as factors with 
structural homology to pro-insulin which can stimulate insulin-like effects (Rinderknecht and 
Humbel 1978a, b). Subsequent studies showed that in mammals a so-called IGF system is 
present which consists of two ligands circulating in the serum (IGF-I and IGF-II) (Daughaday 
and Rotwein 1989) and six classical binding proteins (IGFBP1 to IGFBP6). Downstream signal-
transduction within the IGF system is elicited via the IGF type 1 receptor (IGF-1R) and 
controls mostly mitogenic and apoptotic effects (Gicquel and Le Bouc 2006). In contrast to 
that, the IGF type 2 receptor (IGF-2R/mannose-6-phosphate receptor) is not involved in 
signal transduction since it is devoid of a tyrosine kinase domain but rather controls 
extracellular IGF-II concentrations (Braulke 1999). Mice lacking IGF-2R have an increased 
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birth weight, heart abnormalities and usually die perinatally but can be rescued by depletion 
of IGF-II (Lau et al. 1994; Ludwig et al. 1996). 
IGFBPs share an overall protein sequence identity of 50% and contain 16-18 conserved 
cysteines in the N- and C-terminus (Shimasaki and Ling 1991). Furthermore, a characteristic 
GCGCCXXC motif is present in the N-terminus of all IGFBPs (Oh et al. 1996; Shimasaki and 
Ling 1991). Generally speaking, IGFBPs compete with the IGF receptors for peptide binding 
by sequestering extracellulary IGFs (Baxter and Twigg 2009). Free IGFs have a half-life of 
approx. 10 min whereas when bound in binary 40 kDa complex with IGFBPs1-6 the half-life 
increases to 30 to 90 min. The half-life is even more increased to 12 h when IGFs are bound 
in a ternary 150 kDa complex with either IGFBP3 or IGFBP5 and ALS (acid labile subunit), 
suggesting that the regulation of free and bound IGF by the IGFBPs is of fundamental 
importance (Firth et al. 2001; Guler et al. 1989).  
Nowadays, debate is ongoing whether IGFBPs should be considered as simple IGF carrier 
proteins since newly identified IGF low affinity binders (5 to 25 fold less than conventional 
IGFBPs1-6) such as IGFBP7 (Oh et al. 1996) and IGFBP8 (Kim et al. 1997) show an up to 500-
fold higher affinity to insulin (Yamanaka et al. 1997). Subsequent identification of further 
IGFBP-related proteins such as IGFBP-rP5 (L56/HtrA) (Zumbrunn and Trueb 1996) and 
IGFBP-rP2 (CTGF) (Bork 1993) has led to the proposal to extend the classical IGFBP family to 
a superfamily consisting out of the six classical members IGFBP1-6 as well as 10 IGFBP-
related proteins (Hwa et al. 1999). 
The IGFBP5 gene is located on chromosome 2 only 20 kb away from the IGFBP2 gene, 
suggesting that both genes developed after duplication of an ancestral IGFBP. Similar to 
IGFBP4, which is found in the vicinity of the HOXB genes, IGFBP2 and IGFBP5 map to the 
same chromosomal region as the HOXD cluster. This indicates that these genes were 
probably linked prior to duplication, but a common cis regulatory element has not yet been 
identified (Allander et al. 1994). Within the same work it has been shown that the IGFBP5 
promotor has a simple structure with conserved TATAA and CAAT sequences present 
upstream of the TSS (Allander et al. 1994). Subsequent studies identified an AP2 recognition 
side upstream of the TATA box, explaining the high expression levels in fibroblasts as well as 
the responsiveness to cAMP (Duan and Clemmons 1995). Throughout the human body the 
highest IGFBP5 expression is found in testis, bone, trabecular meshwork, lung, uterus and 
placenta (Schneider et al. 2002). In adult human serum, IGFBP5 amounts are depending on 
the IGF-I concentration (Mohan et al. 1996), which has been verified in the brain of IGF-I 
transgenic mice (Ye and D'Ercole 1998). However, IGFBP5 serum levels as well as skeletal 
content decrease during ageing (Mohan et al. 1995; Rajaram et al. 1997). 
IGFBP5 is synthesized as a 272 aa protein which is secreted after cleavage of 22 aa as a 
29 kDa protein. Similarly to other IGFBPs, IGFBP5 can be cleaved by a variety of proteases 
thus regulating its bioavailability (Schneider et al. 2002). Most proteolytic cleavage sites are 
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found within the midpart, which in contrast to the higly conserved N- and C-terminus differs 
from the other IGFBPs. For example, in fibroblasts IGFBP5 is cleaved among others by 
complement C1r and C1s, resulting in a 22 kDa fragment (Busby et al. 2000). Furthermore it 
has been shown that all four predicted O-glykolysation sites of IGFBP5 (Thr103, Thr104, Thr111 
and Thr152) are indeed used making the protein less prone to proteolysis although some 
modifications may be tissue specific (Conover and Kiefer 1993; Standker et al. 1998).  In 
addition, IGFBP5´s affinity to IGF-I is modulated via phosphorylation in the midpart (Coverley 
and Baxter 1997; Schneider et al. 2002). 
IGFBP5 has been shown to bind the ECM, thereby stimulating osteoblast mitogenesis. 
However, although ECM-binding decreases the proteolysis of IGFBP5, it reduces its affinity to 
IGF-I and –II (Andress and Birnbaum 1992; Arai et al. 1994). Subsequent studies identified 
Arg207 and Arg214 as the most critical aa mediating ECM binding (Parker et al. 1998). 
Furthermore, an association has been shown between IGFBP5 and 420 kDa membrane 
protein which is capable to internalize IGFBP5 in osteoblasts. Although feasible it has not yet 
been proven whether this is an IGFBP5 receptor (Andress 1995).  
In vivo studies using transgenic mice overexpressing IGFBP5 under the control of the 
osteocalcin promoter revealed that these animals had an up to 27% reduced total bone 
mineral density as well as a decreased bone mineral apposition rate most likely due to 
impaired osteoblastic function (Devlin et al. 2002). Ubiquitous overexpression led to 
increased neonatal mortality, growth reduction and retarded muscle development (Salih et 
al. 2004). However, ubiquitous IGFBP5 overexpression was able to rescue the lethal IGF-2R 
phenotype by sequestering the excess of IGF-II (Tripathi et al. 2009). Similar to the IGFBP3-/- 
mice, IGFBP5-/- mice had no obvious phenotype, suggesting that both proteins somehow 
compensate for each other since IGFBP3 and -5 are the only IGFBPs able to form the ternary 
IGF-ALS complex (Ning et al. 2006). This hypothesis was further underlined by experiments 
showing that IGFBP3 mRNA was increased in the jejunum of IGFBP5-/- mice (Murali et al. 
2007).   
In contrast to CD36 and RAR, an almost 10-fold higher expression of IGFBP5 was found in 
Pos-Responders compared to Non-Responders by both qRT-PCR and µ-array (Figure 16). All 
tested Non-Responders exhibit a likewise IGFBP5-expression of approx. 0.3 au, whereas the 
Pos-Responder had a mean expression of around 3.3 au. Within the group of Pos-
Responders, a more than 4-fold expression difference was found between ML17, which 
peaked at 8 au, and ML72, ML16 and ML5 having an expression of around 2 au. However, a 
significant difference in expression was detected when all fibroblast lines were compared 
groupwise (P=0.035). 
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Figure 16 Expression of IGFBP5 in Non- and Pos-Reponders under VPA treatment determined by qRT-
PCR and µ-array. On the right side mean values for both groups are given based on qRT-PCR 
data (PR = 3.30±2.41 au; NR = 0.38±0.22 au; P=0.035). Dashed line represents mean 
expression of all nine tested fibroblast lines. (PR = Pos-Responder; NR = Non-Responder) 
4.1.3.4 Transforming growth factor  (TGF), MIM ID: 190170 
 alias:  protransforming growth factor  
 outline:   2p13 / 6 exons / 160 aa > 17 kDA 
TGF is a small polypeptide growth factor which is structurally related to EGF (35% 
homology) and is secreted by a wide variety of neoplastic cells and during fetal development 
(Coffey et al. 1987; Marquardt et al. 1984). However, subsequent studies revealed that TGF 
expression is not restricted to these instances but rather occurs throughout the whole 
organism, especially in skin keratinocytes (Coffey et al. 1987). Wound healing experiments 
showed that TGF expression by wound macrophages stimulates keratinocyte proliferation 
and migration, thereby closing the wound. Furthermore, it has been shown that PKC 
activation strongly enhances TGF expression, suggesting that TGF is a normal 
physiological ligand in the skin. (Barrandon and Green 1987).  
Similar to EGF, all biological activities of TGF are elicited through the EGF receptor 
(ErbB1/HER1) (Todaro et al. 1980). Thus, both ligands compete for the binding and might 
have complementary functions (Massague 1983). However, TGF has been shown to be far 
more potent than EGF in promoting angiogenesis (Schreiber et al. 1986) and inducing cell 
transformation in vitro (de Larco and Todaro 1978; Rosenthal et al. 1986; Todaro and De 
Larco 1978; Watanabe et al. 1987). The EGF receptor is a member of the ErbB family of 
 
96 Results 
tyrosine-kinase receptors which mediate major cellular functions such as proliferation and 
survival (Blume-Jensen and Hunter 2001). The four members of the ErbB family are EGFR, 
ErbB2 (HER2), ErbB3 (HER3) and ErbB4 (HER4), of which ErbB2 is the most potent signalling 
molecule (Normanno et al. 2006). Nowadays, several antibodies used in cancer therapy, such 
as Herceptin (Trastuzumab), are on the market which directly target different members of 
the ErbB-family. 
From the TGF gene two different mRNAs encoding both for the same protein (1.6 and 4.5 
kb in length) are generated of which the 4.5 kb mRNA is the predominant isoform. As 
compared to the shorter mRNA, the 3´-UTR of the 4.5 kb mRNA possesses a number of 
additional destabilization elements and polyadenylation signals controlling its lifetime (Qian 
et al. 1993). TGF is synthesized as a 160 aa precursor transmembrane molecule which 
contains a 100 aa large extracellular domain, from which the mature TGF peptide is 
released by cleavage with elastase-like enzymes (Lee et al. 1985). Different species of the 
mature TGF have been found depending on the proteolytic cleavage and on differential N- 
and O-glykolysation (Bringman et al. 1987; Gentry et al. 1987). A similar domain undergoing 
proteolytic cleavage has been identified in the EGF precursor (Pfeffer and Ullrich 1985). 
Noteworthy, not only the secreted but also the membrane-bound TGF precursors are 
biologically active and interact with receptors of adjacent cells (Brachmann et al. 1989).  
Studies with mice tried to elucidate the different functions of TGF in an in vivo context. 
Transgenic mice overexpressing TGF in the mammary epithelium showed hyperplasia of 
the alveoli and terminal ducts. In contrast to that, males overexpressing TGF in the 
reproductive organs exhibit no morphological abnormalities (Matsui et al. 1990). 
Subsequently, more general studies underlined the great impact of TGF on angiogenesis 
and proliferation. Ubiquitous overexpression of TGF led to the development of general 
epithelial hyperplasia in liver, pancreas and the gastrointestinal tract as well as tissue-
specific phenotypes such as multifocal hepatocellular carcinomas (Jhappan et al. 1990; 
Sandgren et al. 1990). Moreover, skin-specific overexpression did not induce carcinomas of 
TGF but rather induced spontaneous papillomas (presumably in conjunction with TGF)  in 
regions of wounding and irritation (Vassar and Fuchs 1991). TGF knockout mice are healthy 
and fertile but show a pronounced waviness of the fur and whiskers due to a 
misorganization of the skin and hair follicles (Mann et al. 1993). Subsequent studies showed 
that these mice had an increased proliferation of the prostatic buds (Abbott et al. 2003) and  
reduced mid- and forebrain (Blum 1998).  
More than 20 years ago a polymorphism in TGF was associated with cleft lip with or 
without cleft palate in humans (Ardinger et al. 1989). Interestingly, TGF is expressed during 
palatogenesis in mice but TGF-/- mice do not exhibit oral clefts (Mann et al. 1993). 
Contrariwise, EGFR-/- mice have a high incidence of cleft palate which may explain the 
correlation between the TGF polymorphism and cleft lip in humans (Miettinen et al. 1999). 
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Subsequent meta-analysis of genome scans confirmed this association (Vieira 2006) and 
could furthermore show that certain TGF haplotypes are associated with teeth agenesis 
(Callahan et al. 2009).  
As for IGFBP5, a higher expression of TGF was detected in VPA treated Pos-Responders 
compared to Non-Responders. All four Non-Responders had a quite uniform TGF 
expression of around 0.3 au, whereas the Pos-Responders had an expression of around 
2.8 au. Comparably high expression was detected in ML72, ML17 and ML16, whereas ML67 
expressed only half of the amount, leading to a deviation between 2.4 and 1.2 au within the 
group of Pos-Responders. In summary, the expression differences detected by qRT-PCR were 
slightly less then measured by µ-array but still significant (P=0.001).  
 
Figure 17 Expression of TGF in Non- and Pos-Reponders under VPA treatment determined by qRT-
PCR  and µ-array. On the right side mean values for both groups are given based on qRT-PCR 
data (PR = 2.77±0.95 au; NR = 0.32±0.02 au; P=0.001). Dashed line represents mean 
expression of all nine tested fibroblast lines. (PR = Pos-Responder; NR = Non-Responder) 
4.1.3.5 Validation of candidate genes on protein level 
All previous data were based on RNA expression in fibroblasts. However, the differential 
response to VPA is most likely mediated on protein level e.g. by VPA-binding, transport etc. 
Therefore, proteins from all nine fibroblast lines were prepared and individual candidate 
protein amounts were quantified by quantitative western blotting.  
As shown in Figure 18, levels of IGFBP5 were hard to determine. Although several 
antibodies were tested, no satisfying staining was achieved. Nevertheless, going in line with 
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the RNA data, IGFBP5 seemed to be more abundant in Pos-Responder with the highest 
amounts in ML16 and ML17. For all Non-Responders bands were hardly visible. RAR could 
be clearly detected in all nine tested cell lines. Unexpectedly, highest amounts were found in 
the Pos-Responder ML17. Furthermore, ML16 and ML5 expressed modest RAR levels under 
VPA treatment. The Non-Responder fibroblast lines ML59 and ML73 were found to have 
similarly high RAR levels irrespective of whether VPA was added or not. Nevertheless, these 
data do not confirm the RNA expression levels. Similar findings were obtained for CD36. 
When comparing both groups with each other Pos-Responder seem to express higher 
amounts of CD36 than the Non-Responder and not – as expected – vice versa. Moreover, in 
ML16, ML5 and ML67 a clear increase in CD36 amounts could be detected under VPA 
treatment, which was not seen on RNA level. Within the group of Non-Responders, ML82, 
ML59 and ML69 also increased CD36 amounts under VPA treatment showed in line with the 
RNA data whereas no such effect was seen in ML69. However, the antibody used did not 
recognize glycosylated CD36, which may represent a major portion of the total CD36 
content. However, taken together, these protein data do not confirm, the RNA data with the 
exception of IGFBP5.  
 
Figure 18 Western blot illustrating the individual levels of CD36, RAR and IGFBP5. -Actin was used 
as loading control. Cells were either treated with 500 µM VPA or mock for 16 h. 
4.1.3.6 Confirmation of candidate genes in blood from VPA-treated SMA patients 
If one of the four candidate genes will be validated as the crucial factor making the 
difference why a given SMA patient reacts to VPA or not, it would be of great benefit if this 
gene could be used as a biomarker. Possibly, its expression could be analyzed prior to VPA 
treatment, and depending on the result, it could be individually decided whether this patient 
should undergo VPA treatment. Since the most easily accessible sample from a SMA patient 
is blood, it was checked if the expression pattern found in fibroblasts from Non- and Pos-
Responders (CD36 and RAR ↑ in Non-Responder / IGFBP5 and TGF ↑in Pos-Responder) is 
the same in the respective blood samples. Therefore, RNA from blood samples of eight SMA 
patients treated with VPA was reversily transcribed and analyzed by qRT-PCR. Seven of these 
patients had already participated in the pilot clinical trial with VPA (Brichta et al. 2006), 
whereas one set of blood samples was derived from a newly recruited patient 
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(10197/ML86). From each patient, either one or two samples were collected before 
treatment was started to determine basal SMN levels. Furthermore, three to five samples 
were collected while the patient was under VPA treatment (blood VPA level approx. 70mg/dl) 
in an interval of four weeks to several months. With the exception of P5/ML60 all SMA 
patients showed concordant results regarding the effect of VPA on SMN levels in blood and 
fibroblasts (Table 15). 
In the case of CD36, which showed a higher expression in fibroblasts derived from Non-
Responders, no correlation between the expression levels in blood and the response to VPA 
was found (Figure 19). Although in some cases (P2, P13, P14, 10197) differences between 
the individual samples were tiny, the interindividual differences within e.g. the group Pos-
Responders were too large to allow any correlation. Especially patient P4 showed on the one 
hand extremely high CD36, but on the other hand also very big differences between 
individual samples. 
 
Figure 19 Average CD36 expression measured in blood samples from SMA patients. For each patient 
various samples were collected before and under VPA treatment. For details see Table 28 in 
the appendix. Blood samples from patients showing decreased SMN levels under VPA 
treatment are highlighted in light gray. Those of SMA patients showing increased SMN 
amounts are highlighted in white. Patient 10197, highlighted in dark gray, is a Non-
Responder. All samples included except P5 are derived from SMA patients showing 
concordant fibroblast and blood results. (Sample labeling: Identifier in Brichta et al. 2006 or 
patient ID / fibroblast line) 
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Similar to CD36, expression of IGFBP5 did not correlate between blood and fibroblast 
samples (Figure 20). While IGFBP5 was up-regulated in fibroblasts of Pos-Responder, all but 
P4 exhibited low levels in blood. P2, P13 and P14 displayed comparably low expression 
levels, whereas all three patients exhibiting decreased SMN levels under VPA treatment 
expressed more than twice the amount of IGFBP5. Again, P4 showed exceptionally high 
levels. In general, within sets of samples from individual patients much higher differences 
were detected than in the case of CD36. 
 
Figure 20 Average IGFBP5 expression measured in blood samples from SMA patients. Blood samples 
from patients showing decreased SMN levels under VPA treatment are highlighted in light 
gray, Pos-Responder in white and Non-Responder in dark gray (Sample labeling: Identifier in 
Brichta et al. 2006 or patient ID / fibroblast line). 
Similar to CD36, the expression of TGF was quite uniform for all samples (Figure 21). 
Although up-regulated in fibroblasts of Pos-Responders, no such tendency was observed in 
blood of treated SMA patients. Again samples from patient P4 produced quite confusing 
results which did not fit to the other samples. Most likely, a long-term infection or other 
unknown factors generally change the expression of the tested candidate throughout all 
samples investigated here. 
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Figure 21 Averaged TGF expression measured in blood samples from SMA-patients. Blood samples 
from patients showing decreased SMN levels under VPA-treatment are highlighted in light 
gray, Pos-Responder in white and Non-Responder in dark gray (Sample labeling: Identifier in 
Brichta et al. 2006 or patient ID / fibroblast line). 
Furthermore, it was tried to analyze the expression of RAR in the blood samples. 
However, qRT-PCR results suggested that either RAR is not expressed in blood or its 
expression level is too low to allow detection by qRT-PCR. Consequently, no statement about 
a correlation between RAR-expression and the phenotype could be made.  
Taken together, the expression of none of the four candidate genes in blood can be used 
as a biomarker since at least in this tissue their expression does not correlate with the 
response to VPA. If potentially a correlation between a SNP and the candidate expression 
levels in fibroblasts was found, genotyping of this SNP could be used as a biomarker instead. 
4.1.4 Analysis of differences in the expression of candidate genes 
A distinct expression pattern of the four candidate genes has been demonstrated with two 
of them up-regulated in Pos-Responders and two of them up-regulated in Non-Responders. 
However, the question remained open why these genes are differentially expressed. To 
answer this question, as a first step the most obvious approach was undertaken and the CDS 
as well as the adjacent UTRs of all four candidate genes were sequenced in each patient´s 
fibroblast line included in the µ-array analysis. Therefore, sequencing primers were designed 
for all exons with the online script Exon Primer (http://ihg2.helmholtz-muenchen.de/ihg/ExonPrimer.html). 
Individual exons were amplified and subsequently sequenced. Conditions were set in such a 
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way that primers were located approx. 60 to 100 bp up- or downstream of the respective 
exon to allow also sequencing of the exon-intron-boundaries. If exons were too long for 
amplification or sequencing, exons were split into several pieces. After sequencing, data 
were analyzed and compared to the Ensembl reference sequence. 
Sequencing of CD36 revealed no direct correlation between a SNP-type and the individual 
response to VPA (Appendix, Figure 61). Within all 17 exons sequenced only two SNPs located 
in the 5‘UTR differed between the samples. In exon 1 the SNP rs1878214 was found to be 
heterozygously present (G/A) in three out of four Non-Responders (ML82, ML69, ML59) 
whereas in ML73 and all Pos-Responders the G-allele was homozygously present. This 
suggested that the A-allele may contribute to the higher CD36 expression levels in Non-
Responders. Therefore, another set of five not yet confirmed Non-Responders was 
sequenced for this SNP, but a correlation between the A-allele and the response to VPA 
could not be verified. This discarded the hypothesis that the A-allele may be the molecular 
cause of the elevated CD36 expression in Non-Responders. Another SNP (rs1049654) in exon 
four differed among tested cell lines, but its genotype did not match with either Non- or Pos-
Responders. 
In the case of RAR the previously described SNP (rs1058378) in the terminal exon 8 was 
shown to be G/G in ML17 and ML69 instead of the more common T-allele (Appendix, Figure 
61). Another variation, which was not previously described, was identified in the coding exon 
7 at position +62. In five out of nine cases the C-allele was heterozygously present, whereas 
it was homozygously present in ML73. Nonetheless, the C-allele does lead to an amino-acid 
exchange. 
Sequencing of IGFBP5 revealed that with the exception of ML5 all samples were the same 
(Figure 62). In this case two variations in the 3‘UTR encoded by exon 4 were found 
(rs2241194 and rs11575212). Similarly to the previous three genes, no association between 
a certain SNP-type and the expression levels could be drawn in the case of TGF (Appendix, 
Figure 62). Although 12 variations in the highly polymorphic 3‘UTR were identified to differ 
among the fibroblast lines, none of these could directly be connected to the higher TGF 
expression levels in Pos-Responders. 
Taken together, no association between a certain SNP and the response to VPA and the 
expression pattern, respectively, was found. However, the underlying cause of the 
differential expression of candidate genes must not necessarily be located in the CDS or the 
UTRs but rather in the promoter region. Since promoters are usually of huge dimension, 
sequencing is most often time-consuming. Therefore ChIP analysis of all four candidate 
promoters were performed to directly test if their acetylation status differs between Non- 
and Pos-Responders. A positive result would indicate that the detected expression 
differences are most likely due to different promoter activity which may caused by a 
promoter SNP. 
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Primers specific to the respective promoters were designed on either verified or very 
likely promoter sequences from the Human promoter database (http://zlab.bu.edu/~mfrith/HBP.html) 
(Materials and Methods section, Table 9). All four candidate genes were found to be 
significantly differentially expressed under VPA treatment. Therefore amplicons were 
located 500 to 1000 bp upstream of the TSS since this region is known to be typically 
hyperacetylated under HDACi treatment if this gene is induced by HDACi (Wang et al. 2009). 
To get solid data, ChIP analysis was performed with three Pos-Responders (ML17, ML67, 
ML72) and three Non-Responders (ML59, ML73, ML82) and mean acetylation levels were 
calculated for each group. All fibroblasts were seeded out 24 h before cells were treated for 
16 h with VPA. ChIP analysis was performed with an antibody directed againt acetylated 
histone H3. 
Quantifcation of the different DNA promoter fragments via qRT-PCR revealed that VPA 
increased mean acetylation at all six analyzed promoters in the Pos-Responders (Figure 22). 
In contrast to that, H3K9 acetylation was decreased in all Non-Responders under VPA 
treatment for all tested promoters. Furthermore, the global H3K9 acetylation levels turned 
out to be higher in Non-Responders, but this can be most likely attributed to the small 
sample size since e.g. the Pos-Responder ML69 generally showed very low acetylation levels. 
In conclusion, although differences between Non- and Pos-Responders were detected, no 
direct association between promoter acetylation levels and the expression could be drawn. 
For example, basal CD36 and RAR acetylation levels were, as expected, higher in Non-
Responders. On the other side also basal acetylation levels of IGFBP5 and TGF were higher 
within this group although these transcripts are more abundant in Pos-Responders. 
Furthermore, the promoters AZGP1 (-2-glycoprotein, zinc binding) and CPT1C (carnitine 
palmitoyltransferase 1C) were included in the analysis. AZGP1 was found during the µ-array 
analysis to be exclusively induced in Non-Responders by VPA whereas CPT1C is only 
increased in VPA-treated Pos-Responders. For AZGP1 no corresponding change in promoter 
acetylation could be detected although similarly to the other tested promoters basal 
acetylation levels are higher in Non-Responders. CPT1C promoter acetylation was found to 
be increased in VPA-treated Pos-Responders as expected. 
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Figure 22 Mean H3K9 acetylation levels under mock and VPA treatment in three Pos-Responders and 
three Non-Responders at different promoters. Highlighted in light-gray are those transcripts  
 which were found to be up-regulated in Non-Responders. The corresponding SMN2  
 promoter acetylation data can be found in Figure 9. (PR = Pos-Responder; NR = Non- 
 Responder) 
Since neither sequencing nor ChIP analysis revealed any obvious reason why the candidate 
genes are differentially expressed between Non- and Pos-Responders, other not yet 
appointed mechanisms must account for the detected expression. A commonly used 
mechanism to post-transcriptionally regulate expression is to increase or decrease mRNA-
stability. Modulation is most often done either by mRNA-binding proteins or miRNAs (Ross 
1995; Wahid et al. 2010). A very easy and robust way to analyze mRNA stability is to inhibit 
de novo RNA synthesis by means of Actinomycin D. Therefore, mRNA stability should be 
assessed as a next step using this assay.  
4.1.5 Identification of a putative candidate gene network 
Transcriptome-wide comparison of Non- and Pos-Responders revealed a distinct 
expression pattern with IGFBP5 and TGF being up-regulated in Pos-Responders compared 
to Non-Responders and CD36 and RAR vice versa. Since all of these genes are to a certain 
extent involved in energy metabolism, the question arose whether the observed expression 
is coincidental or whether these genes are somehow connected.  
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4.1.5.1 Knockdown and overexpression studies 
To identify any putative network connecting the four candidate genes two complementary 
sets of experiments were performed. On the one hand each candidate gene was knocked 
down by means of siRNA and the expression of the remaining three candidates was 
determined. On the other hand over-expression studies were performed to test whether the 
observed effects were reversed. Both sets of experiments were performed in parallel in both 
Non- and Pos-Responders and from each group at least two cell lines were tested to exclude 
any fibroblast line specific effects.  A knockdown of RAR could not be performed since none 
of the tested siRNAs gave reproducibly good results.  
Knocking down IGFBP5 had opposite effects on CD36 in Pos- and Non-Responders (Figure 
23a). While in the case of the Pos-Responders the already low expression levels further 
decreased, CD36 merely doubled in the Non-Responders. Similar results were obtained for 
RAR: Typically barely expressed in Pos-Responders, no considerable change in the overall 
amount was detected when knocking down IGFBP5. Contrariwise, transcript amounts of 
RAR increased by around 80% in the group of Non-Responders. In both groups TGF was 
not affected by decreased IGFBP5 amounts. 
In the case of CD36 depletion from the cells the high IGFBP5 levels of Pos-Responders 
more or less remained unaffected (Figure 23b). In contrast to that, IGFBP5 doubled within 
the group of Non-Responders although compared to Pos-Responders overall amounts 
remained infinitesimal. Similar to the knockdown of IGFBP5, reduced CD36 amounts only 
had minimal effects on RAR levels in Pos-Responders. On the other hand, levels of RAR 
increased by almost 100% in Non-Responders. Total amounts of TGF remained unaffected 
under reduced CD36 levels although the great differences between individual Pos-
Responders hamper a definite statement.  
Finally, TGF was knocked down in both groups (Figure 23c). CD36 levels increased in 
Non- as well as Pos-Responders while the effect in the Non-Responders was much more 
obvious. More drastic effects were observed when IGFBP5 levels were determined. High 
levels typically found in Pos-Responders were reduced by approx. 25% whereas in the Non-
Responders IGFBP5 transcript amounts increased by around 30% when TGF was 
knocked-down. Still it has to be taken into account that the high levels of Pos-Responders 
were not reached by the Non-Responders. Expression levels of RAR were modestly 
increased in Non-Responders, whereas the comparably small amounts present in 
Pos-Responders were not considerably altered. 
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Figure 23 Knockdown of either (A) IGFBP5, (B) CD36 or (C) TGF in Non- and Pos-Responders` 
fibroblasts. Expression levels of the respective remaining three candidate genes are 
depicted. For better comparison basal expression levels and the change in expression in % 
are given for each transcript. Data are given as mean ± SMN (PR = Pos-Responder → ML16, 
ML17, ML67 and ML72; NR = Non-Responder → ML59, ML73 and ML82). For RAR 
knockdown no data were available since the siRNA oligos failed to work. 
In addition to the knockdown approach also overexpression studies with plasmids 
encoding the individual candidate genes were performed. Two Pos- (ML17 and ML72) and 
two Non-Responder (ML59 and ML73) were transfected and either mock or VPA treated for 
16 h. By analyzing RNA amounts by qRT-PCR the following observations could be made 
(Figure 24). 
Unfortunately, overexpression of CD36 did not prduce any consistend results. For 
example, IGFBP5 and TGF levels were increase in ML72 and ML59 whereas the opposite 
was detected in ML17 and ML73. Similar results were obtained for RAR, which was either 
increased or decreased in ML17 and ML73, respectively, whereas RAR levels remained 
unchanged in the other two fibroblast lines. However, addition of VPA to 
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CD36-overexpressing fibroblasts dramatically changed the situation. IGFBP5 was increased 
by more than 100% in all tested cell lines with the highest effect in ML59. Non-Responder 
RAR levels increased compared to mock treated cells and a similar effect could be observed 
in ML17. In summary, the greatest difference could be detected in the TGF levels (Figure 
24).  
Transfection with an IGFBP5-encoding plasmid did not have any pronounced effect on 
either CD36 or TGF levels. RAR transcripts decreased by more than 50% in ML17, ML72 
and ML59 while no change could be obtained in ML73. Addition of VPA to the transfected 
cells did not result in an effect as pronounced as in the case of CD36 overexpression. Only 
analysis of TGF revealed consistent results: While in the Pos-Responder levels increased by 
approx. 10%, levels declined in the Non-Responders by 5 to 10% (Figure 24). 
Overexpression of RAR resulted in similar down-regulation of CD36, IGFBP5 and TGF 
with the more pronounced effect in the Non-Responders. However, VPA addition reversed 
this effect in Pos-Responders whereas in the Non-Responders the RAR-induced down-
regulation persisted (Figure 24). 
Transfection with TGF led to a decline in CD36 and IGFBP5 amounts by 20% in Pos- and 
more than 50% in the Non-Responders. Interestingly, RAR levels were elevated in ML72 
whereas they decreased in ML17, ML59 and ML73, suggesting an outlier effect. However, 
VPA treatment changed this relatively consistent picture. Especially the Non-Responders 
ML59 and ML73 exhibited opposite results in their IGFBP5 and CD36 expression. Of note, 
RAR expression was reversed in both Pos- and Non-Responders compared to the untreated 
cells (Figure 24).  
Finally, expression levels of all four analyzed candidate genes in mock and VPA-treated 
fibroblasts transfected with GFP were determined to check whether VPA triggers the 
expected response. In conclusion, the detected alterations corresponded quite well with the 
observations made before implying that VPA treatment worked in principal (Figure 24).  
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In conclusion, it has to be stated that neither the knockdown nor the overexpression 
studies gave a definite hint whether the expression levels of the four candidate genes are 
somehow linked. However, some noteworthy findings could be obtained. On the one hand 
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knockdown of IGFBP5 increased levels of CD36 in both Pos- and Non-Responders by more 
than 80%. Furthermore, knockdown of CD36 dramatically increased RAR levels in Non-
Responders by more than 90%.  Although quite huge alterations in the RAR expression of 
Pos-Responders could be detected in all knockdown experiments, these results have to be 
taken with a pinch of salt. Generally, RAR expression is extremely low in Pos-Responders. 
Any subtle interference with its levels will thus immediately result high numbers while the 
relative change compared to Non-Responders is rather negligible. 
Overexpression of RAR transfection decreased expression of the other three candidate 
genes while the effect could be reversed by VPA in the Pos-Responders. Furthermore, the 
activating effect of VPA on candidate gene expression was boosted by CD36 overexpression. 
But, in general, fibroblasts from the same group exhibited often opposite results, suggesting 
that overexpression might not be the appropriate way to study candidate gene connections 
in fibroblasts. 
Summarized, it may be speculated whether RAR plays the central role in the putative 
candidate gene network. Since it is barely expressed in Pos-Responders while it can be 
robustly detected in Non-Responders, it may control and alter the expression of the other 
candidate genes. Anyhow, the whole system of transfecting fibroblasts is very error-prone 
since the transfection rates of 50-70% are rather low compared to e.g. 293 cells. 
Furthermore, it could be observed that individual fibroblast lines seem to be more sensitive 
to either electroporation or lipofection than others, which of course influences the final 
data. 
4.1.5.2 Determination of the intracellular cAMP content 
Neither overexpression nor knockdown experiments gave a definite clue, whether or how 
the different candidate genes are connected. However, VPA has been shown to alter the 
intracellular content of the second messenger cAMP (Boeckeler et al. 2006; Chang et al. 
2009). Since both SMN and IGFBP5 contain cAMP-responsive elements (CRE) within their 
promoters (Duan and Clemmons 1995; Majumder et al. 2004) and VPA failed to inhibit PKA 
(cAMP-dependent protein kinase A) in Non-Responders (Figure 11), cAMP levels were 
determined in VPA treated fibroblasts by ELISA. Determination of the cAMP concentration in 
three Pos- and Non-Responders each uncovered no differences in basal levels (Figure 25). 
Interestingly, cAMP levels were 24% lower in VPA-treated Pos-Responders compared to 
Non-Responders. This fits well to the observation that PKA activity was exclusively inhibited 
dose-dependently in Pos-Responder. Unexpectedly, application of the adenyl cyclase (AC) 
inhibitor 2′,5′-dideoxyadenosine (ddA) dit not result in a decline in cAMP contents but rather 
increased cAMP levels by 20% in both groups. In contrast to that, 100 µM Forskolin, an AC 
activator, produced the desired effect: In the group of Pos-Responder cAMP levels were 
augmented up to approx. 25 nM cAMP per µg protein whereas in Non-Responders more 
 
110 Results 
than twice the amount was measured (67 nM cAMP per µg protein). Furthermore, inhibition 
of phosphodiesterases (PDE, catalyzing cAMP into ATP) by means of IBMX (3-isobutyl-1-
methylxanthine) increased cAMP levels merely in Non-Responders. Taken together, the 
difference in the response to VPA, Forskolin and IBMX between Pos- and Non-Responders 
suggests an involvement of cAMP in the different responses to VPA. However, the 
underlying cause still needs to be identified. 
 
Figure 25 Determination of the intracellular cAMP content by ELISA. VPA, ddA 
(2′,5′-dideoxyadenosine, AC inhibitor) and IBMX (3-isobutyl-1-methylxanthine, PDE 
inhibitor) were applied for 16 h. Forskolin (AC activator) treatment lasted for 2 h. All data 
are given as mean±SEM of three cell lines each measured in triplicate. 
4.1.5.3 Can a Non-Responder be converted into a Pos-Responder? 
Previous experiments could not fully unravel the underlying network of the four candidate 
genes. However, the essential issue in terms of SMA therapy is whether any of the four 
proteins has a direct effect on SMN and could thus be a target of a drug therapy 
supplemental to normal VPA regimen. To answer this question, knockdown of candidate 
genes combined with parallel VPA treatment was performed in both Pos- and Non-
Responders. 
Following CD36 knockdown in either VPA or mock-treated ML72, SMN almost completely 
vanished (Figure 26). In contrast to that, SMN was strongly augmented when IGFBP5 was 
depleted from the cells irrespective of whether VPA was added or not. Similar to that, 
knocking down TGF slightly increased SMN amounts. This effect was further enhanced by 
the addition of VPA. The observed tendencies were the same in the Non-Responder ML82, 
although the effect of CD36 was not that dramatic. Most importantly, knockdown of IGFBP5 
plus VPA increased SMN amounts more than 3-fold. These experiments were repeated in 
another set of cell lines leading to comparable results. 
 
111 Results 
 
Figure 26 Knockdown of CD36, IGFBP5 and TGF combined w or w/o VPA treatment. -Actin was 
used as loading control. 
Since knocking down CD36, IGFBP5 and TGF altered SMN levels, it was investigated next 
whether SMN RNA or protein was affected. Quantification of SMN transcripts by qRT-PCR 
showed that these declined by 30% when CD36 was knocked down (Figure 27). This implies 
that CD36 depletion directly affects SMN mRNA whereby SMN protein is subsequently 
reduced. In contrast to that, transfection with a siRNA targeting IGFBP5 did not notably 
change SMN levels, suggesting that IGFBP5 acts on SMN protein level. For TGF no definite 
result was obtained. Although SMN levels increased after TGF knockdown in Non- and Pos-
Responders, mRNA levels were changed differently in opposite direction (Figure 26). 
In summary, these results were rather unexpected. Knockdown of CD36 decreased SMN 
protein by acting on SMN transcript level. At least from what is known from the literature 
there is no direct explanation for this observation. Since it has not yet been tested, next 
experiments should address the question whether SMN expression or mRNA stability is 
altered in CD36-depleted cells. In contrast to CD36, knockdown of IGFBP5 notably increased 
SMN protein but not RNA levels. Since no direct interaction between IGFBP5 and SMN has 
yet been shown, it may be speculated whether IGF signalling has generally an impact on 
SMN protein. Further experiments are needed to test this hypothesis. However, if these 
indeed uncover a direct connection between IGF signalling and SMN amounts this may lead 
to the development of drug therapies targeting this connection. 
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Figure 27 qRT-PCR analysis of FL-SMN2 expression following knockdown of either CD36, IGFBP5 or 
TGFa. Data are given as mean of three different Pos- or Non-Responder cell lines. 
(* = P<0.05; ** = P<0.01; *** = P<0.001) 
4.1.6 Analysis of CD36 as a putative VPA transporter 
Comparison of fibroblasts derived from Non- and Pos-Responders by µ-array revealed a 
differential expression of CD36, suggesting that VPA uptake and/or metabolism might differ 
between both groups. Although only CD36-mediated LCFA-uptake has been reported so far 
(Coburn et al. 2000; Ibrahimi et al. 1996), this does not exclude the possibility that also short 
chain fatty acids such as VPA are likewise transported. Furthermore, CD36 is embedded into 
pathyways encompassing PPAR (peroxisome proliferator activator receptor ), LXR (liver X 
receptor) and RXR (retinoid X receptor) (Tontonoz et al. 1998), which are triggered upon 
LCFA stimulus. Based on these data, constitutively high CD36 amounts in Non-Responders 
may alter VPA metabolism in such way that it cannot act as HDACi or PKA inhibitor. 
4.1.6.1 Characterization of VPA uptake in treated fibroblasts by HPLC-MS/MS 
To investigate whether VPA is indeed differentially taken up in Non- and Pos-Responders, 
it was initially tried to measure the VPA content in whole cells lysates from treated 
fibroblasts by gas chromatography at the Institute of Pharmacology in Cologne. 
Unfortunately the intracellular VPA concentrations were too low to be detected (data not 
shown). 
Therefore, a HPLC-MS/MS-method originally published by Cheng et al. 2007 was adopted 
to quantifiy the content of VPA and its major blood metabolite 4-ene VPA 
(2-propyl-4-pentenoic acid) in fibroblasts. By performing the derivatization as described in 
3.10.6.1 with pure VPA or 4-ene VPA in ddH2O, the VPA-derivate was found to elute at 7.05 
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min from the HPLC column whereas the 4-ene VPA-derivate eluted at 6.67 min. Subsequent 
mass spectroscopic analysis was carried out, product ion mass spectra were recorded and 
precursor/product ion pairs (VPA 277.3/120.0; 4-ene VPA 275.2/120.0) were selected for 
quantification of VPA and 4-ene VPA, respectively (Appendix, Figure 70).  
Based on these results, the next round of experiments was performed with lysates from 
VPA-treated fibroblasts. Therefore, 1x105 cells were plated out in a 6-well plate 24 h prior to 
treatment with  500 µM VPA or mock for 16 h. Following drug incubation, fibroblasts were 
harvested and derivates were prepared. In parallel, 100 µl media supernatant from VPA and 
mock treated cells were also derivatizized to quantify elimination of VPA out of the cell 
culture media. Subsequently, derivates were analyzed by HPLC-MS/MS and total ion 
chromatograms were recorded. From these, the precursor/product ion pairs for VPA and 4-
ene VPA were extracted and depicted as counts per second against HPLC retention time. 
Since the retention time of both compounds was determined beforehand, the respective 
peaks were chosen and the peak area was used to quantify VPA or 4-ene VPA amounts 
(Figure 28).  
Analysis of exctracted ion chromatograms (XIC) for VPA of treated and untreated ML17 – a 
Pos-Responder – revealed that in both cases a peak at 277.3/120 and 7.05 min was 
detected. Noteworthy, the peak was half the size in untreated cells, therefore most likely 
corresponding to an intracellular constituent part having the same m/z spectrum and HPLC-
retention time as VPA (Figure 28A). A similar result was obtained for 4-ene VPA. Again, a 
peak half the size was detected in the untreated cells. Taken together, these peaks 
originating from the cellular background determine the lower limit of detection. Since they 
match those peaks of VPA and 4-ene VPA and are present irrespective of whether VPA is 
added or not, fainter signals indeed coming from e.g. VPA will always be cloaked by them. In 
contrast to that, within the cell-free culture medium a clear signal for VPA was detected in 
medium containing 500 µM VPA whereas no such readout was detected in medium without 
VPA. 4-ene VPA was found to be absent in both media (Figure 28B). 
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Figure 28 Extracted ion chromatograms (XIC) for both VPA (277.3/120) and 4-ene VPA (275.2/120). 
Peaks corresponding to VPA or 4-ene VPA based on their HPLC retention time are marked in 
light gray. (A) XIC for VPA- and mock-treated ML17, a Pos-Responder. (B) XIC for the cell 
culture medium of treated ML17.  
Although in the extracts of untreated cells similar signals were detected as in VPA-treated 
fibroblasts, the difference still allowed discrimination of treated and untreated cells. 
Therefore, the Non-Responder ML59 as well as the Pos-Responder ML17 were treated for 
30, 60 and 120 min with 500 µM VPA and after the respective time period cell lysates and 
medium supernatants were derivatizized and analyzed by HPLC-MS/MS to get an impression 
of the VPA uptake kinetics (Figure 29). 
 
 
 
 
115 Results 
 
Figure 29 Quantification of VPA in fibroblasts treated for the indicated time periods as well as the 
VPA content in the supernatant. VPA concentration was calculated using a VPA standard 
curve either prepared in fibroblast media or fibroblast lysate. The gray area  
 indicates the lower limit of detection. 
Analysis of XIC for VPA clearly showed that in both ML17 and ML59 VPA was not 
considerably eliminated from the cell culture medium throughout a time period of 120 min. 
VPA concentration remained at around 800 ng/ml, which – when all dilution factors are 
eliminated – indeed matched the employed 500 µM VPA. This observation suggested that 
only minimal VPA uptake has taken place. This was further underlined by the finding that 
within the lysates of both fibroblast lines only 25 to 60 ng/ml VPA were detected after 30 min 
of incubation. For longer time periods even lower VPA concentrations were detected, which 
were only barely above the detection limit (Figure 29) thereby giving no trustable data. In 
case of 4-ene VPA all samples were below the lower limit of detection (data not shown). 
Since further experiments led to similar results it was doubtful whether derivatization of 
VPA is indeed the most effective method of quantifying the intracellular VPA content. The 
basic hindrance seemed to be the intracellular constituent parts such as any other short-
chain fatty acid giving a very high lower level of detection. Therefore, this assay was not 
employed in further experiments. 
4.1.6.2 Analysis of CD36-mediated VPA import 
So far the question whether higher CD36 amounts present in Non-Responders indeed 
have any impact on VPA uptake could not be answered. Therefore, it was asked if CD36 also 
functions as a VPA importer. To follow up this issue, HEK293 cells were transfected with a 
vector encoding for CD36 (Figure 67) and a stable cell line was established by three weeks 
selection using G-418 in the Institute of Pharmacology in Cologne. Using this cell line an 
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uptake assay with 10 µM VPA was performed. Cells were plated out 24 h prior to treatment, 
washed once and then incubated for 1 min with 10 µM VPA in pre-warmed 1xPBS. 
Subsequently, cells were lysed using 4 mM HClO4 and analyzed by HPLC-MS/MS. Based on 
the previous experiments, the VPA derivatization method was not applied and VPA was 
directly measured without derivatization and fragmentation in single-ion mode (SIM). Using 
pure VPA dissolved in 4 mM HClO4, retention time and the respective ion were determined. 
Once the method was established, VPA contents were measured in the stably CD36 
overexpressing HEK293T cells treated for 10 min with 10 µM VPA. Furthermore, a HEK293 
cell line stably overexpressing SLC16A3 was included into the analysis. SLC16A3 (MCT4) was 
chosen since it is (besides SLC16A1 and SLC16A7) one of the major transporters of butyrate, 
another short-chain fatty acid HDACi (Morris and Felmlee 2008).  
Quantification of the intracellular VPA amounts after 1 min of incubation revealed that 
overexpression of neither CD36 nor SLC16A3 led to an increased influx of VPA into the cells 
(Figure 30). Detected VPA signals in all samples were equal or close to the standard sample 
of 0 ng/ml VPA.  The experiment was repeated with 1 mM VPA to exclude any concentration-
dependent effects, but the results were unchanged. Taken together, these results suggest 
that VPA either diffuses into the cell or is transported by a yet unknown protein. In any case, 
CD36 can be excluded as a VPA importer. 
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Figure 30 (A) XIC for VPA without derivatization. A respresentative picture from a standard dilution is  
 given illustrating the VPA peak (marked in light gray). Furthermore, a respresentative XIC 
for VPA-treated HEK239 cells overexpressing CD36 is given. (B) Intensity counts for HEK293 
either mock or CD36 or SLC16A3 transfected, treated with VPA or mock. Gray area 
represents the lower limit of detection given by 0 
ng
/ml VPA in 4 mM HClO4. All data are 
given as mean ± SD. 
4.1.6.3 Comparison of VPA metabolism in Pos- and Non-Responders 
Neither the derivatization experiments nor the VPA-uptake experiment with HEK293 cells 
provided a definitive clue to whether or how VPA uptake and metabolism differ between 
Non- and Pos-Responders. To clarify this issue, a HPLC-MS/MS shading assay was performed 
as described previously (Grundemann et al. 2005). The underlying principle is the 
comparison of data sets of different samples in a given mass range to identify discrepancies. 
Therefore, from three Pos- and three Non-Responder fibroblast lines some 1x105 cells were 
plated out in a 6-well plate. 24 h later cells were treated with 500 µM VPA and 500 µM 
d15-VPA for 16 h. Subsequently, cells were lysed with 4 mM HClO4 and equal amounts were 
pooled groupwise based on their protein content.  The pooled samples were then analyzed 
by HPLC-MS/MS and total ion chromatograms (TIC) were recorded up to 400 amu. To 
visualize differences between samples (m/z, retention time, intensity) the TICs were 
compared graphically by MS-FullView (Gründemann). First, ion intensities were converted 
into grayscales (high intensities white / low intensities black) to create 2D images with m/z 
and time axis. Next, one sample was converted into red and the other one in blue and both 
2D images were superimposed. Then an algorithm highlighted compounds only present in 
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one sample in orange, whereas compounds present in equal amounts remained in gray 
(Grundemann et al. 2005). Deuterized and non-deuterized VPA were both used to allow 
discrimination between substances which are produced upon VPA treatment and direct VPA 
derivates. In the latter case two adjacent peaks should be detected since VPA and d15-VPA 
differ slightly in their atomic weight whereas for endogenous substances only a single peak 
should be detected. 
As depicted in Figure 31A, both signals for VPA and d15-VPA could easily be identified at 
6.92 min and 144.2 amu or 159.4 amu, respectively, in medium plus VPA/d15-VPA compared 
to medium without. However, when matching media from both treated Pos- and Non-
Responders, no apparent difference could be detected, suggesting that elimination of VPA 
out of the cell culture medium is the same. 
Comparison of pooled lysates of Non- and Pos-Responders did not lead to the 
identification of a differentially produced VPA metabolite. For none of the known VPA 
metabolites (e.g. 4-ene VPA, 3-oxo-VPA, 2-hydroxy-VPA) a differential peak corresponding to 
their atomic mass could be recorded (Figure 31B).  The only signal clearly differing between 
both samples was detected at 192.2 amu / 4.28 min. However, it could be excluded as a VPA 
metabolite for two reasons: First, the atomic mass did not match any of the known 
metabolites. Furthermore, only one signal was recorded whereas a VPA metabolite should 
give two signals since both VPA and d15-VPA were combined. Moreover, lysates of 
VPA/d15-VPA treated Non- and Pos-Responders were compared with untreated ones. 
Unfortunately, again no obvious differences could be identified, suggesting that either all 
VPA metabolites are present at undectable levels or that all VPA is present in higher weight 
(>400 amu) derivates. 
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Figure 31 Comparison of Non- and Pos-Responders by differential shading. (A) Comparison of media 
plus VPA/d15-VPA versus media without. Signals of VPA and d15-VPA are indicated by white 
arrows. (B) Comparison of lysates from Non- and Pos-Responders. The only difference 
detected at 192.2 amu /4.28 min is indicated with a white arrow. Excerpts give inverted 
sections of region of interest to highlight detected differences which appear in dark blue 
and are marked with black arrows. 
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4.1.6.4 Analysis of general fatty acid transport in Non- and Pos-Responders 
CD36 has been shown to facilitate LCFA import into cells (Coburn et al. 2001; Ibrahimi et 
al. 1996). To investigate whether there are any differences between Non- and Pos-
Responders regarding their fatty acid uptake, the internalization of a BODIPY-labelled 
dodecanoic acid analogue (Molecular Devices) was monitored after 6 h of starvation. It could 
be demonstrated that basal LCFA uptake did not significantly differ between both groups, 
but was slightly higher in the Non-Responders (Figure 32A). Furthermore, addition of 
500 µM VPA enlarged this difference even more, leading to a significant lower LCFA uptake 
in Pos-Responders. Interestingly, a similar effect was detected when 1 µM retinoic acid (RA) 
was added. Combination of both VPA and RA led to a synergistic effect. RA was used in these 
experiments for two reasons: First, it has been shown that RA increases CD36 expression 
(Wuttge et al. 2001). Second, the RA receptor RAR was found to be exclusively expressed in 
Non-Responders, which suggested a different response to RA regimen. 
Some further samples were treated with VPA, RA or both combined with 400 µM SSO, a 
CD36-specific inhibitor (Coort et al. 2002) to test whether the observed elevated fatty acid 
uptake was due to a CD36 up-regulation. Surprisingly, addition of SSO led to a higher amount 
of fluorescent labeled fatty acids present in the cytoplasm in all three treatment 
combinations. Since this was verified in another round of experiments (Figure 32B), it may 
be speculated whether CD36 is rather functioning as a fatty acid exporter than an importer 
in fibroblasts. At least this would explain the tremendous BODIPY-FA amounts after SSO 
addition since inhibition of CD36 - which may act as an FA exporter – would theoretically 
lead to a BODIPY-FA accumulation. 
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Figure 32 Determination of fatty acid uptake by fibroblasts using a BODIPY-labelled fatty acid 
analogue. (A) Impact of VPA, RA and SSO on fatty acid uptake. (B) Impact of SSO, OA and 
Oligomycin D on fatty acid uptake. Data are given as mean ± SEM of three Pos- and 3-Non-
Responder fibroblast lines, each measured at least in duplicate (* = P<0.05; ** = P<0.01; 
*** = P<0.001) 
To test whether addition of high amounts of a LCFA augments general fatty acid uptake by 
global up-regulation of fatty acid transporters, fibroblasts of Pos- and Non-Responders were 
treated with 1 mM oleic acid (OA). Analysis of imported BODIPY-FA amounts revealed that 
OA treatment triggers massive FA uptake. Combination of both OA and SSO resulted in a 
synergistic effect suggesting that OA leads to a general induction of fatty acid translocases as 
well as CD36. Treatment of fibroblasts with 10 µg/ml Oligomycin D, an ATPase inhibitor (Lardy 
1980), led not to the expected augmentation in fatty acid import. This implied that the 
coupling of ATP-generation and fatty acid uptake in fibroblasts is rather weak. 
Since BODIPY-FA experiments suggested differences in fatty acid uptake between Pos- and 
Non-Responders, expression levels of several genes associated with fatty acid uptake and 
metabolism were determined by qRT-PCR in three Pos- and Non-Responders each. To rule 
out that any other known SCFA transporter may lead to differential VPA uptake, expression 
levels of MCT1, 2 and 4 were determined. Although most SCFA enter the cell via diffusion, it 
has been demonstrated for these MCTs that they accelerate butyrate uptake in the intestine 
(Thibault et al. 2010). Comparison of MCT expression among Pos- and Non-Responders did 
not show any gross differences (Figure 33A). Furthermore, VPA administration did not result 
in any notable alteration, suggesting that these MCTs are not regulated by VPA thus do not 
account for its transport.  
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Quantification of PPAR levels, which is the upstream effector of CD36 (Zhou et al. 2008), 
revealed no obvious differences (Figure 33B), suggesting that it is not the cause of increased 
CD36 expression.  However, determination of CPT1C levels (carnitine-palmitoyl-transferase 
1C) led to an interesting observation. CPT1C is the rate-limiting enzyme in LCFA oxidation 
since it transfers activated LCFA-CoA onto carnitine, which allows shuttling into the 
mitochondria. Although controversially discussed, it has been suggested that CPT1C 
catalyzes Carnityl-VPA formation from VPA-CoA (Lheureux et al. 2005; Silva et al. 2008). 
Interestingly, CPT1C were twice as high in Non-Responders than in Pos-Responders 
irrespective of whether VPA was added or not (Figure 33B). This suggested that in Non-
Responders the VPA-CoA to Carnityl-VPA reaction may be much faster, thus leading to an 
accelerated elimination of VPA from the cell. However, it still has to be proven whether this 
accounts for the non-responsiveness to VPA. 
 
 
Figure 33 Expression analysis of genes associated with FA uptake and utilization by qRT-PCR. (A) 
Determination of MCT1, 2 and 4 expression, which functioning in butyrate uptake. (B) 
Expression analysis of PPAR the downstream effector of CD36 and CPT1C, the rate-limiting 
enzyme in LCFA oxidation. 
Since BODIY-FA measurements suggested that CD36 may function as a fatty acid 
transporter, a Non-Responder fibroblast line was treated with VPA and SSO in parallel 
(Figure 34A). This was done to test whether inhibition of CD36-mediated by SSO leads to an 
accumulation of VPA in the cell, thus induce SMN2 expression. Although quantification of 
band intensity revealed that also single VPA treatment slightly increased SMN levels by 20%, 
the effect was more pronounced when SSO was added. However, SSO treatment in general 
reduced SMN levels compared to fibroblasts treated with either VPA or mock alone, 
suggesting the induction of either cellular stress or cytotoxic effects. Furthermore, the Pos-
Responder ML16 was treated with VPA, SSO and RA (Figure 34B). RA was included in this 
round of experiments since its application induces CD36 expression in fibroblasts (Redfern 
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and Todd 1992). If CD36 functions as a VPA exporter, RA treatment should accordingly 
abolish VPA mediate up-regulation of SMN. However, this was not the case, although it was 
not tested whether CD36 indeed upregulatated. In addition, SSO treatment was included 
into the experiment. Even though it gave the impression that SSO surpressed the VPA effect, 
it has to taken in account that SSO treatment alone reduces SMN levels. 
 
Figure 34 Effect of SSO and RA on VPA treatment. (A) Non-Responder ML73 treated for 16 h with 500 
µM VPA and 400 µM SSO either alone or in parallel. (B) Pos-Responder ML16 treated for 16 
h with 500 µM VPA, 400 µM SSO and 1 µM RA either alone or in combination. -Actin was 
used as loading control. 
Taken together, these results do not give a definite answer whether CD36 is functioning as 
VPA exporter or not. To clariy this issue, SSO treatment has to be optimized in such a way 
that no alterations in SMN levels are detected. Next steps would include a MTT-assay to 
determine whether the employed concentrations elicit any stress or cytotoxic responses.  
Furthermore, it has to be determined whether RA indeed induces CD36 expression or not. 
However, the finding that CPT1C is constitutively higher expressed in Non-Responders poses 
the question, whether the VPA-CoA to Carnityl-VPA reaction may be the crucial step in the 
Non-Responsiveness to VPA. Therefore it is needed to work out, whether CPT1C levels are 
possibly controlled by CD36. If it could be proven, that CD36 is furthermore controlled by 
RAR levels, this would lead to an interesting causal chain making Carnityl-VPA formation as 
a tertiary effect of high RAR expression in fibroblasts.  
 
In summary, all experiments described so far give no definite clue to why some SMA 
patients respond positively to VPA whereas others do not. Transcriptome wide expression 
analysis led to the identification of four candidate genes differentially expressed between 
Pos- and Non-Responders. However, although knockdown and overexpression studies 
suggested functional links between theses genes, no definite mechanism could be 
established yet. The most overt candidate was CD36, a known LCFA transporter. Although 
HPLC-MS experiments did not indicated any differentially formed VPA metabolites, the 
observation that regulation of FA uptake by RA and VPA differs between Pos- and Non-
Responders still points into this direction. Even though it is still speculative whether this has 
any functional impact, the finding that CPT1C is higher expressed in Non-Responders is of 
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great interest. Therefore, next steps should address the question whether there is any 
functional link between CD36, CPT1C and the response to VPA. 
 
 
 
125 Results 
4.2 Identification and characterization of the putative SMA drug LBH589 
LBH589, put on the market as Panobinostat, is a second generation hydroxamic acid-
derived HDAC inhibitor originally developed by Novartis (Figure 35). LBH589 has been shown 
to inhibit all class I, II and IV HDAC enzymes at low nanomolar doses, suggesting a panHDAC 
activity.  This has been further corroborated by the observation that IC50 values for all HDACs 
with the exception of HDAC4, HDAC7 and HDAC8 were around 13 nM (Atadja 2009). In line 
with this, LBH589 efficiently induces growth arrest and apoptosis in a wide variety of cancer 
cell lines derived from solid tumors and hematologic malignancies such as CTLC, acute 
myeloid leukemia and Hodgkin´s lymphoma. Compared to the well-established and 
FDA-approved HDACi SAHA (Vorinostat), the anti-proliferative effect of LBH589 on cancer 
cells  was up to 100-fold stronger while normal cell lines remained spared (Shao et al. 2010). 
Furthermore, LBH589 inhibited growth of human myeloma cells resistant to standard 
chemotherapeutic agents such as doxorubicin and even potentiated the effects of drugs like 
bortezomib and dexamethasone (Maiso et al. 2006). Furthermore, the potential of LBH589 
was underlined in several mouse studies. In CTLC mouse xenograft model, LBH589 led to 
94% tumor regression compared to vehicle treated animals. Similar results were obtained in 
a colon cancer mouse model (Atadja 2009; Shao et al. 2010). 
Initial phase I trials determined the terminal elimination half-life time (T1/2) of LBH589. 
Depending on the individual study, values varying between 7 and 16 h were obtained (Ellis et 
al. 2008; Giles et al. 2006). Subsequent phase II trials in hematologic malignancies, in 
particular CTLC and Hodgkin´s Lymphoma produced good responses in most of the cases 
[reviewed in (Prince et al. 2009)]. Currently more than 80 clinical trials are ongoing 
employing LBH589 either in mono- or combined therapy for the treatment of diverse types 
of cancer (http://clinicaltrials.gov/search/intervention=lbh-589). 
Based on these promising data, especially the high potency in HDAC inhibition, LBH589 
was tested as a potential candidate for causal SMA therapy. 
 
Figure 35 Chemical structure of LBH589 (Panobinostat) 
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4.2.1 Impact of LBH589 on SMN levels in SMA fibroblasts 
In order to assess whether LBH589 is able to increase SMN protein in SMN1-deleted 
fibroblasts optimal dose and treatment time had to be initially determined. To identify the 
best combination out of both parameters, fibroblasts were treated in a kinetic experiment 
with LBH589 concentrations between 10 nM and 1 mM for time periods between 24 h and 
96 h. It turned out that treatment for 64 h with concentrations between 100 nM and 1 mM 
LBH589 yielded the highest up-regulation of SMN protein compared to mock-treated cells. 
Therefore, all subsequent experiments were performed with a single dose of LBH589 for 
64 h. 
Next, three passages of different SMA fibroblasts (ML16, ML17 and ML5) were treated 
under the above mentioned conditions. Subsequently, SMN levels were analyzed by semi-
quantitative western blotting using -Actin as loading control (Figure 36). For both cell lines 
derived from SMA type I patients (ML16 and ML17) at concentrations between 400 and 
750 nM LBH589 SMN elevated 6- to 8-fold. At lower concentrations between 100 and 
300 nM LBH589, SMN levels were increased 3- to 5-fold. In the case of the fibroblast line 
ML5, derived from a SMA type II patient, SMN levels increased 3- to 4-fold at all 
concentrations higher than 200 nM. In all three cell lines a concentration of 1 µM of LBH589 
did not further increase SMN amounts, suggesting that maximum SMN2 induction already 
occurred at lower concentrations. 
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Figure 36 Analysis of SMN amounts after LBH589 treatment (A) Diagrammatic representation of 
relative SMN amounts after treatment with the indicated concentrations of LBH589 for 
64 h. Results are given as mean ± SEM. (B) Representative western blot stained with an anti-
SMN antibody illustrating SMN protein amounts in ML5 after 64 h LBH589 treatment. 
-Actin served as loading control. (* = P<0.05; ** = P<0.01; *** = P<0.001) 
4.2.2 Analysis of the impact of LBH589 on gems  
Although LBH589 dramatically increased SMN protein amounts, the question remained 
open whether the additionally produced SMN is indeed functional thus fulfilling its normal 
cellular roles. Since studies showed that the number of nuclear SMN foci (“gems”) correlates 
with the amount of SMN protein and inversely correlates with the SMA phenotype (Coovert 
et al. 1997), the elevated SMN protein amounts under LBH589 treatment should be 
reflected by an increased number of gems. To test whether this is indeed the case, 
fibroblasts were stained with a FITC-labelled SMN antibody and gems were counted in each 
300 mock and LBH589 treated fibroblasts. DAPI was used to ensure nuclear localization of 
SMN foci (Appendix, Figure 63). In total three different fibroblast lines were investigated to 
exclude any cell line specific effects.  
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Comparison of both LBH589- and mock-treated cells revealed that in all three fibroblast 
lines the total number of cells containing gems increased equally approx. 7-fold (Figure 37) 
which matches the augmentation of SMN detected by western blotting. Noteworthy, not 
only the proportion of cells containing a single gem increased but also the number of cells 
containing two or more gems increased significantly. Taken together, these immuno-
fluorescence stainings clearly corroborate the previous western blot data. 
 
Figure 37 Comparison of percentages of fibroblasts containing 0 to 4 or more gems. Fibroblasts were 
treated either for 64 h with solvent only or 400 nM LBH589. For each condition 300 cells 
were analysed. 
Based on the increased number of gems, it was investigated whether also other SMN 
complex components are upregulated by LBH589 or whether this is a SMN exclusive effect. 
Analyzing RNA from LBH589-treated SMN1-deleted fibroblasts (ML5) showed that Gemin2 
transcript amounts were increased dose-dependently up to 3-fold whereas those of Gemin3 
barely doubled for all tested concentrations (Figure 38A). In addition, Gemin expression was 
quantified in the fibroblast line ML6, derived from a healthy donor. This was done to 
elucidate whether Gemin2 and -3 are induced by SMN upregulation or whether they are 
generally induced by LBH589. Although SMN amounts in ML6 merely tripled both Gemin 
transcripts were up-regulated similarly to ML5, indicating that Gemin upregulation is most 
likely a general phenomenon of LBH589 treatment.   
Furthermore, protein amounts of Gemin2 and Gemin3 were checked by quantitative 
western blot using -Actin as loading control in ML5 (Figure 38B, C). It could be shown that 
both Gemins were increased 1.5- to 2-fold at 400 nM and 1 µM LBH589 although Gemin3 
transcript amounts were not markedly increased. On the other hand post-translational 
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factors such as e.g. stabilization of Gemin3 by Gemin2 or SMN within the SMN complex 
cannot be excluded. In summary, these data show that not only SMN but also other 
components of the SMN complex are induced by LBH589. 
 
Figure 38 Analysis of Gemin expression in LBH589-treated fibroblasts (A) Quantifcation of Gemin2 
and -3 expression by qRT-PCR in ML5 (SMA type II) and ML6 (healthy donor) following 64 h 
LBH589 treatment. (B) Representative western blots illustrating the increase in Gemin 
expression under LBH589 treatment. -Actin served as loading control. (C) Quantified 
Gemin2 and -3 protein amounts. (* = P<0.05; ** = P<0.01; *** = P<0.001) 
4.2.3 Comparison of the effects of VPA and LBH589 
Nowadays, a number of putative SMA drugs have been investigated. However, only 
Phenylbutyrate (Mercuri et al. 2004) and VPA have yet been tested in vivo by clinical trials 
(Brichta et al. 2003; Swoboda et al. 2009). To compare the efficacy of LBH589 and VPA, 
fibroblasts were treated with either VPA or LBH589 in parallel. In total five different 
fibroblast lines were tested: two of them were VPA Pos-Responder (ML60 and ML67), two 
showed no change in SMN levels under VPA treatment (ML79 and ML82), whereas one 
fibroblast line (ML73) exhibited declined SMN amounts following exposure to VPA. 
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Quantification of SMN protein amounts following drug treatment showed that LBH589 
clearly outscored the effect of VPA in all five tested fibroblast lines (Figure 39). In both cell 
lines reacting positively to VPA (ML60 and ML67), LBH589 increased SMN levels dose-
dependently more than 4-fold and in the case of ML67 at 1 µM LBH589 even 10-fold higher 
SMN amounts were detected. In both VPA Non-Responder cell lines ML79 and ML82, 
LBH589 elevated SMN amounts 2- to 3-fold although the effect was not as strong as in ML67 
and ML60. Most importantly, even in the fibroblast line ML73, which was derived from a 
VPA Non-Responder, LBH589 led to significantly 2- to 3-fold higher SMN amounts in a dose-
dependent fashion. Taken together, LBH589 induces a much higher SMN2 expression than 
VPA and is also effective in cell lines which do not positively respond to VPA. Still it has to be 
taken into account that the effect of LBH589 in fibroblast lines positively reacting to VPA is 
considerably stronger. 
 
Figure 39 Comparison of the effects of VPA or LBH589 treatment of different SMN1-deleted fibroblast 
lines. SMN levels were determined by quantitative western blotting using -Actin as loading 
control. All results are given as mean ± SEM of three independent experiments. (* = P<0.05; 
** = P<0.01; *** = P<0.001) 
4.2.4 Assessment of LBH589 cytotoxicity 
Analysis of LBH589-treated SMN1-deleted fibroblasts gave outstanding results regarding 
the SMN protein levels. Nevertheless, these results are only remarkable if toxic side effects 
are minimal. To test whether LBH589 has any cytotoxic effects, cell viability of 96 h LBH589-
treated fibroblasts was quantified by a MTT assay as described previously (Riessland et al. 
2006). As shown in Figure 40, cell viability was not considerably reduced for LBH589 
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concentrations routinely employed. Starting at concentrations of 100 nM up to 10 µM, cell 
viability was reduced 5 to 15 % compared to mock-treated fibroblasts. However, this 
phenomenon is typically seen when treating cells with HDACi since they induce cell cycle 
arrest while the mock-treated cells still proliferate. Only at very high concentrations of 
>10 µM cell viability was notably reduced by more than 30%. 
 
Figure 40 Diagrammatic representation of cell viability and cytotoxicty determined by a MTT and LDH 
assay. Fibroblasts were treated for 96 h with the indicated LBH589 concentrations. Vertical 
line indicates concentrations regularly used in this thesis. 
To assure that reduced cell viability is indeed caused by cell cycle arrest and not due to 
cytotoxic side effects of LBH589, a LDH assay was performed (Figure 40). It turned out that 
notable cytotoxic effects (>30% dead cells) were detected at LBH589 concentrations starting 
from 750 nM, which become even more pronounced at higher concentrations. At lower 
concentrations up to 500 nM LBH589 cytotoxic effects were less than 5%.  
Summarizing both assays, LBH589 does not severely interfere with cell survival at 
concentrations regularly used in this thesis. Most importantly, low concentrations of 
400 nM, which already markedly induce SMN2, are well tolerated by fibroblasts. 
4.2.5 Confirmation of LBH589 potential in other systems 
So far it could be shown that LBH589 tremendously increases SMN protein amounts while 
showing low cytotoxicity in fibroblasts. However, the question remained whether the 
potential of LBH589 is restricted to human fibroblasts only or if similar effects can be 
observed in other systems which would be of fundamental importance for future clinical 
trials. Therefore, murine embryonic fibroblasts (MEFs) derived from SMAHung mice (Hsieh-Li 
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et al. 2000)) were treated with the standard LBH589 regimen to test whether LBH589 is also 
able to induce SMN2 expression in a murine context (Figure 41). Quantification of SMN 
protein amounts by western blotting showed that SMN levels were up to 12-fold increased 
at 400 nM LBH589. Furthermore, a 5- to 10-fold increase was detected already at 
concentrations between 100 and 300 nM LBH589. Similar to human fibroblasts 1 µM LBH589 
did not further elevate SMN amounts. 
 
Figure 41 (A) Representative western blot of MEFs from SMAHung mice treated for 64 h with the 
indicated LBH589 concentrations. -Actin was used as loading control. (B) Quantification of 
SMN levels following LBH589 treatment of MEFs. Data are given as mean ± SEM from three 
independent experiments. (* = P<0.05; ** = P<0.01; *** = P<0.001) 
Based on these convincing data, it was investigated next whether LBH589 is also capable 
to increase SMN amounts in neural tissue closer ressembling the actual SMA target tissue 
motor neurons. To do so, neural stem cells (NSCs) derived from two epilepsy patients who 
had undergone surgery were treated for 48 h with 200 and 400 nM LBH589 (Figure 42). In 
both cell lines (H23 and H30) SMN amounts were increased 2- to 5-fold while the stronger 
increase was present in H30 at 200 nM LBH589. 
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Figure 42 (A) Representative western blot illustrating the increase of SMN following treatment of 
human NSCs. -Actin served as loading control. (B) Quantified SMN protein amounts of 
LBH589-treated human NSCs.   
Taken together, both murine fibroblasts and human NSCs clearly showed that LBH589 is 
positively acting on SMN levels in various tissue systems. However, if LBH589 should be 
considered for use as a SMA drug it has to pre-clinically tested in SMA-like models. 
Therefore, as a first step towards an in vivo testing of LBH589, unaffected SMA carrier mice 
were subcuteanously injected with 40mg/kg[bodyweight] LBH589. This should address the 
question whether LBH589 is also able to increase SMN2 expression in vivo. And if it does are 
SMN amounts also increased in the CNS implying that LBH589 crosses the blood-brain-
barrier? 
Determination of SMN protein amounts in different tissue extracts showed that following 
LBH589 treatment SMN protein increased by approx. 50% in the brain whereas no notable 
effect was observed in the liver (Figure 43A, D). This suggested that LBH589 is capable of 
crossing the blood-brain-barrier, which is a prerequisite for a prospective SMA therapy. To 
follow up this hypothesis, acetylation levels of histone H3 and H4 were determined in the 
CNS of LBH589-treated mice by ELISA (Figure 43B). In the spinal cord no noteworthy change 
was found in the amount of either acetylated histone H3 or H4. In contrast to that, 
acetylation of histone H3 increased 4 to 8 h after LBH589 injection in the brain by around 
60%, indicating that LBH589 indeed induces histone hyperacetylation in the CNS. To 
corroborate these findings, SMN2 expression was analyzed in spinal cords of LBH589-treated 
mice by qRT-PCR. It could be shown that already 2 h post injection SMN expression was 
increased 2- to 3-fold. This effect lasted for at least 24 h after LBH589 injection (Figure 43C). 
Taken together, these preliminary in vivo experiments with LBH589 underline its potential as 
prospective SMA drug and prove that LBH589 induces SMN expression not only in vitro but 
also in vivo.  
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Figure 43 Analysis of SMA carrier mice subcutaneously injected into the neck pucker with 
40 
mg
/kg(bodyweight) LBH589. (A) Western blot illustrating SMN protein amounts in liver and 
whole brain at different time points post injection. -Actin served as loading control. (B) 
Acetylation leves of histone H3 and H4 of LBH589-injected mice determined by ELISA. (C) 
SMN2 expression in the spinal cord of treated mice. (D) Quantified SMN amounts in liver 
and whole brain extracts 8, 16 and 24 h after injection with LBH589 of mice. (s.c. = sub-
cutaneously) 
4.2.6 Impact of LBH589 on SMN2 mRNA levels and the SMN2 promoter 
4.2.6.1 Analysis of SMN2 splicing 
SMN2 produces two major transcripts, FL-SMN2 and SMN27, of which the latter one is 
the predominant isoform accounting for 80 to 90% of all SMN2 transcripts. To assess 
whether the increased SMN protein amounts following LBH589 treatment were due to 
transcriptional activation or SMN2 splicing correction or a combination of both, SMN2 
transcript amounts in LBH589-treated fibroblasts were analyzed by qRT-PCR. 
In total three fibroblast lines were tested and in all cases a significant increase in FL-SMN2 
amounts was detected whereas SMN27 amounts stayed constant or even decreased 
slightly (Figure 44A). Almost 3-fold increased FL-SMN2 levels were found in ML16 for 400 nM 
and 1 µM LBH589 while for both ML5 and ML17 a doubling of FL-SMN2 was recorded at 
these concentrations.  In contrast to that, SMN27 amounts did not significantly decrease in 
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ML16 and 17, but were reduced for all tested concentrations in ML5. Taken together, in all 
three investigated fibroblast lines the SMN2 splicing pattern was reversed towards FL-SMN2 
encoding for the fully functional and stable protein (Figure 44B). 
Besides other possible explanations such as an altered promoter architecture or pre-
mRNA processing, the detected shift in the SMN2 splicing pattern could also be explained by 
an altered expression of proteins involved in SMN splicing. Since several splice factors are 
well known to bind SMN mRNA and to actively participate in SMN splicing (reviewed in 
(Wirth et al. 2006a)), these were checked for their expression in LBH589-treated cells. By 
performing semi-quantitative western blotting it could be shown that levels of hTRA2-1, a 
splice factor known to promote SMN2 exon 7 inclusion (Hofmann et al. 2000), were 
increased 2- to 3-fold at concentrations of 400 nM and 1 µM LBH589 (Figure 44C, E). 
Contrariwise, levels of SF2/ASF and SRp20 did not change in their expression on protein 
level. 
On RNA level, transcript amounts for all tested splice factors were significantly decreased. 
Both SRp20 and SF2/ASF mRNA levels were dose-dependently reduced to around 40% at 
1 µM LBH589. This effect was not equally pronounced in the case of hTRA2-1. Transcript 
levels settled down to approx. 60% at all three tested concentrations. These observations - 
reduced mRNA amounts while protein amounts increase – could most likely be explained by 
the auto-regulatory feedback circuits described for most of the SR-proteins (Ni et al. 2007) 
but needs of course further validation on protein level. 
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Figure 44 Analysis of SMN splicing under LBH589 treatment. (A) Diagrammatic representation of 
FL-SMN2 and SMN27 amounts in three LBH589-treated fibroblast lines determined by qRT-
PCR. (B) Calculated FL-SMN2/SMN27 ratios. P-values were below 0.001 for each data 
point. (C) Splice factor protein and RNA (D) amounts in LBH589 treated cells. 
(E) Representative western blot stained for splice factors involved in SMN splicing. -Actin 
served as loading control. (* = P<0.05; ** = P<0.01; *** = P<0.001) 
hTRA2-1 was the only splice factor identified that was more abundant under LBH589 
treatment. Based on this, the question came up whether hTRA2-1 is of fundamental 
importance for the increase in SMN protein upon LBH589 treatment. To clarify this issue, 
hTRA2-1 and SMN protein amounts were pursued in a time course experiment with 
400 nM LBH589 treated ML5 up to 72 h (Figure 45A). Interestingly, both proteins increased 
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with a delay of 12 h after LBH589 addition. In the following, SMN amounts steadily increased 
and peaked at 48 h and 64 h at approx. 700%. hTRA2-1 amounts showed the highest 
increase at 12 h with 250% and remained at around 200% for the following time points.  
When looking at SMN transcripts a striking coincidence became obvious (Figure 45B). 
Within the first 12 h of LBH589 SMN27 steadily increased up to 300% while FL-SMN2 
stayed constant. 12 h after LBH589 addition, the splicing pattern was suddenly reversed to 
FL-SMN2 and persisted until the end of the experiment. This time point indeed matched the 
beginning of the steady SMN cumulation as well as the increase in hTRA2-1 protein 
amounts. In conclusion, these data suggested that the up-regulation of hTRA2-1 is a 
prerequisite for the SMN protein increase in SMN1-deleted fibroblasts.   
 
Figure 45 Time course analysis of LBH589 treatment. (A) Quantified protein amounts of hTRA2-1 and 
SMN in 400 nM LBH589 treatment. Western blotting was performed using -Actin as 
loading control. (B) FL-SMN2 and SMN27 amounts measured by qRT-PCR in up to 72 h 
LBH589 treated ML5. (C) Western blot illustrating the diminished response to LBH589 when 
hTRA2-1 is knocked down. Quantified protein amounts are given in (D). (* = P<0.05; 
** = P<0.01; *** = P<0.001). 
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To follow up this hypothesis, a knockdown of hTRA2- was performed to test whether its 
depletion hampers the induction of SMN2 by LBH589 treatment (Figure 45C, D). 
Quantitative western blotting showed that LBH589 treatment of fibroblasts transfected with 
a non-targeting siRNA led to a significant up-regulation of SMN up to 450%. In contrast to 
that, LBH589 did not significantly increase SMN amounts in fibroblasts transfected with a 
siRNA targeting hTRA2-Transfecting a siRNA targeting SRp20 did not reduce SMN2 
induction by LBH589 (data not shown). In summary, these data suggest that hTRA2- 
indeed is one of the first steps within the cascade leading to the tremendous increase in 
SMN protein under LBH589 treatment. 
4.2.6.2 Analysis of the SMN2 promoter 
Previously it could be shown that LBH589 increases total SMN2 transcription (Figure 44 
and Figure 45). Thus, in a next step the SMN2 promoter itself was investigated with regard 
to acetylation of lysine 9 of histone H3 (H3K9), which is a clear sign of active transcription 
(Roh et al. 2005). To this aim, ChIP was performed using an antibody directed against 
acetylated histone H3 with mock and 400 nM LBH589 treated fibroblasts.  
Quantification of precipitated DNA-protein complexes by means of qRT-PCR showed that 
LBH589 elevated acetylation at all four previously described regions of the SMN2 promoter 
(Figure 46) (Kernochan et al. 2005). The highest change (plus 250%) was detected at 
promoter region 2, which is located approx. 1000 bp upstream of the TSS. HuSP3 acetylation 
was increased by nearly 200% while HuSP1 and HuSP4 located directly at the TSS doubled in 
their H3K9 acetylation. To rule out any fibroblast line specific effects, these experiments 
were repeated in another fibroblast line but produced similar results (data not shown). 
 
 
Figure 46 Analysis of the H3K9 acetylation status of the SMN2 promoter in LBH589-treated 
fibroblasts. Data are given as mean ± SEM of three independent experiments. (* = P<0.05; 
** = P<0.01; *** = P<0.001) 
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Based on the ChIP data it was tested whether the elevated H3K9 acetylation is 
accompanied by an increased SMN2 promotor activity. Therefore, a NSC-34 reporter cell line 
stably transfected with the -lactamase under the control of the human SMN2 promoter 
was treated with LBH589. This cell line allows monitoring of SMN2 promoter activity since 
the -lactamase cleaves CCF2-AM (a dye which was added to cells in the course of this 
experiment) in a concentration-dependent manner (Jarecki et al. 2005). By treating this cell 
line with escalating LBH589 concentrations a dose-dependent augmentation in promoter 
activity was detected up to 2.5 au at 500 nM. This clearly shows that the increase in H3K9 
acetylation is indeed accompanied by an activation of the SMN2 promoter. Furthermore, 
already 200 nM LBH589 are sufficient to achieve nearly maximal SMN2 induction. In contrast 
to that, 1 mM VPA increased SMN2 promoter activity only slightly by 40%.  
Calculations using these data by Dr. Christian Tränkle (University of Bonn) determined at 
EC50 of 108 nM for LBH589 which matches its HDAC IC50 (106 nM), suggesting that H3K9 
acetylation and SMN2 promoter activity go hand in hand and act in a 1:1 stoichiometry 
(Appendinx, Figure 64 and Figure 65). 
 
Figure 47 Box plot illustrating the increased SMN2 promotor activity in 64 h LBH589-treated NSC-34 
reporter cell. P-values for all tested concentrations were below 0.001. Boxes represent 50% 
quartiles including median in black, mean in red whereas whiskers display 5 and 95% 
quartiles. 
4.2.7 Characterization of LBH589-induced SMN protein increase 
So far it could be shown that LBH589 elevated SMN protein amounts up to 8-fold and in 
some cases even up to 10-fold. On the other side SMN2 promoter activity merely tripled 
under LBH589 regimen. Hence, the question arose which mechanism may account for this 
tremendous discrepancy. Two different scenarios are conceivable: On the one hand LBH589 
may enhance mRNA stability, thereby allowing more often the translation of one and the 
 
140 Results 
same mRNA. On the other hand, LBH589 may increase SMN protein stability thus leading to 
an accumulation of SMN protein over time.  
4.2.7.1 Analysis of SMN mRNA turnover in treated fibroblasts 
To investigate whether LBH589 increases SMN2 mRNA stability de novo mRNA synthesis 
was blocked with Actinomycin D for different time periods in fibroblasts either treated with 
400 nM LBH589 or mock. RNA was extracted from the respective samples and qRT-PCR was 
performed to quantify individual remaining transcript amounts. Using the resulting values 
mRNA half-life periods (T1/2) were calculated for both FL-SMN2 and SMN27 as well as three 
control transcripts (Figure 48). For none of the tested transcripts any notable difference in 
mRNA stability was detected. Therefore, a stabilizing effect of LBH589 on the SMN2 mRNA 
could be excluded as a factor leading to the discrepancy between promoter activity and SMN 
protein amounts. 
 
Figure 48 Analysis of mRNA stability in LBH589-treated fibroblasts. (A) Diagrammatic comparison of 
FL-SMN2 and SMN27 fractions remaining after incubation for the indicated time periods 
with Actinomycin D. (B) Half life periods (T1/2) of different transcripts calculated by 
approximated e-functions. Values are given as mean values from three independent 
experiments. Control transcripts COL3A1, RPS12 and c-MYC served as control for long, 
medium or short half-life.  
4.2.7.2 Analysis of SMN protein turnover in treated fibroblasts 
Since an increased SMN mRNA half-life could be excluded as the pivotal factor, it was 
investigated next whether rather SMN protein than mRNA turnover is affected by LBH589. 
SMN is degraded via the ubiquitin-proteasome-system (UPS) (Burnett et al. 2009; Chang et 
al. 2004). Hence, as a first step global proteasomal degradation was tested for alterations. 
Inhibition of the proteasome with the proteasome inhibitor MG-132 for 15 h resulted, as 
expected, in a doubling of SMN amounts since it is not longer degraded. However, adding 
MG132 to cells pre-treated for 48 h with LBH589 failed to further elevate SMN protein 
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levels, suggesting that LBH589 either directly inhibits the proteasome or that 
ubiquitinylation of SMN is reduced so that SMN is no longer targeted to the proteasome. 
Similar results were obtained for p53, a protein which is known to be degraded by the 
proteasome. Combined treatment with MG132 and LBH589 failed to further increase 
protein amounts but rather led to a reduction of p53 induction by LBH589. 
 
Figure 49 Analysis of SMN turnover in LBH589 and MG132 treated cells. (A) Typical western blot 
showing combined and single treatment of LBH589 and MG132 of fibroblasts. (B) Analyzed 
SMN protein amounts of three independent experiments using -actin as loading control. 
In total three different proteolytic activities differing by their target sequence have been 
identified within the proteasome (caspase-, trypsin- and chymotrypsin-like) (Kisselev et al. 
1999). To address the question whether LBH589 directly inhibits the proteasome, a luciferin-
coupled degradation assay was employed to determine catabolic rates for all three 
proteolytic activities in LBH589-treated fibroblasts (Figure 50). It turned out that for none of 
the LBH589 concentrations a significant inhibitory effect could be detected. In contrast to 
that, proteolytic activities were decreased by 50 to 80% by MG132. The lysosome inhibitor 
NH4Cl had, as expected, only minimal effects on the proteasome. Interestingly, VPA slightly 
decreased trypsin- and chymotrypsin-like proteolytic rates but led to a notable increase of 
around 30% in caspase-like proteasomal degradation. Nevertheless, these data show that 
LBH589 has no inhibitory effect on the proteasome. 
 
142 Results 
 
 
Figure 50 Diagrammatic representation of the alteration in catalytic activities associated with the 
proteasome in LBH589-treated fibroblasts. MG132 served as positive control whereas 
NH4Cl, a known inhibitor of the lysosome, acted as negative control. Dark gray area 
indicates natural activity fluctuation in mock-treated fibroblasts. (* = P<0.05; ** = P<0.01; 
*** = P<0.001) 
Degradation of proteins via the UPS is a two-step process: First ubiquitinylation of the 
protein and second degradation by the proteasome. Since no differences regarding their 
proteasomal activity in mock and LBH589-treated cells could be detected, focus was shifted 
on SMN ubiquitinylation. Therefore tri- and tetraubiquitinylated proteins were precipitated 
using agarose beads coupled to the ubiquitin-interaction-motif (UIM) of Rpn10/S5A. Total 
portion of ubiquitinylated SMN was determined by resolving equal amounts of non-
ubiquitinylated SMN by western blot (Figure 51A). Quantification of protein amounts 
revealed that abundance of ubiquitinylated SMN was significantly reduced by 70% (Figure 
51B). This suggested that besides promoter activation LBH589 also elevates SMN levels by 
reducing its turnover thereby leading to an accumulation over time. 
Absence of non-ubiquitinylated proteins in the Rpn10/S5A precipitate was proven by 
staining against ODC (Ornithine decarboxylase), a protein which is known not to be 
ubiquitinylated (Figure 51C). Effective LBH589 treatment leading to increased SMN amounts 
was also proven by western blot (Figure 51E). 
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Figure 51 Analysis of the UPS in LBH589-treated cells. (A) Representative western blot illustrating the 
decline in the amount of ubiquitinylated SMN precipitated by the Rpn10/S5A UIM. Equal 
amounts of non-ubiquitinylated SMN were loaded. (B) Mean decline of SMN 
ubiquitinylation in three independent experiments ± SEM. (C) Typical western blot 
illustrating the absence of non-ubiquitinylated proteins in the Rpn10/S5A precipitate by 
staining against ODC. (D) Western blot using whole cell lysates illustrating total 
ubiquitinylation in LBH589-treated cells. (E) Western blot indicating increase in SMN and 
ODC amounts under LBH589 treatment. (* = P<0.05) 
Although SMN ubiquitinylation declined, total protein ubiquitinylation was not reduced 
under LBH589 treatment (Figure 51D). This suggested that the decline in SMN 
ubiquitinylation is rather a secondary than a primary effect of LBH589. It has previously been 
shown that SMN stability is enhanced by the incorporation of SMN into the SMN complex 
(Burnett et al. 2009). Based on this, it was argued that the observed reduction of ubiquitin 
coupling to SMN is rather a consequence of enhanced SMN complex formation whereby 
SMN is kept out of the UPS pathway. This was further underlined by the detected increase in 
Gemin2 and Gemin3 protein amounts – both of them SMN complex partners (Figure 38). 
Summarized, besides transcriptional activation and splicing correction, LBH589 also acts 
post-transcriptionally on SMN levels by reducing SMN ubiquitinylation most likely through 
enhanced SMN complex formation. 
4.2.7.3 Analysis of PKA activity in LBH589-treated fibroblasts 
It has previously been shown that integration of SMN into the SMN complex is favoured by 
activation of PKA. Therefore, PKA activity and expression were analyzed in LBH589-treated 
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fibroblasts (Figure 52). PKA activity decreased dose-dependently to a minimum of 70% at 
1 µM LBH589. In contrast to that, expression of the catalytic subunit  of PKA (termed PKAcat) 
was increased to the same extent. Therefore, PKA activation as the initial trigger leading to 
an increased SMN complex formation could be excluded. 
 
Figure 52 Analysis of PKA activity in LBH589-treated cells. (A) Diagrammatic summary of increased 
PKAcat expression as well as reduced PKA activity following LBH589 treatment of fibroblasts. 
(B) Typical western blot illustrating PKAcat levels at various LBH589 concentrations. 
(* = P<0.05; ** = P<0.01; *** = P<0.001) 
 
In conclusion, these data clearly show that LBH589 is an outstanding candidate for a 
drug-based SMA therapy. Compared to other HDACis, the impact of LBH589 on SMN levels is 
the highest yet reported. Most importantly, LBH589 is able to induce SMN2 expression in 
fibroblasts not responding to the classical HDACi VPA. Therefore, the next step towards a 
putative SMA therapy with LBH589 would be to evaluate its efficacy in a SMA-like mouse 
model like it has recently been reported for SAHA (Riessland et al. 2010).   
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4.3 Identification of Bortezomib (Velcade) as a putative SMA drug 
Based on the finding that LBH589 was able to indirectly increase SMN amounts by 
reducing its ubiquitinylation, the therapeutic proteasome inhibitor Bortezomib (Velcade) 
was tested for its potential to increase SMN amounts. Bortezomib was originally developed 
by Millenium Pharmaceuticals as PS-341 (Adams 2002) as an anticancer drug. Clinical trials 
with diverse types of cancers such as solid tumors (Aghajanian et al. 2002; Papandreou et al. 
2004) have subsequently proven Bortezomib´s efficacy and biocompatibility. Bortezomib 
became the first proteasome inhibitor clinically approved. Nowadays, it is routinely used for 
the monotherapy of progressive multiple myoloma. 
 
Figure 53 Chemical structure of Bortezomib / PS-341 / Velcade 
To determine the concentration and treatment time Bortezomib was initially applied in a 
kinetic experiment to SMN1-deleted fibroblasts. Therefore, ML17 was treated for 8, 24 and 
48 h with Bortezomib concentrations between 10 and 500 nM (Figure 54A). Summarized, 8 h 
of Bortezomib treatment modestly increased SMN amounts up to 170% maximum at 
100 nM. Longer incubation times of either 24 or 48 h elevated SMN amounts up to approx. 
250% for all concentrations higher than 50 nM. Based on these convincing data, a MTT assay 
was performed to test whether Bortezomib hampers cell viability at concentrations tested 
(Figure 54B). It turned out that concentrations higher than 20 nM Bortezomib dramatically 
decreased cell viability by more than 30%. At 200 nM Bortezomib, cell viability was already 
halved although SMN amounts were more than 2-fold increased. Hence, all subsequent 
experiments were performed with Bortezomib concentrations up to 20 nM maximum and an 
incubation time of 24 h. 
In total four different fibroblast lines were treated with Bortezomib (Figure 54C, D). Three 
of them were derived from SMA patients (ML5, ML16 and ML17) whereas ML6 was derived 
from a healthy donor. Quantifying SMN levels by western blotting showed that in all three 
cell lines derived from SMA patients SMN was significantly increased 2- to 3-fold at 10 and 
20 nM Bortezomib. At 1 nM Bortezomib, only tiny augmentations in SMN amounts were 
recorded. In the case of ML6 just 20 nM of Bortezomib led to a significant augmentation in 
SMN protein. 
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Figure 54 Analysis of Bortezomib´s impact on SMN levels. (A) Kinetic experiment with ML17 to 
determine optimal combination of drug concentration and treatment time. Toxic 
concentrations are marked in gray. (B) MTT assay with 96 h Bortezomib treated fibroblasts. 
Starting from 50 nM Bortezomib onwards P<0.0001. (C) Typical western blot with 
fibroblasts treated with the indicated Bortezomib concentrations. Quantified protein 
amounts are given in (D). (* = P<0.05; ** = P<0.01; *** = P<0.001) 
Although these results were very promising, Bortezomib was not further investigated as 
a potential SMA drug since it does not pass the blood-brain-barrier (Hemeryck et al. 2007), 
which is a prerequisite for drug-based SMA therapy. However, it may be speculated whether 
combined therapy of an HDACi and Bortezomib may lead to synergistic effects (e.g. SAHA 
plus bortezomib in multiple myeloma therapy (McConkey 2010)) but these would fail to 
affect the -motor neurons which are the target tissue of causal SMA therapy. 
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4.4 Identification of JnJ-26481585 as a potential SMA drug 
Based on the promising LBH589 data, another auspicous second generation panHDACi, 
JnJ-26481585, was tested as a putative SMA drug. JnJ-26481585, originally developed by 
Johnson and Johnson, is a derivate of LBH589 sharing the same terminal indole-1-methyl-3-
yl-methylamine and acrylamide residues while the central benzene is substituted by a 
2(piperidine-1-yl)pyrimidine (Figure 55). In vitro studies using JnJ-26481585 showed a strong 
anti-proliferative activity in solid tumors at low nanomolar concentrations. This was further 
strengthened by the determination of the IC50 values for HDAC1 (0.11 nM), HDAC2 (0.33 nM) 
and HDAC3 (4.8 nM)(Arts et al. 2009). Moreover, in vivo studies with mice showed that 
combined treatment of bortezomib and JnJ-26481585 strongly reduced bone myeloma 
(Deleu et al. 2009b). Single treatment with JnJ-26481585 of 5T2 and 5T33 multiple myeloma 
mouse models led to a significant reduction in tumor load and angiogenesis (Deleu et al. 
2009a). 
 
Figure 55 Chemical structure of JnJ-26481585. 
To investigate whether JnJ-26481585 is capable of increasing SMN protein in SMN1-
deleted fibroblasts at kinetic experiment was performed initially. Treatment for various time 
periods of up to 72 h with concentrations between 1 nM and 5 µM produced the highest 
augmentation at 64 h with concentrations around 400 nM JnJ-26481585 (data not shown). 
Therefore, all subsequent experiments were performed with this dose. 
Treatment of ML16 with the above described conditions yielded a uniform 4-fold increase 
in SMN levels for concentrations between 100 nM and 1 µM JnJ-26481585 (Figure 56A, B). 
Applying either 10 nM or 5 µM resulted in a doubling of SMN amounts. Compared to the 
effect of LBH589, the impact of JnJ-26481585 on SMN was nearly the same. Similar to 
LBH589 a shift of the SMN2 splicing pattern towards FL-SMN2 was observed starting at 
concentrations of 100 nM JnJ-26481585 (Figure 56C). This effect steadily grew to 750 nM at 
which 250% FL-SMN2 were recorded. Although not yet tested, probably hTRA2-1, SF2/ASF 
and SRp20 are also up-regulated by JnJ-26481585 since transcript amounts were dose-
dependently decreased (Figure 56D). A similar decline in mRNA levels was detected for 
hTRA2-1 under LBH589 treatment while protein amounts were doubled (Figure 44). 
Furthermore, JnJ-26481585 led to an up-regulation of the SMN-complex partners Gemin2 
and Gemin3, suggesting a similar mode of action as discovered for LBH589 (Figure 51). 
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Based on these data, it was decided to routinely use JnJ-26481585 concentrations of 
10 nM, 400 nM and 1 µM for further in vitro experiments. Quantification of SMN mRNA 
levels by qRT-PCR revealed that at 400 nM and 1 µM SMN27 was significantly declined. By 
contrast, FL-SMN2 amounts were increased by 50% for both concentrations, thus confirming 
the previous data from single RNA experiments. 
 
149 Results 
 
Figure 56 Analysis of the impact of JnJ-26481585 on SMN1-deleted fibroblasts. (A) Representative 
western blot illustrating the increase in SMN under JnJ-26481585 treatment. -Actin was 
used as loading control. (B) gives mean protein amounts ± SEM from three independent 
experiments using ML16. (C) Quantification of FL-SMN2 and SMN27 transcript amounts at 
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the indicated JnJ-26481585 concentrations. (D) Expression of splice factors known to bind 
SMN2 mRNA and SMN complex partners (E). (F) Mean SMN expression under JnJ-26481585 
treatment of ML5 with the indicated concentrations. (* = P<0.05; ** = P<0.01; 
*** = P<0.001) 
Furthermore, it was tested whether JnJ-26481585 has any toxic side effects. Using a MTT 
assay, cell viability was determined in fibroblasts treated for 96 h with JnJ-26481585. 
Starting from 100 nM onwards, cell viability was reduced by 30% for all concentrations. 
Although LBH589 was well tolerated in previous experiments (Figure 40A), a similar result 
was obtained for a concentration of 400 nM. This suggested that the used cell line ML103 is 
extremely sensitive to HDACi treatment. 
As a first step towards an in vivo application, 20 mg/kg[bodweight] JnJ-26481585 were 
subcutaneously injected into the neck pucker of unaffected SMA carrier mice. Both animals 
treated with JnJ-26481585 exhibited more than 2-fold increased SMN protein amounts in 
liver (Figure 57B, D). In contrast, no change in SMN levels could be observed in the brain. A 
second mock-treated animal was not analyzed since only extremely weak SMN signals could 
be obtained by western blotting. In addition, global histone H3 acetylation was analyzed by 
ELISA (Figure 57C). Although in the brain of JnJ-26481585-treated mice no increase in SMN 
levels was detected by western blot, histone H3 acetylation was markedly increased 6 h post 
injection. 
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Figure 57 Evaluation of JnJ-26481585´s cytotoxicity and in vivo potential. (A) MTT assay of fibroblasts 
treated for 96 h with the indicated concentrations. Open triangle indicates cell viability of 
cells treated for 96 h with 400 nM LBH589. (B) Representative western blot illustrating SMN 
amounts in different tissues 16 h after subcutaneous injection of 20 
mg
/kg[bodyweight] JnJ-
26481585. (C) Global histone H3 acetylation in the brain of JnJ-26481585-treated mice 6 h 
post injection. (D) Quantified protein from the western blot depicted in (B). (* = P<0.05; 
** = P<0.01; *** = P<0.001) 
Summarized, these data suggest that JnJ-26481585 is indeed a promising candidate for a 
putative SMA therapy since it augmented SMN levels in vivo and in vitro. It may be argued 
that in the brain of JnJ-26481585-treated mice no increase in the SMN amounts could be 
detected, which would question the potential JnJ-26481585 as a SMA therapeutic. However, 
these experiments were performed without any dose optimization, implying that another 
treatment regimen may have led to a different outcome. Therefore, careful testing of 
different concentrations is needed as it has been reported e.g. for SAHA (Riessland et al. 
2010). Once the optimal treatment conditions have been established, the potential of 
JnJ-26481585 as a SMA therapeutic can be investigated in vivo. 
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4.5 Characterization of an intermediate SMA-like mouse model 
Several SMA-like mouse models have been generated of which some have already been 
employed for in vivo drug testing (Lorson et al. 2010). However, none of these animal strains 
exhibits an intermediate SMA-like phenotype, which would be desirable for the long-term 
evaluation of putative drugs. Therefore, it was tried to generate such a phenotype by 
crossbreeding two already established models. Similar to humans, the SMA phenotype in 
mice strongly correlates with the SMN2 copy number. SMAHung (Smn
-/-; SMN2tgTW/tgTW) have 
four SMN2 copies and exhibit no obvious phenotype apart from a necrotic tail. In contrast, 
SMAHung animals having two SMN2 copies (Smn
-/-; SMN2tgTW/-) develop a severe SMA 
phenotype and usually die at an age of 10 days while SMABurghes mice (Smn
-/-; SMN2tgUS/tgUS) 
also possessing SMN2 copies die prenatally. Based on these findings the following breeding 
was performed to generate SMA-like mice carrying three SMN2 copies (marked in bold 
letters). 
SMAHung (Smn
-/-; SMN2tgTW/tgTW)  x SMABurghes (Smn
+/-; SMN2tgUS/tgUS)   
     ↓ 
Smn+/-; SMN2tgUS/tgTW   + Smn-/-; SMN2tgUS/tgTW 
The respective breeding was set up and three litters were observed for a time period of 
more than 250 days. “SMA-like” animals could easily identified by their phenotypic 
appearance, which was also verified by genotyping (data not shown). Compared to their 
healthy litter mates possessing one copy of the murine Smn gene, these animals were lighter 
and also developed necrosis of the ears and tail, but no other noticeable differences were 
observed (Figure 58). 
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Figure 58 Weightprogression of unaffected and SMA-like animals having three SMN2 copies. Within 
the first 21 days of life mice were weighted daily. Afterwards weight was determined once a 
week. 
Since only 24 animals were analyzed of which six were used for protein preparation after 
100 days no final statement about the medium survival could be drawn. Within a period of 
250 days six out of nine unaffected animals died or had to be sacrificed because of open 
wounds due to continuous biting by their cage mates. Within the group of SMA-like animals 
two animals passed away after 150 or 180 days, respectively. Another male SMA-like mouse 
had to be sacrificed at an age of 217 days due to infection of the scrotum. Taken together, 
no obvious reduction in the survival of SMA-like mice could be observed. These findings 
were somehow unexpected because determination of SMN protein amounts in the liver and 
brain in both groups of mice clearly revealed that SMN was declined by 70% in the SMA-like 
animals (Figure 59).  
Summarized, these data suggest that three SMN2 copies seem to be sufficient to rescue 
the SMA phenotype in this experimental setup. A closer and more detailed evaluation would 
be necessary to identify subtle differences which may indicate a very mild SMA phenotype. 
However, this mouse model is not suitable for any drug testing since an increase in survival 
could not be applied as an outcome measurement. 
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Figure 59 Analysis of SMN protein levels in unaffected (Smn
+/-
; SMN2
tgUS/tgTW
) and SMA-like (Smn
-/-
; 
SMN2
tgUS/tgTW
) animals. All assayed mice were females and 103 days of age. (A) Western blot 
illustrating the reduced SMN amounts in SMA-like mice. Quantified amounts are given 
in (B). -Actin served as loading control.  (* = P<0.05; ** = P<0.01; *** = P<0.001) 
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5. Discussion 
Proximal spinal muscular atrophy (SMA) is a unique disorder in the field of human 
genetics. While the molecular cause of SMA is the functional absence of the survival motor 
neuron gene 1 (SMN1), the disease severity is modified by a nearly identical copy gene, 
termed SMN2 (Brahe 2000; Feldkotter et al. 2002; Lefebvre et al. 1995). In contrast to SMN1, 
which almost exclusively produces full-length transcripts, around 90% of SMN2 transcripts 
are lacking exon 7 (Gennarelli et al. 1995; Lefebvre et al. 1995; Lorson et al. 1999). As a 
result, the SMN7 protein is unable to fullfil its normal function, since it is less capable of 
oligomerizing and is rapidly degraded (Burnett et al. 2009; Lorson et al. 1998). The critical 
factor triggering alternative splicing is a translationally silent C to T transition at the 
beginning of exon 7 (Lorson et al. 1999), which leads to the disruption of an exonic splicing 
enhancer (ESE) and creates an exonic splicing silencer (ESS) instead (Kashima and Manley 
2003; Lorson and Androphy 2000). Consequently, the splice factor SF2/ASF is displaced by 
hnRNP-A1, which negatively acts on exon 7 inclusion (Cartegni et al. 2006; Cartegni and 
Krainer 2002; Kashima et al. 2007a). Nevertheless, around 10% of SMN2 transcripts are 
correctly spliced, thus giving rise to the fully functional full-length SMN protein (Gennarelli et 
al. 1995; Lefebvre et al. 1995; Lorson et al. 1999). Therefore, modulation and activation of 
SMN2 has, self-evidently, become a major target for SMA therapy. Among the therapeutic 
strategies tested, activation of SMN2 and correction of its splicing pattern in vitro and in vivo 
by means of HDAC inhibition has turned out to be effective (Brichta et al. 2003; Brichta et al. 
2006; Garbes et al. 2009; Hahnen et al. 2006; Riessland et al. 2010; Riessland et al. 2006; Tsai 
et al. 2008). Especially, the HDAC inhibitor Valproic acid (VPA) has gained particular interest 
for several reasons:  First, VPA is not an experimental drug. It has been used for more than 
30 years in epilepsy therapy. Second, the favorable effects of VPA have been demonstrated 
in vivo in a SMA-like mouse model (Tsai et al. 2008). And most importantly, in a first pilot 
clinical trial with 20 SMA patients, VPA was able to up-regulate blood SMN transcript levels 
in around 1/3 of tested subjects. In 
1/3 of the SMA patients, however, declined SMN levels 
were recorded, whereas in the remaining 1/3 no change was observed (Brichta et al. 2006). 
Consequently, the question arose why a certain subset of SMA individuals is positively 
responding to VPA, whereas others do not. In the present work, the molecular differences 
between these SMA patients were investigated to reveal the underlying cause.  
5.1 SMA-therapy with VPA 
The primary aim of this thesis was the identification of the crucial factor(s), which 
account(s) for the differential response to VPA in SMA patients. Ideally, this factor should be 
of universal meaning, since e.g. a tissue specific one may help to understand the critical 
mechanisms, but would not be a feasible biomarker. The big advantage of such biomarker 
would be that patients could be screened before VPA treatment is started, to avoid futile or 
even harmfull treatment. At least in a few cancer types, some very first biomarkers for the 
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response to HDACi were identified. In a panel of 16 NSCLC (Non small cell lung cancer) cell 
lines, the cytotoxic effects of TSA and SAHA were correlated with the respective expression 
profiles. It could be demonstrated that the expression of three genes (NQO1, SEC23A and 
PSME2) indeed correlated with drug sensitivity (Miyanaga et al. 2008). In another study with 
18 cancer lines of different origin, another four genes (STAT1, ODC1, thymidylate synthetase 
and SKI) were associated with the sensitivity to the HDACi belinostat (PXD101) (Dejligbjerg et 
al. 2008). However, within the field of cancer research debate is still ongoing, whether these 
genes could indeed be considered as general biomarkers for cancer HDACi sensitivity, since 
an in vivo proof is still missing (Stimson and La Thangue 2009). Nevertheless, the 
identification of such biomarker for SMA therapy with VPA would be a valuable tool to 
provide the optimal treatment possible to patients, while at the same time avoiding 
unnecessary side-effects. Furthermore, identification of markers for general VPA 
responsiveness would have vast implications for treatment strategies of other diseases in 
which VPA is indicated (e.g. epilepsy). 
5.1.1 Fibroblasts and blood: Is the response to VPA the same? 
During the first pilot clinical trial with VPA, blood samples from the VPA-treated 
individuals were taken to analyze the impact on SMN mRNA levels (Brichta et al. 2006). In 
some cases also blood-derived protein data could be collected. However, since appropriate 
handling and shipping of blood samples could not be guaranteed in all cases, SMN2 mRNA 
levels were selected as the major read-out for VPA activity.  
From virtually all patients and carriers included in the initial clinical trial fibroblast lines 
were established from standard skin biopsies. This was done for two reasons: First, for all 
subsequent experiments enough sample material was needed and this demand cannot be 
satisfied by blood samples. Second, the fibroblast lines allowed us to test whether the 
response to VPA treatment correlates between the two tissue systems fibroblasts and blood. 
In case of a positive result, one may speculate that a similar response may be elicited in the 
-motor neurons, which are considered as the actual SMA target tissue. 
To investigate whether the response between both tissue systems indeed correlates, all 
estabilished fibroblast lines were treated with VPA concentrations between 5 and 500 µM. 
Various doses of VPA were employed, since it could be demonstrated that primary fibroblast 
lines show striking concentration-dependent differences in their individual response to 
HDACi treatment (Brichta et al. 2003; Garbes et al. 2009). In conclusion, a likewise response 
to VPA in blood and fibroblasts could clearly be observed in nine out of 17 cases (Table 15; 
ML49, ML53, ML68, ML59, ML67, ML71, ML69, ML73 and ML82). In another three fibroblast 
lines, similar tendencies as in blood were obtained, but unfortunately these results lacked 
statistical significance (ML75, ML65 and ML60). In contrast to that, four fibroblast lines 
exhibited a clearly opposite response to VPA than expected from the blood data (ML63, 
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ML66, ML62 and ML71). Of note, the impact of VPA on SMN levels is rather low compared to 
other HDACi. While e.g. M344 elevated SMN levels up to 7-fold (Riessland et al. 2006) or 
LBH589 treatment resulted in 10-fold augmented SMN protein amounts (Garbes et al. 2009), 
VPA only led to a 2-fold increase maximum (ML67). Therefore, distinction between a positive 
response and a natural fluctuation was not unambiguous in single cases (e.g. ML60 and 
ML59). Nevertheless, without any major exceptions, the response to VPA was consistent 
within the individual cell lines, meaning that e.g. in the case a down-regulation was observed 
for 50 µM, similar results were obtained for the other two tested concentrations. In the 
following, additional fibroblast lines were established from SMA patients undergoing VPA 
therapy. In total, five additional fibroblast lines could be identified, which exhibited 
concordant results to the in vivo blood data (Table 16; ML79, ML86, ML94, ML95 and 
ML105), whereas in two fibroblast lines opposite results were obtained (ML89 and ML96). 
Since VPA therapy and sample collection is still ongoing, it could not be decided yet whether 
in vivo and in vitro data in another seven cell lines are similar. Nevertheless, once enough 
additional concordant fibroblast lines are identified, these will be used as a control group to 
verify data. 
The question remained, why only in around 60% of the assayed fibroblasts a clear 
correlation could be observed. Although a study with SAHA, oxamflamtin and FK228 in 
cancer therapy suggested a strong correlation between the in vitro efficacy and the clinical 
outcome (R>0.75) (Lindemann et al. 2007), the situation might be different in SMA therapy. 
It may be conjuctered that tissue-specific expression differences of HDACs (Lucio-Eterovic et 
al. 2008; Thomas 2009) between blood and fibroblasts may hamper a correlation, since VPA 
inhibits only class I and class IIA HDACs. Since no full concordance could be observed, it was 
reasoned that tissue-specific differences in HDAC composition may influence the extent of 
VPA-mediated SMN2 induction, but not whether the fibroblasts respond or not. This is 
further corroborated by the finding that none of the HDACs was found to be differentially 
expressed between Pos- and Non-Responders by µ-array, implying that discrepant HDAC 
expression is not the cause for VPA non-responsiveness. 
Although caution is needed when in vitro findings are extrapolated to in vivo data, the 
obtained concordance of nearly 60% is quite high. Since in several studies going from in vitro 
to a more complex in vivo system quite similar effects of VPA could be observed (Michaelis 
et al. 2004a; Michaelis et al. 2004b), our data coming from the reverse approach, going from 
the SMA patient to the more simplified fibroblast, is rather solid. Of course, the issue of 
inconsistent data within the remaining 40% of fibroblast lines needs to be addressed (e.g. 
ML71, ML62 and ML63). Possible explanations are that the impact of VPA on SMN levels in 
fibroblasts is much weaker than in blood. This may lead to the false negative identification of 
patients who exhibited only modestly increased SMN levels in blood as Non-Responders, if 
they are only evaluated on fibroblast level (e.g. ML60, ML82 and ML79). Such tissue-specific 
effects on the impact of VPA have been shown in rats. Treatment of these animals with VPA 
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results in up to 10-fold discrepant monoamine levels in different regions of the brain (Narita 
et al. 2002), implying that the difference between blood and fibroblasts may lead to such 
observations. Going into the same direction, it may happen that individual factors influecing 
the VPA effect on SMN2 in blood are much more prominent in fibroblast, thus converting 
e.g. a blood Pos-Responder into a Non-Responder or vice versa (e.g. ML62 and ML96). This is 
of particular importance, since elevation of SMN protein due to HDAC inhibition by VPA is a 
multi-step process subjected to various regulatory mechanisms. Clear dose-response curves 
for VPA can be obtained in vitro using standardized rat liver lysates (Hahnen et al. 2006) or in 
blood by measuring glutathione reductase activity (Cotariu et al. 1992). But these 
measurements directly determine the effect of VPA on the respective enzymatic activity. 
Since not all tested fibroblast revealed clear dose-dependent effects (e.g. ML71, ML72, ML94 
and ML105), additional factors, e.g. the co-repressor and co-activator complexes (Grozinger 
and Schreiber 2002), interfering with an absolute relation between VPA concentration and 
SMN protein, must play a role. 
5.1.2 Candidate genes for non-responsiveness to VPA: Network or conincidence? 
To identifiy the pivotal factor(s) accounting for the differential response to VPA, 
transcriptome-wide µ-array analysis of fibroblasts was performed. The comparison was 
designed in such a way that four Non-Responders (ML59, ML69, ML73 and ML82) were 
compared with five Pos-Responders (ML67, ML72, ML5, ML16 and ML17) in both mock and 
VPA treated state (Figure 12). This should address the question of which genes are 
differentially expressed in Pos-Responders versus Non-Responders under VPA treatment? 
And furthermore, is there an initial gene set-up which, most probably, would account for the 
observered differences after VPA application? Interestingly, µ-array analysis revealed that, 
even before the elimination of false-positive hits, the response to VPA treatment in Non-
Responders was much lower than in Pos-Responders (Table 17, 977 transcripts vs. 1987 
transcripts). After data correction, no single transcript was significantly altered by VPA 
treatment in Non-Responders, while in Pos-Responders 58 transcripts remained 
differentially expressed. Although several studies showed that HDACi treatment alters 
expression of up to 20% of all genes (Mariadason et al. 2000; Peart et al. 2005; Stimson and 
La Thangue 2009; Van Lint et al. 1996), the relatively small number of 58 transcripts was 
expected, since long-term VPA treatment of HEK293 merely changed expression of 200 
transcripts (Milutinovic et al. 2007) There again, in this study using only one single cell line 
was used for all experiments. Comparision of several different cell lines or patients normally 
results in low numbers of differentially expressed genes due to the intraindividual 
differences. For example, in a study investigating the gene expression profile of six CTCL 
patients under LBH589 treatment, only 23 genes were identified to be commonly altered, 
while individual patients exhibited up 1,300 differentially expressed genes (Ellis et al. 2008). 
The perhaps most exciting finding of the µ-array analysis was that only nine genes were 
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differentially expressed between untreated Pos- and Non-Responders, which may be the 
initial set-up accounting for VPA non-responsiveness. Among these, the RAR and three HOX 
genes (HOXB3, HOXD10 and HOXD11) were found, suggesting a major developmental factor, 
which differs between Pos- and Non-Respoders.  
To reduce the total number of transcripts to a feasible group, only those were selected 
for further analysis, which revealed a more than 2-fold expression difference. Subsequently, 
these were analyzed by qRT-PCR to verify the µ-array data (Figure 12, Appendix Table 25 and 
Table 26). Of the 18 tested genes, nine could clearly be confirmed, whereas nine gave 
conflicting results. However, this is a phenomenon typically seen when comparing µ-array 
and qRT-PCR data, since µ-array easily gives highly significant values when genes are 
expressed at a low levels (Etienne et al. 2004). For further experiments, a candidate gene 
approach was carried out by literature mining. Out of the remaining nine, the four candidate 
genes CD36, RAR, IGFBP5 and TGF were selected for further analysis (Figure 13).  
Although for none of four the candidate genes any overt function directly linked to VPA 
has been reported so far, it is easily imaginable that RAR, IGFBP5 and TGF may account 
for the different response to VPA due to their involvement in the control of various 
biological processes. However, since the VPA Non-Responders also failed to respond to 
sodium butyrate, it stood to reason that functions related to fatty acids may account for our 
observation. Therefore, CD36, which is involved in lipid homeostasis as well as TSP1 
signalling, was selected in addition. (A detailed description of all four candidate genes is 
given in 4.1.3.1 to 4.1.3.4 in the results part.)   
Since the individual expression patterns of all four candidate genes could well be verified 
(Figure 14 to Figure 17), the next step was to ask why CD36 and RAR are higher expressed 
in Non-Responders, while elevated levels of TGF and IGFBP5 are present in Pos-
Responders. Therefore, the coding regions as well as the 5`- and 3`-UTR of all four genes 
were sequenced. This was done, since e.g. several SNPs in the coding region or promoter of 
CD36 have been associated with obesity, insulin resistance (Bokor et al. 2010; Corpeleijn et 
al. 2006) or even CD36 defiency in Asian and African populations, the so-called Naka-
negative blood group (Fry et al. 2009; Yamamoto et al. 1990). Moreover, also for TGF 
several haplotypes have been linked to cleft lip or teeth agenesis (Callahan et al. 2009; Vieira 
2006). In addition, a SNP upstream of RAR has been associated with variant Creutzfeldt-
Jakob-disease (vCJD) (Mead et al. 2009), but it is not clear whether this SNP influences RAR 
expression. Futhermore, the detection of SNP could have great impact for post-
transcriptionally regulatory mechanism such as miRNAs. For example, it has been shown that 
IGFBP5 is regulated by the miRNAs miR-140 and miR27a in chondrocytes (Tardif et al. 2009). 
However, for none of the four genes an association between a certain SNP-type and the 
expression levels could be detected (Appendix, Figure 61 and Figure 62). Therefore, also an 
altered miRNA target site can be excluded. In summary, this implied that the differential 
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expression is caused either by a cis-acting element like a SNP located in the promoter or by a 
trans-acting element. While the former can easily be answered by promoter sequencing 
(which is currently in progress), the identification of trans-acting elements is rather complex 
and requires techniques like EMSA or newly developed methods such as deconvulution of 
DNA interactions (3D) (Nunez et al. 2008). As a first step towards the identifaction of any cis-
acting elements, ChIP analysis of the promoters of four candidate genes was performed 
(Figure 22) since it is generally believed that promoter acetylation can serve as a surrogate 
marker for transcriptional activitiy (Allfrey et al. 1964; Grunstein 1997; Strahl and Allis 2000). 
Unfortunately, the observed differences were somehow unexpected. While in the Pos-
Responders H3K9 acetylation increased after VPA treatment, the opposite happened in Non-
Responders. There again, in line with these findings, we could demonstrate that VPA also did 
not induce SMN2 promoter hyperacetylation in the Non-Responders or even led to 
hypoacetylation (Figure 9). Based on these ChIP data, the speculation is attractive, that VPA 
is not properly working as an HDACi in Non-Responders. This hypothesis corresponds nicely 
to the observation that no single transcript was differentially expressed in this group under 
VPA treatment, suggesting that either the Non-Responders are generally resistant to HDAC 
inhibition or that a VPA specific effect hampers its effects. However, the basal acetylation 
levels of the candidate promoters did not match with the observed expression pattern. 
While e.g. IGFBP5 is almost 5-fold higher expressed in Pos-Responders, the promoter seems 
to be more active in Non-Responders. Therefore, a more refined analysis of these promoters 
is needed to allow any final conclusion.  
Since all four candidate genes are not located in the same chromosomal region 
(CD36 chr.7q11, RAR chr.2q24, IGFBP5 chr.2q35, TGF chr.2p13), the co-seggregation via a 
common haplotype can be excluded without much doubt. However, since a consistent 
expression pattern was found along all Non- and Pos-Responders, the question arose, 
whether one of the four candidate genes is epistatic to the other ones, thus leading to the 
observed pattern. Therefore, overexpression (Figure 24) and knockdown studies (Figure 23) 
were performed. This was done to test whether e.g. CD36 knockdown in a Non-Responder 
reduces RAR levels and induces IGFBP5 and TGF expression instead, thus creating the 
expression pattern of a Pos-Responder. In conclusion, none of the transfection experiments 
gave a definite hint, whether one of the selected four genes is the crucial factor, which 
controls expression of the other ones. Indeed, e.g. RAR levels were doubled by CD36 
knockdown (Figure 23) or decreased TGF amounts had oppositional effects on RAR 
expression, but it was not possible to create a gene regulatory network, which properly 
summarizes all observations. Nevertheless, since interference with one candidate gene 
altered expression of the others, it may be speculated that e.g. CD36 and RAR or IGFBP5 
and TGF are not differentially expressed but rather differentially co-expressed. In order to 
verify this correlation, and to identify the causal determinant, like a common trans-
regulatory element, a larger set of data is needed (de la Fuente 2010; Tsaparas et al. 2006). 
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However, RAR is still the most interesting piece in this network puzzle, since it is typically 
not expressed in fibroblasts (Redfern and Todd 1992) and  has been suggested to regulate 
CD36 expression (Wuttge et al. 2001). Nevertheless, so far the connecting pieces between 
the candidate genes could not be uncovered.  
Since the candidate network may also include some secondary messengers, the cAMP 
levels in both Non- and Pos-Responders were determined (Figure 25). cAMP was chosen 
since it has been shown that VPA influences cellular cAMP levels (Chang et al. 2009; 
Gallagher et al. 2004; Montezinho et al. 2007). Further evidence came from the observation 
that IGFBP5 is regulated via a cAMP-responsive-element (Duan and Clemmons 1995) and 
that CD36 negatively controls the cAMP amounts via the Src-kinases (Roberts et al. 2010). 
Interestingly, addition of Forskolin and IBMX, both of them elevating cAMP by either 
adenylyl cyclase activation or phosphodiesterase inhibition, led to much higher cAMP levels 
in Non-Responders than in Pos-Responders. Since basal levels were comparable between 
both groups, these findings strongly suggested that the regulation of the second messenger 
cAMP is indeed altered. However, whether there is indeed an impact onto the candidate 
gene levels is not yet clear. 
Moreover, the expression of the four candidate genes was quantified in the blood of VPA 
treated patients, because initially the expression of at least one of them was intended to be 
used as a biomarker. Unfortunately, for none of the four candidate genes a consistent 
picture could be obtained (Figure 19 to Figure 21). Merely a correlation for IGFBP5 between 
the blood and fibroblast data is suggestive, since all Non-Responders with the exception of 
ML69, which gives constantly excess values, exhibit lower levels than the Pos-Responders 
(Figure 20). Because CD36 is also functioning as a scavenger receptor in the innate immune 
system (Hoebe et al. 2005; Jimenez-Dalmaroni et al. 2009; Means et al. 2009), e.g. bacterial 
infection may dramatically influence the expression levels, thus explaining the observed 
CD36 data. TGF was detected to be more or less equally expressed among all samples 
analyzed, leading to the speculation that its regulation in blood is different than in 
fibroblasts. Although RAR was robustly expressed in fibroblasts of Non-Responders, in the 
respective blood samples RAR transcripts could, going in line with the literature, not be 
detected (Szabova et al. 2003). Taken together, these results indicate that expression of 
none of the four candidate genes convincingly correlates between blood and fibroblasts. 
Since the intraindividual differences were too ambiguous, their expression levels cannot be 
used as a biomarker. 
Finally, it was also tried to show the expression differences in CD36, IGFBP5 and RAR on 
protein level. Unfortunately, all tested antibodies were of rather poor quality (Figure 18). 
CD36 was detected to be more or less equally expressed along all tested samples, thus not 
reflecting the RNA data. Typically, CD36 is heavily glycosylated, shifting its molecular weight 
from approx 51 kDA to an around 81 kDa heavy isoform (Hoosdally et al. 2009; Rac et al. 
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2007), which was not recognized by the employed antibody. Therefore, determination of 
CD36 levels after deglycosylation may lead to a different result. This is of particular 
importance since the translocation of CD36 to the plasma membrane is controlled by its 
glycosylation state (Hoosdally et al. 2009). Furthermore, RAR was also found to be quite 
uniformly expressed in all tested fibroblast lines, although RNA results suggested up to 
20-fold differences. However, since RAR is barely expressed, qRT-PCR results may appear 
more drastic than they actually are. At least for IGFBP5 comparable protein and RNA data 
could be obtained. In fact, the achieved staining is very poor, but the observed band 
intensities indicate higher expression levels in the Pos-Responders. For TGF no convincing 
staining could be obtained by either dot or western blot for all tested antibodies. However, 
since also for the neoplastic HeLa and HEK293 cells no TGF signal could be obtained by 
immunoblotting, the results suggest an antibody problem. 
In conclusion, the identified candidates sound quite attractive with regard to VPA Non-
Responders. But an underlying network which, as a whole, controls responsiveness to VPA 
has not yet been identified. Nevertheless, the overexpression and knockdown studies clearly 
indicate a connection between these genes, although the results are rather cryptically. 
Sequencing of the candidate genes suggested that expression is most likely controlled by (a) 
cis- or trans-acting element(s), which still await identification. Among the tested candidate 
genes, IGFBP5 is yet the most convincing one, since its expression could be verified on 
protein level in fibroblasts as well as in the blood of VPA treated patients. However, using 
this data it cannot be yet explained why VPA Non-Responders exist. There again, the 
detailed characterization of VPA non-responsiveness may allow inference on the underlying 
factors. Basically, two possibilities are conceivable why VPA does not induce SMN2 in Non-
Responders: Either these patients or fibroblast lines, respectively, are generally resistant to 
HDACi treatment or our observation is specific to VPA, implicating a differential uptake or 
metabolism of VPA in Non-Responders. To address these issues, several experiments were 
performed, which are discussed in the following.  
5.1.3  VPA treatment of Non-Responders: Resistent against HDACi? 
VPA is an HDACi that induces also SMN2 expression (Brichta et al. 2003; Gottlicher et al. 
2001; Hahnen et al. 2006; Phiel et al. 2001). There again, several points refused that this is 
indeed the case in Non-Responders. First, on a transcriptome-wide scale, no single transcript 
was differentially expressed in Non-Responders. Second, ChIP analysis of the candidate gene 
promoters indicated that rather hypo- than hyperacetylation is triggered in this group. And 
most importantly, we demonstrated that in contrast to the Pos-Responders, VPA treatment 
did not increase H3K9 acetylation at all four previously described SMN2 promoter regions 
(Figure 9) in the Non-Responders (Kernochan et al. 2005). Similar to the published data, the 
highest impact of VPA in Pos-Responders could be detected on HuSP2, while HuSP1 and 
HuSP3 were modestly affected. Interestingly, acetylation of HuSP4, which is located directly 
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at the ATG, was, like HuSP2, almost doubled by VPA treatment, suggesting a differential 
HDAC inhibition by VPA in fibroblasts and NSC-34 cells (Kernochan et al. 2005). In contrast, 
acetylation of the whole SMN2 promoter was, with one single exception, reduced by 5 to 
25% in the Non-Responders. In conclusion, these data clearly showed that VPA is not acting 
as an HDACi in Non-Responders. One may argue, that other genes typically induced by VPA, 
like MMP2 or GAD67, were not directly assayed by qRT-PCR or ChIP (Gavin et al. 2009; 
Milutinovic et al. 2007), but this is refused by our µ-array analysis, which revealed that the 
expression of no single transcript was alterd by VPA treatment. 
 However, the lacking induction of SMN2 expression in Non-Responders can easily be 
explained by the finding that VPA does not induce promoter hyperacetylation. At least two 
scenarios are conceivable why VPA does not induce SMN2 promoter hyperacetylation. Either 
VPA is for any purpose not available as an HDACi in these cells, or the Non-Responders are 
generally inert to HDACi treatment. To test whether the latter hypothesis holds true, Non-
Responders were treated with the well-known HDACi sodium butyrate, phenylbutyrate and 
LBH589 (Figure 10) (Andreassi et al. 2004; Andreassi et al. 2001; Garbes et al. 2009). 
Interestingly, it turned out that the Non-Responders are not generally resistant to HDACi 
treatment, but rather do not respond to a certain subset of HDACi. While the hydroxamic 
acid HDACi LBH589 and the aromatic fatty acid phenylbutyrate robustly increased SMN 
levels, the short-chain fatty acids VPA and Sodium butyrate failed to do so. Both VPA and 
sodium butyrate, which exhibited a comparably low HDAC inhibition potential (Bertrand 
2010; Catalioto et al. 2009; Hahnen et al. 2006), have been suggested to enter the cell in a 
dual way by diffusion as well as active transport (Adkison and Shen 1996; Roy et al. 2006). 
Since both are short-chain fatty acids, it is conceivable that the uptake of the two is impaired 
or lowered to such extent in Non-Responders that they do not inhibit HDACs. To finally 
clarify whether being a VPA Non-Responder is specific to the lack of HDAC inhibition or 
whether general VPA effects are absent, another indicator of VPA´s activity was needed. 
Since it has been reported that VPA dose-dependently inhibits the cAMP-dependent protein 
kinase A (PKA) (Boeckeler et al. 2006; Chang et al. 2009), its catalytic rate was quantified in 
both Pos- and Non-Responders. Determination of PKA activity in Pos-Responders revealed, 
as expected, a dose-dependent decline in activity down to 65% minimum at 1 mM VPA 
(Figure 11). In contrast, the opposite result was detected in all three tested Non-Responders 
with even a 20% elevation in ML103. However, VPA does not directly inhibit the PKA, but 
rather influences the cellular cAMP content by activating the adenylyl cyclases (AC) and 
inhibiting the phosphodiesterases (PDI) (Chang et al. 2009; Gallagher et al. 2004; 
Montezinho et al. 2007). To test whether VPA influences PKA activity by alteration of cAMP 
homeostasis in Pos- and Non-Responder, cellular cAMP levels were determined by ELISA 
(Figure 25). Although not signifant, cAMP levels were lowered, as expected, by 20% in Pos-
Responders. Contrariwise, cAMP amounts remained unchanged or slightly increased in Non-
Responders, which matched to the PKA activity experiments. Taken together, this gives good 
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evidence why the PKA is not inhibited in Non-Responder. Since the two unrelated read-outs 
PKA and HDAC both indicated that VPA is not triggering its normal function, it may 
speculated that either VPA is not taken up by the cell or rapidly exported or completely 
metabolized into an inactive form. The hypothesis of a VPA or short-chain fatty acid HDACi 
specific effect is further strengthened by the finding that both LBH589 and phenylbutyrate 
resulted in the expected increase in SMN protein. 
Similar to SMA, the phenomenon of VPA Non-Responders is also well-known in epilepsy 
therapy (Holland et al. 2010; Ollivier et al. 2009). But the underlying cause has not been 
identified yet. The experiments presented in this thesis, using VPA-treated SMA fibroblasts, 
give a first hint that perhaps a differential VPA metabolism (including uptake, conversion and 
disposal) may account for this observation. However, since so far neither differential uptake 
of HDACi or SCFA between individual fibroblasts lines has been reported, further 
experiments are needed to determine the responsible factor. 
5.1.4 HPLC-MS/MS: Any differences in VPA uptake or metabolism? 
Regardless, whether e.g. IGFBP5 controls CD36 expression or not, the question remained 
unanswered why Non-Responders do not react to VPA treatment. Since both ChIP analyses 
(Figure 9) as well as the PKA activity assay (Figure 11) indicated that VPA is not eliciting its 
normal inhibitory effect, the most obvious speculation was that VPA is simply not taken up 
by Non-Responders fibroblasts.  
To investigate whether VPA is indeed differentially taken up into Non-Responder 
fibroblasts, a HPLC-MS/MS assay was set up to quantify the amount of VPA. The basic 
procedure, which includes a pre-column derivatization of VPA and its metabolites, was 
originally published for human blood plasma (Cheng et al. 2007), but adopted by us for 
primary fibroblasts. Although a couple more straight-forward methods have been published 
(e.g. (Deng et al. 2006; Matsuura et al. 2008)), the derivatization method was chosen, since it 
gave the highest sensitivity. First experiments using pure VPA and its hepatoxic metabolite 
4-ene VPA (Cheng et al. 2007; Rettie et al. 1987; Silva et al. 2008) gave promising results 
corresponding well to the published data (Figure 28). Therefore, treated fibroblasts were 
analyzed in a kinetic experiment (Figure 29). While VPA could easily be quantified in the cell 
culture medium, barely any VPA signal was obtained for the corresponding cells. Moreover, 
4-ene VPA could not be detected in any sample, since signal intensities were always below 
the signal for untreated cells, which was set as threshold. This suggested that the 
intracellular VPA concentrations are negligible. However, this conclusion is refused by the 
finding that VPA inhibits HDACs in cellulo (Eyal et al. 2005; Kernochan et al. 2005) with an 
IC50 between 1.5 and 7.9 mM (Eyal et al. 2005; Hahnen et al. 2006). Therefore, in a Pos-
Responder at least VPA concentrations in the micromolar range should be detected. Hence, 
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the most likely explanation is that the cellular background coming from the derivatization of 
whole-cell-lysates is too high to allow efficient determination of VPA.  
To test whether CD36 facilitates VPA import into the cell, HEK293 cells overexpressing 
CD36 were incubated with 10 µM or 1 mM VPA and the intracellular VPA content was 
measured (Figure 30). Based on the previous observations, VPA was quantified without 
derivatization, although this reduced sensitivity of the assay. In conclusion, for none of the 
analyzed samples a clear increase after VPA stimulus could be obtained, suggesting that 
CD36 is not participating in VPA transport. Further evidence came from the observation that 
MCT1, 2 and 4, which have been demonstrated to mediate butyrate transport (Roy et al. 
2006), were not differentially expressed between Pos- and Non-Responders (Figure 33A). 
Taken together, these data implied that VPA rather slowly enters the fibroblasts via 
diffusion, although an active in- and export has been proposed at least for brain and choroid 
plexus (Adkison and Shen 1996; Gibbs et al. 2004; Naora et al. 1996). Furthermore, the 
metabolism of VPA was compared in Pos- and Non-Responder. Typically, 30-50% of a VPA 
dose appear in the urine as a glucoronide conjugate (Booth et al. 1996), while approx. 40% 
undergo mitochondrial -oxidation. The remaining 15-20% are eliminated by other oxidative 
mechanisms (Silva et al. 2008). The vast majority of mitochondrial oxidation of VPA is 
facilitated by the P450 enzyme system, which catalyzes the formation of metabolites like 
3-hydroxy-VPA, 3-oxo-VPA (Bjorge and Baillie 1991) or 4-ene VPA (Rettie et al. 1987). To 
determine whether differential formation of metabolites occurs between Pos- and Non-
Responders, a shading assay was performed, which allows easy graphical identification of 
discrepancies (Figure 31) (Grundemann et al. 2005). Unfortunately, no obvious differences in 
VPA metabolism could be observed between VPA treated Pos- and Non-Responders in the 
mass-range up to 400 amu (atomic mass unit), which includes all oxidized VPA metabolites. 
The only overt discrepancy was found at 4.28 min and 192.2 amu. But since no additional 
peak could be detected for either the deuterized or undeuterized VPA, this signal could be 
excluded as a direct VPA metabolite. Moreover, addition to VPA to both Pos- and Non-
Responders did not lead to the identification of any difference at all suggesting that no VPA 
has been taken up. Again it may be speculated about the underlying reasons. The most likely 
cause may be again the cellular threshold. Nevertheless, the only way to overcome this 
stumpling block would be to dramatically scale up the whole sample preparation to such 
extent that the signals clear excel the background. On the other side, it is also conceivable 
that the vast majority of internalized VPA is directly conjugated to Co-enzyme A (Aires et al. 
2007) or carnitine (Silva et al. 2001). But these conjugates are out of the experimental 
detection range. 
Taken together, the HPLC-MS/MS experiments did not lead to the identification of a 
differential VPA uptake or metabolism in Pos- and Non-Responders. Although identification 
of VPA and its metabolites has been published several times in urine or blood plasma, its 
quantification in fibroblasts turned out to be rather challenging. 
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5.1.5 VPA-therapy: Can a Non-Responder be turned into a Pos-Responder? 
The most important question in terms of SMA therapy with VPA is whether it is possible 
to make a Non-Responder responding to VPA? And, is this achievable in such a way that 
could also be used in clinics? One popular example for such factor is the treatment of 
chronic hepatitis type C: While it is possible to treat patients in monotherapy with 
interferon-, it has been shown that combined therapy of IFN- and the virostatic ribavarin 
of INF- Non-Responders results in sustained responses (Schalm et al. 1999). 
To finally identify the determinant of VPA non-responsiveness, two different approaches 
were conducted. First, CD36, IGFBP5 and TGF were knocked down and VPA was added to 
investigate whether any of the candidate genes impedes VPA mediate SMN2 induction 
(Figure 26 and Figure 27). Interstingly, it turned out that knockdown of CD36, irrespective of 
whether VPA was added or not, completely deplets SMN from the cell by reducing SMN 
transcription. Since CD36 is a cell surface receptor (Hoosdally et al. 2009), a direct effect on 
SMN transcription is rather unlikely. However, TSP1 signalling is transmitted via CD36 and 
the Src-kinases. And at least in bone remodelling, a functional connection between SMN and 
Src-signalling has been proposed, which may explain the observed SMN2 mRNA decline 
(Shanmugarajan et al. 2007). In contrast, knockdown of IGFBP5 post-transcriptionally 
increased SMN levels by more than 100% in the Pos-Responder ML73, whereas the effect 
was not so pronounced in ML82. Very recently, it has been shown that injection of a vector 
encoding IGF-1 increases life-span and weight of SMA-like animals, suggesting that IGF-1 
modulation by IGFBP5 may cause the increase in SMN levels (Shababi et al. 2010a). 
Especially, since the effect of IGFBP5 knockdown was much more pronounced in ML82 when 
VPA was added, one may speculate that blocking of IGF-1 by IGFBP5 is indeed a possibility to 
convert a Non-Responder into a Pos-Responder. 
The other trace followed was whether constitutive high CD36 levels have any impact on 
general fatty acid uptake. To this aim, LCFA uptake was quantified using a BODIPY-FA 
analogue (Figure 32). As expected from the CD36 expression data, Non-Responders tended 
to import more FA than Pos-Responders. This effect was even pronounced when VPA was 
added. However, addition of retinoic acid (RA) unexpectedly decreased FA uptake, although 
it has been published that it increases CD36 levels (Wuttge et al. 2001). Moreover, addition 
of SSO, a CD36-specific inhibitor (Coort et al. 2002), dramatically increased the amount of 
internalized BODIPY-FA. Both results from SSO and RA strongly suggested that CD36 is rather 
functioning as a FA exporter than importer in the tested fibroblasts. But to finally prove this 
hypothesis, up-regulation of other fatty acid handling proteins has to be excluded, and 
furthermore the fatty acid export itself has to be investigated in an appropriate experiment. 
Nevertheless, it was tested whether inhibition of CD36 via SSO in vitro turns a Non-
Responder into a Pos-Responder (Figure 34). Although the western blot data are suggestive 
to state that this hypothesis is true, the negative effect of SSO itself on SMN levels has to be 
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taken in account. Furthermore, it has been suggested that SSO itself interferes with 
mitochondrial -oxidation (Coort et al. 2002), which also may have implications for VPA 
metabolism. In addition, treatment of fibroblasts with Oligomycin D, an antibiotic, 
decoupling ATP-generation (Lardy 1980), had no boosting effect on FA internalization (Figure 
32). This indicated that coupling between oxidative phosphorylation and FA uptake is very 
weak, thus FAs are no major source of energy in the assayed fibroblasts. In line with this, the 
expression levels of lipogenic protein PPAR were not linked to elevated CD36 levels in all 
tested cell lines (Figure 33) (Zhou et al. 2008). 
Interestingly, expression of CPT1C was found to be almost twice as high in Non-
Responders as in Pos-Responder (Figure 33). CPT1C is of particular interest, since it has been 
speculated, but not yet proven, that CPT1C may catalyze the transfer of activated VPA-CoA 
to carnitine (Lheureux et al. 2005; Silva et al. 2008). This process is of fundamental 
importance for the -oxidation of VPA, since formation of Carnityl-VPA at the outer 
mitochondrial membrane allows VPA to pass the inner mitochondrial membrane via the 
carnitine-acylcarnitine translocase (CACT). Once inside the the mitochondria, CPT2 catalyzes 
the reverse reaction from Carnityl-VPA to VPA-CoA (Silva et al. 2008). The detection of 
elevated CPT1C levels suggests that VPA may not elicit its inhibitory function in Non-
Responders, since it is more rapidly transferred onto carnitine. However, this still needs to 
be proven. 
5.1.6 Future aspects: Tackling VPA Non-Responder 
The data discussed so far shed first light on the underlying cause of VPA non-
responsiveness in SMA therapy. However, a bunch of fundamental questions remain. 
Perhaps the most important one is whether the identified candidate genes are indeed 
responsible for the occurance of VPA Non-Responder or whether they were just found by 
coincidence. Though, to answer this question a better understanding of the role of each 
candidate in VPA uptake and metabolism is needed.  
Among the selected candidates, CD36 was the most overt one, since it is facilitating LCFA 
transport (Abumrad et al. 1993; Coburn et al. 2000; Endemann et al. 1993). Given that 
inhibition of CD36 mediated FA transport by SSO not convincingly turned a Non- into a Pos-
Responder (Figure 34), it is still questionable whether the increased CD36 amounts found in 
Non-Responders indeed account for a differential VPA uptake or metabolism. On the other 
side, CPT1C, which catalyzes the formation of Carnityl-VPA (Lheureux et al. 2005; Silva et al. 
2008), has been found to be higher expressed in Non-Responders than in Pos-Responders. 
Since ChIP as well as the PKA assay both indicated that VPA is not eliciting its typical 
inhibitory function, one may speculate about a more rapid formation of Carnityl-VPA in Non-
Responders. This may sequester VPA, which is in Pos-Responders typically available for 
HDAC inhibition. To clarify this issue, several points have to be addressed: Perhaps the 
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easiest question to answer is whether the increased CPT1C expression indeed hampers 
SMN2 induction by VPA? And if the answer is yes, are indeed higher Carnityl-VPA amounts 
present in Non-Responders? Furthermore, is there a link between CD36 or any other 
candidate gene and CPT1C?   
Nonetheless, so far this work has been focused on the function of CD36 as a fatty acid 
transporter. Though, this is only part of the story since CD36 also functions as a receptor of 
thrombospondin-1 (TSP1). Since TSP1-signalling is mostly involved in angiogenesis, a direct 
connection from thrombospondin signalling to the response to VPA is rather vague. 
However, it has been shown that VPA treatment up-regulates TSP1 amounts in vitro (Cinatl 
et al. 2002), which then triggers via CD36 signalling proteins like p59fyn, caspase 3 and the 
p38 MAPK cascade (Jimenez et al. 2000). Therefore, it is also needed to investigate whether 
increased TSP1-signalling in Non-Responders suppresses the response to VPA. 
Another very interesting candidate is IGFBP5. Recently, it has been demonstrated that 
IGF-1, which is bound by IGFBP5, ameliorates the phenotype of SMA-like mice (Shababi et al. 
2010a). Since knockdown of IGFBP5 increased SMN levels post-transcriptionally, it is 
conceivable that IGF-signalling may impact SMN levels. Although no differential expression 
of either IGF-1 or IGF-2 could be detected by µ-array analysis, up to 5-fold expression 
differences of IGFBP5 may alter the ratio of free to bound IGF. Therefore, it might be worth 
to also have a look on IGF protein, ternary complex formation (Ning et al. 2006) or 
downstream signaling molecules. Furthermore, one may test whether addition of IGF-1 or -2 
or recombinant IGFBP5 alters SMN amounts in cell culture in Non- and Pos-Responders. 
Moreover, the cause for the differential expression of all candidate genes is not yet 
known. Since it is not certain that promoter sequencing will lead to the identification of (a) 
SNP(s), which is associated with the response to VPA, one may also have a look for other cis-
acting elements or test for the differential expression of miRNAs by qRT-PCR. Another still 
unclear issue is the question which of the four candidate genes is cause and which one is 
consequence. Although neither knockdown nor overexpression experiments gave a definite 
hint about the underlying mechanisms so far, one may still think about an epistatic regulator 
of the other three candidate genes. Therefore, the identifaction of a SNP, a cis- or trans-
acting element may help to decipher the underlying network. 
Although speculative yet, the finding of the determinant, which makes up the differences 
between a VPA Pos- and a Non-Responder would not only have an impact SMA therapy but 
would also have fundamental implications for e.g. epilepsy therapy. If the association 
between the determinant and the response could be verified in our control group, one may 
propose that it serves as a biomarker for VPA non-responsiveness in general. This biomarker 
could then be tested in epilepsy VPA Non-Responders to investigate whether the association 
holds true. Taken together, this would be a first step towards a tailor-made individualized 
VPA therapy, which eliminates the possibility of an unnecessary treatment. Moreover, 
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depending on nature of this factor, one may think about specific inhibitors or activators 
which can be given as a supplement to VPA therapy. 
Nevertheless, even though there may be some compounds which in vitro can turn a VPA 
Non- into a Pos-Responder, in vivo confirmation will be needed. This may lead to a dilemma 
that the cause why somebody is not responding to VPA is known, but it is not possible to 
overcome this non-responsiveness. Therefore, the search for novel SMA drugs has to be 
continued. Since several HDACi like M344 or SAHA gave good read-outs in vitro as well as in 
vivo, it is self-evident to also test novel, far more potent HDACi second generation HDACi like 
e.g. LBH589.   
5.2 Identification of LBH589 as a potential SMA drug 
The experiments discussed so far emphasize the urgent need of potential SMA drugs. 
Since the analysis of HDACi as potential SMA therapeutics gave every single one promising 
results in vitro and in vivo, the second generation HDACi LBH589 was selected for further 
analysis for several reasons (Brichta et al. 2003; Brichta et al. 2006; Hahnen et al. 2006; 
Riessland et al. 2010; Riessland et al. 2006). First, in vitro studies as well as pre-clinical trials 
convincingly demonstrated its huge potency in inducing apoptosis in neoplastic enteties 
(Atadja 2009; Ellis et al. 2008; Prince et al. 2009; Shao et al. 2010). Second and most 
importantly, LBH589 already achieved orphan drug status for the treatment of CTCL by the 
FDA in 2007. Currently, more than 80 clinical trials are ongoing to expand the therapeutic 
spectrum from LBH589 onto additional types of cancer.  
5.2.1 LBH589: A feasible drug to up-regulate SMN? 
To test whether LBH589 is able to induce SMN2, initially a kinetic experiment was 
performed to establish the optimal treatment conditions. It turned out that treatment for 
64 h at concentration between 100 nM and 1 µM gave the best results. Already 
concentrations of around 200 nM were sufficient to significantly increase SMN levels more 
than 5-fold (Figure 36). Moreover, SMN amounts were up to 10-fold increased at 
concentrations of 500 nM or 1 µM LBH589 in some cases. This of particular relevance, since 
compared to other HDACi the observed in vitro effect of LBH589 on SMN levels is the 
strongest reported so far (Avila et al. 2007; Brahe et al. 2005; Brichta et al. 2003; Hahnen et 
al. 2006; Riessland et al. 2006). While e.g. SAHA, another second generation HDACi, 
increases SMN levels in SMN1-deleted fibroblasts approx. 3-fold in the low micromolar range 
(Hahnen et al. 2006), 10-fold lower doses of LBH589 are required to induce a similar effect. 
Noteworthy, the HDACi M344 induced similar to LBH589 up to 7-fold elevated SMN 
amounts. However, high M344 concentrations of more than 50 µM turned out to be toxic 
(Riessland et al. 2006). In contrast, toxic side effects of LBH589 were only recorded for 
concentrations higher than 750 nM while 400 nM already fairly induced SMN production 
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6-fold (Figure 40). Of note, the observed up to 10-fold elevation of SMN protein is of such a 
high extent that almost theoretical levels of an unaffected carrier are reached. 
One may speculate whether, as it has been shown previously for VPA, the effect of 
LBH589 is depending on the number of SMN2 which are potentially activated (Brichta et al. 
2003). Although suggestive, rather the opposite could be observed. While ML5, which is 
derived from a SMA type II patient having three SMN2 copies, showed up to 4-fold increased 
SMN levels at maximum, both cell lines derived from type I patients exhibited more than 
7-fold elevated SMN amounts irrespective of whether they carry two SMN2 copies like ML17 
or three SMN2 copies like ML16 (Figure 36). There again, since all fibroblasts treated with 
VPA and LBH589 in parallel were, with the exception of ML82 (type IIIa), derived from SMA 
type II patients. This suggests that rather an individual factor than a correlation with the 
basal SMN levels is accounting for the observed differences in the response to LBH589. 
Since previous results with VPA clearly demonstrated that within the group of SMA 
patients some are VPA Non- or Neg-Responder, the question arose whether the same 
phenomenon could be observed in LBH589 treatment. This is of particular importance, since 
the occurance of HDACi Non-Responder is not unique to VPA. Similar findings also have been 
obtained with MS-275 in several colon cancer models (Bracker et al. 2009). Though, it may 
be argued that the differences between the individual models are responsible for the 
discrepant therapeutic outcome. Nevertheless, also in LBH589 therapy of CTCL patients both 
Non- and Pos-Responders have been observed in vivo (Ellis et al. 2008). To follow up this 
issue, fibroblasts derived from VPA Pos-, Non- and Neg-Responder were treated with 
escalating LBH589 concentrations (Figure 39). It could be demonstrated that in all assayed 
fibroblast lines LBH589 increased SMN levels more than 2-fold. However, these data 
conjectured that the response to VPA may have an impact also on the effect of LBH589. 
While in Neg- and Non-Responder (ML73, ML79 and ML82) SMN was elevated modestly 
2- to 4-fold, in both VPA Pos-Responder the effect was much more pronounced. Especially in 
ML67, which exhibited doubled SMN amounts under VPA treatment, LBH589 augmented 
SMN levels almost 10-fold. Since the underlying cause of VPA non-responsiveness is not 
known yet, it remains speculative which factor accounts for the observed discrepancy.  
The data discussed so far were exclusively produced with SMN1-deleted fibroblasts. Even 
though the results were promising, it had to be proven that LBH589 also induces SMN2 
expression in other systems. Therefore, human neural stem cells (NSC) derived from epilepsy 
surgeries were treated with LBH589 (Figure 42) as well. It could demonstrated that both 
employed LBH589 concentrations increased SMN levels up to 4.5-fold. This verified that 
LBH589 is not only active in dermal fibroblasts, but also in neural tissue, which is the actual 
SMA target tissue. Moreover, treatment of murine embryonic fibroblasts derived from SMA-
like mice (Hsieh-Li et al. 2000) resulted in up to 18-fold elevated SMN amounts indicating 
that LBH589 is also active in a murine context (Figure 41). To finally prove that LBH589 is a 
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promising candidate for SMA therapy, it was examined in vivo by sub-cutaneous injection of 
mice (Figure 41). Analysis revealed that both SMN protein and mRNA were elevated in the 
CNS of treated mice (Figure 43). Furthermore, histone acetylation was increased by 40% in 
the brain of LBH589 injected mice indicating that LBH589 is able to cross the blood-brain-
barrier (Figure 43).  
Taken together, these experiments addressed some very important aspects of a putative 
SMA drug. First, LBH589 is active in vitro in neural tissue. And second, LBH589 elicits its 
beneficial effects also in vivo for at least 24 h, although the half-life of LBH589 in mice is 
relatively short (IV t1/2 = 1.37 hrs, oral t1/2 = 2.90 hrs) (Atadja 2009; Otaegui et al. 2009). Since 
in humans a half-life of around 16 to 17 h for LBH589 was determined (Geng et al. 2006), 
SMN2 activation in humans may be far more long-lasting. Furthermore, these data implicate 
that LBH589 crosses the murine blood-brain-barrier. Several clinical trials are ongoing 
evaluating the potency of LBH589 in the treatment of brain glioma, indicating that it is also 
able to cross the human blood-brain-barrier. In conclusion, LBH589 fullfills all prerequisites 
required for a more detailed evaluation in SMA-like mice. Moreover, compared to other 
small compounds tested for SMA therapy, the in vitro effect of LBH589 was tremendously 
stronger. Therefore, we investigated in detail the underlying cellular mechanism, which are 
altered by LBH589. The deeper understanding of these may help to develope therapeutic 
approaches targeting intermediate steps in the LBH589 cascade. First, SMN2 mRNA under 
LBH589 treatment was investigated. And second, SMN protein under LBH589 treatment was 
tested.  
5.2.2 SMN2 mRNA: Promoter induction, splicing or both? 
The tremendously increased SMN protein amounts under LBH589 may, among others, be 
explained by a strong induction of the SMN2 promoter. To follow up this issue, ChIP analysis 
was performed to compare the effect of LBH589 to other well-known HDACi. Since ChIP 
analysis of the SMN2 in LBH589-treated fibroblasts revealed results similar to those reported 
for VPA or SAHA in NSC-34 cells (Kernochan et al. 2005), promoter induction was excluded to 
account for the observed SMN protein levels. Nevertheless, since promoter acetylation was 
increased with the highest impact on HuSP2 (+220%) and HuSP3 (+170%), we also quantified 
promoter activity by using a SMN2 promoter reporter cell line (Jarecki et al. 2005). By 
treating this cell line with escalating LBH589 concentrations, it could be demonstrated that 
already concentrations of around 200 nM LBH589 increased SMN2 promoter activity 2-fold. 
At 300 nM maximal promoter activity of around 2.2 au was reached, which was not further 
elevated by higher LBH589 doses. Using these data an EC50 concentration of 108 nM was 
calculated. Surprinsingly, this matched the IC50 of 106 nM concentration determined for 
LBH589, suggesting a 1:1 stoichiometry between HDAC inhibition and promoter activity at 
the SMN2 promoter (Appendix, Figure 64 and Figure 65).  
 
172 Discussion 
However, elevation of SMN protein amounts by HDACi treatment is not a sole 
consequence of SMN2 promoter activation, but rather the result of various factors coming 
together. For example, it has been demonstrated for VPA and M344 that also hTRA2-1 is 
increased, which consequently leads to a reversion of the SMN2 splicing pattern (Brichta et 
al. 2003; Riessland et al. 2006). We analyzed SMN2 expression and splicing under LBH589 
regimen and could show that both FL-SMN2 and SMN27 give a common picture in various 
LBH589-treated fibroblasts. While FL-SMN2 was elevated 2-fold, SMN27 remained 
unchanged or even decreased. This resulted in a reversion of SMN2 splicing pattern towards 
the beneficial FL-SMN2 transcript. However, although this data indicated a shift in SMN2 
splicing, the conclusion that LBH589 fully restores correct SMN splicing is wrong. Since SMN2 
typically gives rise to around 10% FL-SMN2 (Gennarelli et al. 1995; Lefebvre et al. 1995; 
Lorson et al. 1999) a doubling in its amounts implies 20% FL-SMN2 from SMN2 are 
generated, while 80% are still incorrectly spliced. Therefore, one would suppose that LBH589 
ameliorates the SMA phenotype but not lead to a complete rescue. Nevertheless, to identify 
the splice factor accounting for this observation, several splice factors known to influence 
SMN splicing were tested (Singh 2007), but only hTRA2-1 was found to be elevated. Based 
on this observation, we assayed the role of hTRA-1 in LBH589 treatment by time-course 
experiments (Figure 45A, B) and knockdown studies (Figure 45C, D). In summary, it turned 
out that hTRA-1 is indispensable for the efficient up-regulation of SMN protein by LBH589, 
since it facilitates the reversion of the SMN2 splicing pattern. In contrast to the protein 
levels, mRNA amounts were significantly decreased for all assayed splice factors. Although 
this sounds contradictionary, these results were not unexpected. The observed discrepancy 
is most likely a result of the auto-regulatory feedback by which SR protein levels are 
controlled (Ni et al. 2007). For example, it has been demonstrated that high hTRA2-1 
amounts promote inclusion of an exon containing a premature stop codon into its own 
mRNA. This triggers Nonsense-mediated mRNA decay (NMD) of the transcript by which 
hTRA2-1 protein amounts decline in the following (Mattox and Baker 1991; Stoilov et al. 
2004). Based on this one may argue that the increased hTRA-1 amounts led to the decrease 
mRNA amounts, whereas in the case of SF2/ASF and SRp20 the declined transcript levels 
already led to normalization of protein amounts. 
Furthermore, the stability of the SMN mRNAs was assayed with Actinomycin D, since an 
enhanced mRNA half-life under LBH589 treatment would allow to more often translate one 
and the same mRNA (Figure 48). For example, the impact of HDACi on mRNA has been 
demonstrated using the examples TSA and Sodium butyrate, which decreased claudin-1 
mRNA stability whereby less protein was produced (Krishnan et al. 2009). However, no 
stabilizing or destabilizing effect on any of the tested mRNAs of LBH589 could be observed. 
Unlike previously reported data, which stated comparable half-lifes for FL-SMN2 and 
SMN27 of around 5 to 6 h in primary fibroblasts (Heier et al. 2007), in our experimental 
setup T1/2 for FL-SMN2 was approx. 8.5 h whereas SMN27 had a half-life of around 11 h. 
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Though, most probably these differences were due to inter-individual differences between 
fibroblast lines used. 
Taken together, the analysis of SMN2 expression showed that LBH589 increases SMN 
levels by two ways: SMN2 expression is induced via H3K9 hyperacetylation of the SMN2 
promoter plus a reversion of the SMN2 splice pattern by increased hTRA2-1 amounts. 
Furthermore, it could be demonstrated, that hTRA-1 is the splice factor facilitating reversal 
of the SMN2 splicing pattern and that SMN2 mRNAs are similarly stable. In summary, the 
effect of LBH589 on SMN2 mRNA is comparable to that of other HDACi reported. Therefore, 
the additional effect, which leads to 12-fold increased protein amounts, has to act on 
protein and not on RNA level.  
5.2.3 SMN protein: More or less breakdown? 
A common way to control protein abundance is to regulate its turnover. SMN is 
degraded via the ubiquitin-proteasome-system (UPS) (Burnett et al. 2009; Chang et al. 2004; 
Hsu et al. 2010). We initially tested whether inhibition of the proteasome by MG-132 in 
LBH589 treated cells leads to an additional elevation of SMN protein. While in mock treated 
cells MG-132 application increased SMN protein 2-fold, no such effect was detected when 
proteasomal SMN degredation was attenuated in fibroblasts under LBH589 treatment 
(Figure 49). This finding suggested that SMN protein turnover is indeed altered by LBH589. 
Hence, two possibilities arose how this is achieved. On the one hand LBH589 could, similar 
to MG-132, have an inhibitory effect on the proteasome. On the other hand, ubiquitinylation 
of SMN could be reduced. To test the former hypothesis, proteasomal degradation (Kisselev 
et al. 1999) in fibroblasts was quantified by a luciferase-coupled assay. In contrast to e.g. 
NVP-LAQ824, which reduced chymotrypsin-like proteasomal activity (Catley et al. 2003), no 
inhibitory effect of LBH589 on the proteasome could be detected (Figure 50). There again, 
clinical trials led to the observation that LBH589 boosts the effect of the protesome inhibitor 
bortezomib (e.g.(Ocio et al. 2010)). One popular line of explanation for this observation is 
that LBH589, similar to SAHA (Mitsiades et al. 2004), affects expression of proteasomal 
subunits, by which the cell becomes more prone for enhanced global protein degradation. In 
line with this, we observed an elevated global protein ubiquitinylation, but at least SMN 
seemed to remain spared. By precipitation of polyubiquitinylated proteins, we were able to 
prove that indeed SMN ubquitinylation was decreased by 70% (Figure 51). Purity of the 
precipitate was assured by staining against ODC, a protein which is known not to be 
ubiquitinylated (Zhang et al. 2003). Since ubiquitinylation of SMN is a prerequisite for its 
degradation, the detected reducting should consequently reduce its turnover, thus leading 
to a steady accumulation of SMN over time. This observation was somewhat surprising, 
since it is generally believed that HDACi treatment enhances protein degradation either 
directly by increasing non histone protein acetylation or indirectly by modulation of 
components of the ubiquitinylation machinery (Caron et al. 2005). For example, it has been 
 
174 Discussion 
shown that both VPA and TSA enhance expression of the E2 ubiquitin conjugase Ubc8, by 
which ubiquitinylation of their substrates is enhanced (Kramer et al. 2003). Since the UCHL1, 
the enzyme fascilitating SMN ubiquitinylation (Hsu et al. 2010), was not identified at that 
time, it was argued that an enhanced SMN complexation may account for our observations.  
Several lines of evidence supported this hypothesis: First, it has been reported that 
incorporation of SMN into the SMN complex increases its half-life from around 4 to 15 h 
(Burnett et al. 2009); presumably by protecting SMN from UCHL1. Second, the time-course 
experiment clearly showed that SMN2 expression remained the same, while SMN protein 
steadly increased, suggesting that SMN accumulates over time due to a decreased turnover. 
Although investigation of PKA activity, which is associated with SMN complexation (Burnett 
et al. 2009; Jablonka et al. 2007; Majumder et al. 2004), did not reveal an increase in PKA 
activity, SMN complexation may still be enhanced, since a third line of evidence came from 
fluorescent microscopy experiments. We counted gems in LBH589-treated fibroblasts and 
were able to show that, corresponding to the elevated expression of Gemin2 and -3 (Figure 
38), the overall portion of fibroblasts containing gems increased as well as the number of 
cells containing multiple gems (Figure 37). Since the two Gemin2 and -3 directly bind to SMN 
inside the SMN complex (Pellizzoni 2007) and are furthermore both co-regulated with SMN 
(Feng et al. 2005), it was suggested that an enhanced SMN complex formation under LBH589 
treatment keeps SMN out of the UPS by which SMN accumulates over time. 
In conclusion, these data give a very detailed insight how the tremendously increased 
SMN amounts under LBH589 treatment come off. Besides transcriptional activation and 
splice pattern correction, LBH589 also stabilizes the SMN protein by increased complexation. 
Although these mechanistical data were reported here for the first time, this mechanism 
must not exclusively apply to LBH589.  Since it has been shown that TSA, SAHA and VPA, 
which all have been tested as SMA drugs (Avila et al. 2007; Brichta et al. 2003; Brichta et al. 
2006; Hahnen et al. 2006; Riessland et al. 2010), interfere with proteasomal degradation 
(Kramer et al. 2003; Mitsiades et al. 2004) one may speculate that these HDACi may elicit a 
similar effect. However, this still needs to be proven. 
5.2.4 Future aspects: LBH589, JnJ-26481585 or even Bortezomib? 
In summary, a quite large number of small molecules have been identified within the 
past years, which positively influence the SMA phenotype. Among these, the six HDACi, VPA 
(Brichta et al. 2003; Brichta et al. 2006), sodium butyrate (Chang et al. 2001), phenylbutyrate 
(Brahe et al. 2005), SAHA (Hahnen et al. 2006; Riessland et al. 2010), TSA (Avila et al. 2007) 
and M344 (Riessland et al. 2006) have been successfully tested and have given promising 
results. Hence, why is a 7th HDACi like LBH589 needed? The answer is quite simple: In vivo 
studies with VPA in SMA patients only gave moderate effects and not all patients responded 
positively (Brichta et al. 2006; Swoboda et al. 2009; Weihl et al. 2006). A similar outcome 
was observed in phenylbutyrate treatment of SMA patients (Brahe et al. 2005; Mercuri et al. 
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2004). Even though, novel HDACi like SAHA (Riessland et al. 2010) and TSA (Avila et al. 2007) 
also proved their effectiveness in SMA-like mice, the questions remain whether the effect is 
the same in humans, and whether these drugs are also well-tolerated by young SMA 
children or even infants. The same problems need to be considered for LBH589. Therefore, 
and since no effective therapy for SMA is available yet, the search for novel, more potent 
SMA drugs has to be continued.  
The in vitro studies described in this thesis characterize LBH589 as the most potent 
HDACi reported so far. None of the other small molecules, which already have been tested 
for SMA therapy, achieved an up to 10-fold elevation of SMN protein as LBH589 does. 
Besides an increase in SMN protein via SMN2 promoter activation and splice pattern 
correction, a stabilizing effect on SMN via enhanced complex formation could be 
demonstrated. The next logical step in the process from an in vitro characterization towards 
a therapeutic SMA drug is an extended in vivo evaluation of LBH589 in SMA-like mice. Similar 
to what has been reported for SAHA (Riessland et al. 2010), the effect of LBH589 on survival, 
weight progression as well as motor neuron number, muscle histology, NMJ architecture or 
synaptic signaling has to be analyzed. Since recent publications showed that reduced SMN 
levels also interfere with normal heart development (Bevan et al. 2010; Shababi et al. 
2010b), one may think about the investigation of the cardiac phenotype as well.  
Nevertheless, the most critical point of the in vivo characterization of LBH589 in mice is the 
selection of a proper animal model. Most of the studies testing therapeutic approaches 
employ mice which are severely affected (Hsieh-Li et al. 2000; Monani et al. 2000). Although 
these models easily give the answer whether the treatment regimens improve survival, the 
long-term surveillance of treated mice is not possible. To overcome this hitch, it was tried to 
generate an intermediate SMA-like mouse by the combination of two already published 
mouse models. Unfortunately, although the SMA-like mice were clearly lighter and exhibited 
typical signs of a murine SMA in mice like necrosis of the tail, these mice survived over 250 
days, which is too long for an in vivo drug evaluation (Section 4.5).The crux of matter was 
that two SMN2 copies in a Smn null background typically lead to early or even embryonic 
lethality (Hsieh-Li et al. 2000; Monani et al. 2000), while the three SMN2 copies, like in our 
intermediate model, seem sufficient to guarantee survival. This suggested that the 
correlation between SMN2 copies and the SMA phenotype in mice is similar to humans but 
the amount of SMN needed is less in mice. Similar observations came from a recent 
publication in which a mouse strain carrying a humanized Smn gene with the C to T 
transition was generated (Gladman et al. 2010). Although full-length transcripts were 
reduced by 60 to 80%, these mice the mean survival was not reduced. Taken together, for a 
contemporary in vivo evaluation of LBH589 one has to rely on the available mouse models. 
Even though these animals might not be the proper model for investigation of long-term 
effects, they allow comparison to the impact of other substances. 
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Based on the convincing data obtained with LBH589, its derivate JnJ-26481585 was also 
tested as a putative SMA drug. Although the in vitro characterization was rather limited 
compared to LBH589, the results were similar (Section 4.4). Concentrations between 400 nM 
and 1 µM JnJ-26481585 elevated SMN levels 6- to 8-fold. On RNA level a reversion of the 
SMN2 splice pattern was observed, which was accompanied by an increased Gemin 
expression. Since also the cytotoxicity was comparable to what we found for LBH589, at 
least in vitro both HDACi are of equal value. 
Moreover, based on the finding that LBH589 reduces SMN turnover, the proteasome 
inhibitor bortezomib was tested for its ability to increase SMN amounts. However, although 
the in vitro data were quite promising, further experiments were not conducted, because 
bortezomib does not pass the blood-brain-barrier (Hemeryck et al. 2007). Nevertheless, 
these results should not be underestimated since one may think of combined therapy of 
HDACi plus bortezomib as it is done in cancer therapy (Deleu et al. 2009b; Ocio et al. 2010). 
In conclusion, these results highlight LBH589 and its derivate JnJ-26481585 as 
outstanding candidates for SMA therapy. Compared to all other small molecules tested so 
far, the in vitro results were superior. Based on the complete in vitro characterization of 
LBH589, it is self-evident to start now its in vivo evaluation. Since in vitro JNJ-26481585 gave 
likewise results, both compounds should be tested in comparison to decide which one gives 
the better outcome. Furthermore, one may treat animals in parallel with e.g. neurotrophic 
factors like IGF-1 or riluzole or combine HDACi treatment with ASO injection to test which 
combinations work best. 
 
Novel therapeutic approaches like stem cell transplation or viral gene therapy are 
currently in vogue. They are inducing high hopes, while the possible side-effects and 
problems are typically underestimated. It remains elusive, whether these techniques will 
ever be a feasible approach for SMA therapy in humans and establishing them will take years 
of development. Marketing and authorization for these doubtless visionary approaches will 
take up yet more time and is likely to be associated with strict restrictions concerning 
indication and patient groups. Meanwhile, patients and their families are suffering from SMA 
and urgently need effective treatment for their disease.  
A number of HDACi have already been approved by the authorities and are commercially 
available or are in the final stages of market approach. The side effects of these HDACi are in 
most of the cases well-known. For this reason, we propose to test LBH589 and JnJ-26481585 
to be tested in vivo in SMA-like mice to take a further step towards SMA therapy. 
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6. Summary 
Proximal spinal muscular atrophy (SMA) is the leading genetic cause of infant death in 
Western Europe. Its major characteristic is the progressive degeneration of the -motor 
neurons in the anterior horns of the spinal cord. To date, no cure is available. SMA is caused 
by homozygous functional absence of the survival motor neuron gene 1 (SMN1). Though, all 
SMA patients retain at least one copy of the nearly identical copy gene SMN2. In contrast to 
SMN1, which only produces full-length transcripts (FL-SMN), almost 90% of SMN2 transcripts 
undergo alternative splicing and lack exon 7 (SMN27). Hence, SMN2 gives predominantly 
rise to a truncated and unstable protein. But even though the amount of fully functional 
SMN2 protein is not sufficient to compensate for the loss of SMN1, it has been shown that 
SMN2 is the major disease modifying gene: The more SMN2 a SMA patient has, the less 
severe is the phenotype. Self-evident, SMN2 became the major target for potential SMA 
therapy. It has been demonstrated that epigenetic therapy by applying histone deacetylase 
inhibitors (HDACi) activates SMN2 transcription and modulates SMN2 splicing by inducing 
splice factor expression. In this way more FL-SMN2 is produced, which gives rise to more full-
length SMN protein. However, in a pilot clinical trial with the short-chain fatty acid HDACi 
valproic acid (VPA), the response to the treatment was quite diverse. Around 1/3 of SMA 
patients exhibited increased FL-SMN2 levels in blood (Pos-Responder). In contrast, in 
another 1/3 no response was detected, while in the remaining 
1/3 SMN levels were even 
decreased (pooled as Non-Responder). 
In the present work, the crucial factors determining VPA non-responsiveness were 
investigated. Fibroblast lines from all SMA patients included in the pilot clinical trial were 
established and treated with VPA. By western blot analysis, we were able to show that the 
response to VPA correlates between fibroblasts and blood in over 60%. To get a deeper 
insight into the reason why SMN2 is not induced in Non-Responders, we performed 
chromatin immunoprecipitation (ChIP) analysis and could demonstrate that VPA does not 
trigger SMN2 promoter hyperacetylation in Non-Responder fibroblast lines. Furthermore, 
we also showed that the cAMP-dependent protein kinase A (PKA) is not inhibited by VPA in 
Non-Responders. While HDACi of distinct chemical classes properly work in Non-Responder 
fibroblasts, the short chain fatty acid HDACi sodium butyrate led to results similar to VPA. 
Therefore, we speculated whether general mechanisms like fatty acid uptake and 
metabolism are causing the divergent response. To identify the crucial factors, fibroblasts of 
both Pos- and Non-Responders were compared by differential µ-array analysis. Data analysis 
revealed that in the Non-Responders no single gene was differentially expressed after VPA 
treatment, indicating that VPA is generally not acting as an HDACi. Furthermore, only nine 
genes were detected to be differentially expressed between untreated Pos- and Non-
Responders, suggesting that these may be a predisposing set-up. After validation by qRT-
PCR, the four candidates cluster of differentiation (CD36), IGF-binding protein 5 (IGFBP5), 
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retinoic acid receptor  (RAR and transforming growth factor  (TGF were selected 
based on literature research. While CD36 and RAR showed a higher expression in Non-
Responders, elevated levels of IGFBP5 and TGF were detected in Pos-Responders. In order 
to identify the cause of differential expression, all four genes were sequenced in both Pos- 
and Non-Responders and the respective promoters were analysed by ChIP. Since no SNP 
could be associated with the phenotype, knockdown and overexpression studies were 
conducted to investigate whether these four genes were identified by chance or are 
connected via a regulatory network. Although no obvious network could yet identified, data 
clearly indicated regulatory feedbacks between the candidate genes. Since CD36 is involved 
in LCFA transport, VPA uptake and metabolism were analyzed by HPLC-MS/MS. In summary, 
we could exclude that VPA is differentially metabolized between Pos- and Non-Responders. 
Futhermore, LCFA uptake in fibroblasts was measured using a fluorescent labeled fatty-acid 
analogue. Interestingly, these data suggest that in fibroblasts CD36 is rather functioning as a 
fatty acid exporter than an importer. While other known SCFA transporters were shown by 
qRT-PCR to be equally expressed, we detected increased carnitine palmityl transferase 1 C 
(CPT1C) levels in Non-Responders. Since this enzyme catalyzes formation of Carnityl-VPA, 
which is the initial step in the mitochondrial oxidation of VPA, it is the current focus of 
interest. 
Futhermore, we identified the second generation HDACi LBH589 as well as its derivate 
JnJ-26481585 as compounds tremendously increasing SMN levels. At concentrations of 
400 nM and 1 µM LBH589, up to 10-fold increased SMN amounts were recorded, which is 
the highest induction reported so far. Futhermore, we could demonstrate by fluorescence 
microscopy that also the number of small nuclear SMN foci termed gems increased in a 
similar fashion. Analysis of the SMN2 promoter by ChIP as well measurement of the SMN2 
promoter activity using a reporter cell line revealed a 1:1 stoichiometry between HDAC 
inhibition and expression rate with an EC50 of approx. 108 nM. On RNA level, we could 
demonstrate that LBH589 increases SMN expression, but also reverses the SMN2 splice 
pattern by up-regulation of hTRA2-1, a splice factor promoting SMN2 exon 7 inclusion. 
Subsequent knockdown and time-course experiments revealed that hTRA2-1 is indeed an 
indispensable factor for LBH589-induced SMN amounts. Moreover, in order to identify the 
crucial factors for the vast SMN up-regulation under LBH589 treatment, we analyzed post-
transcriptional factors like mRNA stability and proteasomal degradation. We were able to 
show that, most likely through enhanced complexation, ubiquitinylation of SMN is reduced, 
thus leading to a SMN accumulation over time. Moreover, by treating murine embryonic 
fibroblasts (MEF) and neural stem cells (NSC) from epilepsy surgeries we could prove that 
LBH589 is also active in both the neural and the murine context. In addition, as a first step 
towards an in vivo evalution, mice were sub-cutaneously injected with LBH589. Using tissue 
extracts, we could demonstrate that LBH589 increases both SMN protein and histone 
acetylation in central nervous system.  
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Based on these convincing results, LBH589 and JnJ-26481585 were proposed for 
extended in vivo testing in SMA-like mice to evaluate their therapeutic potential.
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7. Zusammenfassung 
Die proximal spinale Muskelatrophie (SMA) ist die häufigste genetische 
Kindestodesursache in West-Europa. Charakteristisch für eine SMA-Erkrankung ist eine 
fortschreitende Degeneration der -Motoneuronen in the Vorderhörnern des Rückenmarks. 
Eine Therapie für SMA gibt es bis dato noch nicht. SMA wird durch den homozygoten 
funktionellen Verlust des survival motor neuron Gens 1 (SMN1) verursacht. Allerdings konnte 
gezeigt werden, dass alle SMA-Patienten zumindest über eine Kopie des SMN2-Genes 
verfügen. SMN2 ist beinahe identisch mit SMN1, unterscheidet sich jedoch drastisch in 
seinem Spleißmuster. Während SMN1 ausschließlich Volllängen-Transkripte (FL-SMN) 
produziert, sind 90% aller SMN2 Transkripte alternativ gespleißt. Ihnen fehlt das Exon 7 
(SMN27), was zu einem verkürzten und instabilen Protein führt. Zwar reicht die Menge and 
SMN2 Volllängenprotein nicht aus um für den Verlust von SMN1 zu kompensieren, 
andererseits beeinflusst es jedoch den SMA Phänotyp: Über je mehr SMN2 Kopien ein SMA 
Patient verfügt, desto milder ist der Krankheitsverlauf. Aufgrund dieser Beobachtungen ist 
SMN2 natürlich ein erklärtes Ziel für eine SMA-Therapie. Es konnte gezeigt werden, dass die 
Verwendung von Histon Deacetylase Inhibitoren (HDACi) einerseits das SMN2 Gen aktivieren 
und darüberhinaus auch sein Spleißmuster korregieren. Zusammengefasst führt dies zu einer 
erhöhten FL-SMN2 Menge, welche widerum zu einer erhöhten Menge an Volllängen-Protein 
führt. Eine Pilotstudie mit SMA-Patienten, die mit dem HDACi VPA behandelt wurden,  ergab 
jedoch ein recht unterschiedliches Bild. In knapp einem Drittel der Patienten ist die Menge 
an FL-SMN2 im Blut, wie erhofft, angestiegen (Pos-Responder). In einem weiteren Drittel 
jedoch konnte keine Änderung festgestellt werden, wohingegen im letzten Drittel die Menge 
an FL-SMN2 durch VPA-Gabe sogar reduziert war (zusammengefasst als Non-Responder). 
Die vorliegende Arbeit beschäftigt sich mit der Suche nach den Ursachen, aufgrund derer 
SMA-Patienten nicht positiv auf VPA reagieren. Von allen SMA-Patienten, die an der Pilot-
Studie teilgenommen hatten, wurden Fibroblasten Linien aus Hautstanzen etabliert. Diese 
wurden dann mit VPA behandelt und die Menge an SMN-Protein mittels Western blot 
festgestellt. Es konnte gezeigt werden, dass in mehr als 60% der Fälle beide Gewebe, Blut 
wie Fibroblasten, gleichermaßen auf VPA ansprachen. Um zu verstehen, warum SMN2 nicht 
durch VPA in Non-Respondern aktiviert wird, wurden Chromatin-Immunopräzipitationen 
(ChIP) durchgeführt. Es zeigte sich, dass das SMN Protein in Non-Respondern unter VPA-
Behandlung nicht ansteigt, da VPA nicht zu einer SMN2 Promotor Hyperacetylierung führt. 
Darüberhinaus konnte gezeigt werden, dass in mit VPA behandelten Non-Respondern die 
cAMP-abhängige Proteinkinase A (PKA) nicht inhibiert wird. Der HDACi Natriumbutyrate - 
ebenso wie VPA eine kurzkettige Fettsäure – löste ebenfalls keine SMN2 Aktivierung in Non-
Respondern aus wohingegen Sie eindeutig auf HDACi anderer Substanzklassen ansprachen. 
Daher lag es nahe zu vermuten, dass ein genereller Faktor, wie die Aufnahme von 
kurzkettigen Fettsäuren für unsere Beobachtungen verantwortlich ist. Um die Frage nach 
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den Gründen hierfür zu beantworten, wurde die Transkriptome von Pos- und Non-
Responder Fibroblasten mittels Mikro-Array verglichen. Die Auswertung der Daten zeigte, 
dass in den Non-Respondern kein einziges Transkript differentiell unter VPA-Behandlung 
exprimiert wurde. Dies bedeutete, dass VPA generell nicht als HDACi in Non-Respondern 
wirkt. Interessanterweise wurden lediglich neun Gene gefunden, die signifikant 
unterschiedlich zwischen unbehandelten Pos- and Non-Respondern exprimiert wurden. Die 
einzelnen Transkripte wurden mittels qRT-PCR validiert und basierend auf publizierten Daten 
wurden die Gene Cluster of Differentiation (CD36), IGF-binde Protein 5 (IGFBP5), Retinoic 
Acid Receptor  (RAR und Transforming Growth Factor  (TGF  für weitere Experimente 
ausgewählt. CD36 und RAR sind beide in Non-Respondern höher exprimiert, wohingegen 
höherer Menge von IGFBP5 und TGF in Pos-Respondern gefunden wurden. Um die Ursache 
der differentiellen Expression zu bestimmen, wurden diese vier Gene in allen Fibroblasten-
Linien durchsequenziert. Darüberhinaus wurden die Promotoren mittels ChIP verglichen. Da 
jedoch keine Assoziation zwischen einem SNP und dem VPA-Phänotyp gefunden werden 
konnte, wurden Überexpressions- und RNA-Interferenz-Versuche durchgeführt. Zwar konnte 
bis dato kein einheitliches regulatorisches Netzwerk gefunden werden, allerdings zeigte sich, 
dass es in der Tat verschiedene Mechanismen gibt, welche diese vier Kandidatengene 
regulatorisch koppeln. Da CD36 ein Fettsäuretransporter ist, wurden ebenfalls 
massenspektroskopische Versuche zur Aufnahme und Metabolisierung von VPA 
durchgeführt. Allerdings wurde kein unterschiedliches Metabolitenmuster detektiert, so 
dass eine differentielle Verstoffwechslung von VPA als Ursache für das Auftreten Non-
Respondern ausgeschlossen werden kann. Ausgehend von diesen Daten wurde die generelle 
Fettsäureaufnahme von Fibroblasten verglichen. Interessanterweise lassen diese Daten 
vermuten, dass CD36 zumindest in Fibroblasten eher als Fettsäureexporter denn als -
importer fungiert.  Darüberhinaus konten wir zeigen, dass die Carnintin Palmityl 
Transferase 1 C (CPT1C) höher in Non-Responders exprimiert ist. Da CPT1C die Bildung von 
Carnityl-VPA katalysiert, konzentrieren sich unsere derzeitigen Experimente auf dieses 
Gen/Protein. 
Ferner konnten wir den HDACi LBH589 und sein strukturell nah verwandtes Derivat 
JnJ-26481585 als potentielle SMA-Therapeutika identifizieren, die einem enormen Effekt auf 
die SMN-Protein Menge haben. So stieg die SMN Menge bis zu 10-fach bei LBH589 
Konzentration von 400 nM beziehungsweise 1 µM an. Ein höherer Anstieg wurde bis dato 
noch nicht publiziert. Darüberhinaus konnten wir mittels Fluoreszenz-Mikroskopie zeigen, 
dass auch die Anzahl an Gems, nukleären SMN-Strukturen, gleichermaßen zunahm. ChIP-
Analyse des SMN2 Promoters, sowie die Messung der SMN2 Promotoraktivität in einer 
Reporterzelllinie, zeigten, dass am SMN2 Promoter HDAC-Inhibition und Promoter-Aktivität 
in einer 1:1 Stöichiometrie korrelieren. Es wurde eine EC50 von 108 nM LBH589 bestimmt. 
Auf RNA-Ebene konnten wir zeigen, dass LBH589 einerseits die SMN Expression steigert, 
aber auch das Spleißmuster durch Hoch-Regulation des Spleißfaktors hTRA2-1, welcher den 
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Einbezug des SMN2 Exons 7 fördert, revertiert.  Anschließende RNA-Inteferenz-Experimente 
und Zeitreihen zeigten, dass hTRA2-1 die Schlüsselfigur in der SMN-Steigerung durch 
LBH589 ist. Um die enorme Steigerung der Menge an SMN-Protein zu erklären, wurden des 
Weiteren post-transkriptionale Parameter wie mRNA-Stabilität und Proteinabbau 
untersucht. Mittels Präzipitations-Experimenten konnten wir zeigen, dass die 
Ubiquitinylierung von SMN stark reduziert ist. Ursächlich hierfür ist vermutlich eine 
verstärkte SMN-Komplex Bildung, die dann zu einer Anreicherung von SMN im Laufe der Zeit 
führt. Wir konnte ferner zeigen, dass LBH589 in humanen neuralen Stammzellen wie auch in 
murinen embryonalen Fibroblasten von SMA-Mäusen SMN Protein hochreguliert, was 
bedeutet dass es auch in neuralem oder murinem Zellen aktiv ist. Abschließend wurden 
LBH589 subkutan in Mäuse injiziert um zu untersuchen, ob sich eine in vivo Untersuchung 
von LBH589 anbietet. Die Analyse von Gewebeextrakten aus dem ZNS zeigte einerseits, dass 
die Menge an SMN Protein im Gehirn steigt und gleichermaßen auch die Histonacetylierung 
zunahm. 
Basierend auf dieser überzeugenden Datenlage sollte LBH589, bzw. auch JnJ-26481585, 
in einer größer angelegten Studie im SMA-Tiermodell untersucht werden. 
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CD 36  (ENSG00000135218) 
Amplicon Name Sequence (5´ → 3´) 
Exon 1 
CD36 ex1 fwd aac gtg att tat ttg gaa cgt g 
CD36 ex1 rev gca act caa ctg atg gta ttc g 
Exon 2 
CD36 ex2 fwd tga tgg cag caa tgt gta gag 
CD36 ex2 rev ctt gag ccc ggg agt tc 
Exon 3 
CD36 ex3 fwd gga gtt caa atg act cct ctt tc 
CD36 ex3 rev aga acc aca gtt gac ccc ac 
Exon 4 
CD36 ex4 fwd cat ctg gaa tgg ctg taa tta 
CD36 ex4 rev tgg gga cac aga gcc aaa g 
Exon 5 
CD36 ex5 fwd tta gga caa gcc att cag gc 
CD36 ex5 rev ctc cac cca aca caa cct tc 
Exon 6 
CD36 ex6 fwd aga acg ggc aaa atg ata cg 
CD36 ex6 rev gag ttg cag tgg ttc ata att acc 
Exon 7 
CD36 ex7 fwd aag gct gca aac aat ctt cc 
CD36 ex7 rev gac ttc tca gaa ata cat ggt caa g 
Exon 8 
CD36 ex8 fwd ttg cta gag acc ctg gct g 
CD36 ex8 rev aaa tga cca tgc ctc cat tc 
Exon 9 
CD36 ex9 fwd tgc att ttg agt ttt ggc ag 
CD36 ex9 rev tta gga tat atg tct cca gat cag c 
Exon 10 
CD36 ex10 fwd tca ttt gag taa cca gtg att gag 
CD36 ex10 rev agc aga aca gga gtt tcc ag 
Exon 11 
CD36 ex11 fwd ggt aca ttg caa taa gat aaa agg ttc 
CD36 ex11 rev tgt ggg aaa ggg agg tgg 
Exon 12 
CD36 ex12 fwd cac tgg agg aga gat ttc tag g 
CD36 ex12 rev att ttg tca cct ggg gtc tg 
Exon 13 
CD36 ex13 fwd ttt agt atg tgt taa aat ttc cca atc 
CD36 ex13 rev tgg ttg cat aag gat tat ggt aaa g 
Exon 14 
CD36 ex14 fwd gac ata att ctt ccc cac cc 
CD36 ex14 rev aag cca att aga atc act tca taa ac 
Exon 15 
CD36 ex15 fwd tgc agt ttt aaa agt ttc aat tag tcc 
CD36 ex15 rev cat aag cat tta ata atg att ggt gac 
Exon 16 
CD36 ex16 fwd ccc cga gaa ttt att gaa agg 
CD36 ex16 rev ttc aat tgg atc atc tca aat agg 
Exon 17 
CD36 ex17 fwd gcc ttt ctt gac ttg caa aag 
CD36 ex17 rev tct aca tgc agc aat cct gg 
Table 18  Primers for sequencing of CD36. Primers were designed by Exon Primer and were located  
 between 100 and 200 bp within the adjacent intron. Furthermore a cartoon illustrating 
individual exon length is given. 
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RAR  (ENSG00000077092) 
Amplicon Name Sequence (5´ → 3´) 
Exon 1 
RARB ex1_1 fwd agg gtt cac cga aag ttc ac 
RARB ex1_1 rev ttt ggc acg tag gct gtt g 
RARB ex 1_2 fwd caa gcc tgg aaa atg gta aat g 
RARB ex1_2 rev tgc tac caa tgc agt tta ttt cc 
Exon 2 
RARB ex2 fwd ctg aat ttg ggg cag aag c 
RARB ex2 rev tga tgt tac aca tcc agc cc 
Exon 3 
RARB ex3 fwd 
tca cga gga ttt taa ggt tta tgt 
aag 
RARB ex3 rev cca cat gac tgt gga agg tg 
Exon 4 
RARB ex4 fwd ctc agg agc aca ggc cc 
RARB ex4 rev cat gca cgt aca agg ttt cc 
Exon 5 
RARB ex5 fwd ccc tcc tat aga gct tcc cg 
RARB ex5 rev aat gtc tct tgg tcc cct cc 
Exon 6 
RARB ex6 fwd tga ttg atg att tca gga cag g 
RARB ex6 rev aac tcc aaa agg gga aat gag g 
Exon 7 
RARB ex7 fwd aca agg aag agg gga aaa gg 
RARB ex7 rev gca aca caa cct ggt aag gc 
Exon 8 
RARB ex8_1 fwd tga aaa ttg gtc cct ggt tat c 
RARB ex8_1 rev ttt ctg gtt gca tga aat gg 
RARB ex8_2 fwd caa gaa gga cca aga agt ttt c 
RARB ex8_2 rev gat gca gtt tga gag cat cag 
RARB ex8_3 fwd gga aac agg act att gac agg ac 
RARB ex8_3 rev tta att agc ccc ttg gca tc 
RARB ex8_4 fwd ttg ttc aca agc cat tag gg 
RARB ex8_4 rev aaa atg gaa ctg tgt tct ctg tc 
Table 19 Primers for sequencing of RAR. Primers were designed by Exon Primer and were  located 
between 100 and 200 bp within the adjacent intron. Because of its length exon 8 was 
subdivided into four parts. Furthermore a cartoon illustrating individual exon length is 
given. 
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TGF  (ENSG00000163235) 
Amplicon Name Sequence (5´ → 3´) 
Exon 1a 
TGFa 1a fwd ccc ccg gtc ccc gcc gag ttc 
TGFA 1a rev gcc ctc ggc gga cac cga aac cac 
Exon 1b 
TGFa 1b fwd cga cac cct gct tcc cc 
TGFa 1b rev gga cac cga aac cac ttc tc 
Exon 2 
TGFa 2 fwd cta ccg aac ctt tgc ctg tc 
TGFa 2 rev cca ggg agg gag ctc ttg 
Exon 3 
TGFa 3 fwd ttc ttg act ggt agg gtg gg 
TGFa 3 rev ttg gat att gga ctg acc cc 
Exon 4 
TGFa 4 fwd tcc ctg gag agc tag ggt aac 
TGFa 4 rev tat act gcg gat gtc cct gg 
Exon 5 
TGFa 5 fwd cct agg gca gat gct gta cc 
TGFa 5 rev tgg aga agg tgg tcg ttt tc 
Exon 6 
TGFa 6-1 fwd gct tat ttt ccc aac gtg gc 
TGFa 6-1 rev tct taa agc tag ggt ctt cat gtg 
TGFa 6-2 fwd aat tct gcc caa cac agg ag 
TGFa 6-2 rev aca gag ggg aca gat ccc tg 
TGFa 6-3 fwd aga aat ggt gcc att gaa gc 
TGFa 6-3 rev ttg aag gga ccc act gtt tc 
TGFa 6-4 fwd cct cca cta tgt ggg tct tcc 
TGFa 6-4 rev gcc caa ggg atg taa act tg 
TGFa 6-5 fwd tca gac aat tct atg acc cgt g 
TGFa 6-5 rev ttt gca gct aac caa aga cta cc 
TGFa 6-6 fwd aat gca agc ctg gtt gga c 
TGFa 6-6 rev cat ccc tgg ctt ggt tcc 
TGFa 6-7 fwd cct gac agg aaa tgt ttt ctt cta c 
TGFa 6-7 rev aag cct ggt aaa tca atg gc 
TGFa 6-8 fwd atg ccc aaa acc aag aac ac 
TGFa 6-8 rev tgc aga gaa aag tct tca ttt cc 
Table 20 Primers for sequencing of TGF. Primers were designed by Exon Primer and were    
   located between 100 and 200 bp within the adjacent intron. Because of its length Exon 6  
   was subdivided into 8 parts. Furthermore a cartoon illustrating individual exon length is  
   given. 
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IGFBP5  (ENSG00000115461) 
Amplicon Name Sequence (5´ → 3´) 
Exon 1 
IGFBP5 1-1 fwd ttg cag cta caa act ggc tg 
IGFBP5 1-1 rev caa gca acc acc aaa ata atg 
IGFBP5 1-2 fwd gct gag ggt tag aaa gcg g 
IGFBP5 1-2 rev acc gcg gtg agc aac ac 
IGFBP5 1-3 fwd gca cct gct cta cct gcc 
IGFBP5 1-3 rev cga cta ctc ccg agc tgc 
Exon 2 
IGFBP5 2 fwd ttt att act ccc ctc acc cc 
IGFBP5 2 rev tga atg tcc att tag atg cag g 
Exon 3 
IGFBP5 3 fwd cca ttc gtc agc gca gc 
IGFBP5 3 rev caa ggt gga gtt tcc tgg c 
Exon 4 
IGFBP5 4-1 fwd gta gac aag agg cag ggc ag 
IGFBP5 4-1 rev ctg gtc tcg gtg cat gtc 
IGFBP5 4-2 fwd gaa ggg aag gaa gtg ttt gtg 
IGFBP5 4-2 rev tta aat gag ggc tga aac gg 
IGFBP5 4-3 fwd tgc ata ttt cat tcc cca gg 
IGFBP5 4-3 rev gtc cgg aga ctg tga ctt cc 
IGFBP5 4-4 fwd att ccc cac gtg tgt tca tc 
IGFBP5 4-4 rev agt ctt gtc cct tcc aaa gc 
IGFBP5 4-5 fwd agg aaa gag agg aaa atg gg 
IGFBP5 4-5 rev tcc agg ggc ata gga gat ag 
IGFBP5 4-6 fwd cat gac aca gcg gag acc 
IGFBP5 4-6 rev gag tct ggc gca ctt aca cc 
IGFBP5 4-7 fwd tct tca cgg act gtg tct gg 
IGFBP5 4-7 rev agt cgt ggg aaa gac aga gg 
IGFBP5 4-8 fwd ctc cga atc taa gtg ctg cc 
IGFBP5 4-8 rev atc ctc tct gac tct atg gg 
IGFBP5 4-9 fwd gtt tag tga gac agg gct gc 
IGFBP5 4-9 rev gag gag aga aca gag tta tgg tat g 
IGFBP5 4-10 fwd acc tag ccc aca tgg ata g 
IGFBP5 4-10 rev agg aga atc agg gac ttg cc 
Table 21 Primers for sequencing of IGFBP5 Primers were designed by Exon Primer and were    
 located between 100 and 200 bp within the adjacent intron. Because of their length 
exons 1 and 4 were subdivided into three and 10 parts, respectively. Furthermore a cartoon 
illustrating individual exon length is given. 
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Gene 
Symbol 
Gene Description logFC AveExpr PValue adjPVal 
ANKRD1 
ankyrin repeat domain 1 (cardiac 
muscle) 
1,006 8,985 1,5501E-06 0,0188219 
MLLT11 
"myeloid/lymphoid or mixed-
lineage leukemia (trithorax 
homolog, Drosophila); translocated 
to, 11 " 
0,784 8,758 2,5968E-06 0,0188219 
ACTC1 actin, alpha, cardiac muscle 1 0,722 10,909 7,2896E-06 0,0352235 
OLFML1 olfactomedin-like 1 0,908 7,32 1,15E-05 0,04162 
IGFBP5 
insulin-like growth factor binding 
protein 5 
0,862 9,749 3,0958E-05 0,04162 
SLC7A14 
solute carrier family 7 (cationic 
amino acid transporter, y+ system), 
member 14 
0,852 6,036 3,4781E-05 0,04162 
GPR155 G protein-coupled receptor 155 0,85 6,239 3,1541E-05 0,04162 
PRKAA2 
protein kinase, AMP-activated, 
alpha 2 catalytic subunit 
0,748 6,55 3,9E-05 0,04162 
SLC38A4 solute carrier family 38, member 4 0,718 7,527 3,9259E-05 0,04162 
KCND1 
potassium voltage-gated channel, 
Shal-related subfamily, member 1 
0,708 5,584 4,0422E-05 0,04162 
KRT19 keratin 19 0,68 8,912 2,8872E-05 0,04162 
SV2A synaptic vesicle glycoprotein 2A 0,674 7,195 4,3067E-05 0,04162 
INHBA inhibin, beta A 0,644 8,854 0,00002659 0,04162 
SLC16A4 
solute carrier family 16, member 4 
(monocarboxylic acid transporter 5) 
0,578 7,719 4,1476E-05 0,04162 
LANCL2 
LanC lantibiotic synthetase 
component C-like 2 (bacterial) 
-0,612 8,444 2,7797E-05 0,04162 
LRCH2 
leucine-rich repeats and calponin 
homology (CH) domain containing 2 
0,92 7,484 8,3405E-05 0,0452257 
FRRS1 ferric-chelate reductase 1 0,712 7,348 5,9164E-05 0,0452257 
CXorf57 
chromosome X open reading frame 
57 
0,676 6,064 6,3721E-05 0,0452257 
MCAM melanoma cell adhesion molecule 0,644 6,668 4,9931E-05 0,0452257 
ITGA7 integrin, alpha 7 0,628 7,478 0,00010804 0,0452257 
NAP1L3 
nucleosome assembly protein 1-like 
3 
0,618 7,013 9,7739E-05 0,0452257 
ACSS3 
acyl-CoA synthetase short-chain 
family member 3 
0,61 7,607 9,8556E-05 0,0452257 
QPCT glutaminyl-peptide cyclotransferase 0,594 8,321 7,6237E-05 0,0452257 
CALCRL calcitonin receptor-like 0,592 4,08 8,7176E-05 0,0452257 
F3 
coagulation factor III 
(thromboplastin, tissue factor) 
0,578 9,539 8,6619E-05 0,0452257 
SCN2A 
sodium channel, voltage-gated, 
type II, alpha subunit 
0,568 5,688 0,00010048 0,0452257 
OSAP ovary-specific acidic protein 0,536 8,404 0,00010726 0,0452257 
COL11A1 collagen, type XI, alpha 1 0,532 7,192 8,3956E-05 0,0452257 
AS3MT 
arsenic (+3 oxidation state) 
methyltransferase 
0,53 7,693 6,6562E-05 0,0452257 
JAM2 junctional adhesion molecule 2 0,52 6,658 9,3268E-05 0,0452257 
CRIP2 cysteine-rich protein 2 0,518 9,311 0,00010325 0,0452257 
SPTLC3 
serine palmitoyltransferase, long 
chain base subunit 3 
0,508 6,264 0,00010213 0,0452257 
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Gene 
Symbol 
Gene Description logFC AveExpr PValue adjPVal 
KIAA1305 KIAA1305 0,508 7,662 0,0001092 0,0452257 
--- --- -0,596 6,132 0,00010894 0,0452257 
--- --- -0,706 4,633 9,0227E-05 0,0452257 
RAB38 
RAB38, member RAS oncogene 
family 
0,698 5,951 0,00011558 0,046542 
RFTN2 raftlin family member 2 0,762 6,847 0,00015506 0,0473376 
CASP1 
caspase 1, apoptosis-related 
cysteine peptidase (interleukin 1, 
beta, convertase) 
0,656 6,39 0,00014332 0,0473376 
PSG8 
pregnancy specific beta-1-
glycoprotein 8 
0,634 3,823 0,0001362 0,0473376 
GSTM5 glutathione S-transferase M5 0,61 6,761 0,00012587 0,0473376 
RHOJ ras homolog gene family, member J 0,514 6,835 0,00016001 0,0473376 
RIMS2 
regulating synaptic membrane 
exocytosis 2 
0,508 5,74 0,00015813 0,0473376 
PTPRF 
protein tyrosine phosphatase, 
receptor type, F 
0,486 7,875 0,00014813 0,0473376 
TCEAL7 
transcription elongation factor A 
(SII)-like 7 
0,476 7,49 0,00015295 0,0473376 
KIAA1199 KIAA1199 0,458 11,415 0,00015715 0,0473376 
C2orf79 
chromosome 2 open reading frame 
79 
-0,464 8,344 0,0001307 0,0473376 
HP haptoglobin -0,466 3,087 0,00015865 0,0473376 
SPRYD3 SPRY domain containing 3 -0,478 8,711 0,00013976 0,0473376 
SCD 
stearoyl-CoA desaturase (delta-9-
desaturase) 
-0,5 9,828 0,00012258 0,0473376 
ABCA8 
ATP-binding cassette, sub-family A 
(ABC1), member 8 
0,764 5,68 0,00017098 0,0476628 
KIAA0408 KIAA0408 0,73 5,803 0,00017028 0,0476628 
HSPA2 heat shock 70kDa protein 2 0,456 8,662 0,00016587 0,0476628 
GCA 
grancalcin, EF-hand calcium binding 
protein 
0,572 4,494 0,00017872 0,0482854 
ELTD1 
EGF, latrophilin and seven 
transmembrane domain containing 
1 
0,564 8,478 0,0001832 0,0482854 
CCDC46 coiled-coil domain containing 46 0,452 6,292 0,00018181 0,0482854 
BEX4 BEX family member 4 0,572 8,206 0,00019765 0,0493989 
GPRASP1 
G protein-coupled receptor 
associated sorting protein 1 
0,506 6,013 0,00019714 0,0493989 
LRRC49 leucine rich repeat containing 49 0,49 7,425 0,00019634 0,0493989 
Table 22 Transcripts differentially expressed between mock and VPA-treated Pos-Responders 
detected by µ-array. Negative prefix indicates higher expression in VPA-treated fibroblasts. 
(logFC = log-fold change; AveExpr = average expression; PValue = P-value; adjPVal = P-value 
after BH correction) 
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Gene 
Symbol 
Gene Description logFC AveExpr PValue adjPVal 
LOC404266 hypothetical LOC404266 -1,738 6,93556 1,9006E-10 4,1448E-06 
HOXB3 homeobox B3 -1,1495 7,05167 3,9218E-08 0,00042764 
HOXD10 homeobox D10 2,8315 6,56 7,6585E-07 0,00334034 
TGFA 
transforming growth factor, 
alpha 
1,444 5,53 7,5181E-07 0,00334034 
GALNT12 
UDP-N-acetyl-alpha-D-
galactosamine:polypeptide N-
acetylgalactosaminyltransferase 
12 (GalNAc-T12) 
-1,329 7,27722 7,3105E-07 0,00334034 
HOXD11 homeobox D11 1,9425 6,92833 2,8645E-06 0,0104113 
RARB retinoic acid receptor, beta -1,128 5,185 5,1102E-06 0,0159205 
PITPNM3 PITPNM family member 3 1,381 6,57944 8,1593E-06 0,0222423 
MAB21L1 mab-21-like 1 (C. elegans) 2,0165 6,88944 1,5636E-05 0,0253025 
C11orf87 
chromosome 11 open reading 
frame 87 
1,411 7,605 1,3384E-05 0,0253025 
OLFM1 olfactomedin 1 -0,8175 6,17889 1,3466E-05 0,0253025 
DIO2 
deiodinase, iodothyronine, type 
II 
-1,0715 5,73833 1,4708E-05 0,0253025 
EPHA4 EPH receptor A4 -1,3905 8,04778 1,3385E-05 0,0253025 
KIAA1772 KIAA1772 -2,271 6,21833 1,6243E-05 0,0253025 
TAS2R48 
taste receptor, type 2, member 
48 
-0,69 3,89167 0,00002084 0,026734 
TMTC2 
transmembrane and 
tetratricopeptide repeat 
containing 2 
-0,9985 6,37056 1,9996E-05 0,026734 
CD36 
CD36 molecule 
(thrombospondin receptor) 
-2,2135 5,07333 1,9509E-05 0,026734 
LYPD6 LY6/PLAUR domain containing 6 -1,0215 6,03278 2,4608E-05 0,0298133 
AMIGO2 
adhesion molecule with Ig-like 
domain 2 
-0,9675 7,31389 2,7636E-05 0,0306525 
LYPD6B 
LY6/PLAUR domain containing 
6B 
-1,6675 7,03333 2,8111E-05 0,0306525 
IGFBP5 
insulin-like growth factor 
binding protein 5 
2,4875 8,63722 4,4173E-05 0,0458727 
Table 23 Transcripts differentially expressed between VPA-treated Pos- and Non-Responders 
detected by µ-array. Negative prefix indicates higher expression in VPA-treated Non-
Responders. (logFC = log-fold change; AveExpr = average expression; PValue = P-value; 
adjPVal = P-value after BH correction) 
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Gene 
Symbol 
Gene Description logFC AveExpr PValue adjPVal 
LOC404266 hypothetical LOC404266 -1,5855 6,93556 8,4359E-10 1,8397E-05 
HOXB3 homeobox B3 -1,324 7,05167 4,4899E-09 4,8957E-05 
RARB retinoic acid receptor, beta -1,302 5,185 7,5694E-07 0,00550241 
HOXD10 homeobox D10 2,654 6,56 1,8448E-06 0,0100577 
GALNT12 
UDP-N-acetyl-alpha-D-
galactosamine:polypeptide N-
acetylgalactosaminyltransferase 
12 (GalNAc-T12) 
-1,1965 7,27722 3,0067E-06 0,0131139 
TMTC2 
transmembrane and 
tetratricopeptide repeat 
containing 2 
-1,1145 6,37056 5,1263E-06 0,0186323 
HOXD11 homeobox D11 1,701 6,92833 1,5335E-05 0,0379679 
--- --- 0,6745 5,56833 1,5669E-05 0,0379679 
DIO2 
deiodinase, iodothyronine, type 
II 
-1,081 5,73833 1,3207E-05 0,0379679 
Table 24 Transcripts differentially expressed between mock treated Pos- and Non-Responders 
detected by µ-array. Negative prefix indicates higher expression in VPA-treated Non-
Responders. (logFC = log-fold change; AveExpr = average expression; PValue = P-value; 
adjPVal = P-value after BH correction) 
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Gene Ensembl ID Gene description Function 
DIO2 ENSG00000211448 deiodinase, iodothyronine, type II 
Activation of thyroid hormone              
(Thyrosxine → 3,3,5-triiodothyronine) 
GALNT12 ENSG00000119514 
UDP-N-acetyl-alpha-D-
galactosamine:polypeptide N-
acetylgalactosaminyltransferase 12 
Transfer of GalNAc from UDP-GalNAc to 
to hydroxygroup of peptide                                    
(O-linked glycosylation) 
KIAA1772 ENSG00000141449 KIAA1772 (GREB1L) 
estrogen dependent growth regulation 
in breast cancer 
LYPD6 ENSG00000187123 LY6/PLAUR domain containing 6 not known (defined by LU domain) 
MAP21L1 ENSG0000018066 mab-21-like 1 cell fate decision in C.elegans 
Table 27 Transcripts identified on the µ-array (adj.P<0.05; logFC>1), which were excluded from 
further analysis based on their function. KIAA1772 has recently been renamed as GREB1L. 
(GalNAc = UDP-N-acetyl--D-galactosamine) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xx Appendix 
CD36 
Patient/ fibro-
blast line 
before VPA 
treatment 
under VPA treatment 
Sample 1 Sample 2 Sample 1 Sample 2 Sample 3 Sample 4 Sample 5 
Down-
Regulation 
P2/ML82 1,460 1,260 1,448 1,334 0,363 0,373 --- 
P13/ML59 13,235 5,469 11,402 5,310 14,087 9,102 15,388 
P14/ML73 0,000 --- 0,000 0,000 0,000 --- --- 
P4/ML69 41,319 25,835 35,048 21,687 11,482 --- --- 
Up-
Regulation 
P5/ML60 13,235 5,469 11,402 5,310 14,087 9,102 15,388 
P8/ML67 2,154 2,101 6,591 7,641 3,485 --- --- 
P7/ML72 3,935 3,039 12,564 6,839 4,591 --- --- 
No change 10197/ML86 0,213 --- 0,444 0,745 1,677 --- --- 
IGFBP5 
Patient/ fibro-
blast line 
before VPA 
treatment 
under VPA treatment 
Sample 1 Sample 2 Sample 1 Sample 2 Sample 3 Sample 4 Sample 5 
Down-
Regulation 
P2/ML82 0,528 0,471 1,472 1,159 1,502 1,082 --- 
P13/ML59 0,937 0,843 0,843 0,676 0,844 0,747 0,985 
P14/ML73 0,975 --- 0,701 0,505 0,418 --- --- 
P4/ML69 3,406 3,017 4,174 5,742 4,252 --- --- 
Up-
Regulation 
P5/ML60 1,304 2,679 1,701 5,098 3,895 1,901 3,253 
P8/ML67 0,921 2,812 0,790 1,983 0,559 --- --- 
P7/ML72 0,890 1,611 1,763 0,731 1,267 --- --- 
No change 10197/ML86 0,570 --- 1,202 0,714 1,623 --- --- 
TGF 
Patient/ fibro-
blast line 
before VPA 
treatment 
under VPA treatment 
Sample 1 Sample 2 Sample 1 Sample 2 Sample 3 Sample 4 Sample 5 
Down-
Regulation 
P2/ML82 1,568 0,957 1,599 1,051 0,290 0,480 --- 
P13/ML59 2,683 2,179 2,179 2,319 1,894 1,099 1,236 
P14/ML73 1,122 --- 0,265 0,171 0,643 --- --- 
P4/ML69 6,946 1,890 2,153 1,271 1,128 --- --- 
Up-
Regulation 
P5/ML60 0,769 0,742 0,436 0,365 0,411 0,406 1,017 
P8/ML67 1,321 0,982 0,699 2,019 0,879 --- --- 
P7/ML72 0,888 0,355 0,768 0,904 0,584 --- --- 
No change 10197/ML86 0,034 --- 0,285 0,068 0,136 --- --- 
Table 28 Expression analysis of CD36, IGFBP5 and TGF in the blood of eight SMA-patients. RAR is 
not expressed in blood. From each patient one or two samples were collected before VPA-
treatment was started. Another three to five samples were collected under VPA-treatment. 
For each patient the SMN response to VPA-treatment in blood is given. With the exception 
of P5 the response was concordant between fibroblasts and blood. (Sample labeling: 
Identifier in Brichta et al. 2006 or patient ID / fibroblast line) 
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Figure 60 Agarose gels to separate phosphorylated and unphosphorylated PKA substrate.  
Subsequently bands were cut out, melted and quantified on a plate reader.  
 
 
xxii Appendix 
 
Figure 61 Summarized sequencing results for CD36 and RAR – both found to be up-regulated in Non- 
Responders. For both genes exons are represented by gray rectangles. Exons in which 
differences have been found between cell lines are highlighted in black. In the legend, the 
major allele of found SNPs is written in bold letters. The detected SNP in CD36 exon 1 was 
excluded as the cause of higher CD36 expression by sequencing another five not yet 
confirmed Non-Responders. In exon 7 at Pos +62 of RAR a previously not described silent 
A→C variation was found. 
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Figure 62 Summarized sequencing results for IGFBP5 and TGF – both found to be up-regulated in  
Pos-Responders. For both genes exons are represented by gray rectangles. Exons in which 
differences have been found between cell lines are highlighted in black. In the legend, the 
major allele of found SNPs is written in bold letters. In the 3‘UTR of TGF encoded by the 
terminal exon 6 two previously not described variations were found. At Pos +1500 C→T and 
at Pos +1532 C→T. 
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Figure 63 Representitave picture of fibroblasts stained with a FITC-labelled SMN-antibody and DAPI. 
Gems are indicated by arrows. 
 
Figure 64 Analysis of SMN2 promotor activity. Using a four paramter equotation top and bottom 
plateau as well as slope of the curve were determined. Based on these, an EC50 of 108 nM 
was calculated. 
 
Figure 65 Determinition of HDAC inhibition by LBH589. Using rat liver lysastes, HDAC activity was 
determined and analysed nonlinearly for the indicated LBH589 concentrations. The 
depicted curve was used to determine the following values: IC10 = 12 nM, IC50 = 106 nM and 
IC90 = 953 nM. These data suggest tha LBH589 acts a panHDACi at concentrations regulary 
used in this thesis. LBH589 data is compared to those of SAHA and VPA 
 
xxv Appendix 
 
 
 
Figure 66 Schematic representation of the used IGFBP5-clone (GVO #528) which was purchased from  
   Origene. The insert sequence was taken from the Origene homepage. More detailed  
   information about the construct can be found under 
http://www.origene.com/orf_clone/search/retrieve_results.mspx?accn=NM_000599&sku=RC203797 
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Figure 67 Schematic representation of CD36 cloned into pcDNA3.1/V5-His-TOPO (GVO #526) 
(Invitrogen). More detailed vector information can be found under 
http://tools.invitrogen.com/content/sfs/vectors/pcdna3.1v5histopo_map.pdf  
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Figure 68 Schematic representation of TGF cloned into pcDNA3.1/V5-His-TOPO (GVO #527)  
   (Invitrogen). For a higher resolution of the vector see Figure 67. 
 
Figure 69 Schematic representation of RAR cloned into pcDNA3.1/V5-His-TOPO (GVO #525)  
   (Invitrogen). For a higher resolution of the vector see Figure 67. 
. 
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Figure 70 Precursor ion pairs for VPA and 4-ene VPA. 
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